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5Abstract
This thesis investigates new methods for the environmentally sustainable synthesis of
heterocyclic scaffolds for application in medicinal chemistry. Chapter I introduces
general principles of sustainability in synthetic organic chemistry. This includes the
characterization and application of sustainable solvents and the use of biomass feedstocks
in synthesis.
Chapter II explores the synthesis of substituted isoindolinones via a ruthenium-catalyzed
alkyne cyclotrimerization. The introduction details the synthesis and medicinal
application of isoindolinones and describes previous research involving alkyne
cyclotrimerizations. Following this, the development of a regioselective alkyne
cyclotrimerization reaction in a sustainable solvent is reported. The optimized alkyne
cyclotrimerization conditions are then used to synthesize a selection of isoindolinone
products.
Chapter III describes the application of a kinetically-controlled furan-Diels–Alder
reaction to the synthesis of heterocyclic scaffolds, including the endo-cantharimide. The
study and application of furan-Diels–Alder reactions are introduced. Following this, the
Diels–Alder reaction of a 3-alkoxyfuran under sustainable reaction conditions is explored
experimentally and applied to the diastereoselective synthesis of endo-cantharimides. The
potential application of endo-cantharimides in medicinal chemistry is discussed with the
aid of biological testing and the Diels–Alder reactions of 3-alkoxyfurans is probed with
the aid of computational calculations.
Chapter IV concerns the cyclization of reducing sugars to prepare chiral tetrahydrofurans.
The role of tetrahydrofurans in medicinal chemistry, the synthesis of tetrahydrofurans
from sugar derivatives and the application of hydrazones in synthetic chemistry are
introduced. Following this the development of a hydrazone-mediated cyclization of
L-arabinose under sustainable reaction conditions is reported. The optimized conditions
are applied to prepare tetrahydrofurans from other sugars. The manipulation of the
tetrahydrofuran products is also explored.
Chapter V draws some general conclusions from the thesis and describes potential future
directions for the research. Chapter VI contains the details of experimental procedures
and compound characterization for the results discussed in Chapters II–IV.
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9Summary of Abbreviations
1,3-PDO 1,3-propane diol
2-MeTHF 2-methyltetrahydrofuran
3-HPA 3-hydroxypropanoic acid
9-BBN 9-borabicyclo[3.3.1]nonane
°C degrees centigrade
Ac acetyl
ACS American Chemical Society
Ar generic aryl group
API Active Pharmaceutical Ingredient
aq. aqueous
AZT Azidothymidine
Bn benzyl
Boc tert-butyloxycarbonyl
b.p. boiling point
br. broad
BSTFA bis(trimethylsilyl)trifluoroacetamide
BTX benzene, toluene and xylenes
CED cumulative energy demand
Cp η-5 cyclopentadienyl 
Cp* η-5 pentamethyl cyclopentadienyl 
CPME cyclopentyl methyl ether
cPr cyclopropyl
cod 1,5-cyclooctadiene
conc. concentrated
CSA (±)-camphorsulfonic acid
Cy cyclohexyl
D- dextrorotatory-
Da dalton
DCE 1,2-dichloroethane
DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
DIAD diisopropyl azodicarboxylate
DIBAL diisobutylaluminium hydride
DIPEA N,N-diisopropylethylamine
DMA dimethylacetamide
10
DMAP 4-(dimethylamino)pyridine
DME dimethoxyethane
DMF dimethylformamide
DMSO dimethyl sulfoxide
DPPE 1,2-bis(diphenylphosphino)ethane
DPPF 1,1′-bis(diphenylphosphino)ferrocene 
d.r. diastereoisomeric ratio
EC50 half maximal effective concentration
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
e.e. enantiomeric excess
Et ethyl
ER estrogen receptor
ESI Electro-Spray Ionisation
FGI functional group interconversion
GC glycerol carbonate
GVL γ-valerolactone 
h hour(s)
H8-BINAP (S)-(−)-2,2′-Bis(diphenylphospino)-5,5′,6,6′,7,7′,8,8′-octahydro-
1,1′-binaphthyl 
HDAC histone deacetylase
HIV human immunodeficiency virus
HMDS hexamethyldisilazide
HMF hydroxymethylfurfural
hν ultraviolet irradiation 
HSQC Heteronuclear Single Quantum Coherence
Hz hertz
IC50 half maximal inhibitory concentration
J joule
L generic ligand
L- levorotatory
i iso
LDA lithium diisopropylamide
M molar
MDM2 mouse double minute 2 homolog
Me methyl
11
MMPP magnesium monoperoxyphthalate
mol mole(s)
Ms methanesulfonyl
mw molecular weight
n norm
NBS N-bromosuccinimide
n.d. not determined
NMR Nuclear Magnetic Resonance
P partition-coefficient
p para
PC propylene carbonate
PEG polyethylene glycol
petrol petroleum ether
PMB 4-methoxybenzyl
Ph phenyl
PPA polyphosphoric acid
Ppm parts per million
Pr propyl
R generic alkyl group
Rf retention factor
ROE Rotating-frame Overhauser Enhancement
RT room temperature
SAMP (S)-1-amino-2-methoxymethylpyrrolidine
SCX-2 Strong Cation eXchange cartridge
TBAF tetrabutylammonium fluoride
TBS tert-butyldimethylsilyl
TEMPO 2,2,6,6-tetramethylpiperidinyloxy
t tert
Tf trifluoromethanesulfonyl
TFA trifluoroacetic acid
TFAA trifluoroacetic anhydride
THF tetrahydrofuran
TLC Thin Layer Chromatography
Ts para-toluenesulfonyl
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Chapter I. Introduction
The aim of this thesis is to explore the selective synthesis of novel heterocyclic scaffolds
for medicinal chemistry using sustainable reaction conditions. This research is split into
three independent areas; the synthesis of isoindolinones via ruthenium-catalyzed alkyne
cyclotrimerizations, the synthesis of cantharimides from 3-alkoxyfurans and the
transformation of reducing sugars into chiral tetrahydrofurans. This chapter will introduce
the principles of sustainable organic synthesis, with a focus on the use of sustainable
solvents and biomass-derived feedstocks.
1.1. Principles of Sustainable Synthetic Organic Chemistry
The twentieth century has witnessed rapid progress in the field of chemistry and a large
expansion of materials and medicines that are in production. However, the manufacture
of chemicals is heavily dependent on finite reserves of fossil fuels for both energy and
feedstocks. Industry and governments are recognizing the importance of reducing this
dependence in order to reduce the environmental damaged caused by chemical processes.
A major consumer of fine chemicals and solvents, and ultimately fossil fuels, is the
pharmaceutical industry.1 Reducing the environmental impact of drug manufacture is an
important corporate goal of pharmaceutical companies.2 For example, GlaxoSmithKline
have committed to a carbon-neutral value chain by the year 2050.3 In addition to drug
manufacture, drug development is another significant source of environmental damage
and addressing this is key to improving sustainability in the discovery of new medicines.4
1.1.1. Economy in Synthesis
Twelve Principles of Green Chemistry
An important guide to sustainability in synthesis are the Twelve Principles of Green
Chemistry, proposed by Anastas and Warner (Figure 1).5 In summary, they encourage
the efficient use of renewable raw materials to selectively manufacture chemicals without
the need for dangerous solvents, reagents and processes. This work has inspired other
sustainability guides, including Winterton’s Twelve More Green Chemistry Principles,6
Anastas and Zimmerman’s principles of green engineering7 and Tang’s
PRODUCTIVELY pneumonic.8
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Figure 1. Twelve Principles of Green Chemistry. Reproduced from Ref. 8 with permission from The
Royal Society of Chemistry.
1. It is better to prevent waste than to treat or clean up waste after it is formed.
2. Synthetic methods should be designed to maximize the incorporation of all
materials used in the process into the final product.
3. Wherever practicable, synthetic methodologies should be designed to use and
generate substances that possess little or no toxicity to human health and the
environment.
4. Chemical products should be designed to preserve efficacy of function while
reducing toxicity.
5. The use of auxiliary substances (e.g. solvents, separation agents, etc.) should be
made unnecessary wherever possible and innocuous when used.
6. Energy requirements should be recognized for their environmental and
economic impacts and should be minimized. Synthetic methods should be
conducted at ambient temperature and pressure.
7. A raw material or feedstock should be renewable rather than depleting wherever
technically and economically practicable.
8. Unnecessary derivatization (blocking group, protection/ deprotection,
temporary modification) should be avoided whenever possible.
9. Catalytic reagents (as selective as possible) are superior to stoichiometric
reagents.
10. Chemical products should be designed so that at the end of their function they
do not persist in the environment and break down into innocuous degradation
products.
11. Analytical methodologies need to be further developed to allow for real-time, in-
process monitoring and control prior to the formation of hazardous substances.
12. Substances and the form of a substance used in a chemical process should be
chosen to minimize potential for chemical accidents, including releases,
explosions, and fires.
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E Factor
A useful measure of the economy of a chemical process is the E factor (Environmental
Factor), as proposed by Sheldon.9 The E Factor is defined as the mass of the waste
generated in a process divided by the mass of the product. As such, the E Factor of a
process should be as close to zero as possible. In calculating a value all the raw material
required to produce a product is considered, including all reagents, solvents and the fuel
required. The only exception made is water (minus any organic or inorganic waste
products in the aqueous extracts). While low E Factors can be achieved for petrochemical
and bulk chemical processes, good economy in the pharmaceutical industry is a more
challenging proposition (Table 1).10
Table 1. E Factors in chemical industries.
Industry Product scale/tonnes E Factor
Oil refining 106–108 <0.1
Bulk chemicals 104–106 <1–5
Fine chemicals 102–104 5–50
Pharmaceuticals 10–103 25–100
Reproduced from Ref. 10 with permission from The Royal Society of Chemistry.
Atom Economy
Another metric for sustainable chemistry is atom economy, as proposed by Trost.11 It is
defined as the molecular weight of a product divided by the sum of the molecular weight
of all substances formed for a reaction process. Atom Economy does not account for
catalysts, solvent, excess reagent, reaction yield or the provenance of reagents but is a
very straightforward method to quantify the efficiency of a process. Various other
concepts have been proposed to quantify the economy of a synthesis,12 including process
mass intensity,13 reaction mass efficiency14 and molar efficiency.15
1.1.2. Sustainable Solvents
The biggest individual source of waste in the manufacture of active pharmaceutical
ingredients (APIs) is solvent. A study by Henderson et al. of the waste generated by
GlaxoSmithKline in the production of APIs concluded solvent was responsible for ca.
85% of the non-aqueous waste generated by mass (Figure 2).16 As such, the most
effective way to reduce the environmental impact of a manufacturing process is very often
to address the waste associated with the use of solvent.
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Figure 2. Material inputs by mass for the synthesis of an active pharmaceutical ingredient.16
Ideally reactions should be conducted without solvents or conducted in water to minimize
the environmental waste.17 However, it is rarely possible to eliminate organic solvent
from a synthesis and consideration must be given to which solvents should be used to
minimize environmental impact. Other issues such as occupational health and safety,
which are not directly related to environmental impact, are also often taken into
consideration when rating solvents for their use in organic synthesis. A summary of these
factors is given below.
Manufacture
The industrial production of solvent in an energy intensive process and is often dependent
on the use of fossil fuels.18 Fischer et al.19 have calculated the cumulative energy demand
(CED) for the manufacture of a series of common solvents, including those represented
in Figure 3. It is notable that the energy required to manufacture THF is significantly
greater than that required to manufacture a solvent like MeOH. This is in part because the
synthesis of THF requires multiple steps, whereas MeOH can be prepared in a single step
from synthesis gas.18
solvent
water
reactants
other
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Figure 3. Energy required to manufacture organic solvents.19
Disposal and Recovery
Non-aqueous solvent is typically disposed by incineration and there are two important
factors that determine how economical this is. Firstly, the disposal of chlorinated solvents
is more expensive because they are typically non-flammable and so fuel must be
consumed during incineration. In addition, if a solvent cannot be effectively separated
from an aqueous extract then the aqueous extract must also be incinerated. This is a
significant problem for solvents like THF that are only partly miscible with water.
One method to potentially improve the economy of a process is to recover the solvent at
the end of a reaction through distillation and there are a number of factors that have an
impact on how straightforward this may be. Ideally a solvent will not have a very high
boiling point (to minimize energy use), not have a boiling point within 10 °C of many
other solvents (to aid separation) and would not form an azeotrope with many other
solvents. A low explosive/ flammability risk is also important for safe solvent recovery,
as is good solvent stability. Although solvent distillation can be an energy-intensive
process, an analysis of twenty six common solvents by Fisher et al. concluded that
distillation was generally environmentally superior to incineration.19
Pollution
In addition to the carbon dioxide produced in the manufacture, recovery and disposal of
solvent, there are also a number of other means by which the use of a solvent may result
in environmental damage. Many organic solvents are classified as Volatile Organic
Compounds (VOCs), which are known to reduce air quality when they evaporate.
Solvents such as carbon tetrachloride and 1,1,1-trichloroethane pose a risk to the ozone
0 50 100 150 200 250 300
Methanol
Acetone
Acetonitrile
Ethyl acetate
Tetrahydrofuran
CED per kg of solvent [MJ-equivalents]
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layer, and are subject to strict regulation.20 In addition, many solvents pose a risk to
aquatic life. For example, solvents such as limonene, cyclohexane and dichlorobenzene
are known to be very toxic to aquatic life and potential causes of long-term damage to the
aquatic environment.
Occupational Health
A number of commonly used solvents posse an established or potential occupational
health hazard. Solvents such as benzene and 1,2-dichloroethane (DCE) are known
carcinogens while dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP) and
2-methoxyethanol are possible reproductive toxins.
Patient Safety
The International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use have set limits on the presence of specific
solvents in clinical medicines.21 While solvent such as EtOH, acetone and DMSO may be
present at 5000 ppm the limit on benzene in 2 ppm. Consequently, the Food and Drug
Administration recommend that benzene along with CCl4, 1,1-dichloroethane and
1,2-dichloroethane are avoided in the synthesis of pharmaceutical agents on the grounds
of patient safety.
Occupational Safety
There are numerous safety risks associated with the storage and use of organic solvents.
The flammability risk is associated with physical properties such as the flash point,
boiling point, autoignition temperature, electrical conductivity and vapor pressure. Rare
solvents such as nitromethane pose an additional risk of explosions. Solvents such as THF
are liable to form peroxides over time, which presents an additional explosive hazard
unless special precautions are taken. Other solvents possess specific safety hazards. For
example, AcOH can cause severe burns on contact with skin.
By considering these factors it is possible to assess solvents based on their environmental
credentials.22 To date GlaxoSmithKline,23 AstraZeneca,24 Pfizer,25 Sanofi26 and the ACS
Green Chemistry Institute Pharmaceutical Roundtable27 have all produced solvent guides
to aid synthetic chemists. The summarized version of the GlaxoSmithKline Solvent
Selection Guide is given in Figure 4 as a representative example. There are also solvent
guides for specific transformations, which aim to replace traditional solvents with poor
environmental profiles with more sustainable alternatives.28
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Figure 4. GlaxoSmithKline solvent selection guide. Reproduced from Ref. 23 with permission from
The Royal Society of Chemistry.
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With the need to find alternatives to many traditional solvents with poor environmental
properties, a number of compounds have recently been publicized as alternative green
solvents. Examples include 2-MeTHF,29 cyclopentyl methyl ether (CPME),30 dimethyl
carbonate (DMC),31 propylene carbonate (PC),32 γ-valerolactone (GVL),33 glycerol,34
polyethylene glycol (PEG),35 piperylene sulfone36 and supercritical carbon dioxide.37
Ionic liquids have also been promoted as green solvents,38 although they can require
significant resources to manufacture18 and exhibit acute toxicity to aquatic organisms.39
A particular challenge is to produce new sustainable solvents with similar properties to
the established solvents which need to be avoided.18
1.1.3. The Application of Biomass in Chemical Synthesis
The majority of carbon-based organic compounds manufactured by the chemical industry
are derived directly from petroleum.40 With the supply of readily accessible oil dwindling,
the scientific community has turned its attention to the use of biomass as an alternative
feedstock for synthetic chemistry.41
It is estimated that annually the Earth produces 1011 tonnes of biomass, of which only 3%
is harvested for human consumption.42 Human activity (such as agriculture and
manufacturing) produces a significant quantity of biomass as waste and so it is a
potentially ideal resource for the production of small molecules, materials and fuels.43
The majority of biomass (75%) is composed of carbohydrates such as cellulose,
hemicellulose, chitin, starch, inulin and sucrose (Figure 5). Lignocellulose accounts for
20% of biomass, and comprises ca. 65% cellulose and hemicellulose and ca. 20% lignin.
The remaining 5% of biomass is accounted for by proteins, terpenes and triglycerides.
Chapter I 25
Figure 5. The composition of biomass feedstock.42
Lignin is an abundant biopolymer that has been widely studied as a potential source of
aromatic compounds.44 Lignin is typically extracted from lignocellulose by pre-treatment
with water under high temperature and pressure followed by treatment with glycoside-
degrading enzymes.45 However, the production of small molecules from lignin has proved
extremely challenging and the majority of lignin produced as a by-product of the pulping
industry is still burned as a fuel.43 There have been a number of recent advances in this
area,46 including Westwood’s synthesis of small aromatic building blocks from birch
lignin (Scheme 1).47
birch lignin
(i) 10 wt. % DDQ/tBuONO
2-methyoxyethanol:DME (2:3)
O2, 14 h, 80 °C
(ii) then Zn/NH4Cl, H2O
1 h, 80 °C
HO
OMe
MeO
O
OH
101, 5%
HO
OMe
MeO
FGI
HO
OMe
MeO
OH
HO
OMe
MeO
OH
O
102
103
104
Scheme 1. Westwood’s synthesis of aromatic small molecules from birch lignin. 47
Carbohydrates make up the greatest constituent of biomass and have also been
investigated as a source for high-value small molecules.42 Agricultural biomass is
typically 30–40% cellulose, a regular polysaccharide of D-glucose. An additional 20–30%
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is comprised of hemicellulose; an irregular carbohydrate formed from multiple
polysaccharides. The composition of hemicellulose varies, but is mostly comprised of
xylose, mannose, galactose, arabinose and rhamnose. Both cellulose and hemicellulose
can be cleaved to give the component monosaccharides either under acidic conditions or
using enzymes.48
There are multiple methods to transform the carbohydrates that can be sourced from
cellulose and hemicellulose into valuable small molecules (Scheme 2).49 An industrially
attractive method is fermentation and this has been used to access a series of platform
chemicals that are traditionally prepared by the petrochemical industry. The fermentation
of sugars to form EtOH is an age-old approach that has been adapted into an industrial
process, with production reaching ca. 99 million tonnes in 2010.50 This process has been
adapted for the formation of nBuOH through the engineering of recombinant
microorganisms.51 Dehydration of these compounds also allows access to bio-ethylene
and bio-butene, both valuable intermediates in the bulk chemical industry52. It is
additionally possible to access olefins such as isobutene and butadiene directly through
the fermentation of sugars.53 Other compounds which can be accessed through
fermentation include 3-hydroxypropanoic acid (3-HPA) 105 (a precursor to acrylic
acid),54 1,3-propane diol (1,3-PDO) 106 (a building block for the polyester
polytrimethylene terephthalate)55 and adipic acid 107 (a component of nylon).56
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Scheme 2. Synthesis of platform chemicals from carbohydrates.
Another valuable method for transforming carbohydrates is via chemical manipulation
(Scheme 2). Reducing pentoses and hexoses using hydrogen gas and heterogeneous
catalysts can yield a variety of hydrocarbons,57 such as benzene, PhMe and xylenes
(BTX).58 A selective reduction of D-glucose gives sorbitol 108, which is used as a food
sweetener and as an intermediate for the synthesis of fuels, materials and pharmaceutical
agents.59 Dehydration of pentoses and hexoses under acidic conditions respectively yields
furfural 109 and hydroxymethylfurfural (HMF) 110.60 These versatile intermediates have
both been exploited for the synthesis of small-molecule building blocks,61 fuels,62
surfactants63 and bioactive compounds.64
An important use for biomass-derived compounds is as organic solvents (Scheme 3). As
described previously, solvent is typically the biggest input for the synthesis of
pharmaceutical agents and therefore using renewably-sourced solvent is an effective way
to improve the sustainability of a manufacturing process. For example, MeOH can be
prepared from synthesis gas, which can in turn be prepared by gasification of
lignocellulose.42 This can then be converted into dimethyl carbonate (DMC) through
reaction with carbon monoxide and oxygen.65 As discussed above, higher alcohols such
as EtOH and nBuOH can be prepared by fermentation of carbohydrates.50 Carbohydrates
can be converted into a variety of alcohols and hydrocarbons including some well-
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established solvents. Carbohydrates can also be converted into furfural and HMF, which
can be transformed into various solvents,66 including THF,67 2-MeTHF,68 γ-valerolactone 
(GVL)69 and cyclopentyl methyl ether (CPME).70 Biomass feedstock is also a source of
triglycerides, which can be hydrolyzed to give glycerol.42 Both glycerol34 and glycerol
carbonate (GC) 71 have been proposed as sustainable solvents.
Scheme 3. Preparing solvents from biomass.
1.2. Summary and Project Aims
The better management of natural resources and the reduction of environmental damage
is critical to the future of the chemical industries. For the synthesis of pharmaceutical
agents, the biggest cause of waste and environment damage is from the use, recovery and
disposal of organic solvent. As such it is essential to expand the use of solvents with more
sustainable properties and avoid those that are known to have serious environmental
issues. It is also important to make better use of those resources that can be sourced
sustainably from biomass, whether that be as solvents or molecular building blocks. This
is essential not only for the sustainable manufacture of existing medicines but also for the
sustainable discovery of new drugs.
The aim of this project is to develop sustainable methodologies for the synthesis of novel
heterocyclic scaffolds for medicinal chemistry. Efficiency is key to a successful synthetic
strategy, in terms of step-count, selectivity and yield. For medicinal chemistry it is
important that methodologies are designed for the rapid preparation of compound
libraries, using either convergent or divergent approaches. Substrate scope is also
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essential in this regard. Finally, the principles of sustainable synthesis discussed in this
chapter must be closely considered in developing new synthetic methods, in order to
reduce the environmental impact.
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Chapter II. Highly Regioselective Synthesis of Substituted
Isoindolinones via Ruthenium-Catalyzed Alkyne
Cyclotrimerizations
2.1. Introduction
2.1.1. The Application of Isoindolinones in Medicinal Chemistry
The isoindolinone skeleton has been applied widely within medicinal chemistry to
develop compounds with activity against a range of biological targets, with examples
given in Figure 6. Miyachia et al. developed hydroxamic acid 201 as a novel histone
deacetylase (HDAC) inhibitor which exhibited improved activity over clinically used
HDAC inhibitor Zolinza.72 Hardcastle et al. reported substituted isoindolinone 202 as a
potent MDM2-p53 protein–protein interaction inhibitor (IC50 = 44 ± 6 nM), with a
potential application as an antitumor agent.73 In addition, isoindolinone 203 was
developed by Kawanishi et al.74 and has been shown to be a selective inhibitor of cyclin-
dependent kinase subtype 1 while Spicer et al.75 reported isoindolinone 204 as a cytolytic
protein perforin inhibitor. Medicinal chemists have developed substituted isoindolinones
with biological activity against a variety of other targets76 including the
α1-adrenoceptor,77 DNA gyrase,78 dopamine D2 and D4 receptors,79 hypoxia-inducible
factor-1α,80 metabotropic glutamate subtype 2 receptor81 and tumor necrosis factor-α.82
The isoindolinone motif also forms the core of a wide selection of natural products.83
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Figure 6. Examples of bioactive isoindolinones within medicinal chemistry.
2.1.2 Synthetic Approaches to Substituted Isoindolinones
The regio- (and stereo-) selective synthesis of substituted isoindolinones has recently
generated significant interest within the scientific community. This work has primarily
focused on the generation of isoindolinones from a pre-formed aromatic ring with two
adjacent substituent (X and Y, Scheme 4) that are transformed into a lactam. This general
approach has been developed for a wide range of substrates to access different substituted
isoindolinones products.84 A variety of catalysts have been used including copper,85
palladium,86 nickel,87 rhodium,88 KOtBu,89 platinum nanowires,90 phase-transfer
catalysts,91 chiral amines92 and NBu4OAc.93 A notable example is the Cu(I)-catalyzed
alkynylation/lactamization cascade to convert benzaldehyde 207 into 3-alkynyl
isoindolinone 210 with excellent stereocontrol, as reported by Singh et al. (Scheme 4).94
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Scheme 4. General approach to isoindolinones from 1,2-disubstitued benzenes and an example from
Singh et al.94
Another important route to substituted isoindolinones is via C-H activation strategies
(Scheme 5). This has been achieved using benzamide derivatives via palladium,95
rhodium,96 nickel97 and ruthenium catalysis.98 For example, Manoharan and Jeganmohan
reported a ruthenium-catalyzed synthesis of isoindolinone 215 from benzamide 213 using
a super-stoichiometric copper(II) oxidant and alcohol 214 (Scheme 5).99 Additionally,
Smith et al.100 have reported a similar approach to isoindolinones via directed lithiation
of a substituted arene using stoichiometric tBuLi and Nakata et al.101 developed a
synthesis of isoindolinones from isopropyl benzyl carbamates using a Bischler–
Napieralski-type cyclization.
Scheme 5. General synthesis of isoindolinones using C-H activation and an example from Manoharan
and Jeganmohan.99
A much less explored route to isoindolinones is to prepare the heterocyclic core from
aliphatic precursors.102 An example of such a strategy was reported by Ma et al. (Scheme
6).103 Their approach was based on a palladium/copper-catalyzed oxidative cyclization of
enediyne 217 and internal alkyne 216 to give the highly substituted isoindolinone 218,
34 Alkyne Cyclotrimerizations
although regioselectivity was generally poor when the alkyne was non-symmetrical. In
general this approach of generating an aromatic core from linear precursors allows for a
more convergent approach to substituted isoindolinone products.
Scheme 6. Synthesis of isoindolinones from enediyne 217 and alkyne 216 by Ma et al.103
2.1.3. Synthesis of Aromatic Compounds via Alkyne Cyclotrimerization
Reactions
In 1948 Reppe et al.104 reported the first transition metal-catalyzed [2+2+2]-
cyclotrimerization of alkynes to form substituted benzenes. Since then, alkyne
cyclotrimerizations have been used to make densely functionalized aromatic compounds
using a large range of transition metal catalysts (Scheme 7).105 Alkyne
cyclotrimerizations offer a convergent and atom economical route to highly substituted
unsaturated compounds from readily accessible starting materials. Traditionally,
polysubstituted benzene rings are often prepared via electrophilic aromatic substitution,
a synthetic strategy which typically requires multiple steps, the use of protecting groups,
functional group interconversion and a careful choice of conditions to ensure good
regioselectivity.106 Directed metalation is another widely used technique for aromatic
substitution,107 but it is inherently limited by its nature.106 As such alkyne
cyclotrimerization offers an attractive alternative to these more conventional techniques.
Scheme 7. Alkyne cyclotrimerization reaction.
The main synthetic challenge associated with alkyne cyclotrimerizations is that of
regioselectivity. The homo-trimerization of a terminal alkyne will typically give a mixture
of 1,2,4- and 1,3,5-trisubstituted benzenes, while attempting a 3-component hetero-
trimerization can yield over 30 different products.108 Examples of highly selective
multicomponent [2+2+2]-cycloadditions have been reported but they are limited in
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substrate scope.109 A more successful and general strategy for selective [2+2+2]-
cyclization is to link 2 or 3 π-components with an organic linker (Scheme 8), as was
pioneered by Vollhardt et al.110 The strategy of tethering relies on the lower entropy of
activation associated with intramolecular processes and has been applied to the synthesis
of a wide range of products. However, it does not always eliminate side reactions as the
intermolecular cyclization of tethered components is often observed.111
Scheme 8. Tethered alkyne cyclotrimerization.
The cyclotrimerization of alkynes has been reported with an extensive number of
organometallic catalysts, each with their own distinct reaction scope.105f The metals
which have been most widely studied in this field are cobalt, rhodium, iridium and
ruthenium.105f
Cobalt Catalysis
Much of the initial work on alkyne cyclotrimerizations was developed using CoCp(CO)2
under visible light irradiation. Vollhardt developed a lot of this early chemistry110 and
applied it to the synthesis of B ring aromatic steroids.112 More recently, CoCp(CO)2 has
been exploited by Malacria et al.113 in the synthesis of the taxoid core, by Elwahy and
Hafner in the synthesis of 1,2,4-tris(azulen-1-yl)benzenes114 and by Siebert et al. in the
cyclotrimerization of diborylacetylenes to give hexaborylbenzene derivatives.115
Although CoCp(CO)2 has proved popular for the cyclotrimerization of alkynes, its use
typically requires heating of the reaction in xylene at reflux, the strict exclusion of oxygen
and sometimes a stoichiometric amount of the metal complex.105f
Cheaper catalytic systems based on cobalt halides have been developed.105f In 2006,
Okamoto et al.116 reported a general synthesis of aromatic compounds using a low-cost
cobalt catalyst and Zn dust in THF at 40 °C (Scheme 9). The reaction conditions were
used to cyclize 1,6-diynes with a wide range of monoynes in good yield and with good
functional group tolerance to give highly substituted benzenes 222a. Additionally the
reaction of a terminal monoyne with a mono-substituted diyne proceeded with good
regioselectivity. Okamoto was also able to demonstrate the homo-trimerization of alkynes
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and the intramolecular cyclization of triynes with some success. Okamoto later reported
that adding a substoichiometric quantity of a silver salt to the catalytic system
significantly improved reaction rate and substrate scope.117 This chemistry has since been
applied to the synthesis of polymers118 and anthracenes.119
Scheme 9. Okamoto’s alkyne cyclotrimerization using a low-cost cobalt complex.116
Rhodium Catalysis
Rhodium-catalyzed alkyne cyclotrimerizations were pioneered by Muller,120 who used
RhCl(PPh3)3 to form rhodacyclopentadienes from tethered diynes that formed substituted
benzenes upon treatment with monoynes. In 1982 Griggs et al.121 were the first to report
the catalytic use of RhCl(PPh3)3 for cyclotrimerizations and since then it has been widely
used in organic synthesis.105h Recent examples of note include Sun’s alkyne
cyclotrimerizations on a polymer support,122 Siegel’s synthesis of highly substituted
fluoranthenes and indenocorannulenes123 and Ramana’s total synthesis of (–)-bruguierol
A.124
More recently cationic rhodium complexes have become popular catalysts for
cyclotrimerizations.105h Tanaka et al.125 reported the first benzofuran synthesis via an
alkyne cyclotrimerization, using [Rh(cod)2]BF4 in combination with H8-BINAP (Scheme
10). Although yields were generally reasonable it was limited by poor regioselectivity. It
was also necessary to pre-activate the catalyst using hydrogen gas. Chiral cationic
rhodium complexes have been widely used in the enantioselective synthesis of chiral
aromatic compounds,105h including axially chiral biaryls,126 P-stereogenic alkynyl
phosphine oxides127 and chiral aryl amides.128 Cationic rhodium catalysis has also been
used in the synthesis of polyether cyclophanes and aryl boramides.129
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Scheme 10. Tanaka’s synthesis of benzofurans via rhodium-catalyzed alkyne cyclotrimerizations.125
Iridium Catalysis
Kezuka et al.130 have established [Ir(cod)Cl]2/DPPE as a robust and efficient catalyst for
tethered alkyne cyclotrimerizations. They reported the cyclizations of a broad range of
monoynes with 1,6-diynes with good functional group tolerance. Most significantly
Kezuka reported reasonable regioselectivity for the reaction of a non-symmetrical diyne
and a terminal monoyne, which could be reversed with the choice of ligand (Scheme 11).
Iridium catalysis has been employed in a number of other alkyne cyclotrimerizations,131
which include Murakami’s synthesis of Silafluorenes132 and Shibata’s synthesis of axially
chiral teraryl compounds.133
Scheme 11. Kezuka’s ligand-controlled regioselective cyclotrimerization of a non-symmetrical diyne
and a terminal monoyne.130
Ruthenium Catalysis
Both Grubbs’ first generation catalyst134 and Hoveyda–Grubbs’ catalyst135 have been
used to efficiently mediate alkyne cyclotrimerizations, albeit with limited substrate scope.
Another ruthenium complex that can catalyze cyclotrimerizations is RuCp*Cl(cod).136
Yamamoto and Itoh demonstrated the cyclization of a range of monoynes with different
1,6-diynes using RuCp*Cl(cod) in DCE at RT (Scheme 12). Good regioselectivity was
reported for the cycloaddition of terminal alkynes with non-symmetrical 1,6-diynes,
especially when the diyne possessed a terminal trimethylsilyl substituent.
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Scheme 12. Regioselective ruthenium-catalyzed cyclotrimerization of a non-symmetrical diyne and a
terminal monoyne.136a
2.1.4. Synthesis of Isoindolinones via Alkyne Cyclotrimerizations
In 2004 Yamamoto et al. reported the first use of an amide tether for an alkyne
cyclotrimerization to give an isoindolinone product (Scheme 13).137 The cyclization was
effective with five different monoynes and it was additionally possible to introduce a
methyl group at the propargylic position of the tether (i.e. R3 = Me) without complication.
The cycloaddition of amide-tethered diynes with ethyl cyanoformate and propyl
isocyanate was later reported as a synthesis of pyridines and pyridones.136g
Scheme 13. Synthesis of isoindolinones from amide-tethered diynes.137
Yamamoto et al. demonstrated that a key challenge of using amide-tethered diynes for
alkyne cyclotrimerization reactions was controlling the regioselectivity (Table 2).137 The
authors observed that the cyclotrimerization of an amide-tethered diyne with R1 = H
preferentially formed isoindolinone 229 over its regioisomer 229’, in the ratio 2:1 (Entry
1). This regioselectivity was reinforced by a terminal methyl substituent β to the carbonyl 
(R1 = Me), with only isoindolinone 229 observed (Entry 2). Where the steric influence of
a methyl substituent opposed the electronic influence of the amide (R1 = H, R2 = Me) the
steric effect was dominant, with a product ratio 229:229’ of 1:4 (Entry 3).
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Table 2. Regioselectivity in the cyclotrimerization of amide-tethered diynes 227 and 1-hexyne 228.137
Entry R1 R2 RuCp*Cl(cod)/
mol%
Time/ h Yield (229 and
229’)/ %
229:229’
1 H H 1 0.5 76 2:1
2 Me H 1 0.5 81 229 only
3 H Me 5 2 68 1:4
2.1.5. Mechanisms for RuCpCl(cod)-Catalyzed Alkyne Cyclotrimerizations
Alkyne cyclotrimerizations are believed to proceed via a number of distinct mechanisms,
subject to the catalyst, ligands and substrate. One example that has been studied in detail
with the aid of density functional calculations is the [RuCpCl]-catalyzed
cyclotrimerization of acetylene (Scheme 14).136c, 138 The 1,5-cyclooctadiene (cod) ligand
of RuCp(cod) is believed to be readily displaced by two molecules of acetylene. This
gives intermediate complex 230a that can then undergo an oxidative cyclization to form
ruthenacyclopentatriene 230b, in what is believed to be the rate determining step.138
X-ray crystal structures of analogous ruthenacycles have been acquired, and the C-C and
Ru-C bond lengths are consistent with the aromatic biscarbene structure 230b, as opposed
to its canonical structure 230b’.136b Complex 230b is capable of coordinating with a third
molecule of acetylene to form ruthenacyclopentadiene 230c. It has been calculated that
complex 230c can isomerize to form ruthenabicyclo[3.2.0]heptatriene 230d with an
activation energy of only 0.4 kJ mol–1.136c Intermediate 230d can then ring-open to form
7-membered ruthenacycle 230e, which on reductive elimination gives η2-benzene
complex 230f.138 Finally, displacement of benzene 230g and coordination of two new
molecules of acetylene regenerates catalytically active complex 230a.
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Scheme 14. Reaction mechanism for a [RuCpCl]-catalyzed alkyne cyclotrimerizations.136c, 138
For the cyclization of non-symmetrical alkynes a question of regioselectivity may arise.
Yamamoto et al.137 reported the RuCp*Cl(cod)-catalyzed regioselective cyclization of an
amide-tethered diyne and a monoyne (Scheme 15) and evaluated possible mechanistic
pathways. They assumed that, mechanistically, [RuCp*Cl] would behave in a similar
manner to [RuCpCl].
Scheme 15. Regioselective alkyne cyclotrimerization of amide-tethered diyne 231 and monoyne
232.137
As previously discussed, the cod ligand of the RuCp*Cl(cod) precatalyst is readily
displaced by two neutral electron donors, such as the alkyne units of the starting material
(Scheme 16). The terminal alkyne of the diyne is a better ligand than the internal alkyne
as it is sterically less hindered and it is not electronically deactivated by an adjacent
carbonyl. Once the terminal alkyne reversibly coordinates to Ru, the internal alkyne can
coordinate to the metal to form bidentate complex 234b. This can then undergo a
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cyclization, which is presumed to be the rate determining step. In general, only the diyne
will cyclize with the active catalyst to form ruthenacyclopentatriene 234c as the amide
tether holds the two alkynes in a reactive conformation, lowering the entropy of activation
for the reaction.
Scheme 16. Formation of ruthenacycle 234c.
Once formed, the ruthenacyclopentatriene 234c can undergo a [2+2]-addition with a third
alkyne. If R2 = H then the regioselectivity of this addition will be governed by electronic
effects. Yamamoto et al.137 used natural bond orbital calculations to determine natural
charge for the ruthenacyclopentadiene 235 in Figure 7. A blue color indicates a decrease
in the natural charge relative to an unsubstituted ruthenacycle while a red color indicates
an increase. They demonstrated that the impact of the pyrrolidinone was to increase
electron density of C-4 and decrease it at C-2. They proposed that an increase in charge
at a carbon adjacent to the metal would accelerate the [2+2]-addition at that position, and
this was consistent with experimental observation.
Figure 7. Pyrrolidinone ruthenacyclopentadiene 235 bearing calculated natural charges.137
In cases where R2 ≠ H, steric effects reinforce the electronic-based regioselectivity. If a 
[2+2]-addition occurs β to the carbonyl then the terminal alkyne substituent R2 is forced
above the plane of the pyrrolidinone (Scheme 17). This is sterically unfavorable as R2
clashes with the bulky Cp* ligand. The alternative cycloaddition gives a sterically less
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strained intermediate, such as complex 234e. Consequently, addition into the Ru=C bond
that is distal to the R2 substituent has a lower kinetic barrier.
Scheme 17. Selectivity for the addition of monoyne 232 to ruthenacyclopentatriene 234c.
Having established the metal-carbon bond over which the [2+2]-cycloaddition occurs, it
is also necessary to consider the orientation in which the incoming alkyne reacts. As is
shown in Scheme 18, the cycloaddition can occur to form either complex 234e or 234g.
The steric clashing between the chloride ligand and R3 means that formation of complex
234g is kinetically less favorable than the formation of its regioisomer 234e. Complex
234e isomerizes to form metallacycle 234f, which gives isoindolinone 233 upon
elimination of the catalytic species.
Scheme 18. Regioselective addition of monoyne 232 to ruthenacyclopentatriene 234c.
2.1.6. Chapter II Project Outline
The aim of this part of the PhD was to develop a novel approach to highly-substituted
isoindolinones based upon a regioselective alkyne cyclotrimerization (Scheme 19). This
would allow for the rapid and convergent assembly of isoindolinone products from
readily available alkyne precursors.
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Scheme 19. Proposed synthetic route to highly-substituted isoindolinones.
It was identified that a key challenge of the above approach was controlling the
regioselectivity of the cyclization.137 In order to address this, a trimethylsilyl group was
selected as a potential regiodirecting group (Scheme 19).136a Another important challenge
to address was finding safe and sustainable reaction conditions for the alkyne
cyclotrimerization. In particular, the DCE solvent used by Yamamoto et al. was
something that had to be avoided. 137 Having developed optimal cyclization conditions, it
would then be necessary to prepare different isoindolinones, by exploring then substrate
scope and manipulating the cyclization products. Finally, it would also be interesting to
cleave the lactam of isoindolinone 240 to access monocyclic benzene derivatives. Such a
“temporary tether” strategy has not been widely reported for [2+2+2]-cycloaddition
reactions.113b, 136e, 136h
2.2. Results and Discussion
2.2.1. Starting Material Synthesis
Initial efforts focused on the synthesis of amide-tethered diyne 245a via the coupling of
carboxylic acid 242 and amine 244a (Scheme 20). Firstly, acid 242 was synthesized in
78% isolated yield by carboxylation of ethynyltrimethylsilane 241 according to the
modified procedure of Fleming et al. 139 Amine 244a was formed in 81% isolated yield
from propargyl bromide, using 6.0 eq. of benzylamine, as previously reported by Burton
and Hess.140 Using only 3.0 eq. of benzylamine resulted in a 48% yield of amine 244a
due to significant over-alkylation. The coupling of carboxylic acid 242 and amine 244a
in CH2Cl2 via the corresponding acid chloride gave diyne 245a in 67% isolated yield.
Substituting CH2Cl2 with 2-MeTHF, a solvent noted for its sustainable properties,23
resulted in an improved 85% isolated yield of diyne 245a. Diyne 245a was found to be
sensitive to desilylation on silica, so rapid purification by flash column chromatography
was essential to attain a good yield.
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Scheme 20. Starting material synthesis. Reagents and conditions: (i) EtMgBr, then CO2(s); (ii)
benzylamine; (iii) oxalyl chloride, DMF, 2-MeTHF then amine 244a, 2.5 eq. NEt3, 2-MeTHF.
2.2.3. Preliminary Cyclizations
At the start of this study, the cyclotrimerization of diyne 245a with a selection of
monoynes was briefly investigated. Following Yamamoto’s reported work on alkyne
cyclotrimerizations, RuCp*Cl(cod) was chosen as a catalyst.137 A significant
disadvantage of Yamamoto’s cyclotrimerization protocol is the use of 1,2-dichloroethane
(DCE) as solvent, which is potentially detrimental to human health and is generally
avoided within industry. Consequently DCE was not used in the preliminary
investigations and cyclopentyl methyl ether (CPME) was used as an alternative solvent
because of its more environmentally sustainable properties.23 The results of this study are
summarized in Table 3.
Table 3. Synthesis of substituted isoindolinones using preliminary cyclization conditions.a
Entry R1 Time/h Isolated yield
247/%
Isolated yield
248/%
247:248b
1 nBu 0.5 61 16 2:1
2 tBu 0.5 22 43 1:3
3 4-MeC6H4 1.75c 42 10 2:1
4 CH2OMe 16 47 28 2:1
a A solution of 10 mol% RuCp*Cl(cod) and 4.0 eq. monoyne 246 in CPME was added dropwise over
15 minutes to a stirring solution of diyne 245a in CPME at RT. b As determined from a 1H NMR spectrum
of the crude product. c A co-spot prevented accurate determination of the reaction time by TLC.
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Treating diyne 245a with 4.0 eq. 1-hexyne 246a and 10 mol% RuCp*Cl(cod) gave
isoindolinone 247a, with complete conversion of diyne 245a after 30 minutes (Table 3,
Entry 1). The cyclization was highly regioselective, with no evidence of regioisomer 249
observed in the 1H NMR spectrum of the crude product. However, the 1H NMR spectrum
of the crude product indicated the presence of a second isoindolinone 248a, formed from
the homo-coupling of diyne 245a. Target isoindolinone 247a was readily separated by
flash column chromatography and was isolated in 61% yield. However, homo-coupled
product 248a underwent desilylation on silica gel to give isoindolinone 248b in 16%
yield.
Under the same conditions diyne 245a readily cyclized with tert-butyl acetylene 246b
and 4-ethynyltoluene 246c to give isoindolinones 247b and 247c respectively (Table 3,
Entries 2 and 3). However, the cyclization with tert-butyl acetylene 246b resulted in
significant homo-coupling, with the desired isoindolinone 247b isolated in only 22%
yield. Methyl propargyl ether 246d also cyclized with diyne 245a (Entry 4), with
isoindolinone 247d isolated in 47% yield.
Isoindolinones 247a, 247b and 247d and homo-coupled isoindolinones 248a and 248b
were found to decompose when dissolved in CDCl3. These compounds were stable in
DMSO, so from this point onwards DMSO-d6 was used as a solvent for the acquisition
of NMR data for all isoindolinone products.
2.2.4. Cyclization Optimization
The results of the preliminary cyclizations were promising, giving reasonable yields in a
sustainable solvent under mild reaction conditions. In general the target isoindolinone
was formed preferentially over the homo-coupled product. However, there was still
significant room for improvement, especially in avoiding the high catalytic loading of
RuCp*Cl(cod) and minimizing homo-coupling. To this end a range of reaction conditions
were screened.
The reaction chosen to be optimized was the cyclotrimerization of amide-tethered diyne
245a and 1-hexyne 246a (Table 4). For the purpose of this optimization, all reactions
were carried out over 16 h under an argon atmosphere and the unpurified product was
analyzed by 1H NMR spectroscopy. For simplicity, the 15 minute dropwise addition of a
solution of 1-hexyne 246a and catalyst to a solution of diyne 245a was avoided. Instead
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a solution of diyne 245a was added dropwise to a stirring solution of monoyne 246a and
catalyst over 1 minute (unless stated otherwise).
Table 4. Optimization of the cyclotrimerization of diyne 245a and monoyne 246a.
Entry Solvent Eq. 246a Catalyst [loading/
mol%]
Conversion
245aa/%
247a:248aa
1 PhMeb 4.0 Rh(PPh3)3Cl [10] <5 -
2 PhMeb 4.0 Co2(CO)8 [10] <5 -
3 DCEb 4.0 RuCp*Cl(cod) [1] 5 -
4 CH2Cl2b 4.0 Grubbs I [5] 5 -
5 neatc 4.0 RuCp*Cl(cod) [1] 50 3:2
6 neatc 4.0 RuCp*Cl(cod) [3] 100 3:1
7 CPME 4.0 RuCp*Cl(cod) [3] 100 5:1
8 CPME 4.0 RuCp*Cl(cod) [1] 60 4:1
9 CPME 2.0 RuCp*Cl(cod) [3] 100 2:1
10d CPME 4.0 RuCp*Cl(cod) [3] 100 8:1
11d CPME 2.0 RuCp*Cl(cod) [3] 100 9:1
12d CPME 1.1 RuCp*Cl(cod) [3] 100 2.5:1
13d MTBE 2.0 RuCp*Cl(cod) [3] 100 5:1
14d 2-MeTHF 2.0 RuCp*Cl(cod) [3] 90 5:1
15d CPME/10%
water
2.0 RuCp*Cl(cod) [3] 70 3:1
16 water 4.0 RuCp*Cl(cod) [3] 30 3:1
a Determined from the 1H NMR spectrum of the crude product. b Solvent dried over activated 4 Å molecular
sieves and degassed. c RuCp*Cl(cod) was added to the reaction mixture at 0 °C, which was then allowed
to reach RT. d Diyne 245a in CPME was added dropwise over 3 h to a stirring solution of monoyne 246a
and RuCp*Cl(cod).
Initially four different cyclotrimerization procedures reported in the literature were
screened for the reaction of diyne 245a with 1-hexyne 246a (Table 4, Entries 1–4).
Neither RhCl(PPh3)3141 nor Co2(CO)8142 were effective at catalyzing the reaction, with no
measurable formation of isoindolinone 247a (Entries 1 and 2). Using 5 mol% of Grubbs’
I in anhydrous, degassed CH2Cl2 did generate the desired isoindolinone 247a, but with
only 5% conversion of the diyne 245a (Entry 3).143 Use of 1 mol% RuCp*Cl(cod) in
anhydrous, degassed DCE also gave isoindolinone 247a, again with 5% conversion
(Entry 4).137
Given the poor conversion observed in Entry 4, alternatives to DCE as solvent were
considered. When the reaction was conducted without any solvent a significant increase
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in conversion of diyne 245a was observed (Table 4, Entry 5). With the higher conversion
it was also possible to identify homo-coupled product 248a in the crude reaction mixture,
with 247a and 248a formed in the ratio 3:2. Using 3 mol% of RuCp*Cl(cod) resulted in
the complete consumption of diyne 245a within 16 h, with an improved selectivity for
isoindolinone 247a over homo-coupled product 248a (Entry 6, 247a:248a = 5:1).
Using cyclopentyl methyl ether (CPME) as a solvent gave promising results in the
preliminary cyclizations (Section 2.2.3.), so it was trialled as a solvent in the optimization
study. As shown in Entries 7 and 8 of Table 4, the reaction proceeded in CPME and
3 mol% RuCp*Cl(cod) was sufficient to ensure 100% conversion of 245a within 16 h. In
addition, the formation of homo-coupled product 248a was lower that was observed for
the neat reactions. However, reducing the excess of monoyne 246a resulted in a
significant increase in homo-coupling (Entry 9). It is important to note that, unlike
previously reported methods for alkyne cyclotrimerizations, it was not necessary to dry
or degas the solvent. This was important for both minimizing waste and improving the
practicality of the reaction.
In an attempt to minimize formation of the homo-coupled product 248a, a 3 h dropwise
addition of the diyne was considered.111 As shown in Entry 10 of Table 4, a 3 h dropwise
addition resulted in reduced homo-coupling with no decrease in the conversion of diyne
245a. The 3 h addition also allowed the excess of monoyne 246a to be reduced from 4.0
eq. to 2.0 eq. with no increase in homo-coupling (Entry 11). As shown in Entry 12, using
1.1 eq. of monoyne 246a resulted in a significant increase in homo-coupling, but target
isoindolinone 247a was still formed as the major product.
Alternative solvents to CPME were also considered. It was found that methyl tert-butyl
ether (MTBE) and 2-MeTHF were both effective solvents for the cyclization (Table 4,
Entries 13 and 14) but neither offered an improvement on CPME. The reaction was also
found to be effective when CPME was used in combination with 10% water as a co-
solvent (Entry 15), albeit with reduced conversion and increased homo-coupling. In fact,
isoindolinone 247a was formed where water was exclusively used as solvent, with 30%
conversion of diyne 245a (Entry 16). This is significant as it could enable the extension
of the reaction to aqueous conditions for reactions involving water-soluble substrates.
The conditions described in Entry 11 of Table 4 were taken to be the optimized
cyclization conditions, as they maximized conversion while minimizing catalyst loading
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and homo-coupling. However, before developing the reaction scope, two areas were
investigated further. It was found that the reaction benefited from prolonged dropwise
addition of diyne to a solution of monoyne and catalyst, but the effect of the addition time
had not been fully explored. Secondly, all the experiments in Table 4 were conducted
under an atmosphere of argon. If the reaction could be performed under an atmosphere of
air with no detrimental outcome then this would allow for a more practical reaction. The
results of the investigation are shown in Table 5.
Table 5. Further investigation of the cyclotrimerization of diyne 245a and 1-hexyne 246a.a
Entry Addition
time/h
Conversion
245ab/%
247a:248ab
1 6 100 10:1
2 3 100 9:1
3 1 100 4:1
4c 3 80 3:1
5c 1 100 4:1
a Diyne 245a in CPME was added dropwise over the designated time period to a stirring solution of 2.0 eq.1-
hexyne 246a and 3 mol% RuCp*Cl(cod) in CPME. The reaction was stirred for a total of 16 h. b Determined
from the 1H NMR spectrum of the crude product. c The reaction was conducted under air rather than argon.
As shown in Entries 1 and 2 of Table 5, adding a solution of the diyne dropwise to a
solution of monoyne and catalyst over 6 h rather than 3 h did not significantly reduce
formation of diyne homo-coupling product 248a. However, a shorter addition time
resulted in increased diyne homo-coupling (Entry 3). This suggested that a 3 h dropwise
addition was optimal.
Conducting the reaction with a 3 h dropwise addition under an atmosphere of air resulted
in both reduced conversion of diyne 245a and an increase in diyne homo-coupling (Table
5, Entries 4 and 2). However, when the reaction was conducted under air using a 1 h
dropwise addition the result was analogous to the corresponding reaction under argon
(Entries 5 and 3). This suggested that the reaction was only sensitive to oxygen when the
reaction was prolonged by a long (>1 h) dropwise addition.
The optimized reaction conditions are given below. These reaction conditions were used
to convert diyne 245a (70 mg) and 1-hexyne 246a into isoindolinone 247a with an 81%
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isolated yield (Scheme 21). This represented a significant improvement in terms of
isolated yield compared to the preliminary cyclization conditions. In addition, both
catalytic loading and the excess of monoyne had been reduced. Importantly the reaction
was highly regioselective; regioisomer 249a was not observed at any point in this study.
This reaction was also scaled up to use 500 mg of 245a and isoindolinone 247a was
isolated in 66% yield.
A solution of diyne in CPME was added dropwise over 3 h to a stirring solution of 2.0 eq.
monoyne and 3 mol% RuCp*Cl(cod) in CPME at RT under an atmosphere of argon. The
reaction was stirred at RT for a total of 16 h. CPME was used without degassing or
drying.
Scheme 21. Optimized cyclization of diyne 245a and 1-hexyne 246a.
To confirm that the trimethylsilyl group was responsible for controlling the
regioselectivity of the alkyne cyclotrimerization rather than the reaction conditions, diyne
250 was treated with 1-hexyne 246a and RuCp*Cl(cod) under the optimized conditions
described. As shown in Scheme 22, the regioselectivity of this cyclization was poor. This
suggested that, as expected, the trimethylsilyl group of diyne 245a was acting as an
effective regiodirecting group. The regioselectivity of this cyclization was comparable
with the regioselectivity of the same reaction reported under Yamamoto’s conditions
(Section 2.1.4., Table 2, Entry 1).137
Scheme 22. Cyclization of diyne 250 and 1-hexyne 246a under optimized conditions. Reagents and
conditions: (i) K2CO3, MeOH; (ii) 3 mol% RuCp*Cl(cod), CPME, 16 h, RT.
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2.2.5. Monoyne Scope
Having established optimized reaction conditions for the cyclotrimerization of amide-
tethered diyne 245a with 1-hexyne 246a it was then important to explore the general
applicability of the reaction by considering different monoynes.
Monoyne Synthesis
While the majority of the monoynes used in this section were sourced commercially, three
monoynes were prepared in the laboratory (Scheme 23). Benzoate alkyne 246e was
synthesized in 92% isolated yield over two steps via a Sonogashira coupling of aryl iodide
252 with ethynyltrimethylsilane, followed by desilylation and transesterification using
K2CO3 in MeOH.144 Carbamate 246f was prepared from propargylamine 254 and Boc2O
in 93% isolated yield.145 Alkynyl boramide 246h was prepared over three steps from diol
255. Disilyl ether 256 was prepared from diol 255,146 which was then treated with
potassium ethynyl trifluoroborate 257 and Me3SiCl to give aryl borate ester 258. The
crude aryl borate ester 258 was then treated with naphthalene-1,8-diamine to yield
boramide 246g, which was purified by flash column chromatography without special
precautions.
Scheme 23. Monoyne synthesis. Reagents and conditions: (i) Pd(PPh3)2Cl2, CuI, NEt3, Me3SiC≡CH; (ii) 
K2CO3, MeOH; (iii) (Boc)2O; (iv) NH(SiMe3)2, Me3SiCl; (v) Me3SiCl; (vi) naphthalene-1,8-diamine.
Cyclizations with Different Monoynes
For the purpose of this study a series of monoynes were treated with N-Bn diyne 245a
using the optimized reaction conditions (Scheme 24). Reactions that did not reach
completion within 16 h were left for a total of 24 h. If this failed to result in 100%
conversion of diyne 245a then catalyst loading was increased.
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Scheme 24. Cyclization of diyne 245a with a selection of monoynes.
Aliphatic Monoynes
All the aliphatic monoynes explored in Table 6 cyclized with amide-tethered diyne 245a
to give the corresponding isoindolinones 247 in 65–83% isolated yield without
modification of the optimized reaction conditions. All five reactions were conducted in
duplicate to demonstrate the reproducibility of the reaction. All of these cyclizations
occurred with a low level of homo-coupling, except for the reaction to form isoindolinone
247b from tert-butylacetylene, where 247b:248a = 2:1 (Entries 3 and 4).
Table 6. Cyclization of diyne 245a with aliphatic monoynes.a
Entry R Time/ h [Ru]/
mol %
247 Conversion
of 245a/%a
Isolated
yield
247/%
247:
248ab
1 nBu 16 3 247a 100 81 9:1
2 nBu 16 3 247a 100 82 8:1
3 tBu 16 3 247b 100 65 2:1
4 tBu 16 3 247b 100 65 2:1
5 cPr 16 3 247h 100 78 9:1
6 cPr 16 3 247h 100 81 11:1
7 CH2CH2CH2Cl 16 3 247i 100 83 9:1
8 CH2CH2CH2Cl 16 3 247i 100 81 7:1
9 CH(CH2CH2)2 16 3 247j 100 80 6:1
10 CH(CH2CH2)2 16 3 247j 100 81 6:1
a Reagents and conditions: RuCp*Cl(cod), CPME, RT. The yields quoted with the structures are averaged
over two experiments. b Determined from the 1H NMR spectrum of the crude product by the integration of
peaks relating to compounds 245a, 247 and 248a.
Aromatic Monoynes
The reaction of a diyne 245a with a series of substituted phenyl acetylenes was explored,
with the results summarized in Table 7. The reaction of diyne 245a with phenylacetylene
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(Table 7, Entries 1–3) was slower than the corresponding reaction with 1-hexyne (Table
6, Entries 1 and 2) and the reaction required 4 mol% RuCp*Cl(cod) and 24 h to reach
completion. Following this isoindolinone 247k was isolated in 83% yield (Table 7, Entry
3). In contrast, the reaction of diyne 245a with 2-tolylacetylene required only 3 mol%
RuCp*Cl(cod) to reach completion within 16 h (Entries 4 and 5) The corresponding
isoindolinone 247l was isolated in 93% yield, with negligible diyne homo-coupling
observed in the crude 1H NMR spectrum. It is notable that 4-tolylacetylene behaved like
phenylacetylene (Entries 6–8); 4 mol% RuCp*Cl(cod) and a 24 h reaction time resulted
in 100% conversion of diyne 245a and a 83% isolated yield of 257n.
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Table 7. Cyclization of diyne 245a with aromatic monoynes.a
Entry R Time/ h [Ru]/
mol %
247 Conversion
245a/%b
Isolated
yield
247/%
247:
248ab
1 Ph 16 3 247k 90 n.d. 7:1
2 Ph 24 3 247k 80 n.d. 5:1
3 Ph 24 4 247k 100 83 6:1
4 2-MeC6H4 16 3 247l 100 n.d. >10:1
5 2-MeC6H4 16 3 247l 100 93 >10:1
6 4-MeC6H4 16 3 247c 80 n.d. 3:1
7 4-MeC6H4 24 3 247c 90 79 7:1
8 4-MeC6H4 24 4 247c 100 81 6:1
9 2-BrC6H4 16 3 247m 100 n.d. 6:1
10 2-BrC6H4 16 3 247m 100 80 8:1
11 4-BrC6H4 24 3 247n 100 83 5:1
12 4-BrC6H4 24 3 247n 100 78 5:1
13 4-(MeO2C)C6H4 24 3 247e 100 79 5:1
14 4-(MeO)C6H4 24 4 247o 90 n.d. 5:1
15 4-(MeO)C6H4 24 5 247o 100 79 6:1
16 4-(Me2N)C6H4 24 6 247p 80 n.d. 3:1
17 4-(Me2N)C6H4 24 10 247p 90 79 7:1
a Reagents and conditions: RuCp*Cl(cod), CPME, RT. b Determined from the 1H NMR spectrum of the
crude product by the integration of peaks relating to compounds 245a, 247 and 248a.
The reaction of diyne 245a with 2-bromo and 4-bromophenylacetlyne proceeded
efficiently using 3 mol% RuCp*Cl(cod) to give isoindolinones 247m and 247n in 80%
and 83% isolated yield respectively (Table 7, Entries 9–12). Using
4-(methoxycarbonyl)phenylacetylene as the monoyne similarly gave the desired
isoindolinone 247e in 79% isolated yield, again with only 3 mol% of the catalyst required
(Entry 13). The reaction of diyne 245a with 4-methoxyphenylacetlyene required a higher
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catalyst loading to reach completion (5 mol% RuCp*Cl(cod)), with isoindolinone 247o
isolated in 79% yield (Entries 14 and 15). The reaction of 4-(dimethylamino)
phenylacetylene with diyne 245a required a higher catalyst loading to achieve reasonable
conversion of diyne 245a (Entries 16 and 17). Using 10 mol% RuCp*Cl(cod) resulted in
90% conversion of diyne 245a, with isoindolinone 247p isolated in 79% yield.
Other Monoynes of Interest
Ether 247d and acetal 247q were formed using 3 mol% RuCp*Cl(cod), but in low isolated
yields (56% and 43% respectively) owing to significant diyne homo-coupling (Table 8,
Entries 1–4). The methodology was extended to form aryl boramide 247g using 5 mol%
RuCp*Cl(cod) in 55% isolated yield (Entries 5 and 6). Gandon et al.129b have reported
that aryl boramides can be transformed to the analogous aryl boronic acid under strong
acidic conditions, which can then be used for cross coupling. The reaction to form
isoindolinone 247e occurred with relatively high homo-coupling of diyne 245a, but
isoindolinone 247e was isolated in 63% yield (Entries 7 and 8). The corresponding
reaction of 2-ethynylpyridine 246r was comparatively slow and required 20 mol%
RuCp*Cl(cod) to achieve 80% conversion of diyne 245a (Entries 9–11). The reaction
also occurred with significant diyne homo-coupling and isoindolinone 247r was isolated
in 50% yield.
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Table 8. Cyclization of diyne 245a with other monoynes of interest.
Entry R Time/
h
[Ru]/
mol %
247 Conversion
of 245a/%b
Yield
247/%
247:
248ab
1 CH2OMe 16 3 247d 100 56 3:2
2 CH2OMe 16 3 247d 100 n.d. 3:2
3 CH(OEt)2 16 3 247q 90 29 0.7:1
4 CH(OEt)2 24 3 247q 100 43 0.8:1
5 B(C10H8N2) 16 3 247g 70 n.d. 3:1
6 B(C10H8N2) 24 5 247g 100 56 3:1
7 CH2NHBoc 16 3 247f 80 n.d. 3:1
8 CH2NHBoc 24 5 247f 100 63 2:1
9 pyridin-2-yl 24 3 247r 15 n.d. 3:2
10 pyridin-2-yl 24 10 247r 60 n.d. 3:2
11 pyridin-2-yl 24 20 247r 80 50 2:1
a Reagents and conditions: RuCp*Cl(cod), CPME, RT. b Determined from the 1H NMR spectrum of the
crude product by the integration of peaks relating to compounds 245a, 247 and 248a.
It is important to note that for all of the cyclizations in this section (Table 6, Table 7 and
Table 8) that the target isoindolinone was formed with excellent regioselectivity (Scheme
25). Regioisomer 249 was not observed in the crude 1H NMR spectra of any reaction in
the above study. This suggested that the trimethylsilyl directing group of diyne 245a
could effectively control regioselectivity for the reaction of 245a with a wide variety of
monoynes under the optimized conditions.
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Scheme 25. Highly regioselective cyclizations.
Failed Cyclizations
The monoynes depicted in Scheme 26 failed to cyclize with diyne 245a under the
optimized reaction conditions to form an isoindolinone product. No reaction was
observed when alkynes 246s and 246t were subjected to the cyclization conditions. The
fact that not even homo-coupling was observed suggested that in both cases the monoyne
deactivated the catalyst. The addition of propargyl alcohol 246u to a solution of
RuCp*Cl(cod) resulted in the formation of a precipitate and again no cyclization
occurred. Treating diyne 245a with benzonitrile 246v only resulted in the limited diyne
homo-coupling. Diyne 245a was also treated with internal iodoalkyne 246w but again the
only observed reaction was the homo-coupling of diyne 245a.
Scheme 26. Monoynes that failed to cyclize with diyne 245a under the optimized cyclization
conditions.
2.2.6. Diyne Scope
In addition to demonstrating reaction scope with respect to monoyne, it was important to
demonstrate the versatility of the reaction with different amide-tethered diynes (Scheme
27). The reaction was explored using a variety of amide-tethered diynes with different
substituents at the N-position (R1) and different alkynyl substituents (R2 and R3).
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Scheme 27. Probing the diyne scope of the optimized reaction.
Diyne Synthesis
In order to synthesize a range of new diynes it was necessary to make four different
propargylic amines (Scheme 28). The general approach to synthesize this group of
compounds was to treat the corresponding primary amine was a propargyl halide. Amines
244c147 and 244d148 were both isolated in low yields following vacuum distillation.
Amines 244e and 244f were isolated in 62% and 71% yields respectively following
purification by flash column chromatography.140
Scheme 28. Amine synthesis. Reagents and conditions: (i) propargyl bromide; (ii) propargyl chloride; (iii)
benzylamine.
With the propargylic amines in hand, five amide-tethered diynes were prepared in 66–
83% isolated yield using the coupling procedure developed for N-Bn diyne 245a (Scheme
29). This method was unsuited to the synthesis of diyne 245g, with little formation of the
desired product. However, diyne 245g was prepared in 71% isolated yield using 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC) as coupling reagent.137
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Scheme 29. Diyne synthesis. Reagents and conditions: (i) oxalyl chloride, DMF, 2-MeTHF then amine
244, NEt3, 2-MeTHF; (ii) BnHNCH2C≡CH 244a¸ EDC, DMAP, CH2Cl2.
In addition to the amide-tethered diynes above, N-Boc diyne 245h was identified as an
interesting substrate for an alkyne cyclotrimerization. However, three different strategies
failed to yield N-Boc diyne 245h (Scheme 30). Conversion of carboxylic acid 241 to the
corresponding acid chloride followed by treatment with carbamate 246f failed to yield
the desired diyne. N-H diyne 245b proved to be unstable in the presence of Boc2O and
DMAP in MeCN, with neither starting material nor product recovered from the reaction.
Similarly, treating diyne 245b with Boc2O and NEt3 in CH2Cl2 was unsuccessful.
Scheme 30. Failed attempts at the synthesis of N-Boc diyne 245h. Reagents and conditions: (i) oxalyl
chloride, DMF, 2-MeTHF then carbamate 246f, NEt3, 2-MeTHF; (ii) (Boc)2O, DMAP, MeCN; (iii)
(Boc)2O, NEt3, CH2Cl2.
Cyclizations Involving Different N-Substitution of the Diyne
N-H Diyne
Under the optimized reaction conditions N-H diyne 245b cyclized with 1-hexyne 246a to
form N-H isoindolinone 264a, but with only 50% conversion of diyne 245b and
significant formation of homo-coupled product 265 (Table 9, Entry 1). A longer reaction
time increased the conversion of 245b; but the reaction only reached 75% conversion
after 5 days (Entry 2). Increasing the reaction temperature to 50 °C had no impact on
either the conversion of 245b or the level of homo-coupling (Entry 3). The most effective
method for maximizing conversion and selectivity was to use 10 mol% RuCp*Cl(cod)
and a 24 h reaction time, which gave a 51% isolated yield of isoindolinone 264a (Entry
4). Under the same conditions 2-ethynyltoluene cyclized with N-H diyne 245b with a
62% isolated yield of isoindolinone 254b and 90% conversion of diyne 245b (Entry 5).
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Table 9. Cyclization of N-H diyne 245b with monoynes.
Entry R [Ru]/
mol%
Time 264 Conversion
245b/%a
Isolated
yield
264/%
264:265a
1 nBu 3 16 h 264a 50 - 3:2
2 nBu 3 5 days 264a 75 - 3:2
3b nBu 3 16 h 264a 50 - 3:2
4 nBu 10 24 h 264a 90 51 2:1
5 2-MeC6H4 10 24 h 264b 90 62 7:1
a Determined from the 1H NMR spectrum of the crude product. b Reaction conducted at 50 °C.
The observation that N-H diyne 245b was slower to cyclize with 1-hexyne that N-Bn
diyne 245a was expected when the mechanism was considered (Scheme 31). The
mechanism for RuCp*Cl(cod)-catalyzed alkyne cyclotrimerizations is believed to
proceed through a bidentate complex of the diyne with RuCp*Cl (complex 266c). This is
formed from monodentate complex 266b, where the two alkyne units are syn with respect
to the amide bond. This, however, will be the minor rotamer in solution. It is sterically
more favorable for the diyne to exist in an anti-conformation (complex 266a), where the
propargyl group is pointing away from the internal alkyne, and this would retard the
cyclization. N-Bn diyne 245a would also exist in an analogous rotameric equilibrium
when in solution, but the sterically bulky benzyl substituent can shift the equilibrium
further in favor of the reactive syn-conformation.
Scheme 31. Equilibrium between rotameric intermediates.
N-tBu Diyne
The N-tBu diyne 245c cyclized with 1-hexyne 246a under the optimized reaction
conditions to give isoindolinone 267a in 84% yield and with little formation of homo-
coupled product 268 (Table 10, Entry 1). The reaction of diyne 245c with
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phenylacetylene was slower, requiring 24 h and 4 mol% RuCp*Cl(cod) to reach
completion (Entry 2). However, isoindolinone 267b was formed in 89% yield and with
almost no homo-coupled product 268. Finally, 2-ethynyltoluene also cyclized with diyne
245c to give isoindolinone 267c in 94% yield and very little homo-coupling was observed
(Entry 3).
Table 10. Cyclization of N-tBu diyne 245c with monoynes.
Entry R [Ru]/ mol% Time/ h 267 Isolated yield
267/%
267:268a
1 nBu 3 16 267a 84 10:1
2 Ph 4 24 267b 89 >10:1
3 2-MeC6H4 3 16 267c 94 >10:1
a Determined from the 1H NMR spectrum of the crude product.
N-Allyl Diyne
Subjecting N-allyl diyne 245d to the optimized reaction conditions with 1-hexyne 246a
resulted in no reaction and the recovery of starting material (Scheme 32). Cyclization was
also not observed when the reaction was conducted at 100 °C in a sealed tube with but-
3-yn-1-ylbenzene 270 (chosen for its high boiling point).
Scheme 32. Failed cyclizations involving N-allyl diyne 245d. Reagents and conditions: 3 mol%
RuCp*Cl(cod), CPME.
A possible conclusion from the failure to cyclize N-allyl diyne 245d is that the optimized
reaction conditions are ineffective in the presence of a terminal alkene. To test this
hypothesis, N-Bn diyne 245a was treated with 1-hexyne 246a under the optimized
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conditions in the presence of 2.0 eq. of 1-hexene (Scheme 33). The alkene had no
significant impact on the reaction, with only a slight drop in conversion after 16 h. This
suggested that the optimized reaction conditions could tolerate the presence of alkenes in
general and that a more subtle effect was hampering the reaction of diyne 245d with
monoynes.
Scheme 33. Reaction of diyne 245a and 1-hexyne 246a in the presence of 1-hexene. Reagents and
conditions: 3 mol% RuCp*Cl(cod), CPME, 16 h, RT.
A potential explanation is depicted in Scheme 34. The key step in the cyclization of
N-allyl diyne 245d would be the oxidative cyclization of bidentate complex 272.
However, it is possible that the Ru centre complexes preferentially with the pendent
alkene rather than the internal alkyne to form complex 272’. If the catalytic species
remained in this unreactive complex 272’ then no reaction could proceed.
Scheme 34. Hypothetical complexation between the catalytic species and N-allyl diyne 245d.
Cyclizations Involving Different Alkyne-Substitution of the Diynes
A key strength of this methodology is its regioselectivity; minor regioisomer 274 was not
observed in any cyclotrimerization reported to this point. To expand the reaction scope
further and probe the question of regioselectivity a number of other cyclizations were
examined (Scheme 35). Firstly, an extra substituent R1 was incorporated into the diyne,
weakening the diyne’s regiochemical bias. Secondly, a diyne where the regiodirecting
group R3 was not SiMe3 was examined, to see whether the high regioselectivity was
maintained.
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Scheme 35. Investigating the regioselectivity of alkyne cyclotrimerizations.
Internal Diynes
Preliminary cyclizations of diynes 245e and 245f with 1-hexyne 246a indicated that
10 mol% was a suitable level of catalyst loading to ensure complete conversion of the
diyne within 24 h. They also showed that the internal diynes were not susceptible to
homo-coupling. For this reason, the 3 h dropwise addition of diyne to monoyne and
catalyst was omitted for simplicity. Four cyclizations were conducted and the results are
given in Table 11.
Table 11. Cyclization involving internal diynes.a
Entry Diyne R1 R2 Isolated
products
Yield (273
+ 274)/%
273:274b
1 245e Me nBu 273a/274a 69c 9:1
2 245e Me 2-MeC6H4 273b 88d >20:1
3 245f Et nBu 273c/274c 57c 2:1
4 245f Et 2-MeC6H4 273d/274d 73c 5:1
a A solution of diyne 245 in CPME was added to a stirring solution of 2.0 eq. monoyne 246 and 10 mol%
RuCp*Cl(cod) in CPME over 1 minute. The reaction was stirred at RT for 24 h. Determined from the 1H
NMR spectrum of the crude product. c Isolated yield. d Estimated from the 1H NMR spectrum of the crude
product by integration of peaks corresponding to isoindolinone 245e and those of impurities.
The cyclization of methyl-substituted diyne 245e with 1-hexyne 246a gave a 9:1 mixture
of regioisomers 273a and 274a in 69% combined isolated yield (Table 11, Entry 1). The
reaction of diyne 245e and 2-ethynyltoluene 246l was more regioselective, with no
evidence of isoindolinone 274b in the crude 1H NMR spectrum (Entry 2). Unfortunately,
it was not possible to purify isoindolinone 273b as it was sensitive to degradation on silica
gel to give an unidentified mixture of impurities. Ethyl-substituted diyne 245f also
cyclized with 1-hexyne 246a and 2-ethynyltoluene 246l, but with reduced regioselectivity
in both instances (Entries 3 and 4).
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A Diyne with a Methyl Regiodirecting Group
Using the optimized reaction condition for the cyclization of diyne 245g and 1-hexyne
246a gave isoindolinone 273e in 85% yield as a single regioisomer (Table 12, Entry 1).
Evidence of limited homo-coupling of 245g was observed in the 1H NMR spectrum of
the crude product but these impurities were not isolated. Reducing the loading of
RuCp*Cl(cod) to 1 mol% resulted in a lower conversion of diyne 245g (Entry 2). Diyne
245g also cyclized efficiently with 2-ethynyltoluene 246l to give isoindolinone 273f as
the only product (Entry 3).
Table 12. Cyclization involving diyne 245g.a
Entry R [Ru]/
mol%
Time/h Isolated
product
Conversion
245g/ %b
Isolate yield
273/%
1 nBu 3 16 273e 100 85
2 nBu 1 16 273e 40 27
3 2-MeC6H4 3 16 273f 100 94
a A solution of diyne 245g in CPME was added to a stirring solution of 2.0 eq. monoyne 246 and
RuCp*Cl(cod) in CPME over 3 h. The reaction was stirred at RT for 16 h. Determined from the 1H NMR
spectrum of the crude product.
2.2.7. Functional Group Manipulation of Cyclized Products
Transformation of the 2- and 7-Position.
In order to demonstrate the potential use of the developed methodology, functional group
manipulation of the cyclotrimerization products was investigated to access novel
isoindolinone products. Treatment of isoindolinone 247a with ICl or Br2 in CH2Cl2 led to
aryl iodide 275 and aryl bromide 276 respectively in good yields (Scheme 36).149,150
Replacing the CH2Cl2 solvent for the iodination of isoindolinone 247a with
environmentally more benign 2-MeTHF resulted in no reaction. Treatment of N-tBu
isoindolinone 267a with TfOH resulted in a simultaneous deprotection of the lactam and
protodesilylation within 30 minutes to give N-H isoindolinone 277 in 88% isolated
yield.151 It was not possible to substitute TfOH with TFA; heating 267a in neat TFA at
reflux for 48 h resulted in a complex mixture of products with no evidence of an N-H
isoindolinone product by 1H NMR spectroscopy. Treatment of 267a with ICl followed by
deprotection with TfOH gave 7-iodo isoindolinone 278 in 84% isolated yield over two
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steps. Thus, an N-tBu diyne can be used as an indirect method for the synthesis of N-H
isoindolinones via this acid-mediated deprotection strategy.
Scheme 36. Functional group manipulation of isoindolinones 247a and 267a. Reagents and conditions:
(i) ICl, CH2Cl2; (ii) Br2, CH2Cl2; (iii) TfOH; (iv) ICl, CH2Cl2; (v) TfOH.
A useful transformation for the N-Bn isoindolinone products would be their deprotection
to make the corresponding N-H isoindolinones. Benzyl deprotection of amides is often
carried out via a dissolving metal reduction, but such a reaction is unlikely to be selective
for the benzyl aromatic ring. Hydrogenation was considered to be more amenable towards
the isoindolinone core, but unfortunately resulted in no reaction (Scheme 37).152
Hydrogenation under elevated pressure may be more effective.
Scheme 37. Failed deprotection of N-benzyl isoindolinone 247a.
In 2005 Zhao and Snieckus reported a one-pot procedure for the ipso-borodesilylation of
aryl silanes followed by a Suzuki-Miyaura cross-coupling with aryl halides to access
biaryl products.153 Unfortunately, the application of their protocol to isoindolinone 247a
did not result in any reaction (Scheme 38).
Scheme 38. Failed synthesis of biaryl 279 by Snieckus’ one-pot cross-coupling procedure.153 Reagents
and conditions: BBr3, CH2Cl2, 2 h 0 °C to RT, then concentrated and treated with PhI, Pd(PPh3)4, DME,
2.0 M aq. Na2CO3, 5 h, reflux.
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Lactam Ring-Opening
One of the aims of this project was to cleave the lactam of a cyclotrimerization product,
in order to demonstrate that an amide can be used as a temporary tether to access a
monocyclic benzene derivative (Section 2.1.6.). Initially the hydrolytic cleavage of
isoindolinone 247a was investigated under different reaction conditions (Scheme 39).
Stirring isoindolinone 247a in 1.0 M aq. NaOH and either THF, 2-MeTHF or CPME at
RT resulted in no reaction. Heating isoindolinone 247a in 1:1 1.0 M aq. NaOH:CPME at
reflux over 3 days similarly resulted in no reaction. Heating isoindolinone 247a in 10:1
1.0 M aq. NaOH:MeOH at reflux for 3 days was just as ineffective. Heating isoindolinone
247a at reflux in either 6 M HCl or 1:1 4.5 M H2SO4:dioxane failed to give the hydrolyzed
product in both cases. Finally, treating the isoindolinone 247a with H2O2/LiOH at RT
also failed to hydrolyze the lactam.
Scheme 39. Failed attempts at the hydrolysis of isoindolinone 247a. Reagents and conditions: (i) 1.0 M
aq. NaOH, THF, 16 h, RT; (ii) 1.0 M aq. NaOH, 2-MeTHF, 16 h, RT; (iii) 1.0 M aq. NaOH, CPME, 16 h,
RT; (iv) 1.0 M aq. NaOH, CPME, reflux, 3 days; (v) 1.0 M aq. NaOH, MeOH, 3 days, reflux; (vi) 6.0 M
aq. HCl, 16 h, reflux; (vii) 1:1 4.5 M aq. H2SO4:dioxane, 8 h, reflux; 35% H2O2 in H2O, LiOH, THF, 16 h,
0°C to RT.
Although there was no literature precedent for lactam-cleavage of an N-Bn isoindolinone,
there is limited precedent for the acid-mediated ring-opening of an N-H isoindolinone.154
Heating N-H isoindolinone 277 at reflux in 6.0 M aq. HCl for 16 h resulted in the
formation of a product consistent with ring-opened salt 281 [crude 1H NMR (400 MHz;
DMSO-d6); 4.28 (2H, q, J = 8.8, CH2N)] (Scheme 40). Given the impracticalities
associated with the purification, characterization and modification of hydrogen chloride
salt 281 it was considered sensible to convert the compound in situ into an electronically
neutral organic molecule. The reaction was repeated using 12 M aq. HCl and heated at
reflux for 3 days. After this the volatile components were removed in vacuo and the crude
product immediately treated with Ac2O and NEt3 in CH2Cl2. However, the major product
of this reaction was N-Ac isoindolinone 282. Evidence of ring-opened compound 283
was observed [crude 1H NMR (400 MHz; DMSO-d6); 8.20 (1H, t, J = 5.8, NHAc), 4.82
(2H, d, J = 5.8, CH2N)] but this compound was not isolated. Starting material 277 was
also present in the crude product. Given the forcing reaction conditions and the challenges
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of functionalizing the ring-opened product, this line of inquiry was not pursued any
further.
Scheme 40. Attempted cleavage of N-H lactam 277. Reagents and conditions: (i) 12 M HCl, reflux,
3 days; (ii) Ac2O, NEt3, CH2Cl2.
There is precedent for the hydrolytic ring-opening of an N-Boc isoindolinone,155 so
N-Boc isoindolinone 286 was prepared as a test substrate. Reduction of phthalimide 284
with metallic tin gave isoindolinone 285,156 which was treated with Boc2O to form N-Boc
isoindolinone 286 in 43% isolated yield over two steps (Scheme 41).157
Scheme 41. Preparation of N-Boc isoindolinone 286. Reagents and conditions: (i) Sn, HCl, reflux, 2 h;
(ii) (Boc)2O, DMAP.
The LiOH-mediated hydrolysis of N-Boc isoindolinone 286 proved to be ineffective, with
no reaction observed (Scheme 42). However, with NaBH4 the N-Boc isoindolinone 286
was reduced to the corresponding alcohol 288 in 65% isolated yield.158 This represented
an effective means of cleaving an isoindolinone lactam bond under practical reaction
conditions to access a ring-opened product.
Scheme 42. Attempts to ring-open N-Boc isoindolinone 286. Reagents and conditions: (i) aq. LiOH,
THF; (ii) NaBH4, H2O, THF.
It was then necessary to apply the reductive cleavage conditions to a compound which
had been prepared via the cyclization methodology (Scheme 43). Protection of N-H
isoindolinone 278 resulted in the formation of the corresponding N-Boc isoindolinone
289 in 91% isolated yield. However, the conditions which were effective for the ring-
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opening of test compound 286 were less effective on N-Boc isoindolinone 289. The major
product of this reaction was hemiaminal 290, which was isolated in 50% yield. Target
compound 291 was observed through analysis of the crude 1H NMR spectrum, in addition
to starting material 278. When the reaction was repeated using LiBH4 and MeOH in Et2O
the reaction reached completion and target alcohol 291 was formed in 53% yield.159 A 1H
NMR spectrum of the unpurified product indicated that hemiaminal 290 was also formed
during this reaction, with 290:291 = 1:2.
Scheme 43. Ring-opening of N-Boc isoindolinone 289. Reagents and conditions: (i) (Boc)2O, DMAP; (ii)
NaBH4, H2O, THF; (iii) LiBH4, MeOH, Et2O.
2.3. Chapter II Summary
In conclusion, an efficient, selective and atom economical route to substituted
isoindolinones via amide-tethered alkyne cyclotrimerizations has been established
(Scheme 44). The key alkyne cyclotrimerization was conducted in CPME at RT with a
commercial catalyst, so the reaction is readily transferable to a medicinal chemistry
laboratory. Critically the solvent used for this reaction has a good environmental profile,23
which is highly unusual for an alkyne cyclotrimerization.105
Scheme 44. Alkyne cyclotrimerization summary.
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This approach has been used access a wide selection of isoindolinone products from
readily accessible alkyne starting materials. The alkyne cyclotrimerization was effective
with a selection of monoynes, including those with aliphatic and aromatic substituents.
The reaction was also effective with a selection of different diynes, with various
substituents at R1 and R2 (Scheme 44). Crucially, where R2 = H, the reaction gave
isoindolinone 240 as a single regioisomer.
It was also demonstrated that some of the cyclized products could be used as
intermediates for the preparation of other synthetically interesting compounds (Scheme
45). It was shown that an aryl silane product could be converted to the corresponding aryl
halide through ipso-substitution and that N-tBu isoindolinones could be converted in high
yield to N-H isoindolinones through an acid-mediated deprotection. Finally it was
demonstrated that this cyclization strategy could be used to access monocyclic benzene
derivative 291 through reductive cleavage of the lactam.
Scheme 45. Functional group manipulation of cyclization producted 267a.
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Chapter III. Irreversible endo-Selective Diels–Alder Reactions
of Substituted Alkoxyfurans
3.1. Introduction
3.1.1. The Application of Cantharimides and Related Heterocycles in
Medicinal Chemistry
Cantharidin
Cantharidin 301 (Figure 8) is a blister agent secreted as a defence by many species of
blister beetle, including the Spanish fly (Lytta vesicatoria).160 The natural product has
reportedly been exploited in Chinese medicine under the name of Mylabris for the
treatment of boils and piles since before the Common Era. Physicians in ancient Greece
prescribed cantharidin as an aphrodisiac and it was used in that capacity by both Louis
XV of France and Ferdinand II of Aragon.161 Currently the only clinical application of
the compound is as a 1% solution applied topically for the treatment of benign epithelial
growths,161 but where this compound has generated most interest is in the development
of anticancer agents.162 Cantharidin 301 has exhibited low µM activity against a selection
of tumor cell lines, including cervical, colon, leukaemia, neuroblastoma and bone,
although the cause of this cytotoxicity is not understood.163 Cantharidin 301 is also highly
toxic to humans, with the fatal dose believed to be less than 60 mg.161
Figure 8. Cantharidin 301, norcantharidin 302 and cantharimide 303.
The high toxicity of cantharidin 301 has prevented any clinical exploitation as an
antitumor agent, but it has inspired a new generation of structural analogues. Removing
the two methyl groups gives norcantharidin 302, which retains much of the antitumor
activity with reduced renal and gastrointestinal toxicity (Figure 8).164 Replacing the
anhydride in norcantharidin with an imide led to the cantharimide skeleton 303, which
has been the focus of much interest within the medicinal chemistry community.
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Cantharimides
Following on from the interest in cantharidin as an antitumor agent, substituted
cantharimides have been investigated as potential cancer therapies (Figure 9).165 For
example, cantharimide 303a was reported by Chan et al. and was shown to inhibit the
growth of hepatoma cell line SK-Hep-1.166 Cantharimide 303b was developed as an
inhibitor of androgen receptor signalling for the treatment of prostate cancer,167 although
it was abandoned following Phase I clinical trials. In addition, McCluskey et al. recently
reported cantharimide 303c with a GI50 value of 14–28 µM against eight different human
cancer cell lines.168 Substituted cantharimides have found applications outside of
oncology,169 in the development of positive allosteric modulators of the metabotropic
glutamate receptor 4 (mGlu4),170 as dynamin GTPase inhibitors171 and as nematicides.172
Figure 9. Cantharimides developed as an antitumor agents.
Oxabicyclo[2.2.1]heptane derivatives
The cantharimide is based upon the oxabicyclo[2.2.1]heptane scaffold, and this scaffold
has been used more widely within medicinal chemistry (Figure 10).162, 163, 173 For
example, oxabicyclo[2.2.1]heptane 304a (a ring-opened derivative of a cantharimide) is
an antiplasmodial agent that inhibits D6 and W2 Plasmodium falciparum malarial strains
with low µM activity.169b Compound 304b was developed as an inhibitor of protein
phosphatase 1 (IC50 = 48 ± 9 µM) that is modestly selective over protein phosphatase 2a
(IC50 = 85 ± 3 µM).174 Sulfonate 304c was developed as a ligand for the estrogen receptor,
which functioned as an antagonist for subtypes ERα and ERβ with good affinity.175
Dhanapal et al.176 have reported ketone 304d as a novel antibiotic. It has a MIC (minimum
inhibitory concentration) of 0.004 mg mL–1 against Klebsiella pneumonia (compared to
MIC = 0.007 mg mL–1 for ciprofloxacin) but it lacked good activity against a broad
spectrum of bacteria. In addition, 7-oxabicyclo[2.2.1]heptane derivatives are valuable
intermediates for synthetic chemistry177 and the scaffold can be found in a number of
natural products beyond cantharidin.178
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Figure 10. Examples of biologically active oxabicyclo[2.2.1]heptane derivatives.
3.1.2. [4+2]-Cycloaddition Reactions of Furans and Dienophiles
The most exploited route to oxabicyclo[2.2.1]heptane derivatives is via the [4+2]-
cycloaddition of furans and dienophiles. Following the pioneering work of Diels and
Alder,179 the most widely studied example of a furan [4+2]-cycloaddition is the reaction
of furan with maleic anhydride.180 This reaction is known to be thermodynamically
controlled, ultimately giving exo-307 as a single diastereoisomer. (Scheme 46).181
Scheme 46. [4+2]-Cycloaddition of furan 305 and maleic anhydride 306.181
Svatoš et al. explored the reaction of furan 305 with maleic anhydride 306
computationally using MP2/6-31+G(d) equilibrium geometries.182 They calculated a
small difference in activation energy for endo- and exo-cycloadditions but a significantly
lower ΔG for the formation of exo-307 (Scheme 47). This, along with the small barrier
to the retro-cycloaddition reaction, explains why any endo-307 formed under the reaction
conditions readily isomerizes to give exclusively exo-307.
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Scheme 47. Free energy diagram for the reaction of furan and maleic anhydride.182 Data calculated
for reactions in MeCN at 25 °C using the MP2/6-31+G(d) level of theory. All values in kJ mol–1.
The reaction of furan 305 with maleimide 308 was also explored experimentally and
computationally by Svatoš et al. As part of their study, a purified sample of endo-309 was
dissolved in MeCN-d3 and it was observed to undergo a rapid decomposition at 65 °C to
give furan 305, maleimide 308 and exo-309. This experiment suggested that the
cycloaddition of furan 305 and maleimide 308 was reversible, with exo-309 the
thermodynamic product. This hypothesis was supported by computational calculations,
with the data illustrated in Scheme 48.
Scheme 48. Free energy diagram for the reaction of furan and maleimide.182 Data calculated for
reactions in MeCN at 25 °C using the MP2/6-31+G(d) level of theory. All values in kJ mol–1.
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The reversibility of furan-Diels–Alder reactions is in contrast with the corresponding
reactions of cyclopentadiene, which undergoes a rapid and irreversible reaction with both
maleic anhydride and maleimide. A reasonable justification for this is the loss of
aromaticity that occurs when furan undergoes a cycloaddition reaction, which is not
observed where cyclopentadiene is the dienophile. Svatoš explored this with use of two
thermodynamic cycles detailed in Scheme 49.182 The total reaction free energy ΔE for
the partial hydrogenation of furan 305 to give 2,5-dihydrofuran 310 was 72 kJ mol–1
greater than the corresponding reaction of cyclopentadiene 305’. In contrast, the
difference in ΔE for the second step of the two thermodynamic cycles was only 7.5 kJ
mol–1. This supported the theory that it is the dearomatization of furan 305 that reduces
the thermodynamic driving force for the [4+2]-cycloaddition reaction with maleic
anhydride 306, which contributes to the reversible nature of the reaction.
Scheme 49. Thermodynamic cycle involving the hydrogenation of furan and cyclopentadiene.182 Data
calculated using DFT(B3LYP)/6-311++G(2d,p) level of theory.
In 2011 Boutelle and Northrop published computational and experimental work on the
reaction between substituted furans and maleimide.183 They demonstrated that different
substituents at the 2- and 3-position had a dramatic impact on equilibrium position for the
cycloaddition reaction (Scheme 50). The reaction of maleimide 308 and furan 305 was
calculated to have a low thermodynamic driving force for both exo- and endo-
diastereoisomers and it was shown experimentally that the reaction was reversible at
25 °C in MeCN. The reaction of furfural 311a with maleimide 308 was less favorable,
with the equilibrium favoring the free furan. However, the reaction of 3-methoxyfuran
311b and maleimide 308 was calculated to have a significant thermodynamic driving
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force and the authors suggested that this would be an irreversible cycloaddition reaction.
This reaction was not attempted experimentally.
Scheme 50. The calculated effect of furan substituents on a furan Diels–Alder reaction. All values
calculated for reactions in MeCN at 25 °C using the MP2/6-311+G(d,p) level of theory for single-point
electronic energies and the the CBS-QB3 level of theory for vibrational frequency analysis.
3.1.3. The Synthesis of Cantharimides and Other Oxabicyclo [2.2.1] heptane
Derivatives
The majority of cantharimides that have been prepared in medicinal chemistry programs
have been accessed via the [4+2]-cycloaddition of furans and maleic anhydride.184
Reduction of the alkene unit followed by condensation with a primary amine gives the
corresponding exo-cantharimide as a single diastereoisomer (Scheme 51).
Scheme 51. Synthesis of cantharimide exo-313 from anhydride exo-307.
This approach has been applied to prepare large numbers of N-substituted cantharimides,
however the approach is not well suited to varying substitution about the carbon
framework. There are relatively few examples of exo-cantharimides being prepared from
furans bearing substituents other than alkyl groups. A notable limitation is that there are
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no reported examples of 2-aryl or 2-heteroarylfurans undergoing furan-Diels–Alder
reactions with dienophiles of any type.
A less popular and more challenging route to cantharimides is via the [4+2]-cycloaddition
of furans and maleimides (Scheme 52).182 As described in the previous section, this
reaction is under thermodynamic control at RT, but equilibration is relatively slow and it
is possible to isolate both endo-and exo-cantharimide 309 from a reaction mixture.
However, cantharimide endo-309 was reported by Kwart and Burchuk to rapidly
isomerize in either hot solvent or under visible light irradiation.185 As such there is no
practical route to access endo-cantharimides through [4+2]-cycloaddition reactions and
the scaffold has not been widely reported.186
Scheme 52. [4+2]-cycloaddition of furan 305 and maleimide 308.
The [4+2]-cycloaddition of furan with dienophiles other than maleic anhydride and
maleimides are known, although these reactions typically require either elevated
pressures187 or Lewis acid catalysts.188 The most general set of conditions for the [4+2]-
cycloaddition of furans with various dienophiles were developed by Hayashi et al. and
relied upon HfCl4 as a Lewis acid catalyst (Scheme 53).189 Under these conditions diethyl
fumarate 314a and dimethyl maleate 314b could be converted into the corresponding
furan adducts and in the latter case with excellent endo-selectivity. Furan 305 also
underwent a [4+2]-cycloaddition with benzyl acrylate 314c to give
oxabicyclo[2.2.1]heptene 315c in excellent yield. However, in order to achieve this
110 mol% HfCl4 was required and furan 305 was used in twenty-fold excess. In some
cases reactions were also conducted using only 20 mol% HfCl4 but this resulted in
reduced diastereoselectivity and/or reduced isolated yield. There was also a limited scope
of furans used in this study, with only furan, 2-methylfuran and 2,5-dimethylfuran
considered.
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Scheme 53. HfCl4-caltalyzed [4+2]-cycloaddition of furan and various dienophiles.189
3.1.4. The Synthesis and Application of 3-Alkoxyfurans
Recent work within the Sheppard laboratory on the gold-catalyzed transformation of
propargylic alcohols has led to an efficient synthesis of 3-alkoxyfurans, as summarized
in Scheme 54.190 Treatment of propargylic alcohol 316 with 2.0 mol% PPh3AuNTf2 in an
alcohol solvent gave 3-alkoxyfuran 317 in 58–98% yield. The reaction had a broad
substrate scope both with regard to substituent R1 and the alcohol solvent.
Scheme 54. Summary of a 3-alkoxyfuran synthesis as developed by Sheppard et al.190
Prior to the above work there was no efficient route into 3-alkoxyfurans and so there is
little reported precedent for these compounds being used as dienes in a cycloaddition
reaction.191 It was shown that furan 318 underwent a [4+2]-cycloaddition reaction with
N-methylmaleimide 319 at RT to give the corresponding adduct 320 as a mixture of
diastereoisomers in 93% combined isolated yield (Scheme 55).
Scheme 55. [4+2]-Cycloaddition of furan 318 and N-methylmaleimide 319.190
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3.1.5. Chapter III Project Outline
The cantharimide is a valuable scaffold for drug development but the preparation of
highly substituted cantharimides presents a major synthetic challenge. The aim of this
part of the PhD was to explore the reaction of 2-substitued 3-alkoxyfurans 317 and
maleimides 321 as a novel route to substituted cantharimides (Scheme 56). The synthesis
of endo-cantharimides was of particular interest given that this scaffold was broadly
unexplored within medicinal chemistry. It was important that the conditions developed
for the [4+2]-cycloaddition used sustainable solvents, in order to minimize the waste
generated by the synthetic route.
Scheme 56. Proposed synthetic route to highly-substituted endo-cantharimides.
Another goal for this chapter was to prepare a more diverse range of heterocycles by using
dienophiles other than maleimides, such as maleates, enones and acrylates (Figure 11).
This would allow access to new classes of 7-oxabicyclo[2.2.1]heptane derivatives. It was
also identified that aromatization of the furan-Diels–Alder products would generate
highly substituted benzene-derivatives, such as phthalimides 323c.
Figure 11.Other heterocycles of interest.
3.2. Results and Discussion
3.2.1. Starting Material Synthesis
Preparation of Propargylic Alcohols
A number of propargylic alcohols 316 were prepared by a general procedure from
commercial alkyne 324, as precursors to 3-alkoxyfurans.190 The general procedure is
summarized in Scheme 57.
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Scheme 57. General procedure for the preparation of propargylic alcohols 316. Reagents and
conditions: (i) nBuLi, THF, 1 h, –78 °C; (ii) RCOH, 16 h, –78 °C to RT
Initially four propargylic alcohols were prepared from aldehydes with adjacent sp3-
centres in 71–86% yield (Figure 12). The reaction procedure was effective for preparing
multi-gram quantities of product, with alcohol 316a synthesized from
hydrocinnamaldehyde on a 60.0 mmol scale to give 12.8 g of product. The reaction
tolerated both a cyclopropyl substituent and an N-Boc piperidine to give alcohols 316c
and 316d respectively.
Figure 12. Propargylic alcohols prepared from aliphatic aldehydes.
The general procedure was effective with a range of benzaldehyde derivatives to give
propargylic alcohols bearing aromatic substituents in 78–96% yield (Figure 13). The
reaction was again effective on a multi-gram scale; 10.5 g of alcohol 316e was prepared
from benzaldehyde in 95% yield. The reaction tolerated electron-deficient (317f and
317j) and electron-rich arenes (316g) as well as an aryl bromide (316h) and a sterically
encumbered arene (316i).
Figure 13. Propargylic alcohols prepared from aromatic aldehydes.
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Furthermore, it was possible to prepare propargylic alcohols bearing furan and thiophene
substituents using the general procedure, as shown in Figure 14. While 3-pyridyl alcohol
316m was isolated in 70% yield by this approach, two separate attempts to access
2-pyridyl alcohol 316n gave only a complex mixture of unidentified products.
Figure 14. Propargylic alcohols bearing heteroaromatic substituents prepared by the general
procedure.
Preparation of 3-Alkoxyfurans
According to the method previously developed within the Sheppard Laboratory,
3-alkoxyfurans 317 were prepared from the corresponding propargylic alcohol 316 by a
gold(I)-catalyzed cyclization (Scheme 58).190 The choice of alcohol solvent determined
the alkoxy-substitution in the product.
Scheme 58. General synthesis of 3-alkoxyfurans.190
In general, the 3-alkoxyfurans were found to be relatively volatile and this made isolating
these compound in good yield challenging. For this reason it was found generally best to
avoid a work up and simply purify the reaction mixture (with solvent) directly by flash
column chromatography. In order to avoid significant loss of product upon concentration
the furans were purified using petroleum ether with a boiling point in the range 30–40 °C,
along with TBME. The solvent was then removed using a rotary evaporator water bath at
0 °C at >100 mbar pressure.
Another challenge when isolating 3-alkoxyfurans was that they were liable to oxidize in
the presence of atmospheric oxygen. This was a second reason for cooling the rotary
evaporator water bath to 0 °C; furans were observed to oxidize on the rotary evaporator
even at RT. It was generally necessary to use the furans as soon as they were prepared. In
order to characterize the oxidation, furan 325e was heated in PhMe under an atmosphere
of air and aldehyde 326 was isolated in 55% yield following purification (Scheme 59).
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Scheme 59. Aerobic oxidation of furan 325e.
With the precautions described above, a selection of 3-ethoxyfurans 325 were isolated in
26–84% yield (Scheme 60). Both furans 325a and 325e were prepared using 2.00 g of
the corresponding alcohol. The reaction was tolerant of a number of aliphatic substituents,
most notably an N-Boc piperidine to give furan 325d in 77% yield. The reaction was also
tolerant of a range of electron-rich, electron-poor and sterically encumbered aromatic
substituents. Heteroaromatic substituents could also be accommodated, with bisfuran
325k and thiophene 325l prepared. The yields for bisfuran 325k and 2-cyclopropyl furan
325c were poor (26% and 29% respectively), which is likely due to their exceptionally
high volatility.
Scheme 60. General synthesis of 3-ethoxyfurans 325.
In contrast to the above reactions, pyridine 316m underwent no reaction when it was
treated with EtOH and 2.0 mol% PPh3Au(I)NTf2 (Scheme 61). However, when 5.0 eq. of
MsOH was added to the reaction mixture before the gold catalyst a reaction was observed,
with furan 325m isolated in 73% yield.
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Scheme 61. Synthesis of 2-pyridyl furan 325m.
The reaction was also conducted in other solvents to access furans with different alkoxy
groups. Conducting the reaction at 0.50 M concentration in MeOH resulted in the
formation of the desired 3-methoxyfuran 318 but with a small 3-ethoxyfuran impurity.
However, this side product was avoided by diluting the reaction to 0.20 M (Scheme 62).
These conditions could not be applied to the efficient synthesis of the analogous tert-butyl
alkoxyfuran 327. Conducting the reaction in tBuOH gave the desired furan but in very
low yield and with a 3-ethoxyfuran impurity.190
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Scheme 62. Synthesis of 3-alkoxyfurans from different alcohols.
Synthesis of Dienophiles
The majority of dienophiles used in this work were purchased from commercial sources,
but three compounds were prepared using literature procedures (Scheme 63). Imine 328
was prepared in 64% isolated yield by the condensation of ethyl 2-oxoacetate and
(±)-tert-butyl sulfinamide.192 Maleimides 329a and 329b were made from maleic
anhydride in poor yield (30% and 47% respectively) but on a gram scale.193
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Scheme 63. Synthesis of dienophiles.
3.2.2. Synthesis of Cantharimides via the [4+2]-Cycloadditions of 3-
Alkoxyfurans
The [4+2]-cycloaddition reaction of furan 325a and N-methylmaleimide 319 was found
to proceed efficiently at RT in Et2O, PhMe, EtOH and dimethyl carbonate (DMC) (Table
13, Entries 1–4). The endo- and exo-diastereoisomers of cantharimide 330a were
identified by coupling constant analysis of the 1H NMR spectra, as discussed in the
following paragraph. DMC was selected as a solvent for further work as it resulted in the
highest endo-selectivity (Entry 4) and because of its excellent environmental profile.23 It
was possible to remove the small excess of N-methylmaleimide 319 by flushing the
reaction mixture through an aminopropyl cartridge, giving cantharimide 330a in 93%
yield as a 70:30 mixture of endo- and exo-diastereoisomers (Entry 4). This reaction was
scaled up to use 1.00 g of furan 325a with no significant impact on yield or selectivity
(Entry 5). Cooling the reaction down to 0 °C had little effect on diastereoselectivity, with
cantharimide 330a isolated as a 75:25 mixture of endo- and exo-diastereoisomers (Entry
6). Heating the reaction at 80 °C for 16 h reduced the diastereoselectivity, with
cantharimide 330a isolated with an endo:exo ratio of 45:55 (Entry 7). Heating at the same
temperature over 3 days gave cantharimide 330a with a small selectivity for exo-330a but
in only 40% isolated yield (Entry 8). The conditions in Entry 4 were selected as the
optimized reaction conditions for further studies into furan-Diels–Alder reactions.
Chapter III 83
Table 13. [4+2]-Cycloaddition of furan 325a and N-methylmaleimide 319.
Entry Solvent Temperature/°C Time/h Yield
330a/%
endo:exoa
1 Et2O 25 4 98b 65:35
2 PhMe 25 4 100b 65:35
3 EtOH 25 4 100b 70:30
4d DMC 25 4 93c 70:30
5e DMC 25 4 95c 75:25
6 DMC 0 6 93c 75:25
7 DMC 80 16 93 c 55:45
8 DMC 80 72 40c 45:55
a Determined by analysis of the crude 1H NMR spectrum. b Yield determined by 1H NMR spectroscopy
using pentachlorobenzene as an internal standard. c Isolated yield. d Reaction conducted with 108 mg of
furan 325a. e Reaction conducted with 1.00 g of furan 325a.
For the reactions in Table 13 the diastereoselectivity of the formation of cantharimide
330a was determined by analysis of the 1H NMR spectra. It was observed that the
coupling constant between the bridgehead proton Ha and the adjacent proton Hb, J(Ha-Hb) =
5.3 Hz (Figure 15). This was consistent with the endo-diastereomer, where the dihedral
angle between Ha and Hb was calculated at 36.6 °.194 In contrast, there was no measurable
coupling measured between the corresponding protons for the minor diastereomer. This
is consistent with exo-330a, where the dihedral angle between Ha and Hb was calculated
as 80.6 °. This coupling constant analysis was used to assign the diastereoselectivity of
furan-Diels–Alder reactions throughout this study.
Figure 15. Determining diastereoselectivity by coupling constant analysis.
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An important question regarding the [4+2]-cycloaddition of 3-alkoxyfuran 325a and
N-methylmaleimide 319 at RT was whether the reaction was under kinetic control. The
endo- and exo-diastereoisomers of cantharimide 330a were separated by flash column
chromatography and treating endo-330a under the replicated reaction conditions resulted
in no isomerization (Scheme 64). This observation is consistent with a kinetically
controlled Diels–Alder reaction.
Scheme 64. Furan-Diels–Alder reversibility study.
The optimized furan-Diels–Alder reaction conditions (Table 13, Entry 4) were applied to
the reaction of 3-methoxyfuran 318 and N-methylmaleimide 319 (Scheme 65). Coupling
constant analysis of the crude 1H NMR spectrum confirmed that the reaction was endo-
selective (endo:exo = 80:20). Following flash column chromatography the two
diastereoisomers of cantharimide 320 were isolated separately in 89% combined yield.
Scheme 65. [4+2]-Cycloaddition of furan 318 and N-methylmaleimide 319.
The optimized furan-Diels–Alder reaction conditions were applied to the reaction of
N-methylmaleimide 319 and different 3-ethoxyfurans 325 (Table 14). The [4+2]-
cycloaddition reaction was found to be effective with a range 3-ethoxyfurans with
aliphatic substituents (Entries 2–4). Cantharimides were isolated in 85–95% yield with
reasonable endo-selectivity.
Chapter III 85
Table 14. [4+2]-Cycloadditions of different 3-ethoxyfurans 325 with N-methylmaleimide 319.
Entry R Product Time/h Isolated yield330/% endo:exo
a
1 330a 4 93 70:30
2 330b 4 95 85:15
3 330c 4 90 80:20
4 330d 4 85 75:25
5 330e 6 86 (86)b 80:20
6 330f 24 75 80:20
7 330h 4 90 80:20
8 330g 24 78 80:20
9 330i 24 86 75:25
10 330j 24 83 80:20
11 330k 24 85 90:10
12 330l 24 96 70:30
13 330m 24 92 70:30
a As determined from a 1H NMR spectrum of the crude product. b Conducted using 1.00 g of furan 325e.
The reaction was also conducted with a range of aromatic substituents, giving the
cantharimide product 330 in 75–90% isolated yield and with a consistent endo-
diastereoselectivity (Table 14, Entries 5–10). As such these represent the first reported
examples of furan-Diels–Alder reactions using 2-arylfurans. The reaction tolerated an
electron rich aromatic substituent (Entry 7), an aryl bromide substituent (Entry 8),
electron poor aromatic substituents (Entries 6 and 10) and a sterically hindered substituent
(Entry 9). Isomerically pure samples of endo-330e and exo-330e were recrystallized from
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CH2Cl2/hexane and the relative stereochemistry of both diastereoisomers were confirmed
by single crystal X-ray diffraction (Figure 16).i
Figure 16. Crystal structures of cantharimides endo-330e (left) and exo-330e (right). Ellipsoids are
shown at 50% probability level. Only hydrogen atoms belonging to the cyclic core are shown for clarity.
The furan-Diels–Alder reaction was also successful for furans with heteroaromatic
substituents, as seen in Entries 11 to 13 of Table 14. The 2-furyl example shown in Entry
11 is an excellent demonstration of the strength of this strategy for accessing
cantharimides, as the cycloaddition reaction occurred with high chemoselectivity for the
3-alkoxyfuran over the 3-H furan substituent.
Another substituent was incorporated into the cantharimide skeleton via substituent at the
5-position of the 3-alkoxyfuran (Scheme 66). Treating 3-alkoxyfuran 325a with
Eschenmoser’s salt 331 in MeCN resulted in the formation of furan 332 in 78% yield.
Under the standard cyclization conditions cantharimide 333 was formed in 94% yield
after 24 h as an 80:20 mixture of endo- and exo-diastereoisomers.
Scheme 66. Preparation of a 5-substituted 3-alkoxyfuran and subsequent [4+2]-cycloaddition.
The furan-Diels–Alder conditions could also be applied to reactions using other
N-substituted maleimides, as shown in Table 15. The reaction was effective when the
maleimide possessed a phenyl, benzylic or cyclopropyl substituent, with the
i Dr Dejan-Krešimir Bučar and Dr Laure Benhamou are gratefully acknowledged for conducting and 
analyzing the single crystal X-ray diffraction experiment. Recrystallization was performed by the author.
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cantharimides 334 isolated in 83–94% yield. Interestingly, while N-substitution had no
notable effect on reaction time, substitution had a clear effect on diastereoselectivity. In
particular, the reaction to form cantharimides 334b (Entry 2) lacks the clear endo-
selectivity previously seen for the reaction of 3-alkoxyfurans 325 with
N-methylmaleimide 319 (Table 14). This may be explained by the additional steric bulk
at the N-terminus, which would increase unfavorable steric interactions in the endo-
transition state.
Table 15. [4+2]-Cycloaddition of furan 325a with N-substituted maleimides.
Entry R Product Isolated yield/% endo:exoa
1 Ph 334a 94 65:35
2 4-MeC6H4 334b 83 55:45
3 cPr 334c 87 60:40
a As determined from a 1H NMR spectrum of the crude product.
The cycloaddition reaction and the furan synthesis were combined into in a single step to
generate a cantharimide directly from propargylic alcohol 316a (Scheme 67). However,
rather than forming enol ether 330a as has been observed previously, the isolated product
was diethyl acetal 335. This implied that the direct furan-Diels–Alder product 330a
underwent a solvolysis reaction under the reaction conditions. However, enol ether 330a
was formed in a one-pot procedure from propargylic alcohol 316a by: a) treating alcohol
316a with 2.0 mol% PPh3AuNTf2 in EtOH; b) addition of 2.5 mol% PPh3 upon 100%
conversion of alcohol 316a and; c) addition of N-methylmaleimide 319 after a further
1 h. By following this procedure acetal formation was avoided and enol ether was 330a
isolated in 66% yield. This result suggested that the gold catalyst was responsible for the
acetal formation and that the catalyst was deactivated using PPh3. This rationale was
tested by treating enol ether 330a with 2.0 mol% PPh3AuNTf2 in EtOH, which resulted
in the efficient formation of diethyl acetal 335.
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Scheme 67. One-pot cantharimide synthesis from propargylic alcohol 316a.Reagents and conditions:
(i) N-methylmaleimide 319, 2.0 mol% PPh3AuNTf2, EtOH, 16 h, RT; (ii) 2.0 mol% PPh3AuNTf2, EtOH,
3 h, RT then 2.5 mol% PPh3, 1 h, RT then N-methylmaleimide 319, 16 h, RT; (iii) 2.0 mol% PPh3AuNTf2,
EtOH, 16 h, RT.
3.2.3. Functional Group Manipulation of Cantharimide Products
Enol ether endo-330e was readily hydrolyzed by loading the compound onto a Strong
Cation eXchange cartridge (SCX-2); a silica column with a bound sulfonic acid residue
(Scheme 68). Washing the column after 10 minutes with EtOAc gave the corresponding
ketone 336 in 80% yield. Ketone 336 was then reduced to the corresponding secondary
alcohol 337 using NaBH4 in MeOH, with a 70% isolated yield and complete
stereocontrol. Enol ether endo-330e was also reduced in a diastereoselective manner to
give ethyl ether 338 in 76% isolated yield. Treatment of enol ether endo-330e with
9-borabicyclo[3.3.1]nonane (9-BBN) followed by an oxidative work up gave alcohol 339
in 52% isolated yield with excellent regio- and stereocontrol.
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Scheme 68. Transformations of enol ether endo-330e. Reagents and conditions: (i) SCX-2; (ii) NaBH4;
(iii) H2, 10% Pd/C; (iv) 9-BBN, then H2O2/NaOH.
The transformation of enol ether endo-330e into cantharimide 340 via a Heck arylation
was investigated (Scheme 69).195 Treating endo-330e with 4-bromotoluene in the
presence of N,N-diisopropylethylamine (DIPEA), PPh3 and Pd(OAc)2 in 85:15
DMF:water and heating the reaction to 110 °C resulted in the formation of furan 325e
rather than cantharimide 340. This implied that enol ether endo-330e underwent a retro-
cycloaddition reaction at elevated temperatures and that N-methylmaleimide 319 was
unstable under the reaction conditions. The bromination of enol ether endo-330e was also
explored.196 However treatment of enol ether endo-330e with N-bromosuccinimide
(NBS) in 2-MeTHF resulted in the formation of a complex mixture of products.
Scheme 69. Failed transformations of enol ether endo-330e.
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3.2.4. Physicochemical Properties
In order for a compound to succeed as a drug it must not only have a high and selective
affinity for a target receptor but it must also have appropriate physicochemical properties
to ensure favorable absorption and distribution, while minimizing undesired metabolism,
elimination and toxicity.197 Various physicochemical properties are believed to be
significant, including lipophilicity,198 molecular weight (mw)199 and polar surface area
(PSA).200 It has also been noted that in optimizing the structure of a lead compound into
a potential drug candidate that compounds typically become more lipophilic and increase
in mw.201 As such, the physicochemical properties of a lead can have a direct impact on
the physicochemical properties of a candidate, and its potential success as a drug.
Churcher et al. proposed criteria for “Lead-like space”, where compounds are typically
smaller and more lipophilic than would be typical for a successful drug (Table 16).202
They also emphasized the value of a highly three-dimensional structure, as this is
associated with improved solubility, improved receptor affinity and reduced off-target
effects.203
Table 16. Lead-like properties.202
Lead-likeness guide Preferred values
Lipophilicity guide  –1 ≤ clogP ≤ 3
Molecular size guide 14 ≤ heavy atoms ≤ 26 
(mw = 200–350 Da)
Undesired sub-structure filter • Remove molecules containing chemically reactive,
electrophilic or redox active groups.
•Favor molecules with lower degrees of aromatic
character and/or more 3D shape.
Reproduced from Ref. 202 with permission from John Wiley and Sons.
In order to assess the value of the endo-cantharimide products that can be prepared using
this methodology to medicinal chemistry, some physicochemical properties of three
cantharimides were calculated (Figure 17). According to the criteria set down by
Churcher et al., the values for clogP, mw and polar surface area (PSA) of cantharimides
337, 338 and 339 fall within the acceptable range of values for “lead-like” compounds.
In addition, the structures only contain one aromatic ring and possess a high degree of 3D
character. As such, molecules like these could be valuable additions to compound
libraries for high throughput screening against biological targets.
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Figure 17. Physicochemical properties of endo–cantharimides. Data calculated using ChemDraw 12.
Preliminary biological activity of alcohol 337 and ether 338 was explored using a screen
of 40 medicinally important receptors. Unfortunately, this screen did not reveal any
significant activity that could be a valuable starting point for further investigations.
However, the screen did include the hERG receptor (which is responsible for common
toxicity)204 and no measurable affinity was observed. Finally, the in vitro clearance of
alcohol 337 in the presence of human microsomes was investigated.ii Pleasingly, no
turnover was observed below the detectable limit of 0.53 mL min–1 g–1.
3.2.5. [4+2]-Cycloadditions with other Dienophiles
[4+2]-Cycloadditions without Lewis Acid Catalysis
Furan 325a underwent a reaction with 1.2 eq. of maleic anhydride 306 at RT, with 100%
conversion of furan 325a within 1 h (Scheme 70). Although analysis of the crude 1H
NMR spectrum indicated a product consistent with adduct 342 (endo:exo = 50:50),
attempts to isolate the product by chromatography on silica, using an aminopropyl
cartridge or using MgSiO3 failed to give the target compound. It is known that adducts
formed from furans and maleic anhydride are more liable to undergo a retro-cycloaddition
reaction than the corresponding N-methylmaleimide adducts, which may explain the poor
stability of adduct 342.205
Scheme 70. Reaction of furan 325a with maleic anhydride.
ii IVC testing performed by Cyprotex®, 15 Beech Lane, Macclesfield, Cheshire, SK10 2DR, UK.
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Treating furan 325a with 1.2 eq. of dimethyl maleate in DMC resulted in 100%
conversion of furan 325a after 3 days at RT (Scheme 71). Enol ether 343 was formed
with high endo-selectivity (endo:exo = 12:1), as determined by coupling constant analysis
of the crude 1H NMR spectrum. Enol ether 343 was isolated in 69% yield following
purification by flash column chromatography.
Scheme 71. The reaction of furan 325a with dimethyl maleate.
Both dimethyl and diethyl fumarate reacted readily with furan 325a at RT to give the
corresponding addition products 344, which were purified by flash column
chromatography to give 77% and 89% isolated yields respectively (Scheme 72). The
diastereoselectivity of the reactions were again determined by coupling constant analysis
of 1H NMR spectra and in both cases there was a clear selectivity for the diastereoisomer
that is exo with respect to the 3-position (3-exo-344). The reaction of a fumarate with a
substituted furan was without literature precedent.
Scheme 72. Reaction of furan 325a with dimethyl and diethyl fumarates.
Furan 325a underwent a slow reaction with ethyl vinyl ketone at RT, but at 80 °C the
reaction reached completion within 16 h (Scheme 73). The direct cycloaddition product
proved to be relatively unstable, but hydrolysis of the enol ether gave the corresponding
ketone that was readily purified. Analysis of the crude 1H NMR spectrum indicated the
presence of two regioisomers 345 and 345’ in the ratio 95:5. The major regioisomers 345
was formed as 60:40 mixture of endo- and exo-diastereoisomers. Following column
chromatography ketones 345 and 345’ were isolated in a combined yield of 60%.
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Scheme 73. [4+2]-Cycloaddition of furan 325a with ethyl vinyl ketone.
Furan 325a also reacted with dimethyl acetylenedicarboxylate 346, with 100%
conversion of the furan observed after 5 h at RT (Scheme 74). However, analysis of the
crude 1H NMR spectrum showed that the product was a complex mixture of products
with no clear evidence for the expected adduct 347. A possible explanation was that the
cycloaddition reaction occurred but that the immediate product was unstable and
decomposed under the reaction conditions. The reaction of furan 325a with imide 328
proceeded in a similar manner; again the furan was consumed but only a complex mixture
of unidentified products was isolated from the reaction.
Scheme 74. Failed cycloaddition reactions with furan 325a.
Lewis-Acid Catalyzed [4+2]-Cycloadditions
The reaction of furan 325a and ethyl acrylate was investigated under the standard reaction
conditions but was found to proceed slowly at RT, with ca. 70% conversion of furan 325a
observed after 24 h (Scheme 75). In light of this, the possibility of accelerating the
reaction through use of a Lewis acid catalyst was investigated. It was found that enol ether
349 was unstable to purification by flash silica gel chromatography so it was not possible
to isolate this compound.
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Scheme 75. [4+2]-Cycloaddition of furan 325a and ethyl acrylate.
The reaction of furan 325a and 1.5 eq. of ethyl acrylate was explored at RT with a series
of Lewis acids, with the results given in Table 17. Given the difficulty in isolating enol
ether 349, the crude reaction mixtures were filtered through a SCX-2 plug to hydrolyze
the cycloaddition product and form ketone 350. Both Yb(OTf)3 and HfCl4 were effective
catalysts for the cycloaddition, with 100% conversion of furan 325a observed after 3 h
and 6 h respectively (Entries 1 and 2). In contrast BF3.THF and Cu(OTf)2 were not
effective catalysts for this transformation, with less than 100% conversion observed after
8 h (Entries 3 and 4). While Yb(OTf)3 gave the shortest reaction time, HfCl4 gave the best
yield and, using 2.0 mol% HfCl4 as catalyst, ketone 350 was isolated in 89% yield as a
65:35 mixture of endo- and exo-diastereoisomers (Entry 2).
Table 17. Catalyst screen for that reaction of furan 325a and ethyl acrylate.
Entry Catalyst Time/h Yield 350/%a endo:exoa
1 Yb(OTf)3 3 70 65:35
2 HfCl4 6 90 (89)b 65:35
3 Cu(OTf)2 8c 30 85:15
4 BF3.THF 8c 30 85:15
a As determined from a 1H NMR spectrum of the crude product (using C6HCl5 as an internal standard). b
Isolated yield; c Furan 325e still present.
Unfortunately, the substrate scope with regard to the furan was limited. Treating 2-Ph
furan 325e with ethyl acrylate under the optimized conditions resulted in little conversion
of the furan and no formation of the target product 351 (Scheme 76). A screen of
alternative catalysts in DMC [Hf(OTf)4, Yb(OTf)3, Sc(OTf)3, La(OTf)3] did not yield any
evidence for the formation of a cycloaddition product either. Finally the reaction was
attempted under thermal conditions by heating the furan with 2.0 eq. of ethyl acrylate
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without solvent at 100 °C for 16 h, but no ketone 351 was formed as judged by analysis
of the 1H NMR spectrum.
Scheme 76. Failed reaction of furan 325e and ethyl acrylate.
The dienophile scope was also evaluated. Unfortunately, none of the dienophiles in
Scheme 77 underwent reaction with furan 325a to form a cycloaddition product that could
be isolated. For enones 352a and 352b, 100% conversion of furan 325a was observed
within 16 h but analysis of the crude 1H NMR spectrum revealed a complex mixture of
products. For the case of cyclopentenone 352c, anhydride 352d and acrylamide 352e, no
significant reaction was observed.
Scheme 77. Dienophiles that failed to cyclize with furan 325a.
3.2.6. Effect of a 3-Alkoxygroup on the [4+2]-Cycloaddition of Furans and
N-Methylmaleimide: A Computational Study
The aim of this computational study was to quantify the thermodynamic and kinetic effect
of a 3-alkoxy group on the [4+2]-cycloaddition of 2-substiuted furans with
N-methylmaleimide 319. The reaction of ten furans 353 with N-methylmaleimide 319
were modelled using Gaussian09206 (Scheme 78). A 3-methoxy group was selected over
a 3-ethoxy group in order to simplify structure optimizations.
Scheme 78. Model reactions for the computational study.
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Structure Optimization
Before any reactions could be investigated it was first necessary to find the lowest energy
conformation of starting materials and products. This was done using the M06-2X/6-
31G(d) level of theory, which was chosen after preliminary calculations showed that it
was able to reproduce reported calculated energies for related furans, dienophiles and
adducts that had been published by Svatoš et al.182 The first question that was addressed
was the favored rotamer of 3-methoxyfurans. It was energetically more favorable for the
methoxy group of a 3-methoxyfuran to point away from the adjacent substituent at the
2-postion. For example, furan 353a was 13.3 kJ mol–1 more stable than rotamer 353a’
(Figure 18). A similar effect was observed in the cantharimide products. For example,
endo-354a was 11.6 kJ mol–1 more stable than the corresponding rotamer endo-354a’.
Figure 18. Rotation about the C-OMe bond.
Examining the geometries of 2-cyclopropylfuran 353b and cantharimides 354b revealed
three rotamers for each compound (Scheme 79). For these examples, the lowest energy
conformation for the starting material and product were used to calculate ΔH and ΔG, but
all rotamers were considered to calculate minimum transition state geometries. Then the
lowest energy transition state was used to calculate ΔH‡ and ΔG‡. The same approach
was used for the corresponding 3-H furan.
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Scheme 79. Energy and frequency minimized geometries for furan 353b and cantharimides 354b.
In contrast, where the 2-substituent was an aromatic ring there was a strong preference
for a single conformation in both starting material and adduct. For the 2-aryl furans the
two rings preferred to sit coplanar. For the cantharimides the preferred geometry saw the
aromatic ring approximately coplanar with the ether bridge. The dihedral angle across the
rotatable C-C bond for each isomer changed little as the aromatic ring was varied. The
optimized geometries for furan 353e and cantharimides 354e are illustrated in Scheme
80.
Scheme 80. Energy and frequency minimized geometries for furan 353e and cantharimides 354e.
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Free Energy and Enthalpy Calculation
By calculating minimum gas-phase energies for starting materials, cantharimides and
transition states it was possible to calculate values for ΔH or ΔH‡, ΔG and ΔG‡ for each
reaction, with the results given in Table 18. Transition state searches were conducted
using the QST2 method at the M06-2X/6-31G(d) level of theory. The calculations were
also performed for reactions in a series of solvents (hexane, Et2O, CH2Cl2, PhMe, EtOH,
MeCN and water), but this had little effect on ΔH or ΔH‡, ΔG or ΔG‡. Performing
calculations in DMC was considered but this solvent was not an available option in
Gaussian09 and so was thus not trivial to model.
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Table 18. Calculated reaction and transition state enthalpies and free energies for the formation of
cantharimides 354.a
R X Product  ΔH ΔH‡ ΔG ΔG‡
Me OMe endo-354a –106.4 18.8 –41.5 81.1
Me OMe exo-354a –112.8 23.2 –47.7 82.1
cPr OMe endo-354b –109.4 11.6 –44.1 75.0
cPr OMe exo-354b –116.5 18.7 –53.2 78.6
4-MeOC6H4 OMe endo-354c –90.2 22.3 –32.5 76.8
4-MeOC6H4 OMe exo-354c –88.6 32.6 –30.1 85.3
Ph OMe endo-354d –88.4 25.3 –34.0 83.6
Ph OMe exo-354d –87.3 35.4 –28.2 91.3
4-F3CC6H4 OMe endo-354e –89.2 28.2 –25.3 85.9
4-F3CC6H4 OMe exo-354e –87.9 39.0 –23.8 96.8
Me H endo-354f –73.1 40.5 –11.8 97.9
Me H exo-354f –82.3 41.3 –16.8 96.2
cPr H endo-354g –72.3 40.1 –12.5 92.2
cPr H exo-354g –79.3 43.1 –10.3 92.8
4-MeOC6H4 H endo-354h –59.8 44.1 –6.1 95.4
4-MeOC6H4 H exo-354h –58.7 48.9 –3.6 98.8
Ph H endo-354i –61.5 43.1 –1.7 101.1
Ph H exo-354i –60.0 48.8 0.7 105.5
4-F3CC6H4 H endo-354j –60.6 45.7 –0.9 101.6
4-F3CC6H4 H exo-354j –60.3 51.9 0.9 108.3
aAll values are in kJ mol–1. All data is calculated for species in the gas phase. The optimized geometries of
all compounds and transition states can be found in appendix to this thesis.
Analysis of the data in Table 18 showed that the 3-alkoxy group has a dramatic impact
on the thermodynamic driving force of the furan-Diels–Alder reaction. The introduction
of a methoxy group at the designated position decreases the Gibbs free energy of reaction
(ΔG) by 24–34 kJ mol–1. This impact is most significant where the substituent is aromatic,
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for example the 2-Ph furans illustrated in Scheme 81. For 2-phenylfuran 353i the reaction
to form the thermodynamically more stable adduct endo-354i has a value of ΔG = –
1.7 kJ mol–1. Such a low thermodynamic driving force is not practical for an efficient
synthesis of cantharimide 354i. By comparison, the reaction of 3-methoxyfuran 353d and
N-methylmaleimide 319 has a significant thermodynamic driving force, which is
consistent with kinetic control (ΔGexo = –28.2 kJ mol–1 and ΔGendo = –34.0 kJ mol–1). As
would be expected for an electron rich diene,207 the 3-methyoxy group also reduces the
kinetic barrier for the Diels–Alder reaction. However, this effect was less pronounced,
with a difference of 11–23 kJ mol–1.
Scheme 81. Reaction and activation free energies for the [4+2]-cycloadditions of 2-phenylfurans and
N-methylmaleimide 319. All values are in kJ mol–1.
Transition State Geometries
The energy minimized structures for the endo- and exo-transition states for the formation
of cantharimides 354d are shown in Figure 19. It is notable that in both cases the
transition state geometries of the furan and maleimide components are relatively flat, as
would be expected for an early transition state. The transition state geometries are also
relatively symmetrical, with little difference in the length of the forming bonds.
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Figure 19. Transition states for endo- and exo-cantharimides 354d.
Hydrogenation Thermodynamic Cycle
The reversibility of Diels–Alder reactions where the diene is a furan has been attributed
to the loss of aromatic stabilization upon formation of the adduct, resulting in a facile
retro-cycloaddition.182 In order to examine the effect of a 3-methoxy group on this
phenomenon, thermodynamic cycles involving the partial hydrogenation of
3-methoxyfuran 355a and furan 358a to the corresponding 2,5-dihydrofurans 356a and
359a were considered (Scheme 82). It is notable that the free energy of hydrogenation
for furan 355a is 25.9 kJ mol–1 greater than for 3-methoxyfuran 358a. For the second step
in the cycle to form adducts 357 and 360 no significant difference in ΔG was observed.
In contrast, the analogous thermodynamic cycles for the corresponding cyclopentadienes
355b and 358b revealed little difference in ΔG for either Step A or Step B.
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Scheme 82. Hydrogenation Study.
The observation that the addition of a methoxy group had little impact on ΔG for step B
suggested that the formation of the two C-C bonds was not the determining factor in
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explaining the difference in ΔG for the reactions of furan and 3-methoxyfuran with
N-methylmaleimide. Rather this could be attributed to the change in conjugation
associated with the cycloaddition reaction. These results suggest that the 3-methoxy
group reduced the thermodynamic penalty associated with the loss of conjugation upon
partial hydrogenation to the 2,5-dihydrofuran. The fact that a similar effect is not observed
with the corresponding cyclopentadienes suggested that loss of aromaticity is the
significant factor. In other words, a 3-methoxy group can reduce the energetic cost of
losing aromaticity upon the cycloaddition of a furan with N-methylmaleimide.
3.2.7. Aromatization of Cantharimide Products
The dehydration of 7-oxabicyclo[2.2.1]heptanes under acidic or basic conditions was
identified as a potentially valuable route to highly-substituted aromatic compounds, such
as phthalimides 362 (Scheme 83). In principle, this could be conducted using a mixture
of endo- and exo-diastereoisomers as both would converge to the same product.
Phthalimide is a privileged scaffold for drug discovery and forms the core of a number of
existing and potential therapies.208 Many of these are derivatives of Thalidomide 363,
which is currently used in the treatment of multiple myeloma.209
Scheme 83. Proposed aromatization of cantharimides 361.
Base-Mediated Ring-Opening.
There is reasonable precedent for the aromatization of ether-bridged [4+2]-cycloaddition
products using strong bases (Scheme 84).210 However, treating cantharimide endo-330e
with lithium hexamethyldisilazide (LiHMDS) in anhydrous THF at –78 °C did not result
in any evidence for cleavage of the ether bridge or formation of a phthalimide product. In
addition to recovered starting material, 3-alkoxyfuran 325e was observed in the crude 1H
NMR spectrum. This suggested that the reaction conditions induced a retro-[4+2]-
cycloaddition of cantharimide endo-330e. No such reaction was observed when
cantharimide endo-330e was treated with NaOMe in MeOH, but this only resulted in
significant decomposition. Ketone 336 was also treated with LiHMDS in an attempt at
inducing aromatization, but this too resulted in significant decomposition.
Chapter III 103
Scheme 84. Reaction of enol-ether endo-330e and ketone 336 with LiHMDS.
Tf2O-Mediated Ring-Opening
The possibility of cleaving the ether bridge using Tf2O was briefly considered. It was
found that treating enol-ether exo-330a with Tf2O in anhydrous CH2Cl2 gave a complex
mixture of products. Following purification by flash column chromatography phthalimide
364 was isolated in 31% yield (Scheme 85). It was postulated that the formation of
phthalimide 364 proceed through an acid-mediated electrophilic aromatic substitution of
the pendent phenyl group, followed by aromatization of the resulting
7-oxabicyclo[2.2.1]heptane 366.
Scheme 85. Synthesis of phthalimide 364 from enol ether exo-330a.
In an attempt to convert cantharimide 330a into phenol ether 367, cantharimide 330a was
treated with Tf2O in the presence of 2,6-lutidine (Scheme 86). However, no reaction was
observed and cantharimide 330a was recovered from the reaction. An interpretation of
this result is that it was TfOH rather that Tf2O that was responsible for the aromatization
of intermediate cantharimide 366 in the formation of phthalimide 364 (Scheme 85).
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Scheme 86. Failed aromatization of cantharimide 330a under basic conditions.
Me3SiOTf-Mediated Aromatization
The aromatization of enol ether endo-330e was considered under basic conditions using
Me3SiOTf as a dehydrating agent.211 After 24 h a 3:1 mixture of phthalimide 368 and
starting material endo-330e were isolated. However, column chromatography failed to
generate phthalimide 368 in sufficiently high purity and the yield was estimated at 50%
(Scheme 87). Heating the reaction at reflux for 24 h resulted in 100% conversion of
cantharimide endo-330e and approximately 40% yield of phthalimide 368, but again
purification by silica gel column chromatography gave phthalimide 368 in only modest
purity. Given the challenge of purifying this reaction, these conditions were not pursued
further.
Scheme 87. Aromatization of adduct endo-330e using Me3SiOTf.
Acid-Mediated Ring-Opening
As an initial study, a solution of cantharimide endo-320 in CH2Cl2 was treated with TFA
at RT (Scheme 88). This did not result in any formation of an aromatized product; rather
ether 369 and ketone 370 were formed in the ratio 3:1. These two products were
inseparable by silica gel chromatography so the mixture was treated with NaBH4 in
MeOH to give a separable mixture of ether 369 and alcohol 371. After purification, ether
369 was isolated in 69%.
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Scheme 88. Acid-catalyzed rearrangement of cantharimide endo-320. Reagents and conditions: (i)
TFA, CH2Cl2; (ii) NaBH4, MeOH.
It was unclear whether ketone 370 was formed under the reaction conditions or whether
it was only formed on work up. Repeating the reaction using anhydrous conditions and
leaving the reaction for a further 8 h resulted in the same 3:1 mixture of products. A
possible solution was to add HC(OMe)3 to the reaction to regenerate starting material
endo-320 from any ketone 370 formed in the reaction. However, after a 24 h reaction only
ketone 370 was present in the crude product.
Given the complication of a pendent aromatic group and the apparent sensitivity of enol
ethers to acidic conditions, diethyl acetal 335 was identified as a suitable substrate for
investigating acid-mediated ring-opening (Scheme 89). Five different solvents were
screened for the acid-mediated aromatization of acetal 335 using both 12 M aq. HCl and
BF3.THF as a potential catalyst. Acetal 335 was stirred in a 10:1 mixture of solvent:acid
for 3 days at RT, but in all ten experiments no evidence of aromatization was observed.
The only product formed in this solvent screen was the hydrolyzed product 336.
Scheme 89. Solvent screen for the acid-mediated rearrangement of acetal endo-335.
106 Furan-Diels–Alder Reactions
Given the difficulty in aromatizing acetal 335, more forcing acidic conditions were
investigated. Stirring acetal endo-335 in neat TFA with 5.0 eq. of TFAA as a dehydrating
agent at RT gave phthalimide 368 in 49% yield on a 10 mg scale (Scheme 90). Analysis
of the crude 1H NMR spectrum suggested that phthalimide 368 was formed alongside
ketone 336 in a 1:1 ratio.
Scheme 90. TFA-mediate aromatization of acetal endo-335.
This result suggested that the key to optimizing the aromatization reaction was reducing
the rate of hydrolysis relative to that of aromatization. Given that forcing acidic conditions
appeared to be beneficial, acetal endo-335 was stirred in MsOH at RT for 16 h. (Scheme
91). Pleasingly this resulted in formation of phthalimide 368 without the need for an
additional dehydrating agent. However, these conditions offered no advantage in terms
on minimizing the formation of ketone 336.
Scheme 91. Acid-mediated aromatization of acetal endo-335 using MsOH.
An attempt was made to convert propargylic alcohol 316e into phthalimide 368 without
isolation of the cantharimide intermediates (Scheme 92). Alcohol 316e was converted to
the corresponding cantharimide endo-335 using 2.0 mol% PPh3AuNTf2 and
N-methylmaleimide 319 (Section 4.2.2., Scheme 67). This material was then
concentrated and treated with MsOH along with 10% EtOH by volume, which was added
in an attempt to minimize the formation of ketone 336. After 16 h the reaction was
worked-up and the crude product again treated with MsOH and EtOH (10:1) in order to
convert remaining ketone 336 into phthalimide 368. After this additional step phthalimide
368 was isolated in 47% yield from propargylic alcohol 316e.
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Scheme 92. One-pot synthesis of phthalimide 368 from alcohol 316a.
A key limitation of MsOH as a reagent for the aromatization of cantharimides is the
hydrolysis of diethylacetal 335 to the corresponding ketone 336. Adding EtOH to the
reaction mixture had a limited effect at reducing this hydrolysis because of the
autocatalytic reaction of EtOH and MsOH to form MsOEt. This was confirmed by
treating MsOH with EtOH in the ratio 10:1; after 1 h analysis of the reaction by 1H NMR
spectroscopy clearly showed that all the EtOH had been converted to MsOEt. A possible
solution was to treat acetal 335 with MsOH and then add EtOH dropwise to the reaction
mixture (Scheme 93). However, this proved to be detrimental to the reaction, with a
reduced level of phthalimide 368 formed.
Scheme 93. Aromatization reaction of acetal 335 using MsOH and a dropwise addition of EtOH.
Given the problems associated with the aromatization of acetal 335 in MsOH, alternative
catalysts were considered. Using AcOH, PTSA.H2O, sulfuric acid and hydrochloric acid
in combination with a HC(OEt)3 dehydrating agent did not result in aromatization of
acetal 335. Polyphosphoric acid (PPA) was considered as an aromatization agent, with
the results summarized in Table 19.
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Table 19. Attempts to aromatize acetal 335 using polyphosphoric acid (PPA).
Entry Ratio PPA: HC(OEt)3 Temperature/°C 368:336/%a
1 10:1 RT 1:4
2 10:1 100 decomposition
3 1:1 100 1:4
4 1:1 120 3:2
5 1:1 150 3:1
6b 1:1 150 3:1c
a Determined from the 1H NMR spectrum of the crude product. b Reaction heated for 24 h. c Phthalimide
368 isolated in 42% yield.
Stirring acetal 335 in a 10:1 mixture of polyphosphoric acid (PPA) and HC(OEt)3 resulted
in the formation of phthalimide 368 alongside ketone 336 in the ratio 1:4 (Table 19, Entry
1). Increasing the reaction temperature to 100 °C resulted in decomposition (Entry 2),
however when the proportion of PPA used was decreased it was again possible to isolate
phthalimide 368 alongside ketone 336 (Entry 3). Increasing the reaction temperature
increased the ratio of phthalimide 368 to ketone 336 (Entries 4 and 5), with a 150 °C
reaction temperature giving a ratio of 3:1. However, a longer reaction time of 24 h did
not improve this ratio (Entry 6). Purification of this reaction gave phthalimide 368 in 42%
isolated yield.
A one-pot synthesis of phthalimide 368 over two steps from furan 325e was attempted
(Scheme 94). Furan 325e was treated with N-methylmaleimide 319 in HC(OEt)3 and the
reaction stirred at RT. After 6 h the reaction was treated with PPA and the resulting
solution heated at 120 °C for 16 h. Following purification, phthalimide 368 was isolated
in 33% yield.
Scheme 94. One-pot synthesis of phthalimide 368 from furan 325a.
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Aromatization Conclusion
In conclusion, phthalimide 368 was prepared from the corresponding cantharimide under
a variety of reaction conditions. However, the conditions required to achieve the
aromatization reaction were always forcing and the best isolated yields were relatively
low. While this route offers an interesting new approach into highly substituted
phthalimides it was not pursued further due to these two limitations.
3.3. Chapter III Summary
Highly substituted endo-cantharimides 374 were prepared via the [4+2]-cycloaddition of
3-alkoxyfurans and maleimides under environmentally benign conditions (Scheme 95).
The reaction was effective with a variety of 3-alkoxyfurans, including those bearing
aromatic and heteroaromatic groups at the 2-position, giving cantharimide products in
good yield and with reasonable endo-control. The reaction was also effective with a
number of N-substituted maleimides, allowing cantharimides to be prepared in a highly
convergent fashion. It was shown that the enol ethers formed by this approach could be
efficiently converted into a number of endo-cantharimide products with promising lead-
like properties. In addition, computational calculations were performed to quantify the
effect that a 3-alkoxy group had on the thermodynamics and kinetics of furan-Diels–Alder
reactions.
Scheme 95. Summary of endo-cantharimide synthesis.
In addition to cantharimide products, the methodology was extended to synthesize a
variety of novel heterocycles from other dienophiles (Scheme 96). Finally, acid-mediated
rearrangements of cantharimide products were used to make extended ring system 369
and phthalimide 368.
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Scheme 96. Novel heterocycles prepared from 3-alkoxyfurans.
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Chapter IV. Synthesis of Chiral THFs via the Dehydration of
Pentoses
4.1. Introduction
4.1.1. The Application of THFs in Medicinal Chemistry
Nucleoside analogues are an important class of compounds in medicinal chemistry, which
have been widely developed as antiviral agents, antibiotics and antitumor agents.212
Compounds of this class mimic the tetrahydrofuran (THF) ring of nucleosides and
typically possess a nucleobase at the α-position (Figure 20). Examples include the
chemotherapy agent Cytarabine 401,213 reverse transcriptase inhibitor Zalcitabine 402214
and antiretroviral drug Azidothymidine (AZT) 403.215
Figure 20. Nucleoside analogues in medicinal chemistry.
A structurally related class of drugs are based on a saturated THF scaffold, with examples
illustrated in Figure 21. Alfuzosin 404 and structurally related Terazosin 405 are both
α-1 antagonists and are used in the treatment of benign prostatic hyperplasia.216, 217
Fosamprenavir 406a (a prodrug of protease inhibitor Amprenavir 406b) is used in the
treatment of HIV.218 Naftidrofuryl 407 is a vasodilator and a treatment for cerebral
vascular disorders219 while Mefruside 408 is a diuretic used for the treatment of edema.220
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Figure 21. Clinical drugs containing a THF.
A valuable drug bearing a fused bis-THF core is isosorbide 409, which is used as a
diuretic to treat hydrocephalus (Figure 22). However, isosorbide has also been used more
widely in drug development as a scaffold.221 Both isosorbide mononitrate 410 and
isosorbide dinitrate 411 are used as vasodilators to treat angina.
Figure 22. Isosorbide and its derivatives in medicinal chemistry.
4.1.2. The Synthesis of THFs from Sugars
There has been significant interest in the preparation of isosorbide from sorbitol (which
in turn is generated from carbohydrate feedstock) under acidic or basic conditions.222 For
example, Rokicki et al. reported conditions for the preparation of isosorbide 409 from
D-sorbitol 412 using K2CO3 as a base and DMC as an activating reagent (Scheme 97).223
Scheme 97. The preparation of isosorbide form D-sorbitol.
Another method for the cyclization of sugars is to selectively convert a primary alcohol
into a leaving group followed by an intramolecular nucleophilic substitution.224, 225 This
Chapter IV 113
was demonstrated by Smith et al.,226 who reported the cyclization of glycoside 413 in
26% yield through selective reaction of the primary alcohol with TsCl (Scheme 98, Part
I). Lundt and Frank have reported a similar method for cyclizing lactone 416 in 39% yield
over two steps (Scheme 98, Part II).227 A key limitation of this approach is the poor atom
economy generally associated with converting a primary alcohol into a leaving group.
Scheme 98. THF synthesis through activation of a primary alcohol as leaving groups.226, 227
A more general route to THFs from sugar derivatives is via the reduction of a glycoside
using Et3SiH.228 This transformation can be high yielding, as exemplified by the work of
Robins and Ewing (Scheme 99).229 However, this reduction has not been demonstrated
on unprotected sugars, which limits its synthetic utility and results in low atom economy.
Scheme 99. Reductive THF synthesis from a protected glycoside.229
4.1.3. The Application of N,N-Dialkylhydrazones in Organic Synthesis
N,N-Dialkylhydrazones are a valuable and versatile synthetic tool within organic
chemistry (Figure 23).230 One of the main applications of N,N-dialkylhydrazones 421 is
to increase the acidity of carbonyl compounds. Deprotonation at the α-position gives the 
conjugate base, which can then undergo a reaction with an electrophile.231 The pKa of a
hydrazone has been calculated to be ca. 10 units higher than the parent carbonyl
compound and so the conjugate base of a hydrazone can exhibit greater reactivity towards
electrophiles. Hydrazones can also undergo addition reactions with nucleophilic alkyl
lithium reagents or free radicals to give hydrazine products. 232 Vinyl hydrazones 422 are
also useful synthetic building blocks, acting as Michael acceptors with a variety of
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nucleophiles. In addition, deprotonation at the γ-position generates a carbanion that can 
be trapped with electrophiles. Furthermore, vinyl hydrazones 422 are effective dienes for
heteronuclear Diels–Alder reactions owing to their electron-rich nature.233
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Figure 23. Application of N,N-dialkylhydrazones.230
Hydrazone chemistry was developed most notably by Corey and Enders for the
stereoselective α-alkylation of ketones using chiral N,N-dialkylhydrazones.234 An
application of this approach was reported by Nicolaou et al. as part of the total synthesis
of Epothilones A and B (Scheme 100).235 Treating (S)-1-amino-2-
methoxymethylpyrrolidine (SAMP) hydrazone 423 with lithium diisopropylamide
(LDA) and then alkyl iodide 424 gave alkylated product 425 as a single diastereoisomer
in 70% yield. Numerous methods have been developed to liberate the original carbonyl
functional group from N,N-dialkylhydrazones.236 Nicolaou et al. converted hydrazone
425 into aldehyde 427 via an oxidative cleavage to give nitrile 426, which was then
reduced using diisobutylaluminium hydride (DIBAL).
Scheme 100. Application of SAMP hydrazone 423 to the synthesis of Epothilones A and B.235 Reagents
and conditions: (i) 1.5 eq. 423, 1.5 eq. LDA, THF, 0 °C, 8 h; then 1.0 eq. 424, THF, –100 to –20 °C, 10 h,
70%; (ii) 2.5 eq. MMPP, MeOH:phosphate buffer pH 7 (1:1), 0 °C, 1 h, 80%; (iii) 2.0 eq. DIBAL, PhMe,
–78 °C, 1 h, 82%.
N,N-Dialkylhydrazines have also been used to reverse the inherent reactivity of carbonyl
compounds to generate an “acyl anion” equivalent, which can undergo reactions with
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different electrophiles.237 This approach allows ketones to be generated from aldehydes,
or for higher aldehydes to be prepared from formaldehyde. For example, Mayr et al.
explored the alkylation of N,N-dialkylhydrazones with benzhydrylium ions, with an
example given in Scheme 101.238
Scheme 101. Alkylation of N,N-dialkylhydrazone 428.238
A far less explored synthetic approach is to use a hydrazine to facilitate the elimination
of a leaving group adjacent to a carbonyl.239 In 1953 Warnhoff and Johnson reported that
2,4-dinitrophenylhydrazone 430 underwent an acid mediated elimination of EtOH to give
cyclohexene 431 (Scheme 102, Part I).240 Similarly, Behforouz et al. reported that
hydrazone 432 eliminated water in the presence of H2SO4 to give alkene 433 in 82% yield
(Scheme 102, Part II).241 In addition, Lichtenthaler et al. discovered that treatment of
hydrazone 434 with pyridine resulted in ring-opening of the adjacent oxatane to give enol
ether 436 in 94% yield (Scheme 102, Part III).242 The authors suggested that the reaction
proceeded via vinyl diazeneintermediate 435.
Scheme 102. Elimination of a leaving group adjacent to a hydrazone. Ar = 2,4-dinitrophenyl.
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4.1.4. The Cyclization of Reducing Sugars using NH2NMe2
Where an electron-rich aromatic group possesses a pendant sugar chain the aromatic ring
can induce displacement of the adjacent hydroxyl group to give a resonance-stabilized
cationic intermediate, which can be trapped by a pendent hydroxyl group to form a THF.
This transformation has been used within synthetic chemistry243 and can be invoked in a
proposed biosynthetic pathway for the formation of Saffloflavonesides B 439 (Scheme
103).244
Scheme 103. Proposed biosynthetic pathway for the formation of Safflofavoneside B 439.
A similar cyclization of a sugar chain to give a THF was reported by Koóš and Moscher
(Scheme 104).245 Hydrazone 441a was prepared from the condensation reaction of
L-arabinose and NH2NMe2. Hydrazone 441a was treated with 1.00 eq. of anhydrous
p-toluenesulfonic acid (PTSA) and 4.0 eq. of (MeO)2CMe2 in anhydrous DMF, and THF
442 was isolated in 57% yield as a 65:35 mixture of diastereoisomers.
Scheme 104. Koóš and Moscher’s cyclization of hydrazone 441a.245
4.1.5. Chapter IV Project Outline
The aim of this part of the PhD was to develop a hydrazone-based synthesis of THFs from
biomass-derived reducing sugars using sustainable reaction conditions. This would allow
for the synthesis of low-molecular weight chiral THFs with control over the absolute
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stereochemistry. These products would potentially be valuable building-blocks for chiral
sp3-rich molecular scaffolds.
The reported synthesis of THF 442 by Koóš and Moscher (Scheme 104) was a valuable
start point for this work.245 A feature of this reaction is the simultaneous cyclization of
the sugar chain and formation of an acetonide from (MeO)2CMe2. Protecting groups,
although often a useful synthetic tool, typically have a detrimental impact on the step
economy and atom economy of a synthesis.246 Therefore an attractive alternative reaction
to develop was the cyclization of hydrazone 441a to give unprotected diol 443a (Scheme
105).
Scheme 105. Chapter IV project aim.
A significant drawback of Koóš and Moscher’s reaction conditions that needs to be
addressed (Scheme 104) was the need for the vigorous exclusion of water, including the
use of anhydrous PTSA. Also, DMF has a number of serious environmental drawbacks,
so a more sustainable solvent would be advantageous. It would then be important to
develop reaction scope with different sugars and to demonstrate the transformation of
hydrazone products into a diverse selection of chiral THFs.
4.2. Results and Discussion
4.2.1. Preliminary Studies
Despite literature precedent, stirring L-arabinose 440a with NH2NMe2 in water at RT
failed to afford hydrazone 441a.247 Following this, 20 mol% PTSA.H2O and BF3.THF
were screened as catalysts in MeOH-d4, CDCl3, D2O and DMSO-d6, with
PTSA.H2O/MeOH-d4 giving the greatest conversion of L-arabinose 440a after 24 h at RT.
This reaction was scaled up using 5.0 mol% PTSA.H2O in MeOH, which gave the desired
hydrazone 441a in 79% yield. Replacing PTSA.H2O with Amberlyst 15 acidic resin
(0.100 g/mmol) gave hydrazone 441a in 99% yield on a 90.0 mmol scale, after removal
of the resin by filtration (Scheme 106).
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Scheme 106. Synthesis of hydrazone 441a.
As a starting point for the investigation, an attempt was made to reproduce Koóš and
Moscher’s reported synthesis of THF 442 (Scheme 104).245 Given that anhydrous PTSA
is not readily available and difficult to prepare, (±)-camphorsulfonic acid (CSA) was used
as an alternative acid (Scheme 107). This reaction yielded a complex mixture of products
and analysis of the crude 1H NMR spectrum provided no clear evidence for the formation
of known THF 442. Treating hydrazone 441a with 1.00 eq. of PTSA.H2O and 4.0 eq. of
(MeO)2CMe2 in MeOH-d4, CDCl3, D2O or DMSO-d6 similarly resulted in the 100%
conversion of hydrazone 441a to give a complex mixture of products.
Scheme 107. Failed synthesis of THF 442.
Prior to investigating the acid-catalyzed cyclization of hydrazone 441a, an attempt was
also made at preparing a reference sample of THF 443a using Mitsonobu conditions.
Treating hydrazone 441a with 1.0 eq. of PPh3 and 1.0 eq. of diisopropyl azodicarboxylate
(DIAD) in either THF or MeCN resulted in the trace formation of cyclized product 443a
(Scheme 108).248 Treating hydrazone 441a with TsCl in pyridine also resulted in the
observation of THF 443a in a trace quantity.249 A possible explanation for the failure of
this approach is the poor compatibility of the hydrazone functional group with the
electrophilic species present under the reaction conditions.
Scheme 108. Attempted synthesis of hydrazone 443a through selective activation of the primary
alcohol.
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A series of Lewis acids were screened as catalysts for the cyclization of hydrazone 441a
in MeOH at RT. It was observed that using 20 mol% [Cu(OTf)]2PhMe and Cu(OTf)2 both
resulted in decomposition of the substrate after 8 h, while LiClO4, MgBr2 and Zn(OAc)2
resulted in no reaction. However, 20 mol% BF3.THF catalyzed the formation of THF
443a as a 65:35 mixture of diastereoisomers, with 90% conversion of 441a after 48 h at
RT (Scheme 109).
Scheme 109. Synthesis of THF 443a using BF3.THF.
The cyclization of hydrazone 441a in MeOH using 20 mol% BF3.THF was repeated at
60 °C in order to drive the reaction to completion. The corresponding reaction with
20 mol% CSA was also conducted. Both reactions resulted in 100% conversion of
hydrazone 441a within 16 h, with CSA resulting in fewer impurities (as determined by
analysis of the crude 1H NMR spectra). The reaction with CSA was repeated on a 192 mg
(1.00 mmol) scale and THF 443a isolated in 55% yield (Scheme 110). By crude 1H NMR
spectroscopic analysis the diastereoisomeric ratio was measured as anti:syn = 75:25.
Recrystallization of THF 443a from CH2Cl2 and hexane gave the major diastereoisomer
anti-443a as a single stereoisomer, and the relative stereochemistry was confirmed by
single crystal X-ray diffraction.iii
Scheme 110. Synthesis of THF 443a using CSA. Ellipsoids are shown at 50% probability level. Only
hydrogen atoms belonging to the cyclic core are shown for clarity.
4.2.2. Reaction Optimization
The cyclization of hydrazone 441a using 20 mol% CSA over 16 h at RT was then
investigated using a series of different solvents (Table 20). A screen of NMR solvents
iii Dr Dejan-Krešimir Bučar and Dr Laure Benhamou are gratefully acknowledged for conducting and 
analyzing the single crystal X-ray diffraction experiment. Recrystallization was performed by the author.
120 Chiral THFs
revealed that no formation of THF 443a occurred in either D2O or CDCl3, while using
DMSO-d6 as solvent resulted in ca. 10% conversion of hydrazone 441a (Entries 1–3).
The reaction was favored in alcohol solvents (Entries 4–8), with MeOH and nPrOH giving
the highest yields as judged from 1H NMR spectroscopic analysis. DMF, which was used
in the cyclization reported by Koóš and Moscher (Section 4.1.4., Scheme 104), did
facilitate the formation of THF 443a (Entry 9) but in lower yield than for MeOH and
nPrOH. No significant conversion of hydrazone 441a was observed where MeCN was
used as solvent (Entry 10) and a slow reaction was observed in CPME (Entry 11).
Table 20. Solvent screen for the acid-catalyzed cyclization of hydrazone 443a.
Entry Solvent Conversion of 441a/% Yield 443a/%a anti:syn 443aa
1 D2O - 0 -
2 CDCl3 - 0 -
3 DMSO-d6 - 10b -
4 MeOH 50 50 65:35
5 EtOH 80 30 65:35
6 nPrOH 100 80 75:25
7 iPrOH 40 30 65:35
8 nBuOH 50 35 65:35
9 DMF 65 35 70:30
10 MeCN 20 0 -
11 CPME 25 15 50:50
a Determined by analysis of the crude 1H NMR spectrum (using C6HCl5 as an internal standard). b Estimated
without an internal standard.
A series of acids were screened as catalysts for the cyclization, using nPrOH as reaction
solvent (Table 21). All the strong acids were effective at catalysing the cyclization
(Entries 1–5) while AcOH resulted in no reaction (Entry 6). Both TFA and CSA were
effective catalysts for the cyclization, with 80% yields of THF 443a calculated using 1H
NMR spectroscopy. CSA and TFA are of similar cost (ca. £200/kg of TFA compared to
ca. £150/kg CSA)250 but the molecular weight of CSA is approximately twice that of
TFA. On these grounds TFA was chosen as the more economical catalyst for further
work.
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Table 21. Cyclization catalyst screen.
Entry Catalyst Conversion 441a/% Yield 443a/%a anti:syn 443aa
1 CSA 100 80 75:25
2 HCl (4 M in dioxane) 70 50 75:25
3 conc. H2SO4b 40 25 60:40
4 PTSA.H2O 50 35 65:35
5 TFA 80 80 75:25
6 AcOH 0 0 -
a Determined by analysis of the crude 1H NMR spectrum (using C6HCl5 as an internal standard). b 10 mol%.
The reactions in Table 20 and Table 21 suggested that nPrOH was marginally the best
solvent for the cyclization and TFA was the best catalyst. However, when these conditions
were used on a 1.00 g scale two serious problems were observed. Firstly the reaction
consistently took 72 h to reach completion, even when 4 Å molecular sieves were added
as a dehydrating agent (Scheme 111). Secondly, the THF 443a could not be separated
from an impurity by flash column chromatography, giving THF 443a in only 90% purity.
While the impurity was not isolated or characterized, the 1H NMR spectrum was
consistent with solvolysis product 444.
Scheme 111. Cyclization of hydrazone 441a in nPrOH at RT.
Heating the reaction to 40 °C and increasing the reaction concentration to 0.50 M had a
significant impact on the reaction time, with 100% conversion of hydrazone 441a
observed after 16 h (Scheme 112). This reaction was conducted without 4 Å molecular
sieves, with no detrimental impact on the yield of THF 443a. However, impurity 444 was
still present following column chromatography and so these conditions required further
optimization.
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Scheme 112. Cyclization of hydrazone 441a in nPrOH at 40 °C.
When the reaction solvent was switched to MeOH, THF 443a was isolated in 67% yield
as a 75:25 mixture of diastereoisomers in excellent purity following flash column
chromatography (Scheme 113). These reaction conditions were taken as the optimized
reaction conditions for further investigation.
Scheme 113. Optimized cyclization of hydrazone 441a.
4.2.3. Mechanistic Investigations
As a control reaction, the optimized reaction conditions described in Scheme 113 were
replicated without the TFA additive being present (Scheme 114). Analysis of the crude
1H NMR spectrum showed that this resulted in no formation of THF 443a and no evidence
for the conversion of hydrazone 441a was observed. This control reaction confirmed that
TFA was acting as a catalyst for the formation of THF 443a.
Scheme 114. Control reaction with no TFA additive.
Recrystallization of THF 443a from hot CPME gave the major diastereoisomer anti-443a
in high purity. The optimized cyclization conditions in Scheme 113 were replicated, but
hydrazone 441a was substituted for an isomerically pure sample of THF anti-443a
(Scheme 115). Analysis of the crude 1H NMR spectrum indicated that THF 443a had
epimerized under the reaction conditions to give a 75:25 mixture of anti- and syn-
diastereoisomers. This implied that the diastereoselectivity of the cyclization reaction was
under thermodynamic control.
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Scheme 115. Epimerization of anti-443a under the optimized cyclization conditions.
The epimerization of THF 443a could be explained by a reversible cyclization reaction,
or alternatively via the formation of enamine intermediate 445 (Scheme 116, Part I). In
order to gain insight, the optimized cyclization reaction of hydrazone 441a (Scheme 113)
was replicated using MeOH-d4 as solvent. This resulted in the formation of THF 443a as
a 75:25 mixture of anti- and syn-diastereoisomers, which was isolated in 65% yield
(Scheme 116, Part II). No measurable incorporation of deuterium was observed at the
position adjacent to the hydrazone, which suggests that epimerization is not occurring via
enamine 445.
Scheme 116. Potential enamine intermediate 445 and Cyclization of hydrazone 441a in MeOH-d4.
As a final mechanistic experiment, the optimized cyclization reaction was replicated, but
the reaction quenched after only 1 h. Analysis of the crude 1H NMR spectrum implied ca.
30% conversion of hydrazone 441a and formation of THF 443a as a 70:30 mixture of
anti- and syn-diastereoisomers (Scheme 117). This compares to a 75:25 d.r. when the
same reaction was conducted over 16 h (Scheme 113). While the difference in d.r. at 1 h
and 16 h was only small, the observation was consistent with a reaction where THF 443a
was initially formed with a d.r. < 75:25, but equilibration over 16 h increased the
proportion of the anti-diastereoisomer present.
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Scheme 117. Cyclization of hydrazone 441a after 1 h.
A suggested mechanistic pathway is given in Scheme 118. The protonation of compound
441a to give intermediate 446 and subsequent elimination of water would result in the
formation of a vinyldiazenium species 447. Cyclization of vinyldiazenium intermediate
447 could yield either anti- or syn-443a, depending on the conformation of the
intermediate. The experiments detailed in Scheme 115 and Scheme 117 implied that this
cyclization was reversible, ultimately giving the thermodynamic mixture of anti- and syn-
diastereoisomers.
Scheme 118. Proposed mechanistic pathway for the formation of THF 443a.
4.2.4. Cyclization Scope
The optimized synthetic sequence was applied to a series of reducing sugars, with the
results detailed in Table 22. As discussed previously, L-arabinose was efficiently
converted to hydrazone 441a and this was converted to THF 443a in 67% yield as a 75:25
mixture of anti- and syn-diastereoisomers on a 1.26 g (6.60 mmol) scale (Entry 1). In
addition, the cyclization step was scaled up to use 20.0 g (104 mmol) of hydrazone 441a
with no notable drop in yield or stereoselectivity.
Chapter IV 125
Table 22. Hydrazone-mediated cyclization of sugars 440.
Entry Sugar 440 Step 1 yield/% THF 443b Step 2 yield% d.r.c
1 99 67 (66)d 75:25
2 98 59 75:25
3 98 66 55:45
4 not isolated 61e 55:45
5 not isolated 57e 55:45
6 99 69 60:40
a Step I reagents and conditions: 2.0 eq. NH2NMe2, Amberlyst 15, MeOH, 24 h, RT. b Step II conducted
on a 6.00–6.70 mmol scale unless otherwise stated. c Determined by analysis of the crude 1H NMR
spectrum. d Reaction conducted using 20.0 g (104 mmol) of hydrazone 441a. e Yield over two steps from
xylose.
D-Ribose 440b was converted into the corresponding hydrazone 441b in 98% yield and
without need for purification (Table 22, Entry 2). Under the optimized cyclization
conditions hydrazone 441b was converted into THF ent-443a in 59% yield as a 75:25
mixture of anti- and syn-diastereoisomers. According to the mechanism proposed in
Scheme 118, the cyclization of arabinose- and ribose-derived hydrazones 441a and 441b
proceed via enantiomeric vinyldiazenium intermediates (Scheme 119). The observation
that both reactions resulted in the same ratio of anti- and syn-diastereoisomers is therefore
consistent with the proposed mechanism.
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Scheme 119. Cyclization of hydrazone 441a and 441b through enantiomeric vinyldiazenium
intermediates.
The methodology was also extended to D-lyxose 440c, with the corresponding hydrazone
prepared in 98% isolated yield (Table 22, Entry 3). The optimized cyclization step gave
THF 443b in 66% isolated yield as a 55:45 mixture of diastereoisomers. Given the poor
diastereoselectivity of this reaction, the relative stereochemistry of the major
diastereoisomer was not examined.
The reaction of D-xylose 440d with NH2NMe2 under the optimized conditions resulted in
100% conversion of 440d within 24 h and analysis of the 1H NMR spectrum in DMSO-
d6 confirmed the formation of the corresponding hydrazone. However, the target
hydrazone was not the only species observed by 1H NMR spectroscopy so it was not
possible to calculate an isolated yield. Subjecting the crude hydrazone to the cyclization
conditions gave THF 443b in 61% isolated yield over two steps (Table 22, Entry 4).
Using the same approach, L-xylose ent-440c was converted into ent-443b with a
comparable yield and diastereoselectivity (Entry 5).
The optimized synthetic pathway was also applied to deoxy sugar L-rhamnose 440e
(Table 22, Entry 6). The corresponding hydrazone was accessed in 99% yield and this
was cyclized to give THF 443c as a 60:40 mixture of diastereoisomers in 69% isolated
yield without modification of the cyclization conditions.
The optimized conditions for hydrazone synthesis were also applied to D-galactose
(Scheme 120). This reaction was slower than had been observed with the pentoses, but
significant conversion of the starting material had occurred after 3 days at RT. It was
necessary to purify the reaction by flash column chromatography, with hydrazone 441f
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isolated in 31% yield. The optimized cyclization conditions gave a 60:40 mixture of THF
443d and tetrahydropyran 448 in 53% yield. Both compounds were formed as single
stereoisomers and were separated by flash column chromatography.
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Scheme 120. Cyclization of galactose-derived hydrazone 441f. Reagents and conditions: (i) 2.0 eq.
NH2NMe2, Amberlyst 15, MeOH, 72 h, RT; (ii) 20 mol% TFA, MeOH, 16 h, 40 °C.
An attempt was made to extend the methodology to D-fructose 440g. Under the optimized
condensation conditions very little conversion of D-fructose 440g was observed. Heating
the reaction at reflux for 24 h improved the conversion of D-fructose 440g but yielded a
complex mixture of products (Scheme 121).
Scheme 121. Unsuccessful reaction of D-fructose with NH2NMe2.
4.2.5. Functional Group Manipulation of Cyclized Products
Treatment of hydrazone 443a with an excess quantity of Amberlyst 15 acidic resin
(1.00 g/mmol 443a) in water at RT resulted in rapid hydrolysis of the hydrazone. The
resin was removed by filtration and the filtrate was then concentrated and lyophilized to
yield a white gum. 1H and 13C NMR data of the compound in D2O suggested that the
hydrolyzed product 449 existed as a hydrate 449a-d4, as depicted in Scheme 124. The
NMR data was consistent with an 85:15 mixture of diastereoisomers, without any
impurities [13C NMR (150 MHz; D2O) 90.4 (C(OD)2 anti-449a-d4), 89.2 (C(OD)2 syn-
449a-d4); full characterization in Chapter VI]. However, analysis of the 1H and 13C NMR
spectra in MeOH-d4 revealed a more complex mixture of compounds, with the majority
of material existing as a compound consistent with hemiacetal 449b [13C NMR
(150 MHz; MeOH-d4) 98.9 (C(OD)(OCD3)), 98.7 (C(OD)(OCD3))]. Analysis of 1H and
13C NMR spectra in DMSO-d6 revealed an even more complex mixture of products, but
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with evidence for aldehyde 449c [1H NMR (600 MHz; DMSO-d6) 9.56 (1H, d, J = 2.3,
C(O)H); 13C NMR (150 MHz; DMSO-d6) 201.9 (C(O)H)].
Scheme 122. Hydrolysis of 443a and the identity of hydrolyzed product 449 in NMR solvents.
A possible explanation for this observation is that compound 449 undergoes a reversible
condensation when concentrated to form an oligomeric structure (Scheme 123). Given
that hydrolyzed product 449 was formed in water, it is reasonable to assume it was formed
as hydrate 449a. If upon condensation hydrate 449a eliminated a molecule of water to
give aldehyde 449c, then this could react with a second molecule of 449a to give a dimer,
such as compound 449d. This could then undergo further dehydration reactions to give a
complex mixture of oligomers. An IR spectra of the neat gum only possessed one weak
peak at 1720 cm–1 in the region 1650–1750 cm–1, suggesting that the solid state structure
is not a monomeric aldehyde.
Scheme 123. Proposed reversible oligomerization of hydrolyzed product 449.
Without a definite structure of hydrolyzed product 449, it is not possible to definitively
assign a yield for the hydrolysis reaction (Scheme 121). However, if it is assumed that
during lyophilization one molecule of water is eliminated for every molecule of hydrate
449’, then the isolated yield for compound 449 was 98%. For the remainder of Chapter
IV, compound 449 is depicted as a free aldehyde (as in Scheme 124), however it is
recognized that this is a simplification of its solid-state structure.
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Scheme 124. Hydrolysis of hydrazone 443a.
It is also notable that the reaction proceeds with an increase in the diastereoisomeric ratio.
Under the same reaction conditions isomerically pure anti-443a epimerized to give the
same 85:15 mixture of diastereoisomers. It is therefore likely that the diastereoselectivity
observed is due to thermodynamic control.
Compound 449 was reduced using NaBH4 in MeOH to form triol 450, but isolation of the
product was initially problematic. Flash column chromatography (using either silica or
MgSiO3) failed to yield pure product, in part because of the high polarity of triol 450.
Amberlyst IRA743 boron scavenger was also trialled but this too failed to yield pure
product. However, quenching the reaction with AcOH and subsequent treatment with a
mixture of Amberlyst 15 acidic resin and Amberlyst A26 basic resin gave triol 450 in
quantitative yield as an 85:15 mixture of diastereoisomers (Scheme 125, Part I). The
major product has previously been prepared through the universal protection of D-ribose
using bis(trimethylsilyl)trifluoroacetamide (BSTFA), reduction with TMSOTf/Et3SiH
and subsequent deprotection (Scheme 125, Part II). This allowed the relative
stereochemistry of triol 450 (and, by implication, that of compound 449) to be confidently
determined based on comparison with literature data.251
Scheme 125. Reduction of compound 449 and previous approach to triol 450.256
Compound 449 was treated with a 1:1 mixture of Ac2O in pyridine with the aim of
universal acylation to give aldehyde 451 (Scheme 126). However, analysis of the crude
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1H NMR spectrum indicated 100% conversion of compound 449 to give a complex
mixture of products, with no clear evidence for the target aldehyde 451.
Scheme 126. Failed acylation of compound 449.
Compound 449 was also treated with 5.0 eq. of nBuNH2, 50 mol% AcOH and 10% Pd/C
in MeOH in order to generate amine 452 (Scheme 127). This resulted in 100% conversion
of compound 449 after 4 h, upon which the reaction mixture was filtered through Celite
and concentrated. The crude amine 452 was too polar to purify directly by flash column
chromatography, so it was dissolved in CPME and treated with Boc2O. This generated
carbamate 453 in 66% isolated yield as an 80:20 mixture of diastereoisomers.
Scheme 127. Reductive amination of compound 449.
Treatment of compound 449 with Amberlyst 15 in MeOH resulted in the formation of
dimethyl acetal 454 in 75% yield as a 65:35 mixture of diastereoisomers (Scheme 128).
In order to assign the stereochemistry, acetal 454 was treated with 10 mol% K2CO3 in
dimethyl carbonate (DMC) and the reaction heated at reflux for 16 h. This gave the
corresponding carbonate 455 as a single anti-isomer in 87% yield following purification
using a silica plug. The relative stereochemistry of carbonate 455 was determined from
its 1H NMR spectrum by analysis of proton coupling constants, owing to the more rigid
nature of the THF. Treatment of carbonate 455 with K2CO3 in MeOH-d4 gave diol anti-
454 as a single isomer, confirming the stereochemistry of the acetal formed. Repeating
the carbonate formation step without the silica plug purification, followed by carbonate
hydrolysis with K2CO3 in MeOH gave acetal 455 as a 65:35 mixture of diastereoisomers.
This suggested that syn-455 may readily isomerize on silica to give the
thermodynamically more stable anti-455.
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Scheme 128. Dimethyl acetal formation.
Treatment of compound 449 with trimethylphosphonoacetate and K2CO3 in MeOH
resulted in the formation of olefin 456 in 74% isolated yield (Scheme 129). The alkene
was formed with excellent E-selectivity and the 85:15 mixture of diastereomers reflects
that of compound 449. However, no reaction was observed when compound 449 was
treated with diethyl benzylphosphonate under similar conditions, potentially due to the
higher pKa or the phosphonate.
Scheme 129. Olefination of compound 449.
The hydrolysis/reduction sequence was also applied to the hydrazones 443b and 443c,
derived from D-xylose and L-rhamnose respectively (Scheme 130). In both cases the
hydrazones were transformed to the corresponding triols in good yield and with an
increased diastereoisomeric ratio.
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Scheme 130. Hydrolysis and reduction of hydrazones 458 and 459. Reagents and conditions: (i)
Amberlyst 15, H2O, 5 minutes, RT; (ii) NaBH4, MeOH, 1 h, 0 °C.
It was possible to confirm the relative stereochemistry of triol 458 as the major isomer
has previously been reported by Monrad and Madsen as a by-product from a rhodium-
catalyzed decarbonylation of D-glucose (Scheme 131, Part I). 252 The major isomer of
triol 459 was prepared by Fleet et al. as part of the total synthesis of muscarine analogue
3R-3-hydroxymuscarine from L-rhamnose (Scheme 131, Part II), so again the relative
stereochemistry was established.253
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Scheme 131. Madsen’s decarbonylation of D-glucose and Fleet’s total synthesis of 3R-3-
hydroxymuscarine from L-rhamnose. Reagents and conditions: (i) Br2; (ii)Tf2O; (iii) pyridine, MeOH;
(iv) LiAlH4; (v) TsCl; (vi) NMe3.
It is interesting to compare Fleet’s synthesis of triol 459 (Scheme 131) with the synthesis
described in Scheme 130. Both approaches synthesise triol 459 over 4 steps without the
use of protecting groups (Scheme 132). Fleet’s approach gives triol 459 as a single
stereoisomer but in a lower overall yield. Perhaps the most significant advantages of the
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new methodology for the synthesis of triol 459 is the improvement in atom economy and
redox economy. The new methodology also avoids using water-sensitive Tf2O and
LiAlH4, so it is potentially more amenable to large-scale synthesis.
Scheme 132. Comparison of different approaches to triol 459.253
As was mentioned previously, THF anti-443a was isolated as a single stereoisomer
through recrystallization from hot CPME. The transformation of this product into (single
isomer) THFs was investigated. The cyclization of diol anti-443a using 10 mol% K2CO3
in DMC gave carbonate 467 as a single isomer in quantitative yield (Scheme 133).
Hydrolysis of the hydrazone with Amberlyst 15 in water gave a product which, in D2O,
was consistent with hydrate 468 by 1H NMR spectroscopic analysis, in 87% yield as a
single stereoisomer. However, this product was unstable over a period of approximately
24 h in D2O and was not fully characterized.
Scheme 133. Cyclization of diol anti-443a with DMC.
Diol anti-443a was converted into acetonide 442 in good yield using acetone,
(MeO)2CMe2 and 20 mol% PTSA.H2O (Scheme 134). This reaction occurred with partial
inversion of the epimerizable stereocentre, with acetonide 442 isolated as a 60:40 mixture
of syn- and anti-diastereoisomers. The epimerization potentially occurred through acid-
mediated reversible ring-opening of the THF under the reaction conditions. The 60:40
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diastereoisomeric ratio of acetonide 442 is comparable with 65:35 ratio reported by Koóš
and Moscher for the cyclization of arabinose hydrazone 441a in the presence of
(MeO)2CMe2 in DMF (Section 4.1.4., Scheme 104).245
Scheme 134. Synthesis of acetonide 442.
Reduction of hydrazone anti-443a using hydrogen gas in the presence of Pd(OH)2 in
CPME in the presence of Boc2O gave carbamate 469 in 60% yield as a single stereoisomer
(Scheme 135).254 Conducting the reaction in the absence of Boc2O resulted in the
formation of two compounds consistent with amine 470 and hydrazine 471, with ca. 90%
conversion of hydrazone anti-443a.
Scheme 135. Reduction of hydrazone anti-443a.
It is established that N,N-dialkylhydrazones can be converted to the corresponding nitrile
through oxidation with magnesium monoperoxyphthalate (MMPP).255 Treating
hydrazone anti-443a with 2.50 eq. of MMPP in MeOH at 0 °C resulted in 100%
conversion of hydrazone anti-443a within 10 minutes (Scheme 136). Analysis of the
crude product revealed a product consistent with nitrile 472 as a single isomer with only
minor impurities. However, after a number of attempts it was not possible to isolate a
purified sample of the compound. Why nitrile 472 was so difficult to isolate is unclear,
but it could be due to poor stability on silica, volatility or simply a poor reaction yield.
The reaction was also attempted using 1.20 eq. of MMPP, but this reaction failed to reach
completion after 24 h.
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Scheme 136. Attempted oxidation of diol anti-443a.
The oxidation conditions were also applied to carbonate 467 (Scheme 137). This resulted
in rapid conversion of the starting material but no product was isolated from this reaction.
This result could be due to the instability of the cyclic carbonate group under the reaction
conditions.
Scheme 137. Attempted oxidation of carbonate 467.
In an attempt to find a suitable substrate for the oxidative hydrazone cleavage, diol anti-
443a was converted into cyclic silyl ether 474. Treating diol anti-443a with tBu2Si(OTf)2
in pyridine at 0 °C resulted in the formation of silyl ether 474 but with significant
epimerization. However, the epimerization was avoided by using DMC as a solvent and
2,6-lutidine as a base, giving the desired silyl ether 474 in 48% yield as a single isomer
(Scheme 138). Oxidation with MMPP gave a product consistent with nitrile 475 as a
single diastereoisomer, but column chromatography failed to recover the target material.
Scheme 138. Synthesis and oxidation of cyclic silyl ether 474.
A potentially useful transformation of the cis-diol anti-443a would be oxidation to give
the corresponding dialdehyde 476 (Scheme 139). This could, for example, be condensed
with an amine and reduced to access a chiral morpholine 477. However, treatment of diol
anti-443a with NaIO4 in D2O resulted in the rapid conversion of diol anti-443a to give a
complex mixture of products by TLC and 1H NMR spectroscopic analysis. The reaction
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in MeOH-d4 took 8 h to achieve 100% conversion of diol anti-443a but resulted in an
analogous outcome. A possible explanation is that the hydrazone group was unstable in
the presence of NaIO4.
Scheme 139. Attempted oxidation of THF anti-443a using NaIO4.
Another potentially useful transformation of hydrazone anti-443a would be conversion
to cyclic sulfate 478 (Scheme 140). In principle this could then react with an external
nucleophile in a regioselective fashion to give THF 480.256 However, treatment of
hydrazone anti-443a with SO2Cl2 and NEt3 in CH2Cl2 resulted in the rapid decomposition
of anti-443a with no evidence for the target sulfate 478. An alternative route to cyclic
sulfates is via the corresponding cyclic sulfinate.257 Treatment of THF anti-443a with
SOCl2 and NEt3 in CH2Cl2 gave a compound consistent with target sulfinate 479 in 23%
yield with minor impurities. [1H NMR (600 MHz; CDCl3) 5.80 (1H, d, J = 6.0,
CH2CHCH), 5.45 (1H, dd, J = 6.0, 4.1, CH2CH)]. However, sulfinate 479 decomposed
overnight at RT in a solution of CDCl3. The relative stereochemistry of sulfinate 479 was
not established.
Scheme 140. Attempted synthesis of a cyclic sulfate 478.
4.3. Chapter IV Summary
In conclusion, a hydrazone-based methodology has been developed for the synthesis of
chiral THFs from biomass feedstock under sustainable reaction conditions (Scheme 141).
This approach was effective with different pentoses and L-rhamnose and was
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demonstrated on a multi-gram scale. Furthermore, through reduction and hydrolysis of
the hydrazone group, a diverse selection of chiral THFs were prepared without the use of
protecting groups. This included a formal synthesis of 3R-3-hydroxymuscarine.
Scheme 141. Chapter IV Summary.
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Chapter V. Conclusions and Future Work
5.1. Conclusions
In summary, this project has led to the successful development of novel methods to access
a diverse range of medicinally relevant heterocycles (Figure 24). In Chapter II, conditions
were developed for the regioselective cyclotrimerization of amide-tethered diynes and
monoynes, which was applied to the synthesis of highly substituted isoindolinone
products.258 In Chapter III, the kinetically-controlled Diels–Alder reaction of 3-
alkoxyfurans190 and maleimides was developed for the synthesis of endo-
cantharimides.259 This Diels–Alder reaction was explored with the aid of computational
calculations and the methodology extended to access a variety of sp3-rich molecular
scaffolds. In Chapter IV, a hydrazone-mediated cyclization of reducing sugars was
developed for the synthesis of chiral THFs without the use of protecting groups.260
Crucially, the environmental impact of this research has been reduced by using
sustainable solvents and chemicals from biomass-derived feedstocks.
Figure 24. Summary of heterocycles prepared in Chapters II–IV.
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5.2. Future Work
5.2.1. Alkyne Cyclotrimerizations
In Chapter II, the regioselectivity of alkyne cyclotrimerizations was generally controlled
through use for a SiMe3 regiodirecting group, which could then be substituted to prepare
aryl halides. By investigating different directing groups new isoindolinones could be
synthesized.261 For example, a siletane directing group would give an isoindolinone that
could in principle be oxidized to give phenol 504 (Scheme 142). 262 Aryl siletanes have
also been used as the nucleophilic component of Hiyama-type cross-coupling
reactions.263
Scheme 142. Potential application of a siletanes directing group. Reagents and conditions: (i) H2O2,
KF, KHCO3; (ii) ArI, TBAF, [allylPdCl]2, P(tBu)3.
An alternative to an amide-tethered diyne would be ester-tethered diyne 506, which could
be cyclized to form isobenzofuranone 508 (Scheme 143).137 With different monoynes,
this could be used to prepare a selection of aromatic products. The approach could also
be applied to the total synthesis of isopestacin 508,264 a racemic natural product with
antifungal activity.265
Scheme 143. Proposed cyclotrimerizations of ester-tethered diynes and monoynes.
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The cyclization of ketone-tethered diynes would also be an interesting reaction to
explore.137 This class of diyne could be prepared by the selective alkylation of
commercially available methyl ketone 512 (Scheme 144) and cyclized to generate
different indanones 515.266 Indanone 515 could then be used as a substrate for a whole
cell-catalyzed Baeyer–Villiger oxidation to prepare chiral lactone 516.267 If ketone 515
were racemized under the reaction conditions then lactone 516 could be prepared in an
enantioconvergent fashion via a dynamic kinetic resolution. Alternatively, a transaminase
could be used to convert ketone 515 into amine 517.268 If the transaminase was selective
for the formation of one diastereoisomer over the other, this approach would also be an
effective kinetic resolution strategy.
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Scheme 144. Synthesizing substituted 1-indanones via an alkyne cyclotrimerization. Reagents and
conditions: (i) LDA, R1Br; (ii) LDA, propargyl bromide; (iii) cyclohexanone monooxygenase [see Ref
267], Lewatit MP62; (iv) (R)-ω-transaminase [see Ref 268]. 
An interesting observation made in Chapter II was the unusual behaviour of 2-
ethynyltoluene as a monoyne. The reaction of 2-ethynyltoluene and diyne 245a occurred
at a greater rate than the corresponding reaction of phenylacetylene and the reaction
occurred with negligible diyne homo-coupling (Scheme 145). This reactivity could be
explored further by considering the reaction of 2-ethylnytoluene with other diynes and by
considering other 2-substituted phenylacetylenes. This phenomenon could also be
explored with the aid of computational calculations.
Scheme 145. Unusual reactivity of 2-ethynyltoluene 246l.
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5.2.2. Furan-Diels–Alder Reactions
In Chapter III, endo-cantharimides were prepared from 2-substitued 3-alkoxyfurans. An
alternative route to the endo-cantharimide could be via a fused bicyclic furan 525,
prepared from a propargylic alcohol with a pendent nucleophile 524 (Scheme 146). In
principle a furan could be prepared using a pendent oxygen or nitrogen nucleophile, with
the example of a carbamate nucleophile illustrated below. The Diels–Alder reactions of
3-aminofurans have not been widely explored.269
Scheme 146. Proposed synthesis of cantharimides from fused bicyclic furans.
Another direction for further studies could be an asymmetric cantharimide synthesis.
Manna and Mukherjee reported the organocatalytic asymmetric vinylogous Michael
addition of maleimides and deconjugated butenolides270 and a similar approach could be
explored to prepare cantharimides (Scheme 147). Tautomerism of a substituted
furanone271 530 would afford a 3-hydroxyfuran 533, which could form a hydrogen bond
with a chiral amine catalyst. If the same catalyst activated the maleimide through
hydrogen bonding with a thiourea then it could catalyze the Diels–Alder reaction in an
asymmetric fashion. Such a constrained transition state may also improve the
diastereoselectivity of the reaction. The product of the Diels–Alder reaction would be
enol 535, which would tautomerize to give ketone product 532. The cyclization of 3-
alkoxyfurans and dienophiles using chiral Lewis acid catalysts could also be explored.272
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Scheme 147. Proposed asymmetric synthesis of cantharimide 532.
5.2.3. Hydrazone-Mediated Transformations of Reducing Sugars
An interesting extension of the research in Chapter IV would be to prepare THFs from
ketoses. For example, fructose-derived hydrazone 441g may undergo a double
condensation under acidic conditions to give isosorbide-derivative 537 (Scheme 148).
The stereochemistry of the reaction would in principle be controlled by the reversible
nature of the cyclization and the strong thermodynamic preference for cis-fused [5,5]-
ring systems. As discussed in Chapter IV (Section 4.2.4., Scheme 121), a key challenge
with this approach was the synthesis of hydrazone 441g, which was not possible using
the conditions used to prepare hydrazones from pentoses. This could potentially be
addressed by exploring known literature conditions for related reactions,273 such as
Reeves’ reported use of B(OCH2CF3)3 to facilitate imine condensation.274
Scheme 148. Potential application of the hydrazone-methodology to ketoses.
The optimized cyclization has primarily been applied to the synthesis of THFs. If it were
possible to incorporate an internal nitrogen-based nucleophile the methodology could
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potentially be applied to the synthesis of N-heterocyclic compounds (Scheme 149). A
potential route into these compounds would be via amine 538, formed from the reductive
amination of L-arabinose. 275 A selective oxidation of the primary alcohol would give
amino sugar 539.276 This could then be condensed with NH2NMe2 to generate hydrazone
540 and cyclization would give pyrrolidinone 541. While a strong acid may be an
inefficient catalyst for the cyclization of amines (given the propensity to form a salt in a
polar solvent) the reaction could be more effective with a Lewis acid such as BF3.THF.
Using an electronically deactivated N-nucleophile (such as a carbamate) could also
facilitate the cyclization. Another option would be to attempt a cyclization of hydrazone
540 under thermal conditions, without the use of a catalyst.
Scheme 149. Extending the methodology to N-heterocyclic compounds. Reagents and conditions: (i)
RNH2, NaBH3CN, MeOH; (ii) TEMPO, trichloroisocyanuric acid, CH2Cl2 (iii) NH2NMe2, Amberlyst 15,
MeOH.
Another potential area for further investigations would be the trapping of sugar-derived
hydrazones with external nucleophiles. A potential method would be to transform
arabinose-derived hydrazone 431a into acylated product 542 (Scheme 150). The
acylation would simultaneously deactivate the primary hydroxyl group as a nucleophile
and activate the hydroxyl group adjacent to the hydrazone as a leaving group. In principle,
this could be trapped out with a variety of nucleophiles to access a substituted
carbohydrate derivative 543. In a preliminary study, hydrazone 431a was converted to
the acylated product 542. This compound was not stable enough to purify, but the crude
product was concentrated and redissolved in MeOH before being treated with 4-
chloroaniline. This gave a product consistent with hydrazone 543a in 85% isolated yield
as a 60:40 mixture of diastereoisomers.
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Scheme 150. Proposed substitution of acylated hydrazone derivative 542 with external nucleophiles.
The oxidative ring-opening of diol anti-433a was briefly explored in Chapter IV (Section
4.2.5., Scheme 139) but generated a complex mixture, potentially due to oxidation of the
hydrazone group. An alternative approach would be to oxidize carbamate 458 (which has
been prepared as a single stereoisomer) to the corresponding dialdehyde 544, and trap it
out through a double-reductive amination to give chiral morpholine 545 (Scheme 151).
An alternative approach would be to selectively oxidize ammonium salt 546, which could
be potentially prepared through reduction of hydrazone anti-433a. The corresponding
dialdehyde could then condense with the pendent amine to give imine 547, which could
be selectively reduced to give morpholine 548. A key challenge of this approach would
be to avoid epimerization of the remaining stereocentre following oxidation.
Scheme 151. Potential route to chiral morpholines 545 and 548.
Another potentially valuable transformation for cis-diols prepared in Chapter IV would
be selective displacement of one hydroxyl group with a nucleophile. The transformation
of hydrazone anti-433a into a cyclic sulfate was briefly explored (Section 4.2.5., Scheme
140) but proved challenging, potentially due to the instability of the hydrazone group
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under the reaction conditions. An alternative substrate could be carbamate 458, which
could be converted into cyclic sulfate 549 (Scheme 152). The cyclic sulfate could then
be displaced with an external nucleophile to access a variety of chiral THFs 550 as single
stereoisomers.277 Ideally the regioselectivity of the cyclization would be controlled by the
bulky carbamate sterically hindering attack of the proximal electrophilic centre.
Alternatively, deprotonation of the carbamate using NaH would give an internal
nucleophile, which could displace the cyclic sulfate to give ether 551. The regioselectivity
of this reaction would, in principle, be control by the kinetic preference for the formation
of five-membered rings over four-membered rings.
Scheme 152. Application of cyclic sulfates.
A drawback of the optimized acid-mediated cyclization reaction is the need to use a strong
acid as a catalyst, which has associated safety implications278 and, as discussed above,
potentially limits functional group compatibility. An attractive alternative would be to
cyclize arabinose-derived hydrazone 401a under basic conditions (Scheme 153). This
was achieved in a preliminary study by using ethylene carbonate as an activating reagent.
This gave THF 443a with a preference for the syn-diastereoisomer, which is the opposite
selectivity to that observed for the TFA-mediated cyclization.
Scheme 153. Proposed ethylene carbonate-mediated cyclization.
Chapter IV 147
Chapter VI. Experimental Details
6.1. General Experimental
NMR spectra: 1H and 13C NMR spectra were recorded on Bruker AMX-300, Bruker
AMX-400, Bruker Avance 400, Bruker Avance 500 or Brucker Avance 600
spectrometers. All chemical shifts are quoted in ppm relative to tetramethylsilane (δ = 
0.00 ppm) and referenced to residual protonated solvent unless otherwise stated.
Resonances are described as s (singlet), d (doublet), t (triplet), q (quartet), combinations
thereof or m (multiplet). All coupling constants (J) are quoted in Hz to 1 decimal place.
The 13C NMR spectra of novel compounds were assigned with the aid of HSQC NMR
spectra.
Mass spectra: Mass spectra were obtained using either a VG70-SE or MAT 900XP
spectrometer at the Department of Chemistry, University College London. High
resolution values are quoted in Daltons to 4 decimal places and are within 5 ppm of their
theoretical values.
Other data: Infrared spectra were recorded on a Perkin-Elmer 1605 Fourier transform
spectrometer or a Perkin-Elmer spectrum 100 FT-IR spectrometer as thin films.
Absorption maxima (νmax) are quoted in wavenumbers (cm–1) and are described as s
(strong), m (medium) or w (weak) and where relevant br. (broad). Melting points were
obtained using a Reichert hot-stage apparatus and are uncorrected. All optical rotation
was measured on a Perkin-Elmer 343 polarimeter with a path length of 1 dm.
Chromatography: Analytical TLC was carried out using Merck Keiselgel aluminium-
backed plates coated with silica gel, which were inspected under ultraviolet light and
stained with basic potassium permanganate dip. Retention factors (Rf) are quoted with the
solvent system in parentheses. Flash column chromatography was performed using BDH
(40–60 μm) silica gel. Solvent systems are quoted in parentheses. 
All experiments were conducted under an atmosphere of argon or nitrogen in oven-dried
glassware. Solvent was used as commercially supplied unless otherwise stated.
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6.2. General Experimental Procedures
General Amide Formation Procedure
Oxalyl chloride (1.1 eq.) was added dropwise to a stirring solution of acid 242 (1.2 eq.)
and DMF (a few drops) in 2-MeTHF (0.85 mL/mmol of acid 242) at RT. The reaction
was stirred for 1 h before the crude acid chloride solution was added dropwise to a stirring
solution of amine 244 (1.0 eq.) and NEt3 (2.5 eq.) in 2-MeTHF (4.5 mL/mmol of amine
244) at RT. The reaction was stirred for 1 h before being filtered through a silica plug,
eluting with EtOAc. The filtrate was concentrated in vacuo to give the crude amide.
General Cyclization Procedure A- Cyclotrimerization of amide 245a and a
Monoyne under Preliminary Conditions.
According to the modified procedure of Yamamoto et al.137: A solution of monoyne 246
(2.0 mmol) and RuCp*Cl(cod) (19 mg, 0.050 mmol, 10 mol%) in degassed CPME
(2.0 mL) was added dropwise over 15 minutes to a stirring solution of amide 245a (135
mg, 0.500 mmol) in degassed CPME (3.0 mL) at RT. The reaction was monitored by
TLC and then the reaction mixture was filtered through a silica pad, eluting with EtOAc.
The filtrate was concentrated in vacuo to give the crude isoindolinone product.
General Cyclization Procedure B- Cyclotrimerization of a Diyne and a Monoyne
using a 3 h Dropwise Addition.
A solution of diyne (0.26 mmol) in CPME (1.6 mL) was added dropwise over 3 h to a
stirring solution of monoyne (2.0 eq.) and RuCp*Cl(cod) in CPME (1.1 mL) at RT. The
reaction was stirred for a specific period of time before the reaction mixture was filtered
through a silica pad, eluting with EtOAc. The filtrate was concentrated in vacuo to give
the crude isoindolinone product.
General Cyclization Procedure C- Cyclotrimerization of an Internal Diyne and a
Monoyne using a 1 minute Dropwise Addition.
A solution of diyne (0.26 mmol) in CPME (1.6 mL) was added dropwise over 1 minute
to a stirring solution of monoyne (2.0 eq.) and RuCp*Cl(cod) (10 mol%) in CPME
(1.1 mL) at RT. The reaction was stirred for 24 h before the reaction mixture was filtered
through a silica pad, eluting with EtOAc. The filtrate was concentrated in vacuo to give
the crude isoindolinone product.
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General Alkynylation Procedure: Addition of 3,3-diethoxyprop-1-yne to Aldehydes
According to the procedure of Sheppard et al.190: A solution of nBuLi (1.1 eq., 1.6 M in
hexanes) was added dropwise to a stirring solution of 3,3-diethoxyprop-1-yne (1.2 eq.) in
anhydrous THF (2.0 mL/mmol of aldehyde) at –78 °C. The reaction mixture was stirred
at –78 °C for 1 h before the aldehyde (1.0 eq.; neat unless otherwise indicated) was added
dropwise. The reaction was stirred for 16 h, with the reaction allowed to slowly reach RT.
The reaction was then cooled to 0 °C and was quenched by dropwise addition of aq. sat.
NH4Cl (20 mL). The reaction mixture was diluted with EtOAc (20 mL) and the aq. extract
washed with EtOAc (3 × 20 mL). The combined organic extracts were dried (phase
separator) and the filtrate was concentrated in vacuo to give the crude product.
General Furan Procedure: Gold(I)-Catalyzed Cyclization of Propargylic Alcohols
According to the modified Procedure of Sheppard et al.190: A solution of
[PPh3AuNTf2]2PhMe (1 mol%, 2.0 mol% [Au]) in EtOH (50% of total volume) was
added dropwise to a stirring solution of propargylic alcohol 316 in EtOH (50% of total
volume) at RT to give a solution of the stated concentration. The resulting solution was
stirred for 16 h before being purified by flash column chromatography (0 to 10% petrol
30–40 °C: TBME) to give the indicated 3-alkoxyfuran.
General Cycloaddition Procedure: Catalyst-Free [4+2]-Cycloaddition
A solution of dienophile (1.2 eq.) and 3-alkoxyfuran (1.0 eq.) in DMC (1.0 M with respect
to the 3-alkoxyfuran) were stirred at RT until the reaction was judged to be complete by
TLC or LC-MS analysis. The reaction was then diluted with EtOAc and loaded onto an
aminopropyl cartridge. After 5 minutes the cartridge was then washed with EtOAc and
the filtrate was concentrated in vacuo to give the indicated product.
General Hydrazone Synthesis Procedure
A stirring mixture of sugar 440 in MeOH (2.0 M) was treated with NH2NMe2 (2.0 eq.)
and Amberlyst 15 (1.00 g/100 mmol sugar 440) at RT. The resulting mixture was stirred
at RT for 24 h before the mixture was filtered and the filtrate concentrated in vacuo to
give the crude hydrazone.
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General Acid-Catalyzed Cyclization Procedure
A stirring mixture of hydrazone 441 in MeOH (0.50 M) was treated with TFA (20 mol%)
at RT and the reaction stirred at 40 °C for 16 h. The reaction was then quenched with aq.
sat. NaHCO3 and concentrated in vacuo to give the crude hydrazone.
6.3. Compound Synthesis: Experimental Details & Compound
Characterisation
3-(Trimethylsilyl)propiolic acid (242)139
According to the modified procedure of Fleming et al.139: A solution of
ethynyltrimethylsilane (22 mL, 15 g, 150 mmol) in anhydrous THF (120 mL) was added
slowly to a stirring solution of ethyl magnesium bromide (1.0 M in THF, 191 mL,
191 mmol) at 0 °C. The reaction mixture was stirred for 2 h at RT before being cooled to
–20 °C. The solution was cautiously added to solid carbon dioxide (20 g, 450 mmol) and
was stirred for 16 h, with the reaction allowed to slowly reach RT. The reaction was
cooled to 0 °C and was quenched by dropwise addition of 1.0 M aq. HCl. The mixture
was extracted with petrol 40–60 °C (4 × 100 mL), washed with brine (200 mL), dried
(MgSO4) and concentrated in vacuo to give the crude product, which was purified by
vacuum distillation (b.p. 78–80 °C at 8 Torr) to the carboxylic acid 242 as a white
crystalline solid (16.7 g, 117 mmol, 78%); m.p. 38–40 °C; b.p. 78–80 °C at 8 Torr
(literature 108–100 °C at 10 Torr)279; Rf = 0.25 (1:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 3000m br. (O-H), 2965s (C-H), 2181w (C≡C), 1691s (C=O), 1402m, 1254s, 
919s, 847s; 1H NMR (400 MHz; CDCl3) 10.28 (1H, br. s, C(O)OH), 0.28 (9H, s,
Si(CH3)3); 13C NMR (100 MHz; CDCl3) 157.5 (CO2H), 97.5 (C≡C), 93.7 (C≡C), –1.0 
(Si(CH3)3); data in accordance with the literature.139
N-Benzylprop-2-yn-1-amine (244a)140
According to the modified procedure of Burton and Hess140: Propargyl bromide (6.7 mL,
8.8 g, 80 wt. % in PhMe, 60 mmol) was added dropwise to benzylamine (40 mL, 39 g,
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360 mmol) with continuous stirring at RT. The reaction was stirred for 16 h and then
partitioned between 2.0 M aq. NaOH (50 mL) and Et2O (50 mL). The aq. extract was
washed with Et2O (2 × 50 mL) and the combined organic extracts were washed with brine
(100 mL), dried (MgSO4) and concentrated in vacuo. The crude product was purified by
flash column chromatography (3:1 petrol 40–60 °C:EtOAc) to give the amine 244a as a
yellow oil (7.05 g, 48.6 mmol, 81%); Rf = 0.36 (3:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 3292s (CC-H, N-H), 2838s (C-H), 1494s, 1453s; 1H NMR (400 MHz; CDCl3)
7.39–7.26 (5H, m, ArH), 3.91 (2H, s, CH2Ph), 3.46 (2H, d, J = 2.4, CH2C≡C), 2.29 (1H, 
t, J = 2.4, C≡CH); 13C NMR (100 MHz; CDCl3) 139.4 (Ar), 128.5 (Ar), 128.5 (Ar), 127.2
(Ar), 82.1 (C≡C), 71.6 (C≡C), 52.3 (CH2N), 37.4 (CH2N); data in accordance with the
literature.140
N-(tert-Butyl)prop-2-yn-1-amine (244c)147
According to the modified procedure of Sulpizo et al.147: Propargyl bromide (13 mL, 17 g,
80 wt. % in PhMe, 120 mmol) was added dropwise to a stirring solution of 2-
methylpropan-2-amine (37 mL, 26 g, 350 mmol) in Et2O (35 mL) at RT. The reaction
was stirred at RT for 36 h before being concentrated in vacuo. The crude product was
purified by distillation at atmospheric pressure (b.p. = 125–127 °C) to give the amine
244c as a colorless oil (4.10 g, 79 wt. % with PhMe, 29 mmol, 24%); νmax (film/cm–1)
3306s (CC-H), 3245m br. (N-H), 2963s (C-H), 1476s; 1H NMR (600 MHz; CDCl3) 3.27
(2H, d, J = 2.3, CH2N), 2.11 (1H, t, J = 2.3, CCH), 1.03 (9H, s, C(CH3)3); 13C NMR
(150 MHz; CDCl3) 83.4 (C≡CH), 70.8 (C≡CH), 50.9 (C(CH3)3), 32.0 (CH2N), 28.8
(C(CH3)3); data in accordance with the literature.147
N-(Prop-2-ynyl)prop-2-en-1-amine (244d) 280
According to the modified procedure of Li and Marks148: Propargyl chloride (6.8 mL,
7.0 g, 93 mmol) was added dropwise to allylamine (50 mL, 38 g, 660 mmol) with
continuous stirring and the resulting solution was stirred at reflux for 48 h. The reaction
mixture was allowed to cool to RT before being partitioned between water (300 mL) and
Et2O (300 mL). The aq. extract was washed with Et2O (300 mL) and the combined
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organic extracts were dried (MgSO4) and concentrated in vacuo. The crude product was
distilled at atmospheric pressure (b.p. 126–128 °C) to give the-amine 244d as a colorless
oil (3.00 g, 31.5 mmol, 33%); b.p. 126–128 °C at atmospheric pressure (literature 44–
46 °C at 0.22 Torr)280; νmax (film/cm–1) 3297s (CC-H) 3250m br. (N-H), 2832m (C-H),
1644s (C=C), 1452s; 1H NMR (500 MHz; CDCl3) 5.80–5.72 (1H, m, CHCH2N), 5.10
(1H, dq, J = 17.3, 1.2, CHH=CH), 5.00 (1H, dq, J = 10.3, 1.2, CHH=CH), 3.30 (2H, d,
J = 2.5, CH2C≡C)), 3.21 (2H, dt, J = 6.1, 1.2, C=CHCH2), 2.14 (1H, t, J = 2.5, C≡CH);
13C NMR (125 MHz; CDCl3) 135.9 (CH2=CH), 116.6 (CH2=CH), 82.0 (C≡C), 71.5 
(C≡C), 50.8 (CH2CH), 37.2 (CH2C≡C); data in accordance with the literature.280
N-Benzylbut-2-yn-1-amine (244e)281
According to the modified procedure of Burton and Hess140: 1-Bromobut-2-yne (0.66 mL,
1.0 g, 7.5 mmol) was added dropwise to benzylamine (4.9 mL, 4.8 g, 45 mmol) with
continuous stirring at 0 °C. The reaction was stirred for 16 h at RT and then partitioned
between 1.0 M aq. NaOH (30 mL) and Et2O (30 mL). The aq. extract was washed with
Et2O (2 × 30 mL) and the combined organic extracts were washed with brine (100 mL),
dried (MgSO4) and the concentrated in vacuo. The crude product was purified by flash
column chromatography (5:1 petrol 40–60 °C:EtOAc) to give the amine 244e as a
colorless oil (738 mg, 4.64 mmol, 62%); Rf = 0.38 (2:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 3319m (N-H), 2917s (C-H), 1495s, 1453s; 1H NMR (600 MHz; CDCl3) 7.36–
7.31 (4H, m, ArH), 7.27–7.23 (1H, m, ArH), 3.85 (2H, s, CH2Ph), 3.38 (2H, q, J = 2.3,
CH2C≡C), 1.85 (3H, t, J = 2.3, CH3), 1.51 (1H, br. s, NH); 13C NMR (150 MHz; CDCl3)
139.8 (Ar), 128.5 (Ar), 128.5 (Ar), 127.2 (Ar), 79.3 (C≡C), 77.3 (C≡C), 52.7 (PhCH2),
38.0 (CH2C≡C), 3.7 (CH3); data in accordance with the literature.281
N-Benzylpent-2-yn-1-amine (244f)140
According to the modified procedure of Burton and Hess140: 1-bromopent-2-yne
(0.72 mL, 1.0 g, 7.0 mmol) was added dropwise to benzylamine (4.5 mL, 4.5 g, 42 mmol)
with continuous stirring at 0 °C. The reaction was stirred for 16 h at RT and then
partitioned between 1.0 M aq. NaOH (30 mL) and Et2O (30 mL). The aq. extract was
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washed with Et2O (2 × 30 mL) and the combined organic extracts were washed with brine
(100 mL), dried (MgSO4) and the concentrated in vacuo. The crude product was purified
by flash column chromatography (10:1 petrol 40–60 °C:EtOAc) to give the amine 244f
as a pale yellow oil (858 mg, 4.96 mmol, 71%); Rf = 0.24 (5:1 petrol 40–60 °C:EtOAc);
νmax (film/cm–1) 3313w br. (N-H), 2975s (C-H), 1639s, 1453s; 1H NMR (400 MHz;
CDCl3) 7.38–7.32 (4H, m, ArH), 7.30–7.28 (1H, m, ArH), 3.88 (2H, s, CH2Ph), 3.42 (2H,
t, J = 2.2, NCH2C≡C), 2.25 (2H, qt, J = 7.5, 2.2, CH2CH3), 1.53 (1H, br. s, NH), 1.17,
(3H, t, J = 7.5, CH3); 13C NMR (150 MHz; CDCl3) 139.8 (Ar), 128.5 (Ar), 128.5 (Ar),
127.2 (Ar), 85.4 (C≡C), 77.4 (C≡C), 52.6 (CH2Ph), 38.0 (NCH2C≡C), 14.3 (CH3), 12.6
(CH2CH3); data in accordance with the literature.140
N-Benzyl-N-(prop-2-yn-1-yl)-3-(trimethylsilyl)propiolamide (245a)
Prepared from amine 244a (2.84 g, 19.6 mmol) according to the General Coupling
Procedure and purified by flash column chromatography (9:1 petrol 40–60 °C:EtOAc) to
give the amide 245a as a yellow oil (4.48 g, 16.6 mmol, 85%); Rf = 0.44 (6:1 petrol 40–
60 °C:EtOAc); νmax (film/cm–1) 3292m (CC-H), 2962m (C-H), 1634s (C=O), 1417s;
1H NMR (400 MHz; CDCl3) a mixture of rotamers R1 (major) and R2 (minor); 7.40–7.28
(5H, m, ArH R1; 5H, m, ArH R2), 4.93 (2H, s, CH2Ph R1), 4.74 (2H, s, CH2Ph R2), 4.27
(2H, d, J = 2.5, CH2C≡C R2), 4.12 (2H, d, J = 2.5, CH2C≡C R1), 2.35 (1H, t, J = 2.5,
C≡CH R2), 2.25 (1H, t, J = 2.5, C≡CH R1), 0.25 (9H, s, Si(CH3)3 R2), 0.22 (9H, s,
Si(CH3)3 R1); 13C NMR (125 MHz; CDCl3) a mixture of rotamers; 153.6 (C(O)), 153.5
(C(O)), 135.7 (Ar), 135.5 (Ar), 128.9 (Ar), 128.7 (Ar), 128.6 (Ar), 128.2 (Ar), 128.0 (Ar),
127.9 (Ar), 98.7 (C≡C), 98.5 (C≡C), 95.7 (C≡C), 95.3 (C≡C), 77.7 (C≡C), 77.6 (C≡C), 
73.3 (C≡C), 72.6 (C≡C), 51.5 (CH2N), 46.5 (CH2N), 37.6 (CH2C≡CH), 32.3 (CH2C≡CH), 
–0.7 (Si(CH3)3), –0.8 (Si(CH3)3); HRMS (ESI+) found [M+H]+ 270.1308; C16H20NOSi
requires 270.1314.
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N-(Prop-2-ynyl)-3-(trimethylsilyl)propiolamide (245b)
Prepared from propargylamine (0.34 mL, 0.29 g, 5.5 mmol) according to the General
Coupling Procedure and purified by flash column chromatography (5:1 petrol 40–
60 °C:EtOAc) to give the amide 245b as a white crystalline solid (789 mg, 4.40 mmol,
80%); m.p. 42–44 °C; Rf = 0.38 (5:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 3275s
(CC-H and N-H), 2963m (C-H), 1638s (C=O), 1526s; 1H NMR (600 MHz; DMSO-d6)
9.15 (1H, t, J = 5.3, NH), 3.85 (2H, dd, J = 5.3, 2.4, CH2N), 3.13 (1H, t, J = 2.4, C≡CH),
0.21 (9H, s, Si(CH3)3); 13C NMR (125 MHz; DMSO-d6) 151.4 (C(O)), 98.3 (C≡C), 90.5 
(C≡C), 80.1 (C≡C), 73.3 (C≡CH), 28.1 (CH2N), –0.8 (Si(CH3)3); HRMS (CI+) found
[M+H]+ 180.0847; C9H14NOSi requires 180.0847.
N-(tert-Butyl)-N-(prop-2-yn-1-yl)-3-(trimethylsilyl)propiolamide (245c)
Prepared from amine 244c (0.500 mg, 87 wt. % in PhMe, 3.9 mmol) according to the
General Coupling Procedure and purified by flash column chromatography (12:1 petrol
40–60 °C:EtOAc) to give the amide 245c as a white crystalline solid (612 mg, 2.6 mmol,
66%); m.p. 25–27 °C; Rf = 0.34 (12:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 3252s
(CC-H), 2965s (C-H), 1633s (C=O); 1H NMR (600 MHz; DMSO-d6) a mixture of
rotamers R1 (major) and R2 (minor); 4.44 (2H, d, J = 0.5, CH2N R1), 4.23 (2H, br. s, CH2N
R2), 3.35 (1H, t, J = 0.5, CCH R1), 3.32 (1H, br. s, CCH R2), 1.60 (9H, s, C(CH3)3 R2),
1.42 (9H, s, C(CH3)3 R1), 0.22 (9H, s, Si(CH3)3 R1; 9H, s, Si(CH3)3 R2); 13C NMR
(125 MHz; DMSO-d6) 153.4 (C(O)), 97.9 (C≡C), 94.7 (C≡C), 80.9 (C≡C), 74.7 (HC≡C), 
57.6 (C(CH3)3), 29.8 (CH2N), 27.6 (C(CH3)3), –0.8 (Si(CH3)3); HRMS (ES+) found
[M+Na]+ 258.1294; C13H21NNaOSi requires 258.1290.
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N-Allyl-N-(prop-2-ynyl)-3-(trimethylsilyl)propiolamide (245d)
Prepared from amine 244d (300 mg, 3.15 mmol) according to the General Coupling
Procedure and purified by flash column chromatography (10:1 petrol 40–60 °C:EtOAc)
to give the amide 245d as a colorless oil (574 mg, 2.62 mmol, 83%); Rf = 0.43 (10:1
petrol 40–60 °C:EtOAc); νmax (film/cm–1) 3249m (CC-H), 2963m (C-H), 1632s (C=O),
1449s, 1411s; 1H NMR (600 MHz; DMSO-d6) a mixture of rotamers R1 (major) and R2
(minor); 5.90–5.83 (1H, m, CH=CH2 R1), 5.76–5.70 (1H, m, CH=CH2 R2), 5.24–5.16
(2H, m, CH=CH2 R1; 2H, m, CH=CH2, R2), 4.32 (2H, d, J = 2.4, CH2C≡C R2), 4.22 (2H,
d, J = 5.7, NCH2CH R1), 4.11 (2H, d, J = 2.4, CH2C≡C R1), 3.99 (2H, d, J = 5.7, NCH2CH
R2), 3.36 (1H, t, J = 2.4, C≡CH R2), 3.23 (1H, t, J = 2.4, C≡CH R1), 0.24 (9H, s, Si(CH3)3
R2), 0.22 (9H, s, Si(CH3)3 R1); 13C NMR (125 MHz; DMSO-d6) a mixture of rotamers
152.4 (C(O)), 152.3 (C(O)), 132.7 (CH=CH2), 132.0 (CH=CH2), 118.1 (CH=CH2), 118.1
(CH=CH2), 97.3 (C≡C), 96.9 (C≡C), 95.8 (C≡C), 95.7 (C≡C), 98.7 (C≡C), 98.6 (C≡C), 
75.3 (C≡CH), 74.5 (C≡CH), 50.7 (NCH2CH), 46.3 (NCH2CH), 38.0 (CH2C≡C), 33.2 
(CH2C≡C), –0.9 (Si(CH3)3), –0.9 (Si(CH3)3); HRMS (ES+) found [M+H]+ 220.1163;
C12H18NOSi requires 220.1158.
N-Benzyl-N-(but-2-yn-1-yl)-3-(trimethylsilyl)propiolamide (245e)
Prepared from amine 244e (650 mg, 4.09 mmol) according to the General Coupling
Procedure and purified by flash column chromatography (11:1 petrol 40–60 °C:EtOAc)
to give the amide 245e as a colorless oil (826 mg, 2.92 mmol, 71%); Rf = 0.31 (12:1 petrol
40–60 °C:EtOAc); νmax (film/cm–1) 2961s (C-H), 1631s (C=O), 1496s; 1H NMR
(500 MHz; DMSO-d6) a mixture of rotamers R1 (major) and R2 (minor); 7.40–7.21 (5H,
m, ArH R1; 5H, m, ArH R2), 4.81 (2H, s, PhCH2 R1), 4.56 (2H, s, PhCH2 R2), 4.25 (2H,
q, J = 2.3, CH2C≡C R2), 4.01 (2H, q, J = 2.3, CH2C≡C R1), 1.77 (3H, t, J = 2.3, CCH3
R2), 1.74 (3H, t, J = 2.3, CCH3 R1), 0.22 (9H, s, Si(CH3)3 R2), 0.17 (9H, s, Si(CH3)3 R1);
13C NMR (125 MHz; DMSO-d6) a mixture of rotamers; 152.6 (C(O)), 152.5 (C(O)),
136.3 (Ar), 136.2 (Ar), 128.6 (Ar), 128.5 (Ar), 127.8 (Ar), 127.7 (Ar), 127.4 (Ar), 97.6
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(C≡C), 97.3 (C≡C), 96.2 (C≡C), 95.8 (C≡C), 80.9 (C≡C), 80.0 (C≡C), 73.7 (C≡C), 73.6 
(C≡C), 51.3 (CH2Ph), 46.9 (CH2Ph), 38.5 (CH2C≡C), 33.4 (CH2C≡C), 3.0 (CCH3), 3.0
(CCH3), –0.9 (Si(CH3)3), –1.0 (Si(CH3)3); HRMS (CI+) found [M+H]+ 284.1459;
C17H22NOSi requires 284.1465.
N-Benzyl-N-(pent-2-yn-1-yl)-3-(trimethylsilyl)propiolamide (245f)
Prepared from amine 244f (710 mg, 4.10 mmol) according to the General Coupling
Procedure and purified by flash column chromatography (12:1 petrol 40–60 °C:EtOAc)
to give the amide 245f as a colorless oil (823 mg, 2.95 mmol, 72%); Rf = 0.39 (12:1 petrol
40–60 °C:EtOAc); νmax (film/cm–1) 2964s (C-H), 1632s (C=O), 1415s; 1H NMR
(600 MHz; DMSO-d6) a mixture of rotamers R1 (major) and R2 (minor); 7.40–7.23 (5H,
m, ArH R1; 5H, m, ArH R2), 4.82 (2H, s, PhCH2 R1), 4.57 (2H, s, PhCH2 R2), 4.28 (2H,
t, J = 2.0, NCH2C≡C R2), 4.05 (2H, t, J = 2.0, NCH2C≡C R1), 2.18–2.11 (3H, m, CH2CH3
R1; 3H, m, CH2CH3 R2), 1.03–0.98 (3H, m, CH2CH3 R1; 3H, m, CH2CH3 R2), 0.24 (9H,
s, Si(CH3)3 R2), 0.18 (9H, s, Si(CH3)3 R1); 13C NMR (125 MHz; DMSO-d6) a mixture of
rotamers; 152.7 (C(O)), 152.5 (C(O)), 136.4 (Ar), 136.3 (Ar), 128.7 (Ar), 128.5 (Ar),
127.9 (Ar), 127.7 (Ar), 127.5 (Ar), 127.5 (Ar), 97.6 (C≡C), 97.4 (C≡C), 96.2 (C≡C), 95.8 
(C≡C), 86.4 (C≡C), 85.7 (C≡C), 74.0 (C≡C), 73.8 (C≡C), 51.4 (CH2Ph), 47.1 (CH2Ph),
38.6 (NCH2C≡C), 33.5 (NCH2C≡C), 13.6 (CH2CH3), 11.6 (CH2CH3), 11.6 (CH2CH3), –
0.9 (Si(CH3)3), –1.0 (Si(CH3)3); HRMS (CI+) found [M+H]+ 298.1617; C18H24NOSi
requires 298.1622.
N-Benzyl-N-(prop-2-yn-1-yl)but-2-ynamide (245g)137
According to the modified procedure of Yamamoto et al.137: A solution of 2-butynoic
acid (410 mg, 4.88 mmol) in anhydrous CH2Cl2 (3.0 mL) was added dropwise to a stirring
solution of amine 244a (653 mg, 4.50 mmol), DMAP (62 mg, 0.51 mmol) and EDC
(978 mg, 5.09 mmol) in anhydrous CH2Cl2 (8.6 mL) at 0 °C. The reaction was stirred for
16 h at RT before the reaction was partitioned between EtOAc (30 mL) and 1.0 M NaOH
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(30 mL). The aq. extract was washed with EtOAc (3 × 30 mL) and the combined organic
extracts were washed with brine (100 mL), dried (MgSO4) and concentrated in vacuo to
give the crude product. This was dissolved in EtOAc (30 mL) and stirred with Amberlyst
15 (1.00 g) for 5 minutes. The mixture was then filtered and the resin washed with EtOAc
(30 mL). The filtrate was concentrated in vacuo and purified by flash column
chromatography (4:1 petrol 40–60 °C:EtOAc) to give the amide 245g as a colorless oil
(678 mg, 3.21 mmol, 71%); Rf = 0.28 (4:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1)
3290s (CC-H), 2919w (C-H), 1624s (C=O), 1415s; 1H NMR (600 MHz; DMSO-d6) a
mixture of rotamers R1 (major) and R2 (minor); 7.41–7.38 (2H, m, ArH R1/R2), 7.36–7.27
(6H, m, ArH, R1/R2), 7.24–7.21 (2H, m, ArH R1/R2), 4.82 (2H, s, PhCH2 R1), 4.57 (2H,
s, PhCH2 R2), 4.30 (2H, d, J = 2.4, CH2C≡C R2), 4.02 (2H, d, J = 2.4, CH2C≡C R1), 3.37
(1H, t, J = 2.4, C≡CH R2), 3.22 (1H, t, J = 2.4, C≡CH R1), 2.06 (3H, s, CH3 R2), 2.03
(3H, s, CH3 R1); 13C NMR (125 MHz; DMSO-d6) a mixture of rotamers; 153.5 (C(O)),
153.4 (C(O)), 136.3 (Ar), 136.2 (Ar), 128.8 (Ar), 128.6 (Ar), 127.8 (Ar), 127.8 (Ar), 127.5
(Ar), 127.5 (Ar), 90.7 (C≡C), 90.4 (C≡C), 78.7 (C≡C), 79.5 (C≡C), 75.6 (C≡CH), 74.7
(C≡CH), 72.8 (C≡C), 72.6 (C≡C), 51.2 (CH2Ph), 46.8 (CH2Ph), 38.0 (CH2C≡C), 32.7 
(CH2C≡C), 3.5 (CH3), 3.4 (CH3); data in accordance with the literature.137
N-Benzyl-N-(prop-2-yn-1-yl)propiolamide (250)282
K2CO3 (14 mg, 0.10 mmol) was added to a stirring solution of amide 245a (40 mg,
0.15 mmol) in MeOH (2.0 mL) at RT. The reaction was stirred for 10 minutes before
being filtered through a silica plug, eluting with EtOAc. The filtrated was concentrated in
vacuo and the crude product purified by flash column chromatography (3:1 petrol 40–
60 °C:EtOAc) to give the amide 250 as a colorless oil (26 mg, 0.13 mmol, 90%); Rf = 0.21
(4:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 3280s (CC-H), 2106s (C≡C), 1633s (C=O), 
1449s, 1419s; 1H NMR (600 MHz; DMSO-d6) a mixture of rotamers R1 (major) and R2
(minor); 7.41–7.24 (5H, m, ArH R1; 5H, m, ArH R2), 4.85 (2H, s, PhCH2 R1), 4.72 (1H,
s, HC≡CC(O) R2), 4.67 (1H, s, HC≡CC(O) R1), 4.59 (2H, s, PhCH2 R2), 4.32 (2H, d,
J = 2.4, CH2C≡C R2), 4.06 (2H, d, J = 2.5, CH2C≡C R1), 3.19 (1H, t, J = 2.4, CH2C≡CH
R2), 3.24 (1H, t, J = 2.5, CH2C≡CH R1); 13C NMR (150 MHz; DMSO-d6) a mixture of
rotamers; 152.7 (C(O)), 152.6 (C(O)), 136.0 (Ar), 135.9 (Ar), 128.8 (Ar), 128.6 (Ar),
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127.9 (Ar), 127.9 (Ar), 127.6 (Ar), 127.4 (Ar), 83.3 (C≡C), 83.0 (C≡C), 78.5 (C≡C), 78.2 
(C≡C), 75.8 (C≡C), 75.5 (C≡C), 75.3 (C≡C), 74.9 (C≡C), 51.3 (CH2Ph), 47.2 (CH2Ph),
38.2 (CH2C≡C), 33.1 (CH2C≡C); data in agreement with the literature.282
Ethyl 4-((trimethylsilyl)ethynyl)benzoate (253)283
According to the modified procedure of Keana et al.144: Ethyl 4-iodobenzolate (0.43 mL,
700 mg, 2.5 mmol), ethynyltrimethylsilane (0.43 mL, 300 mg, 3.0 mmol), Pd(PPh3)2Cl2
(53 mg, 0.075 mmol, 3.0 mol%) and CuI (29 mg, 0.15 mmol, 6.0 mol%) were added to a
stirring degassed solution of NEt3 (1.3 mL, 0.94 g, 9.3 mmol) in THF (5.0 mL) in a sealed
tube. The reaction mixture was stirred at 80 °C for 2 h before it was allowed to cool to
RT. The reaction mixture was filtered and the residue washed with EtOAc. The filtrate
was concentrated in vacuo and the crude product was purified by flash column
chromatography (40:1 petrol 40–60 °C:EtOAc) to give the ester 253 as a white crystalline
solid (615 mg, 3.00 mmol, 100%); m.p. 24–26 °C (literature 30 °C)283; Rf = 0.29 (40:1
petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2961s (C-H), 2159s (C≡C), 1718s (C=O), 
1605s; 1H NMR (600 MHz; DMSO-d6) 7.98–7.95 (2H, m, ArH), 7.52–7.49 (2H, m, ArH),
4.36 (2H, q, J = 7.2, CH2O), 1.38 (3H, t, J = 7.2, CH3CH2), 0.26 (9H, s, Si(CH3)3); 13C
NMR (125 MHz; DMSO-d6) 166.1 (C(O)), 131.9 (Ar), 130.1 (Ar), 129.4 (Ar), 127.7 (Ar),
104.2 (C≡C), 97.6 (C≡C), 61.2 (CH2O), 14.4 (CH3CH2), –0.1 (Si(CH3)3); data in
accordance with the literature.283
Methyl 4-ethynylbenzoate (246e)284
K2CO3 (345 mg, 0.250 mmol) was added to a stirring solution of ester 253 (615 mg,
2.50 mmol) in MeOH (5.0 mL) at RT. The suspension was stirred for 30 minutes before
the reaction mixture was filtered through a silica plug, eluting with EtOAc. The filtrate
was concentrated in vacuo and the crude product was purified by flash column
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chromatography (40:1 petrol 40–60 °C:EtOAc) to give the ester 246e as a white
crystalline solid (366 mg, 2.28 mmol, 92%); m.p. 80–82 °C (literature 87–88 °C)284;
Rf = 0.26 (40:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 3242s (CC-H), 2952m (C-H),
1700s (C=O), 1607s, 1434s; 1H NMR (600 MHz; DMSO-d6) 7.94 (2H, d, J = 8.3, ArH),
7.61 (2H, d, J = 8.3, ArH), 4.49 (1H, s, CCH), 3.85 (3H, s, CH3O); 13C NMR (150 MHz;
DMSO-d6) 165.6 (C(O)), 132.1 (Ar), 129.6 (Ar), 129.5 (Ar), 126.5 (Ar), 84.0 (CCH), 82.6
(CCH), 52.4 (CH3O); data in accordance with the literature.283
tert-Butyl prop-2-yn-1-ylcarbamate (246f)145
According to the modified procedure of Molander and Cadoret145: Boc2O (7.50 g,
34.4 mmol) was added portionwise to a stirring solution of propargylamine (2.2 mL, 1.9 g,
34 mmol) in CH2Cl2 (60 mL) at RT. The reaction mixture was stirred at RT for 1 h before
it was concentrated in vacuo to give the crude product, which was purified by
recrystallization (Et2O/hexane) to give the amine 246f as an off-white crystalline solid
(4.98 g, 32.1 mmol, 93%); m.p. 32–34 °C (literature 41–42 °C)145; Rf = 0.29 (12:1 petrol
40–60 °C:EtOAc); νmax (film/cm–1) 3306s (CC-H or N-H), 3281s (CC-H or N-H), 2980s
(C-H), 1809m, 1682s (C=O); 1H NMR (500 MHz; CDCl3) 4.85–4.69 (1H, br. s, NH),
3.92–3.81 (2H, br. s, CH2N), 2.20 (1H, t, J = 2.5, C≡CH), 1.43 (9H, s, C(CH3)3); 13C NMR
(500 MHz; CDCl3) 155 (C(O)), 80.2 (C≡C), 80.2 (CMe3), 71.3 (C≡C), 30.4 (CH2N), 28.4
(C(CH3)3); data in accordance with the literature.145
2,2,5,5,8,8-Hexamethyl-3,7-dioxa-2,8-disilanonane (256)146
According to the procedure of Vaultier et al.146: 2-dimethylpropane-1,3-diol (5.00 g,
48.0 mmol) was added portionwise to a stirring mixture of NH(SiMe3)2 (10 mL, 7.7 g,
48 mmol) and Me3SiCl (1.2 mL, 1.0 g, 9.6 mmol) at RT. The reaction was heated to 70 °C
for 2 h before being allowed to cool to RT. Water (50 mL) and Et2O (50 mL) were added
to the reaction mixture and the aq. layer was extracted with Et2O (3 × 50 mL). The
combined organic extracts were dried (MgSO4) and concentrated in vacuo to give the
silyl ether 256 as a colorless oil (10.0 g, 40.7 mmol, 84%); Rf = 0.66 (100:1 petrol 40–
60 °C:EtOAc); νmax (film/cm–1) 2957s (C-H), 1476m; 1H NMR (500 MHz; CDCl3) 3.28
(4H, s, CH2O), 0.80 (6H, s, C(CH3)2), 0.08 (18H, Si(CH3)3); 13C NMR (125 MHz; CDCl3)
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67.9 (CH2O), 37.2 (C(CH3)2), 21.4 (C(CH3)2), –0.5 (Si(CH3)3); data in accordance with
the literature.146
2-Ethynyl-2,3-dihydro-1H-naphtho[1,8-de][1,3,2]diazaborinine (246g)129b
According to the modified procedure of Gandon et al.129b: Silyl ether 256 (4.46 g,
17.9 mmol) and Me3SiCl (4.6 mL, 3.9 g, 36 mmol), were added dropwise to a stirring
solution of potassium ethynyltrifluoroborate (2.50 g, 95% purity, 17.5 mmol) in
anhydrous acetone (22 mL) at RT. The reaction was stirred at RT for 20 h before the
reaction mixture was filtered and the filtrate concentrated in vacuo. The crude
intermediate was dissolved in PhMe (300 mL) and 1,8-diaminonapthaline (2.06 g,
13.0 mmol) was added portionwise to the stirring solution at RT. The reaction was heated
at reflux for 24 h before it was allowed to cool to RT. The reaction was concentrated in
vacuo to give the crude product, which was purified by flash column chromatography
(6:1 petrol 40–60 °C:EtOAc) to give the boramide 246g as a white crystalline solid
(0.950 g, 4.95 mmol, 38%); m.p. 87–89 °C (literature 92 °C)129b; Rf = 0.26 (40:1 petrol
40–60 °C:EtOAc); νmax (film/cm–1) 3426s (N-H), 3405s (N-H), 3241s (CC-H), 2076s
(C≡C), 1595s, 1500s, 1403s; 1H NMR (600 MHz; DMSO-d6) 8.30 (2H, s, NH), 7.03 (2H,
t, J = 8.1, ArH), 6.88 (2H, d, J = 8.1, ArH), 6.42 (2H, d, J = 8.1, ArH), 3.42 (1H, s,
C≡CH); 13C NMR (150 MHz; DMSO-d6) 141.7 (Ar), 135.9 (Ar), 127.6 (Ar), 119.9 (Ar),
116.7 (Ar), 105.5 (Ar), 94.1 (HC≡C), 85.4 (br., BC≡C); data in accordance with the 
literature.129b
2-Benzyl-5-butyl-7-(trimethylsilyl)isoindolin-1-one (247a)
Prepared from amide 245a and 1-hexyne according to General Cyclization Procedure A
(crude ratio 247a:8a = 2:1) and purified by flash column chromatography (16:1 petrol
40–60 °C:EtOAc) to give the isoindolinone 247a (107 mg, 0.304 mmol, 61%).
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Prepared from amide 245a, 1-hexyne and RuCp*Cl(cod) (3 mg, 3 mol%) over 16 h
according to General Cyclization Procedure B (crude ratio 247a:248a = 9:1) and purified
by flash column chromatography (13:1 petrol 40–60 °C:EtOAc) to give the isoindolinone
247a (75 mg, 0.21 mmol, 81%).
The isoindolinone 247a was isolated as a colorless oil; Rf = 0.36 (6:1 petrol 40–
60 °C:EtOAc); νmax (film/cm–1) 2955m (C-H), 2930m (C-H), 1688s (C=O), 1454m,
1409m; 1H NMR (600 MHz; DMSO-d6) 7.34–7.21 (7H, m, ArH), 4.68 (2H, s, CH2N),
4.24 (2H, s, CH2N), 2.60 (2H, t, J = 7.7, ArCH2CH2), 1.51 (2H, m, ArCH2CH2), 1.26 (2H,
m, CH2CH3), 0.83 (3H, t, J = 7.4, CH2CH3), 0.34 (9H, s, Si(CH3)3); 13C NMR (125 MHz;
DMSO-d6) 168.5 (C(O)), 144.8 (Ar), 142.1 (Ar), 137.7 (Ar), 136.9 (Ar), 134.3 (Ar), 134.0
(Ar), 128.6 (Ar), 127.6 (Ar), 127.2 (Ar), 123.7 (Ar), 48.9 (CH2N), 45.4 (CH2N), 35.1
(ArCH2CH2), 33.2 (ArCH2CH2), 21.8 (CH2CH3), 13.7 (CH2CH3), –0.4 (Si(CH3)3);
HRMS (EI+) found [M]+ 351.2011; C22H29NOSi requires 351.2013.
2-Benzyl-5-(tert-butyl)-7-(trimethylsilyl)isoindolin-1-one (247b)
Prepared from 3,3-dimethyl-1-butyne according to General Cyclization Procedure A
(crude ratio 247b:258a = 1:3) and purified by flash column chromatography (12:1 petrol
40–60 °C:EtOAc) to give the isoindolinone 247b (38 mg, 0.11 mmol, 22%).
Prepared from amide 245a, 3,3-dimethyl-1-butyne and RuCp*Cl(cod) (3 mg, 3 mol%)
over 16 h according to General Cyclization Procedure B (crude ratio 247b:248a = 2:1)
and purified by flash column chromatography (12:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 247b (60 mg, 0.17 mmol, 65%).
The isoindolinone 247b was isolated as a white crystalline solid; m.p. 100–102 °C;
Rf = 0.31 (12:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2958s (C-H), 1689s (C=O),
1598m, 1410s; 1H NMR (600 MHz; DMSO-d6) 8.00 (1H, s, ArH), 7.97 (1H, s, ArH),
7.77–7.73 (2H, m, ArH), 7.69–7.66 (3H, m, ArH), 5.13 (2H, s, CH2N), 4.72 (2H, s,
CH2N), 1.71 (9H, s, C(CH3)3), 0.79 (9H, s, Si(CH3)3); 13C NMR (125 MHz; DMSO-d6)
168.8 (C(O)), 153.2 (Ar), 142.4 (Ar), 138.1 (Ar), 136.8 (Ar), 134.5 (Ar), 130.9 (Ar), 129.0
(Ar), 128.0 (Ar), 127.6 (Ar), 121.5 (Ar), 49.5 (CH2N), 45.7 (CH2N), 31.5 (CMe3), 29.5
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(C(CH3)3), 0.0 (Si(CH3)3); HRMS (CI+) found [M+H]+ 352.2093; C22H30NOSi requires
352.2097.
2-Benzyl-5-cyclopropyl-7-(trimethylsilyl)isoindolin-1-one (247h)
Prepared from amide 245a, cyclopropyl acetylene and RuCp*Cl(cod) (3 mg, 3 mol%)
over 16 h according to General Cyclization Procedure B (crude ratio 247h:248a = 10:1)
and purified by flash column chromatography (13:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 247h as a white crystalline solid (72 mg, 0.21 mmol, 81%); m.p. 66–68 °C;
Rf = 0.31 (13:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2951s (C-H), 1686s (C=O),
1600m, 1454s, 1410s; 1H NMR (600 MHz; DMSO-d6) 7.35–7.23 (6H, m, ArH), 7.13
(1H, s, ArH), 4.69 (2H, s, CH2N), 4.25 (2H, s, CH2N), 2.03–1.98 (1H, m, CH(CH2)2),
1.00–0.97 (2H, m, CH(CHH’)2), 0.73–0.69 (2H, m, CH(CHH’)2), 0.35 (9H, s, Si(CH3)3);
13C NMR (150 MHz; DMSO-d6) 168.5 (C(O)), 146.5 (Ar), 142.3 (Ar), 137.7 (Ar), 136.7
(Ar), 134.0 (Ar), 131.9 (Ar), 128.7 (Ar), 127.6 (Ar), 127.3 (Ar), 120.0 (Ar), 48.9 (CH2N),
45.4 (CH2N), 15.5 (CH(CH2)2), 10.1 (CH(CH2)2), –0.4 (Si(CH3)3); HRMS (CI+) found
[M+H]+ 336.1784; C21H26NOSi requires 336.1784.
2-Benzyl-5-(3-chloropropyl)-7-(trimethylsilyl)isoindolin-1-one (247i)
Prepared from amide 245a, 5-chloro-1-pentyne and RuCp*Cl(cod) (3 mg, 3 mol%) over
16 h according to General Cyclization Procedure B (crude ratio 247i:248a = 9:1) and
purified by flash column chromatography (12:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 247i as a colorless oil (81 mg, 0.22 mmol, 83%); Rf = 0.31 (12:1 petrol 40–
60 °C:EtOAc); νmax (film/cm–1) 2951s (C-H), 1684s (C=O), 1600m, 1453s, 1409s;
1H NMR (600 MHz; DMSO-d6) 7.40 (1H, s, ArH), 7.36 (1H, s, ArH), 7.35–7.32 (2H, m,
ArH), 7.30–7.24 (3H, m, ArH), 4.70 (2H, s, CH2N), 4.29 (2H, s, CH2N), 3.61 (2H, t,
J = 6.5, CH2Cl), 2.78 (2H, t, J = 7.6, CH2CH2CH2Cl), 2.01 (2H, m, CH2CH2Cl), 0.36
(9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.4 (C(O)), 143.3 (Ar), 142.3 (Ar),
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137.7 (Ar), 137.1 (Ar), 134.7 (Ar), 134.2 (Ar), 128.7 (Ar), 128.5 (Ar), 127.3 (Ar), 125.1
(Ar), 49.0 (CH2N), 45.4 (CH2N), 44.7 (CH2Cl), 33.8 (CH2CH2Cl), 32.5 (CH2CH2CH2Cl),
–0.4 (Si(CH3)3); HRMS (CI+) found [M+H]+ 372.1548; C21H27ClNOSi requires
372.1550.
2-Benzyl-5-cyclopentyl-7-(trimethylsilyl)isoindolin-1-one (247j)
Prepared from amide 245a, cyclopentyl acetylene and RuCp*Cl(cod) (3 mg, 3 mol%)
over 16 h according to General Cyclization Procedure B (crude ratio 247j:248a = 6:1)
and purified by flash column chromatography (15:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 247j as a colorless oil (78 mg, 0.21 mmol, 81%); Rf = 0.43 (15:1 petrol 40–
60 °C:EtOAc); νmax (film/cm–1) 2951s (C-H), 1686s (C=O), 1599m, 1453s, 1409s;
1H NMR (600 MHz; DMSO-d6) 7.45–7.23 (7H, m, ArH), 4.70 (2H, s, CH2N), 4.28 (2H,
s, CH2N), 3.06–3.00 (1H, m, CH(CH2)2), 2.03–1.98 (2H, m, CHCHH’), 1.78–1.72 (2H,
m, CHCH2CHH’), 1.66–1.59 (2H, m, CHCH2CHH’), 1.56–1.49 (2H, m, CHCHH’), 0.35
(9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.5 (C(O)), 148.6 (Ar), 142.2 (Ar),
137.7 (Ar), 136.8 (Ar), 134.5 (Ar), 133.0 (Ar), 128.7 (Ar), 127.6 (Ar), 127.3 (Ar), 122.4
(Ar), 49.0 (CH2N), 45.6 (CH(CH2)2), 45.4 (CH2N), 34.5 (CH(CH2)2), 25.1 (CHCH2CH2),
–0.4 (Si(CH3)3); HRMS (CI+) found [M+H]+ 364.2091; C23H30NOSi requires 364.2097.
2-Benzyl-5-phenyl-7-(trimethylsilyl)isoindolin-1-one (247k)
Prepared from amide 245a, phenylacetylene and RuCp*Cl(cod) (4 mg, 4 mol%) over 24 h
according to General Cyclization Procedure B (crude ratio 247k:248a = 6:1) and purified
by flash column chromatography (15:1 petrol 40–60 °C:EtOAc) to give the isoindolinone
247k as a white crystalline solid (81 mg, 0.22 mmol, 83%); Rf = 0.25 (15:1 petrol 40–
60 °C:EtOAc); m.p. 117–119 °C; νmax (film/cm–1) 2950s (C-H), 1687s (C=O), 1597m,
1454s, 1409s; 1H NMR (600 MHz; DMSO-d6) 7.80 (1H, s, ArH), 7.75 (1H, d, J = 1.3,
ArH), 7.69–7.66 (2H, m, ArH), 7.50 (2H, t, J = 4.8, ArH), 7.42–7.35 (3H, m, ArH), 7.30–
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7.27 (3H, m, ArH), 4.75 (2H, s, CH2N), 4.40 (2H, s, CH2N), 0.41 (9H, s, Si(CH3)3); 13C
NMR (150 MHz; DMSO-d6) 168.3 (C(O)), 142.7 (Ar), 142.2 (Ar), 140.1 (Ar), 137.8 (Ar),
137.6 (Ar), 135.7 (Ar), 132.6 (Ar), 129.1 (Ar), 128.8 (Ar), 128.0 (Ar), 127.7 (Ar), 127.4
(Ar), 127.2 (Ar), 127.8 (Ar), 49.2 (CH2N), 45.5 (CH2N), –0.4 (Si(CH3)3); HRMS (CI+)
found [M+H]+ 372.1779; C24H26NOSi requires 372.1784.
2-Benzyl-5-o-tolyl-7-(trimethylsilyl)isoindolin-1-one (247l)
Prepared from amide 245a, 1-ethynyl-2-methylbenzene and RuCp*Cl(cod) (3 mg,
3 mol%) over 16 h according to General Cyclization Procedure B (crude ratio 247l:248a
>10:1) and purified by flash column chromatography (17:1 petrol 40–60 °C:EtOAc) to
give the isoindolinone 247l as a colorless oil (95 mg, 0.25 mmol, 93%); Rf = 0.28 (17:1
petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2956s (C-H), 1689s (C=O), 1598m, 1454s,
1410s; 1H NMR (600 MHz; DMSO-d6) 7.52 (1H, s, ArH), 7.45 (1H, s, ArH), 7.38–7.21
(9H, m, ArH), 4.74 (2H, s, CH2N), 4.38 (2H, s, CH2N), 2.22 (3H, s, ArCH3), 0.38 (9H, s,
Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.3 (C(O)), 143.1 (Ar), 142.0 (Ar), 140.9
(Ar), 137.6 (Ar), 136.9 (Ar), 135.3 (Ar), 134.7 (Ar), 134.6 (Ar), 130.5 (Ar), 129.6 (Ar),
128.8 (Ar), 127.8 (Ar), 127.7 (Ar), 127.4 (Ar), 126.1 (Ar), 124.8 (Ar), 49.2 (CH2N), 45.5
(CH2N), 20.2 (ArCH3), –0.4 (Si(CH3)3); HRMS (CI+) found [M+H]+ 386.1939;
C25H28NOSi requires 386.1935.
2-Benzyl-5-(p-tolyl)-7-(trimethylsilyl)isoindolin-1-one (247c)
Prepared from 4-ethynyltoluene according to General Cyclization Procedure A (crude
ratio 247c:248a = 2:1) and purified by flash column chromatography (6:1 petrol 40–
60 °C:EtOAc) to give the isoindolinone 247c (82 mg, 0.21 mmol, 42%).
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Prepared from amide 245a, 4-ethynyltoluene and RuCp*Cl(cod) (4 mg, 4 mol%) over
24 h according to General Cyclization Procedure B (crude ratio 247c:248a = 6:1) and
purified by flash column chromatography (15:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 247c (82 mg, 0.22 mmol, 81%).
The isoindolinone 247c was isolated as a white crystalline solid; Rf = 0.50 (6:1 petrol 40–
60 °C:EtOAc); m.p. 78–80 °C; νmax (film/cm–1) 2950s (C-H), 1686s (C=O), 1453s, 1409s;
1H NMR (600 MHz; DMSO-d6) 7.76 (1H, s, ArH), 7.73–7.72 (1H, m, ArH), 7.58–7.56
(2H, m, ArH), 7.38–7.34 (2H, m, ArH), 7.30–7.27 (5H, m, ArH), 4.74 (2H, s, CH2N),
4.38 (2H, s, CH2N), 2.34 (3H, s, ArCH3), 0.40 (9H, s, Si(CH3)3); 13C NMR (150 MHz;
DMSO-d6) 168.3 (C(O)), 142.7 (Ar), 142.1 (Ar), 137.7 (Ar), 137.6 (Ar), 137.4 (Ar), 137.1
(Ar), 135.4 (Ar), 132.3 (Ar), 129.7 (Ar), 128.8 (Ar), 127.7 (Ar), 127.3 (Ar), 127.0 (Ar),
122.4 (Ar), 49.2 (CH2N), 45.5 (CH2N), 20.7 (ArCH3), –0.4 (Si(CH3)3); HRMS (ESI+)
found [M-Me]+ 370.1620; C24H24NOSi requires 370.1627.
2-Benzyl-5-(2-bromophenyl)-7-(trimethylsilyl)isoindolin-1-one (247m)
Prepared from amide 245a, 1-ethynyl-2-methylbenzene and RuCp*Cl(cod) (3 mg,
3 mol%) over 16 h according to General Cyclization Procedure B (crude ratio 247m:248a
= 8:1) and purified by flash column chromatography (20:1 petrol 40–60 °C:EtOAc) to
give the isoindolinone 247m as a colorless oil (95 mg, 0.21 mmol, 80%); Rf = 0.37 (15:1
petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2974s (C-H), 1688s (C=O), 1602m, 1452s,
1409s; 1H NMR (600 MHz; DMSO-d6) 7.74 (1H, dd, J = 8.0, 0.8, ArH), 7.56 (2H, d,
J = 2.9, ArH), 7.47–7.45 (1H, m, ArH), 7.42–7.40 (1H, m, ArH), 7.37–7.26 (6H, m, ArH),
4.75 (2H, s, CH2N), 4.38 (2H, s, CH2N), 0.38 (9H, s, Si(CH3)3); 13C NMR (150 MHz;
DMSO-d6) 168.2 (C(O)), 142.1 (Ar), 141.8 (Ar), 141.4 (Ar), 137.6 (Ar), 136.7 (Ar), 135.9
(Ar), 134.9 (Ar), 133.2, (Ar), 131.5 (Ar), 129.8 (Ar), 128.7 (Ar), 128.2 (Ar), 127.8 (Ar),
127.4 (Ar), 125.0 (Ar), 121.6 (Ar), 49.2 (CH2N), 45.5 (CH2N), –0.4 (Si(CH3)3); HRMS
(CI+) found [M+H]+ 450.0870; C24H2579BrNOSi requires 450.0889.
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2-benzyl-5-(4-bromophenyl)-7-(trimethylsilyl)isoindolin-1-one (247n)
Prepared from amide 245a, 1-ethynyl-2-methylbenzene and RuCp*Cl(cod) (3 mg,
3 mol%) over 24 h according to General Cyclization Procedure B (crude ratio 247n:248a
= 5:1) and purified by flash column chromatography (12:1 petrol 40–60 °C:EtOAc) to
give the isoindolinone 247n as a colorless oil (98 mg, 0.22 mmol, 83%); Rf = 0.20 (15:1
petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2950s (C-H), 1684s (C=O), 1600s, 1495s,
1453s, 1409s; 1H NMR (600 MHz; DMSO-d6) 7.77 (1H, s, ArH), 7.72 (1H, s, ArH), 7.29–
7.26 (3H, m, ArH), 7.37–7.33 (2H, m, ArH), 7.66–7.60 (4H, m, ArH), 4.74 (2H, s, CH2N),
4.37 (2H, s, CH2N), 0.40 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.2
(C(O)), 142.7 (Ar), 140.8 (Ar), 139.2 (Ar), 137.9 (Ar), 137.6.9 (Ar), 136.0 (Ar), 132.4
(Ar), 132.0 (Ar), 129.3 (Ar), 128.7 (Ar), 127.7 (Ar), 127.4 (Ar), 122.6 (Ar), 121.6 (Ar),
49.2 (CH2N), 46.2 (CH2N), –0.4 (Si(CH3)3); HRMS (CI+) found [M+H]+ 450.0877;
C24H2579BrNOSi requires 450.0889.
Methyl 4-(2-benzyl-1-oxo-7-(trimethylsilyl)isoindolin-5-yl)benzoate (247e)
Prepared from amide 245a, methyl 4-ethynylbenzoate 246e and RuCp*Cl(cod) (3 mg,
3 mol%) over 24 h according to General Cyclization Procedure B (crude ratio
247e:248a = 5:1) and purified by flash column chromatography (15:1 petrol 40–
60 °C:EtOAc) to give the isoindolinone 247e as a colorless oil (89 mg, 0.21 mmol, 79%);
Rf = 0.29 (9:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2951s (C-H), 1720s (ester C=O)
1686s (lactam C=O), 1608s, 1434s, 1410s; 1H NMR (600 MHz; DMSO-d6) 8.05 (1H, s,
ArH), 8.03 (1H, s, ArH), 7.83–7.77 (4H, m, ArH), 7.36–7.32 (2H, m, ArH), 7.29–7.26
(3H, m, ArH), 4.73 (2H, s, CH2N), 4.37 (2H, s, CH2N), 3.89 (3H, s, OCH3)), 0.41 (9H, s,
Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.1 (C(O)), 166.0 (C(O)), 144.5 (Ar),
142.7 (Ar), 140.8 (Ar), 138.0 (Ar), 137.5 (Ar), 136.5 (Ar), 132.7 (Ar), 129.9 (Ar), 128.9
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(Ar), 128.7 (Ar), 127.7 (Ar), 127.5 (Ar), 127.4 (Ar), 123.1 (Ar), 52.2 (OCH3), 49.2
(CH2N), 45.5 (CH2N), –0.4 (Si(CH3)3); HRMS (ES+) found [M+Na]+ 452.1642;
C26H27NNaO3Si requires 452.1658.
2-Benzyl-5-(4-methoxyphenyl)-7-(trimethylsilyl)isoindolin-1-one (247o)
Prepared from amide 245a, 1-ethynyl-4-methoxybenzene and RuCp*Cl(cod) (5 mg,
5 mol%) over 24 h according to General Cyclization Procedure B (crude ratio
247o:248a = 6:1) and purified by flash column chromatography (12:1 petrol 40–
60 °C:EtOAc) to give the isoindolinone 247o (83 mg, 0.21 mmol, 79%) as a colorless oil;
Rf = 0.28 (15:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2952s (C-H), 1685s (C=O),
1606s 1516s, 1454s, 1409s; 1H NMR (600 MHz; DMSO-d6) 7.73 (1H, s, ArH), 7.71 (1H,
s, ArH), 7.61 (2H, d, J = 8.7, ArH), 7.36–7.33 (2H, m, ArH), 7.28–7.26 (3H, m, ArH),
7.04 (2H, d, J = 8.7 ArH), 4.72 (2H, s, CH2N), 4.35 (2H, s, CH2N), 3.78 (3H, s, OCH3),
0.40 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.4 (C(O)), 159.3 (Ar), 142.7
(Ar), 141.8 (Ar), 137.6 (Ar), 137.6 (Ar), 135.0 (Ar), 132.3 (Ar), 132.1 (Ar), 128.7 (Ar),
128.3 (Ar), 127.7 (Ar), 127.4 (Ar), 122.1 (Ar), 114.5 (Ar), 55.2 (OCH3), 49.1 (CH2N),
45.5 (CH2N), –0.4 (Si(CH3)3); HRMS (ES+) found [M+Na]+ 424.1694; C25H27NNaO2Si
requires 424.1709.
2-Benzyl-5-(4-(dimethylamino)phenyl)-7-(trimethylsilyl)isoindolin-1-one (247p)
Prepared from amide 245a, 4-ethynyl-N,N-dimethylaniline and RuCp*Cl(cod) (10 mg,
10 mol%) over 24 h according to General Cyclization Procedure B (crude ratio
247p:248a = 7:1) and purified by flash column chromatography (10:1 petrol 40–
60 °C:EtOAc) to give the isoindolinone 247p (86 mg, 0.21 mmol, 79%) as a colorless oil;
Rf = 0.27 (10:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2897s (C-H), 1682s (C=O),
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1609s, 1592s 1526s, 1452s, 1409s; 1H NMR (600 MHz; DMSO-d6) 7.70 (2H, s, ArH),
7.53 (2H, d, J = 8.8, ArH), 7.37–7.34 (2H, m, ArH), 7.30–7.26 (3H, m, ArH), 6.81 (2H,
d, J = 8.8, ArH), 4.72 (2H, s, CH2N), 4.35 (2H, s, CH2N), 2.93 (6H, s, N(CH3)2)), 0.40
(9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.5 (C(O)), 150.2 (Ar), 142.7 (Ar),
142.3 (Ar), 137.7 (Ar), 137.4 (Ar), 134.2 (Ar), 131.4 (Ar), 128.7 (Ar), 127.7 (Ar), 127.7
(Ar), 127.4 (Ar), 127.1 (Ar), 121.2 (Ar), 112.7 (Ar), 49.2 (CH2N), 45.5 (CH2N), 39.9
(N(CH3)2), –0.3 (Si(CH3)3); HRMS (ES+) found [M+H]+ 415.2219; C26H31N2OSi
requires 415.2206.
2-Benzyl-5-(methoxymethyl)-7-(trimethylsilyl)isoindolin-1-one (247d)
Prepared from 3-methoxy-1-propyne according to General Cyclization Procedure A
(crude ratio 247d:248a = 2:1) and purified by flash column chromatography (6:1 petrol
40–60 °C:EtOAc) to give the isoindolinone 247d (79 mg, 0.23 mmol, 47%).
Prepared from amide 245a, 3-methoxy-1-propyne and RuCp*Cl(cod) (3 mg, 3 mol%)
over 16 h according to General Cyclization Procedure B (crude ratio 247d:248a = 3:2)
and purified by flash column chromatography (12:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 247d (50 mg, 0.15 mmol, 56%).
The isoindolinone 247d was isolated as a white crystalline solid; m.p. 57–59 °C; Rf = 0.26
(12:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2896s (C-H), 1684s (C=O), 1453s, 1409s;
1H NMR (600 MHz; DMSO-d6) 7.48 (s, 2H, ArH), 7.37–7.33 (2H, m, ArH), 7.29–7.26
(3H, m, ArH), 4.71 (2H, s, CH2N), 4.49 (2H, s, CH2O), 4.33 (2H, s, CH2N), 3.31 (3H, s,
OCH3), 0.36 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.4 (C(O)), 142.1 (Ar),
140.7 (Ar), 137.6 (Ar), 137.0 (Ar), 135.9 (Ar), 132.9 (Ar), 128.7 (Ar), 127.7 (Ar), 127.4
(Ar), 123.1 (Ar), 73.5 (CH2O), 57.8 (OCH3), 49.1 (CH2N), 45.5 (CH2N), –0.4 Si(CH3)3);
HRMS (ESI+) found [M]+ 339.1647; C20H25NO2Si requires 339.1649.
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2-Benzyl-5-(diethoxymethyl)-7-(trimethylsilyl)isoindolin-1-one (247q)
Prepared from amide 245a, 3,3-diethoxyprop-1-yne and RuCp*Cl(cod) (3 mg, 3 mol%)
over 24 h according to General Cyclization Procedure B (crude ratio 247q:248a = 0.8:1)
and purified by flash column chromatography (17:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 247q (45 mg, 0.11 mmol, 43%) as a colorless oil; Rf = 0.27 (17:1 petrol
40–60 °C:EtOAc); νmax (film/cm–1) 2874s (C-H), 1689s (C=O), 1454s, 1409s; 1H NMR
(600 MHz; DMSO-d6) 7.59 (1H, s, ArH), 7.57 (1H, s, ArH), 7.37–7.26 (5H, m, ArH),
5.56 (1H, s, CH(OEt)2), 4.72 (2H, s, CH2N), 4.36 (2H, s, CH2N), 3.59–3.53 (2H, m,
OCHH’), 3.32–3.46 (2H, m, OCHH’), 1.14 (6H, t, J = 7.0, CH2CH3), 0.36 (9H, s,
Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.3 (C(O)), 141.9 (Ar), 141.3 (Ar), 137.6
(Ar), 136.8 (Ar), 136.6 (Ar), 132.0 (Ar), 128.7 (Ar), 127.7 (Ar), 127.4 (Ar), 122.4 (Ar),
100.9 (CH(OEt)2), 61.1 (OCH2), 49.2 (CH2N), 45.5 (CH2N), 15.2 (CH2CH3), –0.4
(Si(CH3)3); HRMS (ES+) found [M+Na]+ 420.1970; C23H31NNaO3Si requires 420.1971.
2-Benzyl-5-(1H-naphtho[1,8-de][1,3,2]diazaborinin-2(3H)-yl)-7-
(trimethylsilyl)isoindolin-1-one (247g)
Prepared from amide 245a, boramide 246g and RuCp*Cl(cod) (5 mg, 5 mol%) over 24 h
according to General Cyclization Procedure B (crude ratio 247g:248a = 3:1) and purified
by flash column chromatography (3:1 petrol 40–60 °C: Et2O) to give the isoindolinone
247g as a white crystalline solid (67 mg, 0.15 mmol, 55%); m.p. 96–98 °C; Rf = 0.56 (2:3
petrol 40–60 °C: Et2O); νmax (film/cm–1) 3333s (N-H), 2952s (C-H), 1672s (C=O), 1599s,
1512s, 1405s; 1H NMR (600 MHz; DMSO-d6) 8.35 (2H, s, NH), 8.02 (1H, s, ArH), 7.96
(1H, s, ArH), 7.39–7.36 (2H, m, ArH), 7.31–7.28 (3H, m, ArH), 7.09 (2H, t, J = 8.0,
ArH), 6.91 (2H, d, J = 8.0, ArH) 6.59 (2H, d, J = 7.2, ArH), 4.76 (2H, s, CH2N), 4.42
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(2H, s, CH2N), 0.44 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.6 (C(O)),
142.3 (Ar), 140.8 (Ar), 138.0 (Ar), 137.9 (Ar), 137.7 (Ar), 136.0 (Ar), 136.0 (Ar), 128.8
(Ar), 128.4 (Ar), 127.7 (Ar), 127.7 (Ar), 127.4 (Ar), 119.8 (Ar), 116.4 (Ar), 105.8 (Ar),
49.2 (CH2N), 45.5 (CH2N), –0.1 (Si(CH3)3), N2BC not observed; HRMS (EI+) found [M]+
461.2089; C28H28BN3OSi requires 461.2089.
tert-Butyl ((2-benzyl-1-oxo-7-(trimethylsilyl)isoindolin-5-yl)methyl)carbamate
(247f)
Prepared from amide 245a, carbamate 246f and RuCp*Cl(cod) (5 mg, 5 mol%) over 24 h
according to General Cyclization Procedure B (crude ratio 247f:248a = 2:1) and purified
by flash column chromatography (8:1 petrol 40–60 °C:EtOAc) to give the isoindolinone
247f as a white crystalline solid (71 mg, 0.17 mmol, 63%); m.p. 124–126 °C; Rf = 0.44
(4:1 petrol 40–60 °C: Et2O); νmax (film/cm–1) 3334s (N-H), 2975s (C-H), 1685s (lactam
and carbamate C=O), 1516s, 1454s, 1411s; 1H NMR (600 MHz; DMSO-d6) a mixture of
rotamers R1 (major) and R2 (minor) 7.51–7.45 (2H, m, ArH, NH R1; 2H, m, ArH, NH
R2), 7.38–7.34 (3H, m, ArH R1; 3H, m, ArH R2), 7.30–7.24 (3H, m, ArH R1; 3H, m, ArH
R2), 4.71 (2H, s, CH2NCH2 R1; 2H, s, CH2NCH2 R2), 4.32 (2H, s, CH2NCH2 R1; 2H, s,
CH2NCH2 R2), 4.20 (2H, s, J = 6.2, CH2NH R1) 4.13 (2H, br. s, CH2NH R2) 1.39 (9H, s,
C(CH3)3 R1), 1.29 (9H, s, C(CH3)3 R2), 0.35 (9H, s, Si(CH3)3 R1; 9H, s, Si(CH3)3 R2); 13C
NMR (150 MHz; DMSO-d6) 168.4 (lactam C(O)), 155.9 (carbamate C(O)), 142.7 (Ar),
142.1 (Ar), 137.7 (Ar), 136.9 (Ar), 135.2 (Ar), 132.6 (Ar), 128.7 (Ar), 127.7 (Ar), 127.3
(Ar), 122.6 (Ar), 77.9 (C(CH3)3), 49.1 (CH2NCH2), 45.5 (CH2NCH2), 43.5 (CH2NH),
28.3 (CMe3), –0.4 (Si(CH3)3); HRMS (ES+) found [M+H]+ 425.2274; C24H33N2O3Si
requires 425.2260.
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2-Benzyl-5-(pyridin-2-yl)-7-(trimethylsilyl)isoindolin-1-one (247r)
Prepared from amide 245a, 2-ethynylpyridine and RuCp*Cl(cod) (20 mg, 20 mol%) over
24 h according to General Cyclization Procedure B (crude ratio 247r:248a = 2:1) and
purified by flash column chromatography (3:1 petrol 40–60 °C: Et2O) to give the
isoindolinone 247r as a colorless oil (49 mg, 0.13 mmol, 50%); Rf = 0.40 (1:1 petrol 40–
60 °C: Et2O); νmax (film/cm–1) 2973s (C-H), 1686s (C=O), 1587s, 1409s; 1H NMR
(600 MHz; DMSO-d6) 8.71–8.70 (1H, m, ArH), 8.26–8.25 (1H, m, ArH), 8.20–8.20 (1H,
m, ArH), 7.99–7.98 (1H, m, ArH), 7.93–7.89 (1H, m, ArH), 7.40–7.35 (3H, m, ArH),
7.31–7.27 (3H, m, ArH), 4.75 (2H, s, CH2N), 4.42 (2H, s, CH2N), 0.42 (9H, s, Si(CH3)3);
13C NMR (150 MHz; DMSO-d6) 168.2 (C(O)), 155.7 (Ar), 149.8 (Ar), 142.5 (Ar), 140.3
(Ar), 137.6 (Ar), 137.5 (Ar), 137.5 (Ar), 137.1 (Ar), 132.3 (Ar), 128.8 (Ar), 127.7 (Ar),
127.4 (Ar), 123.1 (Ar), 122.5 (Ar), 121.0 (Ar), 49.3 (CH2N), 45.6 (CH2N), –0.3
(Si(CH3)3). HRMS (CI+) found [M+H]+ 371.1708; C23H25N2OSi requires 373.1731.
5-Butyl-7-(trimethylsilyl)isoindolin-1-one (264a)
Prepared from amide 245b, 1-hexyne and Cp*RuCl(cod) (10 mg, 10 mol%) over 24 h
according to the General Cyclization Procedure B (crude ratio 264a:265 = 2:1) and
purified by flash column chromatography (5:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 264a as a white crystalline solid (35 mg, 0.13 mmol, 51%); m.p. 140–
142 °C; Rf = 0.57 (2:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 3307m (N-H), 2968s (C-
H), 1690s (C=O); 1H NMR (600 MHz; DMSO-d6) 8.37 (1H, s, NH), 7.36 (1H, s, ArH),
7.33 (1H, s, ArH), 4.30 (2H, s, CH2N), 2.66 (2H, t, J = 7.7, ArCH2CH2), 1.59–1.53 (2H,
m, ArCH2CH2), 1.32 (2H, sextet, J = 7.4, CH2CH3), 0.90 (3H, t, J = 7.4, CH2CH3), 0.32
(9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 171.2 (C(O)), 144.7 (Ar), 144.6 (Ar),
136.6 (Ar), 134.9 (Ar), 133.9 (Ar), 124.1 (Ar), 44.7 (CH2N), 35.1 (ArCH2CH2), 33.3
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(ArCH2CH2), 21.9 (CH2CH3), 13.8 (CH2CH3), –0.3 (Si(CH3)3); HRMS (ES+) found [M-
Me]+ 246.1302; C14H20NOSi requires 246.1314.
5-(o-Tolyl)-7-(trimethylsilyl)isoindolin-1-one (264b)
Prepared from amide 245b, 2-ethynyltoluene and RuCp*Cl(cod) (10 mg, 10 mol%) over
24 h according to the General Cyclization Procedure B (crude ratio 264b:265 = 7:1) and
purified by flash column chromatography (2:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 264b as a white crystalline solid (48 mg, 0.16 mmol, 62%); m.p. 133–
135 °C; Rf = 0.30 (2:1 EtOAc: petrol 40–60 °C); νmax (film/cm–1) 3190 (N-H), 2947s (C-
H), 1690s (C=O), 1450s; 1H NMR (600 MHz; DMSO-d6) 8.53 (1H, s, NH), 7.53 (1H, s,
ArH), 7.43 (1H, s, ArH), 7.33–7.24 (4H, m, ArH), 4.40 (2H, s, CH2N), 2.24 (3H, s,
ArCH3), 0.32 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 171.0 (C(O)), 144.4
(Ar), 143.0 (Ar), 141.0 (Ar), 136.7 (Ar), 135.9 (Ar), 134.7 (Ar), 134.4 (Ar), 130.5 (Ar),
129.6 (Ar), 127.7 (Ar), 126.1 (Ar), 125.0 (Ar), 45.0 (CH2N), 20.2 (ArCH3), –0.3
(SiCH3)3); HRMS (CI+) found [M+H]+ 296.1458; C18H22NOSi requires 296.1470.
2-(tert-Butyl)-5-butyl-7-(trimethylsilyl)isoindolin-1-one (267a)
Prepared from amide 245c, 1-hexyne and RuCp*Cl(cod) (3 mg, 3 mol%) over 16 h
according to General Cyclization Procedure B (crude ratio 267a:268 = 10:1) and purified
by flash column chromatography (30:1 petrol 40–60 °C:EtOAc) to give the isoindolinone
267a (70 mg, 0.22 mmol, 84%); Rf = 0.36 (30:1 EtOAc:petrol 40–60 °C); νmax (film/cm–
1) 2957s (C-H), 1681s (C=O), 1455s; 1H NMR (600 MHz; DMSO-d6) 7.32 (1H, s, ArH),
7.31 (1H, s, ArH), 4.48 (2H, s, CH2N), 2.65 (2H, t, J = 7.7 ArCH2CH2), 1.54 (2H, m,
ArCH2CH2), 1.47 (9H, s, C(CH3)3), 1.30 (2H, sextet, J = 7.3, CH2CH3), 0.89 (3H, t,
J = 7.3, CH2CH3), 0.31 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.9 (C(O)),
144.3 (Ar), 141.7 (Ar), 136.3 (Ar), 136.0 (Ar), 134.0 (Ar), 123.4 (Ar), 53.5 (CMe3), 47.8
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(CH2N), 35.1 (ArCH2CH2), 33.4 (ArCH2CH2), 27.5 (C(CH3)3), 21.8 (CH2CH3), 13.8
(CH2CH3), –0.2 (Si(CH3)3); HRMS (CI+) found [M+H]+ 318.2252; C19H32NOSi requires
318.2248.
2-(tert-Butyl)-5-phenyl-7-(trimethylsilyl)isoindolin-1-one (267b)
Prepared from amide 245c, phenylacetylene and RuCp*Cl(cod) (4 mg, 4 mol%) over 24 h
according to General Cyclization Procedure B (crude ratio 267b:268 > 10:1) and purified
by flash column chromatography (35:1 petrol 40–60 °C:EtOAc) to give the isoindolinone
267b as a white crystalline solid (79 mg, 0.23 mmol, 89%); m.p. 73–75 °C; Rf = 0.36
(30:1 EtOAc: petrol 40–60 °C); νmax (film/cm–1) 2963s (C-H), 1677s (C=O), 1448s;
1H NMR (600 MHz; DMSO-d6) 7.78 (1H, s, ArH), 7.72–7.70 (1H, m, ArH), 7.69–7.67
(2H, m, ArH), 7.50 (2H, t, J = 9.3, ArH), 7.43–7.39 (1H, m, ArH), 4.60 (2H, s, CH2N),
1.51 (9H, s, C(CH3)3), 0.37 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.6
(C(O)), 142.2 (Ar), 141.8 (Ar), 140.2 (Ar), 137.7 (Ar), 137.0 (Ar), 132.4 (Ar), 129.1 (Ar),
127.9 (Ar), 127.2 (Ar), 122.2 (Ar), 53.7 (CMe3), 48.1 (CH2N), 27.5 (C(CH3)3), –0.3
(Si(CH3)3); HRMS (ES+) found [M+H]+ 338.1940; C21H28NOSi requires 338.1940.
2-(tert-Butyl)-5-(o-tolyl)-7-(trimethylsilyl)isoindolin-1-one (267c)
Prepared from amide 245c, 2-ethynyltoluene and RuCp*Cl(cod) (3 mg, 3 mol%) over
16 h according to the General Cyclization Procedure B (crude ratio 267c:268 >10:1) and
purified by flash column chromatography (20:1 petrol 40–60 °C:EtOAc) to give the
isoindolinone 267c as a yellow oil (87 mg, 0.25 mmol, 94%); Rf = 0.31 (20:1 EtOAc:
petrol 40–60 °C); νmax (film/cm–1) 2973s (C-H), 1680s (C=O), 1452s; 1H NMR
(600 MHz; DMSO-d6) 7.48 (1H, s, ArH), 7.40 (1H, s, ArH), 7.31–7.21 (3H, m, ArH),
7.21–7.18 (1H, m, ArH), 4.58 (2H, s, CH2N), 2.21 (3H, s, ArCH3), 1.49 (9H, s, C(CH3)3),
0.33 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.6 (C(O)), 142.9 (Ar), 141.5
(Ar), 141.1 (Ar), 137.3 (Ar), 136.1 (Ar), 134.7 (Ar), 134.4 (Ar), 130.5 (Ar), 129.6 (Ar),
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127.6 (Ar), 126.0 (Ar), 124.3 (Ar), 53.6 (CMe3), 48.0 (CH2N), 27.4 (C(CH3)3), 20.2
(ArCH3), –0.3 (Si(CH3)3); HRMS (CI+) found [M+H]+ 352.2088; C22H30NOSi requires
352.2097.
2-Benzyl-5-butyl-4-methyl-7-(trimethylsilyl)isoindolin-1-one (273a) and 2-Benzyl-
6-butyl-4-methyl-7-(trimethylsilyl)isoindolin-1-one (274a)
Prepared from amide 245e and 1-hexyne according to the General Cyclization Procedure
C (crude ratio 273a:274a = 9:1) and purified by flash column chromatography (15:1
petrol 40–60 °C:EtOAc) to give a mixture of the isoindolinone 273a and the isoindolinone
274a as a colorless oil (10 mg, 0.027 mmol, 11%; 273a:274a = 3:1). Further elution of
the column gave more of the isoindolinone 273a as a colorless oil (55 mg, 0.15 mmol,
58%).
Isoindolinone 273a: Rf = 0.75 (9:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2956s (C-
H), 1688s (C=O), 1454s, 1409s; 1H NMR (600 MHz; DMSO-d6) 7.37–7.34 (2H, m, ArH),
7.31 (1H, s, ArH), 7.29–7.26 (3H, m, ArH), 4.71 (2H, s, NCH2), 4.27 (2H, s, NCH2), 2.65
(2H, t, J = 7.8, ArCH2CH2), 2.17 (3H, s, ArCH3), 1.50–1.45 (2H, m, ArCH2CH2), 1.35
(2H, sextet, J =7.3, CH2CH3), 0.91 (3H, t, J = 7.3, CH2CH3), 0.34 (9H, s, Si(CH3)3); 13C
NMR (150 MHz; DMSO-d6) 169.0 (C(O)), 143.0 (Ar), 141.6 (Ar), 137.8 (Ar), 135.0 (Ar),
134.2 (Ar), 133.6 (Ar), 131.6 (Ar), 128.7 (Ar), 127.7 (Ar), 123.3 (Ar), 48.6 (CH2N), 45.5
(CH2N), 32.5 (ArCH2CH2), 32.4 (ArCH2CH2), 22.1 (CH2CH3), 13.8 (CH3), 13.7 (CH3),
–0.3 (Si(CH3)3); HRMS (CI+) found [M+H]+ 366.2246; C23H32NOSi requires 366.2248.
A NOESY experiment showed an NOE between; 2.65 (ArCH2CH2) and 2.17 (ArCH3);
7.31 (ArH) and 2.65 (ArCH2CH2); 7.31 (ArH) and 0.34 (Si(CH3)3).
Isoindolinone 274a: Rf = 0.77 (9:1 petrol 40–60 °C:EtOAc); 1H NMR (600 MHz;
DMSO-d6) 7.37–7.34 (2H, m, ArH), 7.30–7.26 (3H, m, ArH), 7.13 (1H, s, ArH), 4.70
(2H, s, NCH2), 4.22 (2H, s, NCH2), 2.73 (2H, t, J = 7.7, ArCH2CH2), 2.20 (3H, s, ArCH3),
1.44–1.40 (2H, m, ArCH2CH2), 1.32 (2H, sextet, J =7.4, CH2CH3), 0.89 (3H, t, J = 7.4,
CH2CH3), 0.40 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 168.9 (C(O)), 149.1
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(Ar), 139.1 (Ar), 137.4 (Ar), 133.7 (Ar), 133.3 (Ar), 132.4 (Ar), 128.5 (Ar), 127.7 (Ar),
47.7 (CH2N), 45.6 (CH2N), 36.4 (ArCH2CH2), 35.7 (ArCH2CH2), 22.1 (CH2CH3), 16.9
(ArCH3), 14.0 (CH2CH3), 3.4 (Si(CH3)3). Two aromatic 13C resonances were obscured
by compound 273a.
2-Benzyl-4-methyl-5-(o-tolyl)-7-(trimethylsilyl)isoindolin-1-one (273b)
Prepared from amide 245e and 2-ethynyltoluene according to the General Cyclization
Procedure C to give the isoindolinone 273b as a yellow oil (114 mg, approximately 90%
pure by 1H NMR, 0.23 mmol, 88%); Rf = 0.22 (18:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 3950s (C-H), 1688s (C=O), 1410s; 1H NMR (600 MHz; DMSO-d6) 7.37–
7.21 (9H, m, ArH), 7.06 (1H, d, J = 7.2, ArH), 4.78 (1H, d, J = 15.4, CH2N), 4.74 (1H, d,
J = 15.4, CH2N), 4.39 (1H, d, J = 17.4, CHH’N), 4.34 (1H, d, J = 17.4, CHH’N), 1.98
(3H, s, ArCH3), 1.92 (3H, s, ArCH3), 0.34 (9H, s, Si(CH3)3); 13C NMR (150 MHz;
DMSO-d6) 168.8 (C(O)), 143.1 (Ar), 141.6 (Ar), 140.1 (Ar), 137.3 (Ar), 135.4 (Ar), 135.2
(Ar), 134.9 (Ar), 133.8 (Ar), 131.6 (Ar), 130.0 (Ar), 129.1 (Ar), 128.7 (Ar), 127.8 (Ar),
127.6 (Ar), 127.1 (Ar), 125.8 (Ar), 48.7 (CH2N), 45.6 (CH2N), 19.6 (ArCH3),
14.7(ArCH3), –0.3 (Si(CH3)3); HRMS (CI+) found [M+H]+ 400.2106; C26H30NOSi
requires 400.2091. This compound was unstable to flash column chromatography.
2-Benzyl-5-butyl-4-ethyl-7-(trimethylsilyl)isoindolin-1-one (273c) and 2-Benzyl-6-
butyl-4-ethyl-7-(trimethylsilyl)isoindolin-1-one (274c)
Prepared from amide 245f and 1-hexyne according to the General Cyclization Procedure
C (crude ratio 273c:274c = 2:1) and purified by flash column chromatography (18:1 petrol
40–60 °C:EtOAc) to give a mixture of the isoindolinone 273c and the isoindolinone 274c
as a colorless oil (40 mg, 0.11 mmol, 40%, 273c:274c = 2:3). Further elution of the
176 Experimental Details
column gave more of the isoindolinone 273c as a colorless oil (17 mg, 0.045 mmol, 17%);
νmax (film/cm–1) 2957s (C-H), 1690s (C=O), 1409s; HRMS (CI+) found [M+H]+
380.2410; C24H34NOSi requires 380.2404.
Isoindolinone 273c: Rf = 0.25 (18:1 petrol 40–60 °C:EtOAc); 1H NMR (600 MHz;
DMSO-d6) 7.36–7.33 (3H, m, ArH), 7.29–7.26 (3H, m, ArH), 4.71 (2H, s, CH2N), 4.33
(2H, s, CH2N), 2.65 (2H, t, J = 7.9, ArCH2CH2), 2.58 (2H, q, J = 7.6, ArCH2CH3), 1.52–
1.47 (2H, m, ArCH2CH2), 1.37 (2H, sextet, J = 7.4, CH2CH2CH3), 1.06 (3H, t, J = 7.6,
ArCH2CH3), 0.91 (3H, t, J = 7.4, CH2CH2CH3), 0.34 (9H, s, Si(CH3)3); 13C NMR
(150 MHz; DMSO-d6) 169.0 (C(O)), 142.4 (Ar), 140.9 (Ar), 137.8 (Ar), 137.4 (Ar), 135.5
(Ar), 134.4 (Ar), 133.9 (Ar), 128.7 (Ar), 127.7 (Ar), 127.3 (Ar), 48.2 (CH2N), 45.5
(CH2N), 33.6 (ArCH2CH2), 31.5 (ArCH2CH2), 22.2 (ArCH2CH2CH2), 21.4 (ArCH2CH3),
14.3 (ArCH2CH3), 13.9 (CH2CH2CH3), –0.3 (Si(CH3)3).
Isoindolinone 274c: Rf = 0.31 (18:1 petrol 40–60 °C:EtOAc); 1H NMR (600 MHz;
DMSO-d6) 7.36–7.32 (2H, m, ArH), 7.29–7.25 (3H, m, ArH), 7.14 (1H, s, ArH), 4.69
(2H, s, CH2N), 4.25 (2H, s, CH2N), 2.74 (2H, t, J = 7.9, ArCH2CH2), 2.52 (2H, q, J = 7.6,
ArCH2CH3), 1.45–1.40 (2H, m, ArCH2CH2), 1.31 (2H, sextet, J = 7.2, CH2CH2CH3),
1.13 (3H, t, J = 7.6, ArCH2CH3), 0.87 (3H, t, J = 7.2, CH2CH2CH3), 0.40 (9H, s,
Si(CH3)3); 13C NMR (150 MHz; DMSO-d6) 169.0 (C(O)), 149.3 (Ar), 139.0 (Ar), 138.3
(Ar), 137.5 (Ar), 135.5 (Ar), 132.6 (Ar), 131.9 (Ar), 127.7 (Ar), 47.4 (CH2N), 45.6
(CH2N), 36.5 (ArCH2CH2), 35.9 (ArCH2CH2), 23.9 (ArCH2CH3), 22.1 (ArCH2CH2CH2),
14.0 (CH2CH3), 13.8 (CH2CH3), 0.3 (Si(CH3)3). Two aromatic 13C resonances were
obscured by compound 273c.
2-Benzyl-4-ethyl-5-(o-tolyl)-7-(trimethylsilyl)isoindolin-1-one (273d) and 2-benzyl-
4-Ethyl-6-(o-tolyl)-7-(trimethylsilyl)isoindolin-1-one (274d)
Prepared from amide 245f and 2-ethynyltoluene according to the General Cyclization
Procedure C (crude ratio 273d:274d = 5:1). This was purified by flash column
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chromatography (18:1 petrol 40–60 °C:EtOAc) to give a mixture of the isoindolinone
273d and the isoindolinone 274d as a colorless oil (80 mg, 0.19 mmol, 73%; 273d:274d
= 5:1); Rf = 0.33 (18:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2964s (C-H), 1690s
(C=O), 1410s; 1H NMR (600 MHz; DMSO-d6) 7.39–7.23 (8H, m, ArH 273d; 8H, m,
ArH 274d), 7.19 (1H, s, ArH 273d), 7.11 (1H, d, J = 7.6, ArH 273d), 7.04 (1H, s, ArH
274d), 7.00 (1H, d, J = 7.6, ArH 274d), 5.78–4.73 (2H, m, CH2N 273d; 2H, m, CH2N,
274d), 4.48–4.40 (2H, m, CH2N 273d; 2H, m, CH2N, 274d), 2.60 (2H, q, J = 7.8, CH2CH3
274d), 2.50–2.42 (1H, m, CHH’CH3 273d), 2.27–2.19 (1H, m, CHH’CH3 273d), 2.05
(3H, s, ArCH3 274d), 1.98 (3H, s, ArCH3 273d), 1.15 (3H, t, J = 7.6, CH2CH3 274d), 0.82
(3H, t, J = 7.7, CH2CH3 273d), 0.34 (9H, s, Si(CH3)3 273d), –0.06 (9H, s, Si(CH3)3 274d);
13C NMR (150 MHz; DMSO-d6) 168.8 (C(O)), 168.7 (C(O)), 148.4 (Ar), 144.0 (Ar),
142.6 (Ar), 141.0 (Ar), 140.0 (Ar), 139.4 (Ar), 138.8 (Ar), 137.8 (Ar), 137.7 (Ar), 137.4
(Ar), 135.9 (Ar), 135.4 (Ar), 135.2 (Ar), 135.1 (Ar), 134.1 (Ar), 133.1 (Ar), 131.5 (Ar),
130.0 (Ar), 129.7 (Ar), 129.2 (Ar), 128.7 (Ar), 127.8 (Ar), 127.7 (Ar), 127.7 (Ar), 127.5
(Ar), 127.4 (Ar), 125.6 (Ar), 125.3 (Ar), 48.4 (CH2N), 47.7 (CH2N), 45.7 (CH2N), 45.6
(CH2N), 23.8 (CH2CH3), 22.2 (CH2CH3), 20.2 (ArCH3), 19.9 (ArCH3), 13.6 (CH2CH3),
1.6 (Si(CH3)3), –0.3 (Si(CH3)3); HRMS (CI+) found [M+H]+ 414.2245; C27H32NOSi
requires 414.2248.
2-Benzyl-5-butyl-7-methylisoindolin-1-one (273a)137
Prepared from amide 245g, 1-hexyne and RuCp*Cl(cod) (3 mg, 3 mol%) over 16 h
according to the General Cyclization Procedure B and purified by flash column
chromatography (7:1 petrol 40–60 °C:EtOAc) to give the isoindolinone 273a as a
colorless oil (65 mg, 0.22 mmol, 85%); Rf = 0.31 (7:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 2927s (C-H), 1681s (C=O), 1615s, 1453s, 1407s; 1H NMR (600 MHz;
DMSO-d6) 7.36–7.32 (2H, m, ArH), 7.28–7.24 (3H, m, ArH), 7.13 (1H, s, ArH), 7.04
(1H, s, ArH), 4.67 (2H, s, CH2N), 4.24 (2H, s, CH2N), 2.61–2.57 (5H, m, ArCH3;
ArCH2CH2), 1.53 (2H, quintet, J = 7.5, ArCH2CH2), 1.28 (2H, sextet, J = 7.5, CH2CH3),
0.87 (3H, t, J = 7.5, CH2CH3); 13C NMR (150 MHz; DMSO-d6) 168.2 (C(O)), 145.9 (Ar),
142.6 (Ar), 137.7 (Ar), 136.0 (Ar), 129.9 (Ar), 128.7 (Ar), 127.7 (Ar), 127.3 (Ar), 126.8
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(Ar), 120.6 (Ar), 48.5 (CH2N), 45.1 (CH2N), 34.9 (ArCH2CH2), 33.1 (ArCH2CH2), 21.8
(CH2CH3), 16.7 (ArCH3), 13.8 (CH2CH3); data in accordance with the literature.137
2-Benzyl-7-methyl-5-(o-tolyl)isoindolin-1-one (273b)
Prepared from amide 245g, 2-ethynyltoluene and RuCp*Cl(cod) (3 mg, 3 mol%) over
16 h according to the General Cyclization Procedure B to give the isoindolinone 273b as
a yellow oil (80 mg, 0.24 mmol, 94%); Rf = 0.31 (5:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 2923s (C-H), 1684s (C=O), 1614s 1495s, 1453s; 1H NMR (600 MHz;
DMSO-d6) 7.37–7.34 (2H, m, ArH), 7.30–7.22 (7H, m, ArH), 71.9–7.17 (2H, m, ArH),
4.71 (2H, s, CH2N), 4.31 (2H, s, CH2N), 2.63 (3H, s, ArCH3), 2.21 (3H, s, ArCH3); 13C
NMR (150 MHz; DMSO-d6) 168.0 (C(O)), 144.1 (Ar), 142.4 (Ar), 140.7 (Ar), 137.7 (Ar),
136.1 (Ar), 134.7 (Ar), 130.5 (Ar), 130.4 (Ar), 129.5 (Ar), 128.7 (Ar), 127.8 (Ar), 127.7
(Ar), 127.4 (Ar), 126.0 (Ar), 121.5 (Ar), 48.7 (CH2N), 45.3 (CH2N), 20.2 (ArCH3), 16.8
(ArCH3); HRMS (CI+) found [M+H]+ 328.1688; C23H22NO requires 328.1696.
N-Benzyl-N-((2-benzyl-1-oxo-7-(trimethylsilyl)isoindolin-5-yl)methyl)-3-
(trimethylsilyl)propiolamide (248a)
Isolated from the certain alkyne cyclotrimerization reaction involving amide 245a.
The isoindolinone 248a was isolated as a colorless oil; Rf = 0.24 (6:1 petrol 40–60
°C:EtOAc); νmax (film/cm–1) 3279s (CC-H), 2960w (C-H), 2108w (C≡C), 1630s (C=O), 
1415s; 1H NMR (600 MHz; DMSO-d6) a 1:1 mixture of rotamers; 7.46–7.17 (12H, m,
ArH; 12H, m, ArH), 4.79 (2H, s, CH2N), 4.73 (2H, s, CH2N), 4.72 (2H, s, CH2N), 4.71
(2H, s, CH2N), 4.55 (2H, s, CH2N), 4.47 (2H, s, CH2N), 4.32 (2H, s, CH2N), 4.30 (2H, s,
CH2N), 0.34 (9H, s, Si(CH3)3), 0.33 (9H, s, Si(CH3)3), 0.17 (9H, s, Si(CH3)3), 0.13 (9H,
s, Si(CH3)3); 13C NMR (125 MHz; DMSO-d6) a mixture of rotamers; 168.2 (C(O)), 168.2
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(C(O)), 153.3 (Ar), 153.3 (Ar), 142.3 (Ar), 138.9 (Ar), 138.7 (Ar), 137.6 (Ar), 137.6 (Ar),
137.4 (Ar), 137.2 (Ar), 136.5 (Ar), 136.5 (Ar), 136.0 (Ar), 135.7 (Ar), 133.6 (Ar), 133.0
(Ar), 128.7 (Ar), 128.7 (Ar), 128.5 (Ar), 127.9 (Ar), 127.7 (Ar), 127.7 (Ar), 127.7 (Ar),
127.5 (Ar), 127.4 (Ar), 127.4 (Ar), 123.4 (Ar), 123.3 (Ar), 97.4 (C≡C), 97.4 (C≡C), 96.4 
(C≡C), 51.9 (CH2N), 51.9 (CH2N), 49.0 (CH2N), 47.3 (CH2N), 47.3 (CH2N), 45.4
(CH2N), –0.4 (Si(CH3)3), –0.4 (Si(CH3)3), –1.0 (Si(CH3)3), –1.0 (Si(CH3)3); HRMS (EI+)
found [M+H]+ 539.2548; C32H39N2O2Si2 requires 539.2550.
N-Benzyl-N-((2-benzyl-1-oxo-7-(trimethylsilyl)isoindolin-5-
yl)methyl)propiolamide (248b)
Isolated from the specific alkyne cyclotrimerization reaction involving amide 248b.
The isoindolinone 248b was isolated as a colorless oil; Rf = 0.10 (6:1 petrol 40–60
°C:EtOAc); νmax (film/cm–1) 3288s (CC-H), 2932s (C-H), 2104w (C≡C), 1653s (C=O), 
1601, 1453s; 1H NMR (600 MHz; CDCl3) a 1:1 mixture of rotamers; 7.44–7.14 (12 H,
m, ArH; 12H, m, ArH), 4.80 (2H, s, CH2N), 4.73 (2H, s, CH2N), 4.71 (2H, s, CH2N), 4.70
(2H, s, CH2N), 4.64 (1H, s, HC≡C), 4.63 (1H, s, HC≡C), 4.53 (2H, s, CH2N), 4.45 (2H,
s, CH2N), 4.32 (2H, s, CH2N), 4.29 (2H, s, CH2N), 0.34 (9H, s, Si(CH3)3), 0.32 (9H, s,
Si(CH3)3); 13C NMR (125 MHz; DMSO-d6) a mixture of rotamers; 168.2 (C(O)), 168.1
(C(O)), 153.3 (Ar), 153.3 (Ar), 142.3 (Ar), 142.2 (Ar), 138.6 (Ar), 138.6 (Ar), 137.6 (Ar),
137.6 (Ar), 137.4 (Ar), 137.2 (Ar), 136.3 (Ar), 136.2 (Ar), 136.0 (Ar), 135.7 (Ar), 133.5
(Ar), 133.0 (Ar), 133.1 (Ar), 128.7 (Ar), 128.4 (Ar), 127.8 (Ar), 127.7 (Ar), 127.6 (Ar),
127.4 (Ar), 127.4 (Ar), 123.4 (Ar), 123.1 (Ar), 82.9 (C≡C), 75.9 (C≡C), 51.6 (CH2N),
51.6 (CH2N), 49.0 (CH2N), 49.0 (CH2N), 47.1 (CH2N), 47.0 (CH2N), 45.4 (CH2N), –0.5
(Si(CH3)3).
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N-((1-Oxo-7-trimethylsiyl)isoindolin-5-yl)methyl)-3-(trimethylsilyl)propiolamide
(265)
A solution of RuCp*Cl(cod) (10 mg, 0.026 mmol, 10 mol%) in CPME (1.1 mL) was
added dropwise to a stirring solution of amide 245b (47 mg, 0.26 mmol) in CPME
(1.6 mL) at RT. The reaction was stirred for 16 h before the reaction mixture was filtered
through a silica pad, eluting with EtOAc. The filtrate was concentrated in vacuo to give
the crude product, which was purified by flash column chromatography (2:1
EtOAc:petrol 40–60 °C) to give the isoindolinone 265 as a white crystalline solid (47 mg,
0.10 mmol, 79%); m.p. 104–106 °C; Rf = 0.36 (2:1 EtOAc:petrol 40–60 °C); νmax
(film/cm–1) 3321m (N-H), 3208m (N-H), 2957m (C-H), 1674s (C=O), 1655s (C=O),
1601m; 1H NMR (600 MHz; DMSO-d6) 9.30 (1H, t, J = 5.7, NH straight chain amide),
8.46 (1H, s, NH lactam), 7.42 (1H, s, ArH), 7.40 (1H, s, ArH), 4.38–4.31 (4H, m, CH2N,
CH2N), 0.32 (9H, s, Si(CH3)3), 0.30 (9H, s, Si(CH3)3); 13C NMR (150 MHz; DMSO-d6)
171.0 (C(O) lactam), 151.8 (C(O) straight chain amide), 144.6 (Ar), 140.7 (Ar), 136.9
(Ar), 136.1 (Ar), 133.1 (Ar), 123.3 (Ar), 98.8 (C≡C), 90.1 (C≡C), 44.8 (CH2N), 42.5
(CH2N), –0.4 (Si(CH3)3), –0.7 (Si(CH3)3); HRMS (CI+) found [M+H]+ 359.1617;
C18H27N2O2Si2 requires 359.1611.
N-(tert-Butyl)-N-((2-(tert-butyl)-1-oxo-7-(trimethylsilyl)isoindolin-5-yl)methyl)-3-
(trimethylsilyl)propiolamide (268)
RuCp*Cl(cod) (8 mg, 0.011 mmol, 10 mol%) was added dropwise to a stirring solution
of amide 245c (50 mg, 0.11 mmol) in CPME (2.2 mL) at RT. The reaction was stirred for
16 h before the reaction mixture was filtered through a silica pad, eluting with EtOAc.
The filtrate was concentrated in vacuo to give the crude product, which was purified by
flash column chromatography (10:1 EtOAc:petrol 40–60 °C) to give the isoindolinone
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268 as a colorless oil (50 mg, 0.11 mmol, 100%); νmax (film/cm–1) 2963s (C-H), 1680s
(C=O), 1631s (C=O); 1H NMR (400 MHz; DMSO-d6) 7.47 (1H, s, ArH) 7.41 (1H, s,
ArH), 5.00 (2H, s, CH2N), 4.54 (2H, s, CH2N), 1.47 (9H, s, C(CH3)3), 1.31 (9H, s,
C(CH3)3), 0.31 (9H, s, Si(CH3)3), 0.00 (9H, s, Si(CH3)3); 13C NMR (125 MHz; DMSO-
d6) 168.5 (C(O) lactam), 154.4 (C(O) straight chain amide), 141.8 (Ar), 141.1 (Ar), 137.5
(Ar), 136.2 (Ar), 131.6 (Ar), 121.4 (Ar), 98.6 (C≡C), 93.6 (C≡C), 57.7 (CMe3), 53.6
(CMe3), 50.4 (CH2N), 47.9 (CH2N), –0.4 (Si(CH3)3), –1.1 (Si(CH3)3); HRMS (CI+) found
[M]+ 470.2791; C26H42N2O2Si2 requires 470.2779.
2-Benzyl-5-butyl-7-iodoisoindolin-1-one (275)
According to the modified procedure of Clayden et al.149: A solution of ICl (93 mg,
0.57 mmol) in CH2Cl2 (0.57 mL) was added dropwise to a stirring solution of
isoindolinone 247a (26 mg, 0.074 mmol) in CH2Cl2 (17 mL) at RT. The reaction was
stirred for 3.5 h and aq. sat. Na2S2O3 was added to afford a colorless solution. The reaction
was extracted with CH2Cl2 (2 × 20 mL), dried (MgSO4), and concentrated in vacuo. The
crude product was purified by flash column chromatography (5:1 petrol 40–
60 °C:EtOAc) to give the isoindolinone 275 as a colorless oil (27 mg, 0.067 mmol, 90%);
Rf = 0.20 (6:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2929s (C-H), 1690s (C=O),
1609s, 1453s, 1408s; 1H NMR (600 MHz; DMSO-d6) 7.74 (1H, s, ArH), 7.38 (1H, s,
ArH), 7.36–7.33 (2H, m, ArH), 7.29–7.25 (3H, m, ArH), 4.69 (2H, s, CH2N), 4.23 (2H,
s, CH2N), 2.60 (2H, t, J = 7.7, ArCH2CH2), 1.53 (2H, m, ArCH2CH2), 1.27 (2H, sextet,
J = 7.4, CH2CH3), 0.87 (3H, t, J = 7.4, CH3); 13C NMR (150 MHz; DMSO-d6) 165.9
(C(O)), 148.1 (Ar), 144.6 (Ar), 139.0 (Ar), 137.4 (Ar), 129.4 (Ar), 128.7 (Ar), 127.7 (Ar),
127.4 (Ar), 123.4 (Ar), 89.9 (CI), 47.7 (CH2N), 45.6 (CH2N), 34.2 (ArCH2CH2), 32.9
(ArCH2CH2), 21.7 (CH2CH3), 13.8 (CH3); HRMS (ES+) found [M+H]+ 406.0663;
C19H21INO requires 406.0668.
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2-Benzyl-7-bromo-5-butylisoindolin-1-one (276)
According to the modified procedure of Snieckus et al.150: A solution of Br2 (118 mg,
0.738 mmol) in CH2Cl2 (0.36 mL) was added dropwise to a stirring solution of the
isoindolinone 247a (26 mg, 0.074 mmol) in CH2Cl2 (0.36 mL) at RT. The reaction was
stirred for 16 h and aq. sat. Na2S2O3 was added to afford a colorless solution. The reaction
was extracted with CH2Cl2 (2 × 20 mL), dried (MgSO4), and concentrated in vacuo. The
crude product was purified by flash column chromatography (10:1 petrol 40–
60 °C:EtOAc) to give the isoindolinone 276 as a colorless oil (21 mg, 0.058 mmol, 78%);
Rf = 0.50 (5:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2928s (C-H), 1692s (C=O),
1615s, 1453s, 1408s; 1H NMR (600 MHz; DMSO-d6) 7.49 (1H, s, ArH), 7.37–7.33 (3H,
m, ArH), 7.29–7.26 (3H, m, ArH), 4.69 (2H, s, CH2N), 4.28 (2H, s, CH2N), 2.64 (2H, t,
J = 7.7, ArCH2CH2), 1.54 (2H, m, ArCH2CH2), 1.28 (2H, sextet, J = 7.4, CH2CH3), 0.87
(3H, t, J = 7.4, CH3); 13C NMR (150 MHz; DMSO-d6) 165.3 (C(O)), 148.3 (Ar), 145.0
(Ar), 137.4 (Ar), 132.4 (Ar), 128.7 (Ar), 127.7 (Ar), 127.4 (Ar), 126.9 (Ar), 122.9 (Ar),
117.2 (Ar), 48.1 (CH2N), 45.4 (CH2N), 34.4 (ArCH2CH2), 32.9 (ArCH2CH2), 21.7
(CH2CH3), 13.8 (CH3); HRMS (ESI+) found [M+H]+ 358.0807; C19H2179BrNO requires
358.0807.
5-Butylisoindolin-1-one (277)
According to the modified procedure of Miranda et al.151: TfOH (0.50 mL) was added to
the isoindolinone 267a. (50 mg, 0.16 mmol). The resulting solution was stirred at RT for
30 minutes before being partitioned between EtOAc (20 mL) and water (20 mL). The aq.
extract was washed with EtOAc (2 × 20 mL) and the combined organic extracts were
washed with aq. sat. Na2CO3 (50 mL) and brine (50 mL), dried (MgSO4) and concentrated
in vacuo to give the crude product. This was purified by flash column chromatography
(3:1 EtOAc:petrol 40–60 °C) to give the isoindolinone 277 as a white crystalline solid
(26 mg, 0.014 mmol, 88%); m.p. 145–147 °C; Rf = 0.57 (2:1 petrol 40–60 °C:EtOAc);
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νmax (film/cm–1); 3203s (N-H), 3083s (C-H), 2932s (C-H), 1673s (C-H), 1451s; 1H NMR
(600 MHz; DMSO-d6) 8.50 (1H, s, NH), 7.56 (1H, d, J = 7.7, ArH), 7.37 (1H, d, J = 7.7,
ArH), 4.32 (2H, s, CH2N), 2.67 (2H, t, J = 7.7, ArCH2CH2), 1.59–1.54 (2H, m,
ArCH2CH2), 1.30 (2H, sextet, J = 7.4, CH2CH3), 0.89 (3H, t, J = 7.4, CH3); 13C NMR
(150 MHz; DMSO-d6) 170.0 (C(O)), 146.2 (Ar), 144.5, (Ar), 130.4 (Ar), 128.0 (Ar), 123.4
(Ar), 122.6 (Ar), 44.8 (CH2N), 39.1 (ArCH2CH2), 35.0 (ArCH2CH2), 21.8 (CH2CH3),
13.8 (CH2CH3); HRMS (EI+) found [M]+ 189.1153; C12H15NO requires 189.1148.
2-(tert-Butyl)-5-butyl-7-iodoisoindolin-1-one
According to the modified procedure of Clayden et al.149: A solution of ICl (400 mg,
2.49 mmol) in CH2Cl2 (5.0 mL) was added dropwise to a stirring solution of isoindolinone
267a (158 mg, 0.498 mmol) in CH2Cl2 (5.0 mL) at RT. The reaction was stirred for 2 h
and the reaction mixture was diluted with sat. aq. NaHCO3, before sat. aq. Na2S2O3 was
added dropwise to afford a colorless solution. The reaction was extracted with CH2Cl2
(2 × 20 mL), dried (MgSO4), and concentrated in vacuo to give the isoindolinone as a
yellow oil (183 mg, 0.492 mmol, 99%); Rf = 0.31 (6:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 2957s (C-H), 2928s (C-H), 1678s (C=O), 1607s, 1455s; 1H NMR (600 MHz;
DMSO-d6) 7.67 (1H, s, ArH), 7.33 (1H, s, ArH), 4.39 (2H, s, CH2N), 2.57 (2H, t, J = 7.6,
ArCH2CH2), 1.52–1.47 (2H, m, ArCH2CH2), 1.44 (9H, s, C(CH3)3), 1.25 (2H, sextet, J =
7.4, CH2CH3), 0.85 (3H, t, J = 7.4, CH2CH3); 13C NMR (150 MHz; DMSO-d6) 165.8
(C(O)), 147.4 (Ar), 144.1 (Ar), 138.8 (Ar), 130.5 (Ar), 122.9 (Ar), 89.0 (CI), 53.8 (CMe3),
46.3 (CH2N), 34.3 (ArCH2CH2), 33.0 (ArCH2CH2), 27.4 (C(CH3)3), 21.7 (CH2CH3), 13.8
(CH2CH3); HRMS (CI+) found [M+H]+ 372.0837; C19H23INO requires 372.0824.
5-Butyl-7-iodoisoindolin-1-one (278)
TfOH (0.75 mL) was added to 2-(tert-butyl)-5-butyl-7-iodoisoindolin-1-one (156 mg,
0.420 mmol). The resulting solution was stirred at RT for 2 days before being partitioned
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between EtOAc (20 mL) and water (20 mL). The aq. extract was washed with EtOAc
(2 × 20 mL) and the combined organic extracts were washed with aq. sat. Na2CO3 (50 mL)
and brine (50 mL), dried (MgSO4) and concentrated in vacuo to give the crude product.
This was purified by flash column chromatography (1:1 EtOAc:petrol 40–60 °C) to give
the isoindolinone 278 as a white crystalline solid (112 mg, 0.355, 85%); m.p. 137–139 °C;
Rf = 0.37 (2:1 EtOAc:petrol 40–60 °C); νmax (film/cm–1) 3171s (N-H), 3073s (C-H) 2928s
(C-H) 1702s (C=O), 1607s, 1457s; 1H NMR (600 MHz; DMSO-d6); 8.64 (1H, s, NH),
7.73 (1H, s, ArH), 7.41 (1H, s, ArH), 4.23 (2H, s, CH2N), 2.63 (2H, t, J = 7.7, ArCH2CH2),
1.59–1.53 (2H, m, ArCH2CH2), 1.29 (2H, sextet, J = 7.4, CH2CH3), 0.88 (3H, t, J = 7.4,
CH3); 13C NMR (150 MHz; DMSO-d6); 168.5 (C(O)), 147.9 (Ar), 146.8 (Ar), 138.8 (Ar),
129.7 (Ar), 123.6 (Ar), 89.7 (CI), 43.0 (CH2N), 34.2 (ArCH2CH2), 33.0 (ArCH2CH2),
21.7 (CH2CH3), 13.8 (CH3); HRMS (ES+) found [M]+ 315.0108; C12H14INO requires
315.0120.
2-Acetyl-5-butylisoindolin-1-one (282)
According to the modified procedure of Clift and Silverman154: aq. HCl (8.0 mL, 12 M)
was added to isoindolinone 277 (37 mg, 0.20 mmol). The reaction mixture was heated at
reflux for 3 days before it was allowed to cool to RT. The reaction mixture was
concentrated in vacuo and then it was dissolved in CH2Cl2 (5.0 mL). The resulting
solution was stirred at RT and treated with NEt3 (0.14 mL, 100 mg, 1.0 mmol) and Ac2O
(95 μl, 100 mg, 1.0 mmol). The reaction was stirred at RT for 16 h, quenched with water 
(1.0 mL) and filtered through a silica plug, eluting with EtOAc. The filtrate was
concentrated in vacuo to give the crude product, which was purified by flash column
chromatography (10:1 EtOAc:petrol 40–60 °C) to give the isoindolinone 282 as a white
crystalline solid (26 mg, 0.11 mmol, 56%); m.p. = 69–71 °C; Rf = 0.29 (10:1 petrol 40–
60 °C:EtOAc); νmax (film/cm–1) 2930s (C-H), 1712s (C=O ester), 1693s (C=O lactam),
1589s, 1439s; 1H NMR (600 MHz; DMSO-d6); 7.73 (1H, d, J = 7.9, ArH), 7.48 (1H, s,
ArH), 7.39 (1H, d, J = 7.9, ArH), 4.74 (2H, s, CH2N), 2.71 (2H, t, J = 7.7 ArCH2CH2),
2.53 (3H, s, CH3C(O)), 1.61–1.56 (2H, m, ArCH2CH2), 1.31 2H, sextet, J = 7.4,
CH2CH3), 0.90 (3H, t, J = 7.4, CH2CH3); 13C NMR (150 MHz; DMSO-d6); 170.2 (C(O)),
167.7 (C(O)), 149.6 (Ar), 142.1 (Ar), 129.0 (Ar), 128.5 (Ar), 124.3 (Ar), 123.6 (Ar), 47.9
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(CH2N), 35.2 (ArCH2CH2), 33.0 (ArCH2CH2), 24.6 (CH3C(O)), 21.8 (CH2CH3), 13.8
(CH2CH3); HRMS (EI+) found [M]+ 231.1252; C14H17NO2 requires 231.1259.
tert-Butyl 1-oxoisoindoline-2-carboxylate (286)157
According to the procedure of Motherwell et al.156: Tin (41.7 g, 351 mmol) was added
portionwise to a vigorously stirring suspension of phthalimide (20.0 g, 136 mmol) in
AcOH (100 mL) and aq. HCl (50 mL, concentrated). The resultant suspension was heated
at reflux for 2 h before being allowed to cool to RT. The reaction mixture was diluted
with chloroform (100 mL) and the aq. extract washed with chloroform (2 × 100 mL). The
combined organic extracts were dried (MgSO4) and concentrated in vacuo to give the
crude product, which was washed with hot ether and recrystallized (hot EtOAc/ether) to
give an impure sample isoindolin-1-one 285 as a yellow solid (13.0 g, ca. 80% purity by
1H NMR). Then according to the modified procedure of Cativiela et al.157: Boc2O (3.04 g,
13.9 mmol) and DMAP (68 mg, 0.56 mmol) were added to a stirring solution of
isoindolin-1-one (800 mg, ca. 80% purity, ca. 4.8 mmol) in THF (45 mL) at RT. The
reaction was stirred at RT for 16 h before the volatile components were removed in vacuo
to give the crude product. This was purified by flash column chromatography (4:1 petrol
40–60 °C: EtOAc) to give the isoindolinone 286 as a white crystalline solid (832 mg,
3.57 mmol, 43% over 2 steps); m.p. 110–112 °C (literature 117–119 °C157); Rf = 0.25 (4:1
petrol 40–60 °C:EtOAc); νmax (film/cm–1); 2980s (C-H), 1777s, 1742s, 1714s, 1618s,
1470s, 1454s; 1H NMR (600 MHz; DMSO-d6); 7.76 (1H, d, J = 7.6, ArH), 7.72 (1H, t,
J = 7.6, ArH), 7.64 (1H, d, J = 7.6, ArH), 7.53 (1H, t, J = 7.6, ArH), 4.79 (2H, s, CH2N),
1.52 (9H, s, C(CH3)3); 13C NMR (150 MHz; DMSO-d6) 165.9 (C(O)C), 149.7 (C(O)O),
141.5 (Ar), 133.7 (Ar), 130.8 (Ar), 128.4 (Ar), 124.0 (Ar), 123.9 (Ar), 81.9 (CMe3), 49.1
(CH2N), 27.8 (C(CH3)3); data in agreement with the literature.157
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tert-Butyl 2-(hydroxymethyl)benzylcarbamate (288)
According to the modified procedure of Murata et al.158: A solution of NaBH4 (105 mg,
2.78 mmol) in water (1.2 mL) was added dropwise to a stirring solution of isoindolinone
286 (100 mg, 0.429 mmol) in THF (4.0 mL) at 0 °C over 1 minute. The resulting mixture
was stirred vigorously for 24 h with the reaction allowed to slowly reach RT. Amberlyst
A-26 was added and the resulting mixture filtered. The filtrate was concentrated in vacuo
to give the crude product, which was purified by flash column chromatography (5:1 petrol
40–60 °C:EtOAc) to give the isoindolinone 288 as a white crystalline solid (66 mg,
0.28 mmol, 65%); m.p. 90–92 °C; Rf = 0.33 (2:1 petrol 40–60 °C:EtOAc); νmax (film/cm–
1) 3352s (O-H), 2977s (C-H), 1686s (C=O), 1519s, 1454s; 1H NMR (600 MHz; DMSO-
d6) a mixture of rotamers R1 (major) and R2 (minor) 7.37–7.35 (1H, m, ArH R1; 1H, m,
ArH R2), 7.26 (1H, t, J = 6.0, NH R1; 1H, t, J = 6.0, NH R2), 7.23–7.20 (3H, m, ArH R1;
3H, m, ArH R2), 5.13 (1H, t, J = 5.4, OH R1; 1H, t, J = 5.4, OH R2), 4.54 (2H, d, J = 5.4,
CH2OH R1; 2H, d, J = 5.4, CH2OH R2), 4.16 (2H, d, J = 6.0, CH2N R1; 2H, d, J = 6.0,
CH2N R2) 3.36 (9H, s, C(CH3)3 R1) 3.33 (9H, s, C(CH3)3 R2); 13C NMR (150 MHz;
DMSO-d6) 155.7 (C(O)), 139.4 (Ar), 137.1 (Ar), 127.1 (Ar), 126.9 (Ar), 126.8 (Ar), 126.5
(Ar), 77.8 (CMe3), 60.6 (CH2OH), 40.3 (CH2N), 28.3 (C(CH3)3); HRMS (CI+) found
[M+H]+ 238.1438; C13H20NO3 requires 238.1443.
tert-Butyl 5-butyl-7-iodo-1-oxoisoindoline-2-carboxylate (289)
Boc2O (55 mg, 0.25 mmol) and DMAP (1.5 mg, 0.012 mmol) were added to a stirring
solution of isoindolinone 278 (40 mg, 0.13 mmol) in THF (2.0 mL) at RT. The resulting
solution was stirred at RT for 16 h, after which a further quantity of Boc2O (55 mg,
0.25 mmol) and DMAP (1.5 mg, 0.012 mmol) were added. After a further 3 h the reaction
mixture was concentrated in vacuo to give the crude product, which was purified by flash
column chromatography (10:1 petrol 40–60 °C:EtOAc) to give the isoindolinone 289 as
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a colorless oil (48 mg, 0.12 mmol, 91%); Rf = 0.24 (10:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1), 2930s (C-H), 1777s (C=O), 1747s (C=O), 1712s (C=O), 1605s, 1456s;
1H NMR (600 MHz; DMSO-d6); 7.82 (1H, s, ArH), 7.47 (1H, s, ArH), 4.63 (2H, s,
CH2N), 2.64 (2H, t, J = 7.7, ArCH2CH2), 1.59–1.53 (2H, m, ArCH2CH2), 1.52 (9H, s,
C(CH3)3) 1.30 (2H, sextet, J = 7.4, CH2CH3), 0.89 (3H, t, J = 7.4, CH2CH3); 13C NMR
(150 MHz; DMSO-d6); 164.1 (C(O)C), 150.2 (C(O)O), 149.8 (Ar), 144.5 (Ar), 139.7 (Ar),
128.0 (Ar), 123.5 (Ar), 91.3 (CI), 82.0 (CMe3), 47.3 (CH2N), 34.4 (ArCH2CH2), 32.7
(ArCH2CH2), 27.7 (C(CH3)3), 21.8 (CH2CH3), 13.7 (CH2CH3); HRMS (CI+) found
[M+H]+ 416.0717; C17H23INO3 requires 416.0723.
tert-Butyl 5-butyl-1-hydroxy-7-iodoisoindoline-2-carboxylate (290)
According to the modified procedure of Murata et al.158: A solution of NaBH4 (19 mg,
0.49 mmol) in water (0.22 mL) was added dropwise to a stirring solution of isoindolinone
289 (32 mg, 0.077 mmol) in THF (0.70 mL) at 0 °C over 1 minute. The resulting mixture
was stirred vigorously for 16 h with the reaction allowed to slowly reach RT. A further
portion of NaBH4 (19 mg, 0.49 mmol) was added to the reaction mixture at RT and the
reaction was stirred vigorously of a further 24 h. Amberlyst A-26 was added and the
resulting mixture filtered. The filtrate was concentrated in vacuo to give the crude
product, which was purified by flash column chromatography (10:1 petrol 40–
60 °C:EtOAc) to give hemiaminal 290 as a colorless oil (16 mg, 0.038 mmol, 50%);
Rf = 0.20 (10:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2974s (C-H), 1755s, 1707s
(C=O), 1456s; 1H NMR (600 MHz; DMSO-d6) a 50:50 mixture of rotamers R1 and R2;
7.55 (1H, s, ArH R1; 1H, s, ArH R2) 7.20 (1H, s, ArH R1 or R2), 7.18 (1H, s, ArH R1 or
R2), 6.39 (1H, d, J = 8.0, OH R1), 6.22 (1H, d, J = 8.3, OH R2), 6.03 (1H, d, J = 8.0, CHO
R1), 5.94 (1H, d, J = 8.3, CHO R2), 4.59–4.45 (2H, m, CH2N R1; 2H, m, CH2N R2), 2.56
(2H, t, J = 7.7, ArCH2CH2 R1; 2H, t, J = 7.7, ArCH2CH2 R2), 1.54–1.50 (2H, m,
ArCH2CH2 R1; 2H, m, ArCH2CH2 R2), 1.47 (9H, s, C(CH3)3 R1 or R2), 1.46 (9H, s,
C(CH3)3 R1 or R2), 1.28 (2H, sextet, J = 7.3, CH2CH3 R1; 2H, sextet, J = 7.3, CH2CH3
R2), 0.88 (3H, d, J = 7.3, CH2CH3 R1; 3H, d, J = 7.3, CH2CH3 R2); 13C NMR (150 MHz;
DMSO-d6) a mixture of rotamers; 153.1 (C(O)), 153.0 (C(O)), 145.4 (Ar), 140.7 (Ar),
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140.2 (Ar), 138.7 (Ar), 138.4 (Ar), 136.9 (Ar), 136.9 (Ar), 122.6 (Ar), 122.5 (Ar), 91.7
(CI), 85.6 (CHO), 85.6 (CHO), 79.4 (CMe3), 79.2 (CMe3), 50.7 (CH2N), 50.4 (CH2N),
34.1 (ArCH2CH2), 33.1 (ArCH2CH2), 28.1 (C(CH3)3), 21.7 (CH2CH3), 13.8 (CH2CH3);
HRMS (CI+) found [M+H]+ 418.0870; C17H25INO3 requires 418.0874.
tert-Butyl 5-butyl-2-(hydroxymethyl)-3-iodobenzylcarbamate (291)
According to the modified procedure of Ohno et al.159: LiBH4 (4.2 mg, 0.19 mmol) was
added to a solution of isoindolinone 289 (32 mg, 0.077 mmol) and MeOH (3.7 mg,
0.12 mmol) in Et2O (1.0 mL) at 0 °C. The resulting solution was stirred at RT for
90 minutes, after which a further portion of LiBH4 (42 mg, 0.19 mmol) was added. The
reaction was stirred at RT for a further 16 h before the reaction was diluted with aq. sat.
NH4Cl (10 mL) and Et2O (10 mL). The aq. extract was washed with Et2O (3 × 10 mL)
and the combined organic extracts were washed with water (10 mL) and brine (10 mL),
dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by
flash column chromatography (8:1 petrol 40–60 °C:EtOAc) to give the carbamate 291 as
a white crystalline solid (17 mg, 0.041 mmol, 53%); m.p. 78–76 °C; Rf = 0.11 (5:1 petrol
40–60 °C:EtOAc); νmax (film/cm–1), 3353s (O-H, N-H), 2958s (C-H), 2925s (C-H), 2856s
(C-H), 1687s (C=O) 1601s, 1507s, 1458s; 1H NMR (600 MHz; DMSO-d6) 7.47 (1H, s,
ArH), 7.26 (1H, t, J = 5.9, NH), 7.09 (1H, s, ArH), 5.01 (1H, t, J = 5.0, CH2OH), 4.62
(2H, d, J = 5.0, CH2OH), 4.28 (2H, d, J = 5.9, CH2N), 2.51–2.48 (2H, m, ArCH2CH2 and
solvent peak), 1.49 (2H, quintet, J = 7.4, ArCH2CH2), 1.39 (9H, s, C(CH3)3), 1.27 (2H,
sextet, J = 7.4, CH2CH3), 0.87 (3H, t, J = 7.4, CH2CH3); 13C NMR (150 MHz; DMSO-
d6); 155.7 (C(O)), 143.8 (Ar), 140.4 (Ar), 137.7 (Ar), 137.4 (Ar), 127.8 (Ar), 102.5 (CI),
78.0 (CMe3), 64.8 (CH2OH), 42.7 (CH2N), 33.9 (ArCH2CH2), 32.9 (ArCH2CH2), 28.2
(C(CH3)3), 21.6 (CH2CH3), 13.8 (CH2CH3); HRMS (CI+) found [M+H]+ 420.1027;
C17H27INO3 requires 420.1030.
Chapter IV 189
6,6-Diethoxy-1-phenylhex-4-yn-3-ol (316a)190
Prepared from 3-phenylpropanal (8.8 mL, 9.0 g, 90% purity by weight, 60 mmol)
according to the General Alkynylation Procedure and purified by flash column
chromatography (4:1 petrol 40–60 °C:EtOAc) to give the propargylic alcohol 316a as a
colorless oil (12.8 g, 48.8 mmol, 81%); Rf = 0.33 (4:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 3426s (O-H), 2976s (C-H), 1454s; 1H NMR (500 MHz; CDCl3); 7.30–7.25
(2H, m, ArH), 7.21–7.18 (3H, m, ArH), 5.31 (1H, s, CH(OEt)2), 4.45–4.40 (1H, m,
CHOH), 3.78–3.71 (2H, m, C(OCHH’)2), 3.68–3.57 (2H, m, C(OCHH’)2), 2.80 (2H, t,
J = 7.8, PhCH2), 2.08–2.01 (2H, m, CH2COH), 1.89 (1H, d, J = 5.1, OH), 1.24 (6H, t,
J = 7.1, CH3); 13C NMR (125 MHz; CDCl3) 141.3 (Ar), 128.6 (Ar), 128.5 (Ar), 126.1
(Ar), 91.4 (C(OEt)2), 86.7 (C≡C), 80.3 (C≡C), 61.3 (COH), 61.1 (OCH2), 61.0 (OCH2),
39.1 (PhCH2), 31.5 (CH2COH), 15.2 (CH2CH3); data in accordance with the literature.190
1-Cyclohexyl-4,4-diethoxybut-2-yn-1-ol (316b)190
Prepared from cyclohexanecarbaldehyde (2.0 mL, 1.3 g, 14.0 mmol) according to the
General Alkynylation Procedure and purified by flash column chromatography (0 to 50%
EtOAc:cyclohexane) to give the propargylic alcohol 316b as a colorless oil (2.39 g,
9.94 mmol, 86%); Rf = 0.29 (10:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 3416s br.
(O-H), 2925s (C-H), 1450s; 1H NMR (600 MHz; CDCl3) 5.28 (1H, s, CH(OEt)2), 4.18
(1H, d, J = 6.0, CHOH), 3.74–3.68 (2H, m, OCHH’), 3.59–3.53 (2H, m, OCHH’), 2.20
(br. s, CHOH), 1.89–1.79 (2H, m, CHCHH’), 1.76–1.72 (2H, m, CHCH2CHH’), 1.67–
1.62 (1H, m, CHCH2CH2CHH’), 1.57–1.51 (1H, m, CHCH2), 1.26–1.18 (8H, m, 2 × CH3,
2 × CHCH2CHH’), 1.16–0.99 (3H, m, 2 × CHCHH’, CHCH2CH2CHH’); 13C NMR
(150 MHz; CDCl3) 91.3 (CH(OEt)2), 85.7 (C≡C), 80.9 (C≡C), 67.0 (CHOH), 61.0
(OCH2), 60.9 (OCH2), 43.9 (CHCH2), 28.6 (CHCH2), 28.2 (CHCH2), 26.4
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(CHCH2CH2CH2), 25.9 (CHCH2CH2), 25.9 (CHCH2CH2), 15.2 (CH2CH3); data in
accordance with the literature.190
1-Cyclopropyl-4,4-diethoxybut-2-yn-1-ol (316c)190
Prepared from cyclopropanecarbaldehyde (0.90 mL, 0.84 g, 12 mmol) according to the
General Alkynylation Procedure and purified by flash column chromatography (0 to 50%
EtOAc:cyclohexane) to give the propargylic alcohol 316c as a colorless oil (1.97 g,
9.94 mmol, 83%); Rf = 0.29 (3:1 cyclohexane:EtOAc); νmax (film/cm–1) 3403s br. (O-H),
2977s (C-H), 1444m; 1H NMR (400 MHz; CDCl3) 5.32–5.29 (1H, m, CH(OEt)2), 4.27–
4.21 (1H, m, CHOH), 3.78–3.69 (2H, m, OCHH’), 3.64–3.54 (2H, m, OCHH’), 2.40–
1.93 (1H, m, OH); 1.31–1.21 (7H, m, CH2CH3, CH(CH2)2), 0.63–0.42 (4H, m,
CH(CH2)2); 13C NMR (100 MHz; CDCl3) 89.6 (CH(OEt)2), 82.7 (C≡C), 78.7 (C≡C), 63.9 
(CHOH), 59.3 (OCH2), 59.2 (OCH2), 15.3 (CH2CH3), 13.4 (CH(CH2)2), 1.6 (CH(CH2)2);
data in accordance with the literature.190
tert-Butyl 4-(5,5-diethoxy-2-hydroxypent-3-yn-1-yl)piperidine-1-carboxylate (316d)
Prepared from a solution of tert-butyl 4-(2-oxoethyl)piperidine-1-carboxylate (1.50 g,
6.60 mmol) in anhydrous THF (4.0 mL) according to the General Alkynylation Procedure
and purified by flash column chromatography (0 to 100% heptane:TBME) to the
propargylic alcohol 316d as a colorless oil (1.67 g, 4.70 mmol, 71%); Rf = 0.47 (1:1 40–
60 °C:EtOAc); νmax (film/cm–1) 3417s br. (O-H), 2929s (C-H), 1693s (C=O), 1669s
(C=O), 1424s; 1H NMR (400 MHz; CDCl3) 5.31 (1H, s, (CH(OEt)2), 4.54 (1H, q, J = 5.9,
CHOH), 4.10 (2H, br. s, NCHH’), 3.79–3.71 (2H, m, OCHH’), 3.64–3.57 (2H, m,
OCHH’), 2.71 (2H, br. t, NCHH’), 1.89 (1H, m, OH), 1.76–1.62 (5H, m,
OCHCH2CH(CHH’)2), 1.47 (9H, s, C(CH3)3), 1.26 (6H, t, CH2CH3), 1.20–1.12 (2H, m,
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OCHCH2CH(CHH’)2); 13C NMR (100 MHz; CDCl3) 154.8 (C(O)), 91.3 (CH(OEt)2),
86.3 (C≡C), 80.4 (C≡C), 79.3 (C(CH3)3), 61.0 (OCH2), 60.9 (OCH2), 60.0 (CHOH), 43.05
(NCH2, OCHCH2), 32.5 (OCHCH2CH), 32.3 (OCHCH2CH(CH2)(CH2)’), 31.8
(OCHCH2CH(CH2)(CH2)’), 28.5 (C(CH3)3), 15.1 (CH2CH3); HRMS (ESI+) found
[M+Na]+ 378.2202; C19H33NNaO5 requires 378.2256.
4,4-Diethoxy-1-phenylbut-2-yn-1-ol (316e)190
Prepared from benzaldehyde (4.9 mL, 5.0 g, 47 mmol) according to the General
Alkynylation Procedure and purified by flash column chromatography (7:1 40–
60 °C:EtOAc) to give the propargylic alcohol 316e as a colorless oil (10.5 g, 44.6 mmol,
95%); Rf = 0.33 (5:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 3317s br. (O-H), 2977s
(C-H), 1493m, 1455s; 1H NMR (400 MHz; CDCl3) 7.57–7.54 (2H, m, ArH), 7.43–7.33
(3H, m, ArH), 5.83 (1H, s, CH(OEt)2), 5.55 (1H, d, J = 6.2, CHOH), 3.81–3.73 (2H, m,
OCHH’), 3.67–3.58 (2H, m, OCHH’), 2.43 (1H, d, J = 6.2, OH), 1.25 (6H, t, J = 7.1,
CH2CH3); 13C NMR (125 MHz; CDCl3) 140.1 (Ar), 128.7 (Ar), 128.5 (Ar), 126.7 (Ar),
91.4 (CH(OEt)2), 85.2 (C≡C), 82.0 (C≡C), 64.5 (CHOH), 61.1 (OCH2), 61.0 (OCH2),
15.1 (CH2CH3); data in accordance with the literature.190
4,4-Diethoxy-1-(4-(trifluoromethyl)phenyl)but-2-yn-1-ol (316f)190
Prepared from 4-(trifluoromethyl)benzaldehyde (1.6 mL, 2.0 g, 12 mmol) according to
the General Alkynylation Procedure and purified by flash column chromatography (0 to
50% EtOAc:cyclohexane) to give the propargylic alcohol 316f as a colorless oil (2.88 g,
9.94 mmol, 79%); Rf = 0.22 (3:1 cyclohexane:EtOAc); νmax (film/cm–1) 3408s br. (O-H),
2981s (C-H), 1620s, 1416s; 1H NMR (400 MHz; CDCl3) 7.69–7.64 (4H, m, ArH), 5.60
(1H, d, J = 5.9, CHOH), 5.37 (1H, s, CH(OEt)2), 3.80–3.72 (2H, m, OCHH’), 3.66–3.58
(2H, m, OCHH’), 2.66–1.63 (1H, m, COH), 1,26 (6H, t, J = 7.0, CH2CH3); 13C NMR
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(100 MHz; CDCl3) 143.7 (Ar), 130.6 (q, JC-F = 30.0, Ar), 126.9 (Ar), 125.6 (q, JC-F = 3.5,
Ar), 124.0 (q, JC-F = 272.2, CF3), 91.2 (CH(OEt)2), 84.2 (C≡C), 82.6 (C≡C), 63.7 
(CHOH), 61.1 (OCH2), 61.1 (OCH2), 15.0 (CH2CH3); data in accordance with the
literature.190
4,4-Diethoxy-1-(4-methoxyphenyl)but-2-yn-1-ol (316g)190
Prepared from 4-methoxybenzaldehyde (1.4 mL, 1.6 g, 11 mmol) according to the
General Alkynylation Procedure and purified by flash column chromatography (0 to 50%
EtOAc:cyclohexane) to give the propargylic alcohol 316g as a yellow oil (2.92 g,
11.1 mmol, 96%); Rf = 0.18 (3:1 cyclohexane:EtOAc); νmax (film/cm–1) 3423s br. (O-H),
2976s (C-H), 1611s, 1511s; 1H NMR (400 MHz; DMSO-d6) 7.43–733 (2H, m, ArH),
6.96–9.88 (2H, m, ArH), 5.97 (1H, br. s, CHOH), 5.37 (1H, br. s, CHOH), 5.37 (1H, s,
CH(OEt)2), 3.75 (3H, s, OCH3), 3.67–3.56 (2H, m, OCHH’), 3.55–3.45 (2H, m, OCHH’),
1.13 (6H, t, J = 7.1, CH2CH3); 13C NMR (100 MHz; DMSO-d6) 159.2 (Ar), 134.3 (Ar),
128.1 (Ar), 114.1 (Ar), 91.2 (CH(OEt)2), 87.2 (C≡C), 80.7 (C≡C), 62.3 (CHOH), 60.6
(OCH2), 55.6 (OCH3), 15.4 (CH2CH3); data in accordance with the literature.190
1-(4-Bromophenyl)-4,4-diethoxybut-2-yn-1-ol (316h)190
Prepared from a solution of 4-bromobenzaldehyde (2.15 g, 11.9 mmol) in anhydrous THF
(12 mL) according to the General Alkynylation Procedure and purified by flash column
chromatography (0 to 100% EtOAc:cyclohexane) to give the propargylic alcohol 316h as
a colorless oil (3.01 g, 9.61 mmol, 83%); Rf = 0.69 (1:1 cyclohexane:EtOAc); νmax
(film/cm–1) 3410s br. (O-H), 2978s (C-H), 1486s; 1H NMR (400 MHz; CDCl3) 7.55–7.51
(2H, m, ArH), 7.45–7.41 (2H, m, ArH), 5.51 (1H, d, J = 6.0, CHOH), 5.36 (1H, s,
CH(OEt)2), 3.80–3.71 (2H, m, OCHH’), 3.66–3.58 (2H, m, OCHH’), 2.40 (1H, d, J = 6.0,
COH), 1.26 (3H, t, J = 7.1, CH2CH3), 1.26 (3H, t, J = 7.1, CH2CH3); 13C NMR (100 MHz;
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CDCl3) 138.4 (Ar), 131.7 (Ar), 128.3 (Ar), 122.5 (Ar), 91.3 (CH(OEt)2), 84.4 (C≡C), 82.4 
(C≡C), 63.8 (CHOH), 61.1 (OCH2), 61.0 (OCH2), 15.1 (CH2CH3); data in accordance
with the literature.190
4,4-Diethoxy-1-(o-tolyl)but-2-yn-1-ol (316i)
Prepared from 2-methylbenzaldehyde (1.3 mL, 1.4 g, 11 mmol) according to the General
Alkynylation Procedure and purified by flash column chromatography (0 to 100%
EtOAc:cyclohexane) to give the propargylic alcohol 316i as a colorless oil (2.58 g,
10.4 mmol, 92%); Rf = 0.24 (3:1 cyclohexane:EtOAc); νmax (film/cm–1) 3422s br. (O-H),
2977s (C-H), 1487s, 1460s; 1H NMR (400 MHz; CDCl3) 7.68–7.63 (1H, m, ArH), 7.28–
7.18 (3H, m, ArH), 5.70 (1H, dd, J = 6.0, 1.2, CHOH), 5.37 (1H, d, J = 1.2, CH(OEt)2),
3.81–3.72 (2H, m, OCHH’), 3.67–3.58 (2H, m, OCHH’), 2.46 (3H, s, ArCH3), 2.20 (1H,
d, J = 6.0, OH), 1.26 (3H, t, J = 7.1, CH2CH3), 1.25 (3H, t, J = 7.1, CH2CH3); 13C NMR
(100 MHz; CDCl3) 137.0 (Ar), 136.0 (Ar), 130.8 (Ar), 128.6 (Ar), 126.6 (Ar), 126.2 (Ar),
91.4 (CH(OEt)2), 84.7 (C≡C), 82.0 (C≡C), 62.3 (CHOH), 61.0 (OCH2), 61.0 (OCH2),
18.9 (ArCH3), 15.1 (CH2CH3); HRMS (CI+) found [M]+ 248.1409; C15H20O3 requires
248.1412.
Methyl 3-(4,4-diethoxy-1-hydroxybut-2-yn-1-yl)benzoate (316j)190
Prepared from a solution of methyl 3-formylbenzoate (1.31 g, 7.98 mmol) in anhydrous
THF (8.0 mL) according to the General Alkynylation Procedure and purified by flash
column chromatography (0 to 100% TBME:cyclohexane) to give the propargylic alcohol
316j as a colorless oil (1.83 g, 6.26 mmol, 78%); Rf = 0.71 (3:1 cyclohexane:EtOAc);
νmax (film/cm–1) 3433s br. (O-H), 2887s (C-H), 1721s (C=O), 1481s; 1H NMR (400 MHz;
MeOH-d4) 8.22 (1H, s, ArH), 7.98 (1H, d, J = 7.8, ArH), 7.77 (1H, d, J = 7.8, ArH), 7.51
(1H, t, J = 7.8, ArH), 5.56 (1H, s, CHOH), 5.37 (1H, s, CH(OEt)2), 3.93 (3H, s, OCH3),
3.80–3.70 (2H, m, OCHH’), 3.67–3.56 (2H, m, OCHH’), 1.21 (6H, t, J = 7.1 CH2CH3);
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13C NMR (100 MHz; MeOH-d4) 166.8 (C(O)), 141.8 (Ar), 131.0 (Ar), 130.2 (Ar), 128.8
(Ar), 128.4 (Ar), 127.3 (Ar), 91.3 (CH(OEt)2), 85.0 (C≡C), 81.1 (C≡C), 62.8 (CHOH),
60.7 (OCH2), 60.7 (OCH2), 51.3 (OCH3), 14.0 (CH2CH3); data in accordance with the
literature.190
4,4-Diethoxy-1-(furan-2-yl)but-2-yn-1-ol (316k)190
Prepared from furfural (0.96 mL, 1.1 g, 12 mmol) according to the General Alkynylation
Procedure and purified by flash column chromatography (0 to 50% EtOAc:cyclohexane)
to give the propargylic alcohol 316k as a yellow oil (2.23 g, 9.96 mmol, 86%); Rf = 0.30
(3:1 cyclohexane:EtOAc); νmax (film/cm–1) 3411s br. (O-H), 2978s (C-H); 1H NMR
(400 MHz; CDCl3) 7.43–7.42 (1H, m, ArH), 6.47 (1H, d, J = 3.2, ArH), 6.38–6.36 (1H,
m, ArH), 5.53 (1H, d, J = 6.9, CHOH), 5.37–5.36 (1H, m, CH(OEt)2), 3.82–3.73 (2H, m,
OCHH’), 3.68–3.60 (2H, m, OCHH’), 2.69–1.50 (1H, m, OH), 1.25 (6H, t, J = 6.8, CH3);
13C NMR (100 MHz; CDCl3) 152.4 (Ar), 143.1 (Ar), 110.4 (Ar), 108.0 (Ar), 91.2
(CH(OEt)2), 82.6 (C≡C), 81.2 (C≡C), 61.1 (OCH2), 61.0 (OCH2), 58.0 (CHOH), 15.0
(CH2CH3); data in accordance with the literature.190
4,4-Diethoxy-1-(thiophen-2-yl)but-2-yn-1-ol (316l)190
Prepared from thiophene-2-carbaldehyde (1.6 mL, 1.9 g, 17 mmol) according to the
General Alkynylation Procedure and purified by flash column chromatography (0 to
100% TBME:cyclohexane) to give the propargylic alcohol 316l as a yellow oil (2.00 g,
8.32 mmol, 49%); Rf = 0.61 (1:1 cyclohexane:EtOAc); νmax (film/cm–1) 3403s br. (O-H),
2926s (C-H); 1H NMR (400 MHz; CDCl3) 7.33–7.31 (1H, m ArH), 7.21–7.17 (1H, m,
ArH), 7.00–6.98 (1H, m ArH), 5.74 (1H, d, J = 6.9, CHOH), 5.37 (1H, s, CH(OEt)2),
3.83–3.74 (2H, m, OCHH’), 3.67–3.58 (2H, m, OCHH’), 2.69 (1H, d, J = 6.9, OH), 1.26
(6H, t, J = 7.1, CH2CH3); 13C NMR (100 MHz; CDCl3) 143.9 (Ar), 126.8 (Ar), 126.2 (Ar),
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125.7 (Ar), 91.2 (CH(OEt)2), 84.3 (C≡C), 81.4 (C≡C), 61.1 (OCH2), 61.0 (OCH2), 60.1
(CHOH), 15.1 (CH2CH3); data in accordance with the literature.190
4,4-Diethoxy-1-(pyridin-3-yl)but-2-yn-1-ol (316m)
Prepared from nicotinaldehyde (1.1 mL, 1.3 g, 12 mmol) according to the General
Alkynylation Procedure and purified by flash column chromatography (0 to 100%
cyclohexane: EtOAc) to give the propargylic alcohol 316m as a yellow oil (1.93 g,
8.20 mmol, 70%); Rf = 0.40 (40:1 cyclohexane:EtOAc); νmax (film/cm–1) 3160s br. (O-
H), 2977s (C-H), 1427s; 1H NMR (400 MHz; DMSO-d6) 8.65 (1H, d, J = 1.8, ArH), 8.53
(1H, dd, J = 4.9, 1.8, ArH), 7.84 (1H, dt, 7.8, 1.8, ArH), 7.42 (1H, dd, J = 7.8, 4.9, ArH),
6.31 (1H, d, J = 6.1, CHOH), 5.55 (1H, d, J = 6.1, CHOH), 5.37 (1H, s, CH(OEt)2), 3.66–
3.58 (2H, m, OCHH’), 3.55–3.47 (2H, m, OCHH’), 1.13 (6H, t, J = 7.1, CH2CH3);
13C NMR (100 MHz; DMSO-d6) 148.9 (Ar), 147.8 (Ar), 137.1 (Ar), 134.0 (Ar), 123.5
(Ar), 90.7 (CH(OEt)2), 85.6 (C≡C), 81.0 (C≡C), 60.8 (CHOH), 60.3 (OCH2), 60.2
(OCH2), 14.9 (CH2CH3); HRMS (CI+) found [M+H]+ 236.1281; C14H17NO3 requires
236.1287.
3-Methoxy-2-phenethylfuran (318)190
A solution of [PPh3AuNTf2]2PhMe (30 mg, 0.019 mmol, 1.0 mol%, 2.0 mol% [Au]) in
MeOH (4.8 mL) was added dropwise to a stirring solution of propargylic alcohol 316a
(500 mg, 1.91 mmol) in MeOH (4.8 mL) at RT. The resulting solution was stirred for
16 h before being filtered through a silica plug, eluting with TBME. The filtrate was
concentrated in vacuo to give the crude product, which was purified by flash column
chromatography (0 to 10% petrol 30–40 °C: TBME) to give the furan 318 as a colorless
oil (266 mg, 1.32 mmol, 69%); Rf = 0.29 (40:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1)
2935s (C-H), 1637s, 1496s, 1454s 1410s; 1H NMR (600 MHz; CDCl3) 7.28–7.26 (2H,
m, ArH), 7.20–7.16 (3H, m, ArH), 7.14 (1H, d, J = 2.1, ArH), 6.26 (1H, d, J = 2.1, ArH),
3.59 (3H, s, OCH3), 2.94–2.86 (4H, m, PhCH2CH2); 13C NMR (150 MHz; CDCl3) 143.7
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(Ar), 141.6 (Ar), 139.2 (Ar), 139.2 (Ar), 128.6 (Ar), 128.4 (Ar), 126.0 (Ar), 103.3 (Ar),
59.6 (OCH3), 34.4 (CH2) 27.2 (CH2); data in accordance with the literature.190
3-Ethoxy-2-phenethylfuran (325a)190
Prepared according to the General Furan Procedure from propargylic alcohol 316a
(500 mg, 1.91 mmol) in EtOH (0.50 M) to give the furan 325a as a colorless oil (737 mg,
3.41 mmol, 45%); Rf = 0.72 (10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2927s (C-H),
1635s, 1495s, 1453s, 1420s; 1H NMR (400 MHz; MeOH-d4) 7.27–7.09 (6H, m, ArH),
6.28 (1H, d, J = 2.0, ArH), 3.74 (2H, q, J = 7.1, OCH2), 2.93–2.81 (4H, m, CH2CH2Ph),
1.19 (3H, t, J = 7.1, CH2CH3); 13C NMR (125 MHz; CDCl3) 142.4 (Ar), 141.3 (Ar), 139.3
(Ar), 139.0 (Ar), 128.1 (Ar), 127.8 (Ar), 125.5 (Ar), 103.6 (Ar), 67.4 (OCH2), 33.9 (CH2),
26.6 (CH2), 14.0 (CH2CH3);. data in accordance with the literature.190
2-Cyclohexyl-3-ethoxyfuran (325b)
Prepared according to the General Furan Procedure from propargylic alcohol 316b
(0.500 g, 2.08 mmol) in EtOH (2.0 M) to give the furan 425b as a colorless oil (273 mg,
1.41 mmol, 68%); Rf = 0.33 (40:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2927s (C-H),
1627s; 1H NMR (600 MHz; CDCl3) 7.09 (1H, s, ArH), 7.08 (1H, s, ArH), 3.91 (2H, q, J
= 7.0, OCH2), 2.70 (1H, tt, J = 11.7, 3.2, ArCH), 1.84–1.76 (4H, m, 2 × CHCHH’, 2 ×
CHCH2CHH’), 1.71–1.66 (1H, m, CHH’CH2CH2CH), 1.58–1.51 (2H, m, CHCHH’),
1.37–1.29 (5H, m, CH2CH3; 2 × CHCH2CHH’), 1.28–1.23 (1H, m, CHH’CH2CH2CH);
13C NMR (150 MHz; CDCl3) 145.0 (Ar), 140.6 (Ar), 138.6 (Ar), 140.2 (Ar), 68.1 (OCH2),
35.3 (CHCH2), 31.3 (CHCH2), 26.5 (CHCH2CH2), 26.1 (CHCH2CH2CH2), 15.4
(CH2CH3); HRMS (CI+) found [M+H]+ 195.1389; C12H19O2 requires 195.1385.
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2-Cyclopropyl-3-ethoxyfuran (325c)190
Prepared according to the General Furan Procedure from propargylic alcohol 316c (250
mg, 1.26 mmol) in EtOH (2.0 M) to give the furan 325c as a colorless oil (56 mg,
0.368 mmol, 29%); Rf = 0.78 (10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2991s (C-H),
1666s, 1600s, 1432s; 1H NMR (400 MHz; DMSO-d6) 7.24 (1H, d, J = 2.0, ArH), 6.41
(1H, d, J = 2.0, ArH), 3.91 (2H, q, J = 7.1, OCH2), 1.86–1.79 (1H, m, CH(CH2)2), 1.24
(3H, t, J = 7.1, CH2CH3), 0.84–0.80 (2H, m, CH(CHH’)2), 0.73–0.69 (2H, m,
CH(CHH’)2); 13C NMR (100 MHz; DMSO-d6) 142.0 (Ar), 139.1 (Ar), 128.6 (Ar), 104.5
(Ar), 66.8 (OCH2), 14.9 (CH2CH3), 6.3 (CH(CH2)2), 5.3 (CH(CH2)2); data in accordance
with the literature.190
tert-Butyl 4-((3-ethoxyfuran-2-yl)methyl)piperidine-1-carboxylate (325d)
Prepared according to the General Furan Procedure from propargylic alcohol 316d
(500 mg, 1.41 mmol) in EtOH (1.0 M) to give the furan 325d as a colorless oil (335 mg,
1.08 mmol, 77%); Rf = 0.34 (10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2930s (C-H),
1693s (C=O), 1422m; 1H NMR (400 MHz; DMSO-d6) 7.20 (1H, d, J = 2.0, ArH), 6.35
(1H, d, J = 2.0, ArH), 4.07–4.01 (2H, m, NCHH’), 3.95 (2H, q, J = 7.1, OCH2), 2.83–
2.68 (2H, m, NCHH’), 2.53 (2H, d, J = 6.9, ArCH2), 1.86–1.75 (1H, m, ArCH2CH), 1.67–
1.61 (2H, m, CH(CHH’)2), 1.47 (9H, s, C(CH3)3), 1.31 (3H, t, J = 7.1, CH2CH3), 1.19–
1.07 (2H, m, CH(CHH’)2); 13C NMR (100 MHz; DMSO-d6) 156.6 (C(O)), 144.4 (Ar),
140.6 (Ar), 139.7 (Ar), 104.6 (Ar), 80.9 (CMe3), 68.6 (OCH2), 36.9 (ArCH2CH), 33.0
(CH(CH2)2), 32.5 (ArCH2), 28.7 (C(CH3)3), 15.5 (CH2CH3); HRMS (CI+) found [M+H]+
310.2012; C17H27NO4 requires 310.2018.
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3-Ethoxy-2-phenylfuran (325e)190
Prepared according to the General Furan Procedure from propargylic alcohol 316e
(2.00 g, 8.54 mmol) in EtOH (2.0 M) to give the furan 325e as a colorless oil (910 mg,
4.83 mmol, 57%); Rf = 0.33 (40:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2980s (C-
H), 1612s, 1510s, 1427s; 1H NMR (600 MHz; CDCl3) 7.81 (2H, d, J = 7.7, ArH), 7.37
(2H, t, J = 7.7, ArH), 7.27 (1H, d, J = 1.6, ArH), 7.17 (1H, t, J = 7.7, ArH), 6.40 (1H, d,
J = 1.6, ArH), 4.10 (2H, q, J = 7.0, OCH2), 1.44 (3H, t, J = 7.0, CH2CH3); 13C NMR (150
MHz; CDCl3) 144.4 (Ar), 140.2 (Ar), 136.9 (Ar), 131.1 (Ar), 128.5 (Ar), 125.8 (Ar), 123.1
(Ar), 104.1 (Ar), 67.3 (OCH2), 15.4 (CH2CH3); data in accordance with the literature.190
3-Ethoxy-2-(4-(trifluoromethyl)phenyl)furan (325f)190
Prepared according to the General Furan Procedure from propargylic alcohol 316f
(500 mg, 1.65 mmol) in EtOH (2.0 M) to give the furan 325f as a colorless oil (357 mg,
1.39 mmol, 84%); Rf = 0.50 (10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2985s (C-H),
1614s; 1H NMR (600 MHz; MeOH-d4) 7.92 (2H, d, J = 8.3, ArH), 7.34 (2H, d, J = 8.3,
ArH), 7.47 (1H, d, J = 2.1, ArH), 6.62 (1H, d, J = 2.1, ArH), 4.19 (2H, q, J = 7.1, OCH2),
1.46 (3H, t, J = 7.1, CH2CH3); 13C NMR (150 MHz; MeOH-d4) 146.5 (Ar), 141.7 (Ar),
134.8 (Ar), 134.4 (q, JC-F = 1.3, Ar), 126.5 (q, JC-F = 32.3, Ar), 124.9 (q, JC-F = 3.9, Ar),
124.5 (q, JC-F = 271.0, CF3), 122.3 (Ar), 103.6 (Ar), 66.9 (OCH2), 14.0 (CH2CH3); data
in accordance with the literature.190
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3-Ethoxy-2-(4-methoxyphenyl)furan (325g)190
Prepared according to the General Furan Procedure from propargylic alcohol 316g
(500 mg, 1.89 mmol) in EtOH (0.50 M) to give the furan 325g as a colorless oil (334 mg,
1.53 mmol, 81%); Rf = 0.48 (10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2980s (C-H),
1606s, 1520s, 1431s; 1H NMR (400 MHz; MeOH-d4) 7.72–7.69 (2H, m, ArH), 7.30 (1H,
d, J = 2.2, ArH), 7.95–7.91 (2H, m, ArH), 6.51 (1H, d, J = 2.2, ArH), 4.08 (2H, q, J =
7.0, OCH2), 3.90 (3H, s, OCH3), 1.40 (3H, t, J = 7.0, CH2CH3); 13C NMR (100 MHz;
MeOH-d4) 157.9 (Ar), 142.7 (Ar), 139.3 (Ar), 136.9 (Ar), 128.5 (Ar), 124.0 (Ar), 113.5
(Ar), 103.8 (Ar), 66.8 (OCH2), 54.3 (OCH3), 14.2 (CH2CH3); data in accordance with the
literature.190
2-(4-Bromophenyl)-3-ethoxyfuran (325h)
Prepared according to the General Furan Procedure from propargylic alcohol 316h
(500 mg, 1.60 mmol) in EtOH (2.0 M) to give the furan 325h as a colorless oil (334 mg,
1.25 mmol, 78%); Rf = 0.57 (10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2980s (C-H),
1669m, 1612s, 1504s, 1431s; 1H NMR (400 MHz; DMSO-d6) 7.67–7.65 (5H, m, ArH),
6.75 (1H, d, J = 2.0, ArH), 4.10 (2H, q, J = 6.8, OCH2), 1.35 (3H, t, J = 6.8, CH2CH3);
13C NMR (100 MHz; DMSO-d6) 145.1 (Ar), 141.9 (Ar), 134.2 (Ar), 131.6 (Ar), 129.6
(Ar), 124.0 (Ar), 118.1 (Ar), 104.8 (Ar), 66.8 (OCH2), 14.9 (CH2CH3); HRMS (CI+) found
[M+H]+ 265.9942; C12H1279BrO2 requires 265.9945.
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3-Ethoxy-2-(o-tolyl)furan (325i)
Prepared according to the General Furan Procedure from propargylic alcohol 316i
(500 mg, 2.01 mmol) in EtOH (2.0 M) to give the furan 325i as a colorless oil (177 mg,
0.875 mmol, 44%); Rf = 0.64 (10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2979s (C-H),
1618s; 1H NMR (400 MHz; MeOH-d4) 7.52–7.48 (1H, m, ArH), 7.41 (1H, d, J = 2.0,
ArH), 7.24–7.17 (3H, m, ArH), 6.53 (1H, d, J = 2.0, ArH), 4.02 (2H, q, J = 7.1, OCH2),
2.39 (3H, s, ArCH3), 1.32 (3H, t, J = 7.1, CH2CH3); 13C NMR (100 MHz; MeOH-d4)
145.1 (Ar), 141.7 (Ar), 139.2 (Ar), 137.0 (Ar), 131.6 (Ar), 131.3 (Ar), 129.5 (Ar), 128.4
(Ar), 126.4 (Ar), 104.9 (Ar), 68.2 (OCH2), 21.1 (ArCH3), 15.5 (CH2CH3); HRMS (CI+)
found [M+H]+ 203.1075; C13H15O2 requires 203.1072.
Methyl 3-(3-ethoxyfuran-2-yl)benzoate (325j)
Prepared according to the General Furan Procedure from propargylic alcohol 316j
(500 mg, 1.71 mmol) in EtOH (0.50 M) to give the furan 325j as a pale wax (302 mg,
1.23 mmol, 72%); Rf = 0.47 (10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2981s (C-H),
1720s (C=O), 1667s, 1431s; 1H NMR (400 MHz; MeOH-d4) 8.43 (1H, t, J = 1.4, ArH),
8.00 (1H, dt, J = 7.8, 1.4, ArH), 7.80 (1H, dt, J = 7.8, 1.4, ArH), 7.47 (1H, t, J = 7.8,
ArH), 7.43 (1H, d, J = 2.1, ArH), 6.61 (1H, d, J = 2.1, ArH), 4.17 (2H, q, J = 7.0, OCH2),
3.94 (3H, s, OCH3), 1.46 (3H, t, J = 7.0, CH2CH3); 13C NMR (100 MHz; MeOH-d4) 167.2
(C(O)), 145.3 (Ar), 140.9 (Ar), 135.4 (Ar), 131.4 (Ar), 130.2 (Ar), 128.3 (Ar), 126.7 (Ar),
125.9 (Ar), 123.3 (Ar), 103.7 (Ar), 66.9 (OCH2), 51.2 (OCH3), 14.1 (CH2CH3); HRMS
(CI+) found [M+H]+ 247.0971; C14H15O4 requires 247.0970.
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3-Ethoxy-2,2'-bifuran (325k)
Prepared according to the General Furan Procedure from propargylic alcohol 316k
(500 mg, 2.23 mmol) in EtOH (0.50 M) to give the furan 325k as a colorless oil (102 mg,
0.572 mmol, 26%); Rf = 0.50 (10:1 cyclohexane:EtOAc); νmax (film/cm–1); 3150m, 2981s
(C-H), 1629s, 1575s, 1415s; 1H NMR (400 MHz; MeOH-d4) 7.47 (1H, d, J = 2.0, ArH),
7.35 (1H, d, J = 2.2, ArH), 6.53 (1H, d, J = 2.2, ArH), 6.50 (1H, dd, J = 3.4, 2.0, ArH),
6.45 (1H, d, J = 3.4, ArH), 4.10 (2H, q, J = 6.9, OCH2), 1.39 (3H, t, J = 6.9, CH2CH3);
13C NMR (100 MHz; MeOH-d4) 145.5 (Ar), 143.2 (Ar), 140.6 (Ar), 140.5 (Ar), 112.0
(Ar), 110.7 (Ar), 103.9 (Ar), 103.6 (Ar), 67.01 (OCH2), 14.0 (CH2CH3); HRMS (CI+)
found [M+H]+ 179.070; C10H10O3 requires 179.0708.
3-Ethoxy-2-(thiophen-2-yl)furan (325l)
Prepared according to the General Furan Procedure from propargylic alcohol 316l
(500 mg, 2.23 mmol) in EtOH (0.50 M) to give the furan 325l as a colorless oil (328 mg,
1.69 mmol, 78%); Rf = 0.52 (10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2980s (C-H),
1620s; 1H NMR (400 MHz; MeOH-d4) 7.32 (1H, d, J = 2.2, ArH), 7.27–7.22 (2H, m,
ArH), 7.05–7.02 (1H, m, ArH), 6.52 (1H, d, J = 2.2, ArH), 4.12 (2H, q, J = 7.1, OCH2),
1.42 (3H, t, J = 7.1, CH2CH3); 13C NMR (100 MHz; MeOH-d4) 142.6 (Ar), 139.9 (Ar),
134.6 (Ar), 132.3 (Ar), 126.6 (Ar), 122.1 (Ar), 120.0 (Ar), 103.7 (Ar), 67.1 (OCH2), 14.1
(CH2CH3); HRMS (CI+) found [M+H]+ 195.0473; C10H11O2S requires 195.0473.
3-(3-Ethoxyfuran-2-yl)pyridine (325m)
Subjecting propargylic alcohol 316m to the General Furan Procedure in EtOH (0.50 M)
resulted in no reaction.
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A stirring solution of propargylic alcohol 316m (200 mg, 0.851 mmol) and MsOH
(0.28 mL, 0.48 g, 4.3 mmol) in EtOH (4.2 mL) was treated with [PPh3AuNTf2]2PhMe
(33 mg, 0.021 mmol, 2.5 mol%, 5.0 mol% [Au]) at RT. The resulting solution was stirred
for 2 h at RT before it was treated with water (5.0 mL) and stirred for a further 1 h. The
reaction was then cooled to 0 °C, diluted with Et2O (20 mL) and quenched with aq. sat.
NaHCO3 (20 mL). The aq. extract was washed with Et2O (3 × 20 mL) and the combined
organic extracts were dried (phase separator) and concentrated in vacuo to give the crude
product, which was purified by flash column chromatography (0 to 10% petrol 30–40 °C:
TBME) to give the furan 325m as a colorless oil (117 mg, 0.619 mmol, 73%); Rf = 0.23
(10:1 cyclohexane:EtOAc); νmax (film/cm–1) 2959w (C-H), 1659s, 1678s, 1440s; 1H NMR
(400 MHz; MeOH-d4) 8.94 (1H, d, J = 1.7, ArH), 8.31 (1H, dd, J = 4.9, 1.7, ArH), 8.14
(1H, d, J = 8.1, ArH), 7.49 (1H, d, J = 2.2, ArH), 7.44 (1H, dd, J = 8.1, 4.9, ArH), 6.64
(1H, d, J = 2.2, ArH), 4.19 (2H, q, J = 7.0, OCH2), 1.45 (3H, t, J = 7.0, CH2CH3);
13C NMR (100 MHz; MeOH-d4) 146.5 (Ar), 145.0 (Ar), 142.9 (Ar), 142.1 (Ar), 132.9
(Ar), 129.9 (Ar), 127.8 (Ar), 123.8 (Ar), 103.6 (Ar), 67.0 (OCH2), 14.0 (CH2CH3); HRMS
(CI+) found [M+H]+ 190.0863; C11H12NO2 requires 190.0868.
(E)-3-Ethoxy-4-oxo-4-phenylbut-2-enal (326)
A solution of furan 325e (103 mg, 0.548 mmol) in PhMe (2.0 mL) was heated at reflux
under an atmosphere of air for 24 h. The reaction was then allowed to cool to RT before
it was concentrated in vacuo to give the crude product. This was purified by flash column
chromatography (4:1 petrol 40–60 °C:EtOAc) to give the aldehyde 326 as a white
crystalline solid (61 mg, 0.30 mmol, 55%); m.p. 52–54 °C; Rf = 0.50 (1:1 petrol 40–
60 °C:EtOAc); νmax (film/cm–1) 2981s (C-H), 1757s (C=O), 1675s (C=O), 1630s, 1597s,
1451s; 1H NMR (600 MHz; CDCl3) 9.51 (1H, d, J = 7.8, C(O)H), 7.93 (2H, d, J = 7.6,
ArH), 7.66 (1H, t, J = 7.6, ArH), 7.52 (2H, t, J = 7.6), 5.73 (1H, d, J = 7.8, EtOCCH),
4.12 (2H, q, J = 7.1, OCH2), 1.44 (3H, t, J = 7.1, CH2CH3); 13C NMR (150 MHz; CDCl3)
189.8 (C(O)H), 189.6 (C(O)Ph), 172.0 (EtOC), 134.9 (Ar), 134.7 (Ar), 130.1 (Ar), 129.1
(Ar), 107.8 (C(O)CH), 66.3 (OCH2), 14.1 (CH2CH3); HRMS (CI+) found [M+H]+
205.0859; C12H13O3 requires 205.0859.
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(E)-Ethyl 2-((tert-butylsulfinyl)imino)acetate (328)192
According to the modified procedure of Fei et al.192: 2-Methylpropane-2-sulfinamide
(3.00 g, 24.8 mmol) was added to a stirring mixture of ethyl 2-oxoacetate (50% in PhMe,
4.9 mL, 25 mmol) and activated 4 Å molecular sieves (16.0 g) in PhMe (50 mL). The
reaction mixture was stirred at 50 °C for 24 h before it was allowed to reach room
temperature. The reaction was filtered and the volatile components were removed in
vacuo to give imine 328 as a yellow oil (3.24 g, 15.8 mmol, 64%); Rf = 0.27 (5:1
cyclohexane:EtOAc); νmax (film/cm–1) 2982s (C-H), 1744s, 1724s, 1695s, 1606s, 1470s;
1H NMR (400 MHz; CDCl3) 8.01 (1H, s, N=CH), 4.39 (2H, q, J = 7.1, CH2CH3), 1.39
(3H, t, J = 7.1, CH2CH3), 1.28 (9H, s, C(CH3)3); 13C NMR (125 MHz; CDCl3) 161.1
(C(O)), 155.6 (C=N), 62.4 (CH2CH3), 58.9 (C(CH3)3), 22.7 (C(CH3)3), 14.1 (CH2CH3);
data in accordance with the literature.192
1-(4-Methylbenzyl)-1H-pyrrole-2,5-dione (329a)
According to the modified procedure of Ordónez et al.193: p-Tolylmethanamine (2.6 mL,
2.4 g, 20 mmol) was added to a stirring solution of maleic anhydride (2.00 g, 20.4 mmol)
in AcOH (40 mL) at RT and the resulting solution was heated at reflux for 3 h. The
reaction was then allowed to cool to RT and concentrated in vacuo before being
redissolved in EtOAc (50 mL) and washed with aq. sat. NH4Cl. The aq. extract was
washed with EtOAc (3 × 50 mL) and the combined organic extracts were dried (phase
separator) and concentrated in vacuo to give the crude product. This was purified by flash
column chromatography (0 to 100% cyclohexane: EtOAc) to give imide 329a as a white
crystalline solid (1.23 g, 6.11 mmol, 30%); m.p. = 100–102 °C; Rf = 0.62 (1:1
cyclohexane:EtOAc); νmax (film/cm–1) 3097m (C-H), 2941m (C-H), 1696s (C=O), 1515s,
1443s; 1H NMR (400 MHz; MeOH-d4) 7.15–7.10 (4H, m, ArH), 7.06 (2H, s, HC=CH),
4.55 (2H, s, NCH2), 2.27 (3H, s, ArCH3); 13C NMR (100 MHz; MeOH-d4) 170.8 (C(O)),
204 Experimental Details
136.6 (Ar), 134.6 (CH=CH), 133.7 (Ar), 129.1 (Ar), 127.2 (Ar), 40.7 (NCH2), 20.6
(ArCH3); HRMS (CI+) found [M+H]+ 202.0860; C12H12NO2 requires 200.0868.
1-Cyclopropyl-1H-pyrrole-2,5-dione (329b)
According to the modified procedure of Ordónez et al.193: Cyclopropanamine (1.4 mL,
1.1 g, 20 mmol) was added to a stirring solution of maleic anhydride (2.00 g, 20.4 mmol)
in AcOH (40 mL) at RT and the resulting solution was heated at reflux for 2 h. The
reaction was then allowed to cool to RT and concentrated in vacuo before being dissolved
in EtOAc (50 mL) and washed with aq. sat. NaHCO3. The aq. extract was washed with
EtOAc (3 × 50 mL) and the combined organic extracts were dried (phase separator) and
concentrated in vacuo to give the crude product. This was purified by flash column
chromatography (0 to 100% TBME:cyclohexane) to give imide 329b as a white
crystalline solid (1.30 g, 9.48 mmol, 47%); m.p. = 57–59 °C; Rf = 0.55 (1:1
cyclohexane:EtOAc); νmax (film/cm–1) 2977s (C-H), 1775m, 1757s (C=O), 1400s;
1H NMR (400 MHz; DMSO-d6) 6.93 (2H, s, HC=CH), 2.52–2.45 (1H, m, NCH), 0.85–
0.79 (2H, m, CH(CHH’)2) 0.78–0.72 (2H, m, CH(CHH’)2); 13C NMR (100 MHz; DMSO-
d6) 171.4 (C(O)), 134.2 (CH=CH), 19.7 (NCH), 4.4 (NCH(CH2)2); HRMS (CI+) found
[M+H]+ 138.0555; C7H8NO2 requires 138.0555.
Chapter IV 205
(3aS,4R,7R,7aR)-5-Ethoxy-2-methyl-4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-330a) and (3aR,4R,7R,7aS)-5-Ethoxy-2-
methyl-4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione
(exo-330a)
Method A (0.500 mmol): Prepared from furan 225a (108 mg, 0.500 mmol) and N-
methylmaleimide according to the General Cycloaddition Procedure to give a mixture of
the cantharimides 330a as a colorless oil (153 mg, 0.467 mmol, 93%; endo:exo = 70:30).
Method A (4.62 mmol): Prepared from furan 225a (1.00 g, 4.62 mmol) and N-
methylmaleimide according to the General Cycloaddition Procedure to give the crude
product (endo:exo = 75:25). Purification by flash column chromatography (0 to 100%
TBME:cyclohexane) gave the cantharimide endo-330a (906 mg, 2.77 mmol, 60%).
Further elution of the column gave a mixture of the cantharimide endo-330a and the
cantharimide exo-330a (202 mg, 0.618 mmol, 13%). Further elution of the column gave
the cantharimide exo-330a (310 mg, 0.948 mmol, 21%).
Method B: A solution of N-methylmaleimide (67 mg, 0.60 mmol) and furan 225a
(108 mg, 0.500 mmol) in DMC (0.50 mL) was stirred at 80 °C for 16 h. The reaction was
then allowed to cool to RT before it was diluted with EtOAc and loaded onto an
aminopropyl cartridge. After 5 minutes the cartridge was then washed with EtOAc and
the filtrate was concentrated in vacuo to give a mixture of the cantharimides 330a as a
colorless oil (153 mg, 0.467 mmol, 93%; endo:exo = 55:45).
Method C: A solution of [PPh3AuNTf2]2PhMe (60 mg, 1.0 mol%, 2.0 mol% [Au]) in
EtOH (1.9 mL) was added dropwise to a stirring solution of propargylic alcohol 325a
(1.00 g, 3.81 mmol) in EtOH (1.9 mL) at RT. The resulting solution was stirred for 3 h
before it was treated with PPh3 (25 mg, 2.5 mol%). After a further 1 h the reaction was
treated with N-methylmaleimide (508 mg, 4.57 mmol) and stirred for 16 h at RT. The
reaction mixture was then loaded onto an aminopropyl cartridge and, after 5 minutes,
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eluted with EtOAc. The filtrate was concentrated in vacuo to give the crude product
(endo:exo = 70:30), which was purified by flash column chromatography (0 to 100%
TBME:cyclohexane) to give a mixture of the cantharimides 330a as a colorless oil
(828 mg, 2.53 mmol, 66%; endo:exo = 70:30).
Cantharimide endo-330a: Isolated a white crystalline solid. m.p. 90–92 °C; Rf = 0.62
(2:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2981s (C-H), 1774m (C=O), 1710s (C=O),
1623s, 1432s; 1H NMR (600 MHz; CDCl3) 7.29 (2H, t, J = 7.3, ArH), 7.23 (2H, d, J = 7.3,
ArH), 7.19 (1H, t, J = 7.3, ArH), 5.18 (1H, dd, J = 5.3, 1.4, COCH), 4.96 (1H, d, J = 1.4,
C=CH), 3.85–3.80 (1H, m, OCHH’), 3.67 (1H, dd, J = 7.6, 5.3, OCHCHCH), 3.57–3.51
(1H, m, OCHH’), 3.19 (1H, d, J = 7.6, OCHCHCH), 2.83–2.79 (5H, m, NCH3; PhCH2),
2.62–2.55 (1H, m, PhCH2CHH’), 2.28–2.22 (1H, m, PhCH2CHH’), 1.27 (3H, t, J = 7.0,
CH2CH3); 13C NMR (150 MHz; CDCl3) 175.7 (C(O)), 174.2 (C(O)), 164.1 (EtOC), 141.7
(Ar), 128.5 (Ar), 128.5 (Ar), 126.1 (Ar), 96.6 (C=CH), 89.6 (COCH), 78.2 (COCH), 66.9
(OCH2), 51.4 (OCHCHCH), 49.8 (OCHCHCH), 31.9 (PhCH2CH2), 30.5 (PhCH2), 24.5
(NCH3), 14.2 (CH2CH3); HRMS (CI+) found [M+H]+ 328.1544; C19H22NO4 requires
328.1543.
Cantharimide exo-330a: Isolated as a pale wax. Rf = 0.50 (1:1 cyclohexane:EtOAc);
1H NMR (400 MHz; MeOH-d4) 7.36–7.16 (5H, m, ArH), 5.20 (1H, d, J = 2.0, C=CH),
5.13 (1H, d, J = 2.0, COCH), 3.94–3.76 (2H, m, OCH2), 3.15 (1H, d, J = 6.4, CHC(O)),
2.95 (1H, d, J = 6.4, CHC(O)), 2.90–2.74 (2H, m, PhCH2), 2.44–2.36 (1H, m,
PhCH2CHH’), 2.31–2.22 (1H, m, PhCH2CHH’), 1.39 (3H, t, J = 7.1, CH2CH3); 13C NMR
(150 MHz; MeOH-d4) 177.1 (C(O)), 175.6 (C(O)), 166.6 (COEt), 142.1 (Ar), 128.0 (Ar),
127.9 (Ar), 125.5 (Ar), 99.5 (C=CH), 88.8 (COCH), 79.9 (COCH), 66.5 (OCH2), 54.3
(CHC(O)), 49.1 (CHC(O)), 30.4 (CH2), 29.7 (CH2), 23.4 (NCH3), 13.2 (CH2CH3).
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(3aS,4R,7R,7aR)-5-Methoxy-2-methyl-4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-320) and (3aR,4R,7R,7aS)-5-Methoxy-2-
methyl-4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione
(exo-320)190
Prepared from furan 318 (101 mg, 0.500 mmol) and N-methylmaleimide according to the
General Cycloaddition Procedure over 4 h to give the crude product (endo:exo = 80:20).
This was purified by flash column chromatography (0 to 100% TBME:cyclohexane) to
give the cantharimide endo-320 as a white crystalline solid (105 mg, 0.335 mmol, 67%).
Further elution of the column gave the cantharimide exo-320 as a white crystalline solid
(34 mg, 0.11 mmol, 22%).
Cantharimide endo-320: m.p. 94–96 °C; Rf = 0.40 (1:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 2931s (C-H), 1774s, 1699s (C=O), 1625s, 1433s; 1H NMR (600 MHz;
CDCl3) 7.27 (2H, t, J = 7.5, ArH), 7.24 (2H, d, J = 7.5, ArH), 7.19 (1H, t, J = 7.5, ArH),
5.20 (1H, dd, J = 5.2, 1.3, COCH), 5.02 (1H, d, J = 1.3, C=CH), 3.70 (1H, dd, J = 7.5,
5.2, OCHCHCH), 3.53 (3H, s, OCH3), 3.21 (1H, d, J = 7.5, OCHCHCH), 2.85 (3H, s,
NCH3), 2.83–2.78 (2H, m, PhCH2), 2.62–2.56 (1H, m, PhCH2CHH’), 2.28–2.22 (1H, m,
PhCH2CHH’); 13C NMR (150 MHz; CDCl3) 175.6 (C(O)), 174.3 (C(O)), 165.4 (MeOC),
141.6 (Ar), 128.5 (Ar), 128.5 (Ar), 126.1 (Ar), 96.9 (C=CH), 89.7 (COCH), 78.2 (COCH),
58.2 (OCH3), 51.3 (OCHCHCH), 49.8 (OCHCHCH), 31.9 (PhCH2CH2), 30.5 (PhCH2),
24.6 (NCH3); data in accordance with the literature.190
Cantharimide exo-320: m.p. 149–151 °C; Rf = 0.50 (1:2 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 2922s (C-H), 1764s, 1698s (C=O), 1633s, 1440s; 1H NMR (600 MHz;
CDCl3) 7.29–7.25 (2H, m, ArH), 7.24–7.21 (2H, m, ArH), 7.17 (1H, t, J = 7.2, ArH), 5.18
(1H, s, C=CH), 5.16 (1H, s, COCH), 3.66 (3H, s, OCH3), 3.14 (1H, d, J = 6.4, CHC(O)),
2.96 (3H, s, NCH3), 2.93 (1H, d, J = 6.4, CHC(O)), 2.85–2.73 (2H, m, PhCH2), 2.39–2.33
(1H, m, PhCH2CHH’), 2.30–2.20 (1H, m, PhCH2CHH’); 13C NMR (150 MHz; CDCl3)
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176.4 (C(O)), 174.9 (C(O)), 168.4 (MeOC), 141.9 (Ar), 128.5 (Ar), 128.4 (Ar), 126.0
(Ar), 99.6 (C=CH), 89500 M.3 (COCH), 79.9 (COCH), 58.3 (OCH3), 54.4 (CHC(O)),
49.2 (CHC(O)), 30.8 (PhCH2), 25.0 (PhCH2CH2), 25.0 (NCH3); data in accordance with
the literature. 190
(3aS,4R,7R,7aR)-4-Cyclohexyl-5-ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-330b) and (3aR,4R,7R,7aS)-4-Cyclohexyl-5-
ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (exo-
330b)
Prepared from furan 325b (97 mg, 0.50 mmol) and N-methylmaleimide according to the
General Cycloaddition Procedure over 4 h to give a mixture of the cantharimides 330b
as a colorless oil (145 mg, 0.475 mmol, 95%, endo:exo = 85:15); Rf = 0.51 (1:1
cyclohexane:EtOAc); νmax (film/cm–1) 2983s (C-H), 1773m, 1702s (C=O), 1624s, 1433s;
1H NMR (400 MHz; MeOH-d4) 5.21 (1H, dd, J = 2.1, 1.0, C=CH exo-330b), 5.06 (1H,
dd, J = 5.0, 2.1, COCH endo-330b), 5.00 (1H, d, J = 2.1, C=CH endo-330b), 4.96 (1H,
d, J = 2.1, COCH exo-330b), 3.88–3.75 (1H, m, OCHH’ endo-330b; 2H, m, OCH2 exo-
330b), 3.63 (1H, dd, J = 7.4, 5.0, OCHCHCH endo-330b), 3.58–3.51 (1H, m, OCHH’
endo-330b), 3.51 (1H, d, J = 7.4, CyCCH endo-330b), 3.18–3.13 (2H, m, 2 × CHC(O)
exo-330b), 2.91 (3H, s, NCH3 exo-330b), 2.79 (3H, s, NCH3 endo-330b), 2.36–2.29 (1H,
m, CHH’ exo-330b), 2.14–1.91 (3H, m, 3 × CHH’ endo-330b), 1.91–1.66 (4H, m, 4 ×
CHH’ endo-330b), 1.44–1.14 (3H, m, CH2CH3 endo-330b; 3H, m, CH2CH3 exo-330b;
3H, 3 × CHH’ endo-330b) [9 × CHH’ protons of exo-330b cannot be assigned with
confidence]; 13C NMR (100 MHz; MeOH-d4) 177.1 (C(O)), 176.3 (C(O)), 175.3 (C(O)),
175.1 (C(O)), 167.4 (COEt), 164.3 (COEt), 100.6 (C=CH exo-330b), 96.6 (C=CH endo-
330b), 92.3 (CyC), 91.8 (CyC), 79.3 (COCH exo-330b), 77.3 (COCH endo-330b), 66.4
(OCH2), 66.2 (OCH2), 54.3 (CHC(O) exo-330b), 51.3 (OCHCHCH endo-330b), 47.9
(CHC(O) exo-330b), 46.2 (CyCCH endo-330b), 39.2 (CH(CH2)2 exo-330b), 37.0
(CH(CH2)2 endo-330b), 27.8 (CH2), 27.5 (CH2), 26.7 (CH2), 26.4 (CH2), 26.3 (CH2), 26.3
(CH2), 26.2 (CH2), 26.1 (CH2), 26.1 (CH2), 26.0 (CH2), 23.5 (NCH3), 23.2 (NCH3), 13.3
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(CH2CH3), 13.2 (CH2CH3); HRMS (CI+) found [M+H]+ 306.1700; C17H24NO4 requires
306.1705.
(3aS,4R,7R,7aR)-4-Cyclopropyl-5-ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-330c) and (3aR,4R,7R,7aS)-4-Cyclopropyl-5-
ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (exo-
330c)
Prepared from furan 325c (76 mg, 0.50 mmol) and N-methylmaleimide according to the
General Cycloaddition Procedure over 4 h to give a mixture of the cantharimides 330c as
a colorless oil (118 mg, 0.448 mmol, 90%, endo:exo = 80:20); Rf = 0.48 (1:1
cyclohexane:EtOAc); νmax (film/cm–1) 2980s (C-H), 1702s (C=O), 1624m; 1H NMR
(400 MHz; MeOH-d4) 5.15 (1H, d, J = 2.0, C=CH exo-330c), 5.04 (1H, dd, J = 5.1, 2.0,
COCH endo-330c), 5.00 (1H, d, J = 2.0, C=CH endo-330c), 4.96 (1H, d, J = 2.0, COCH
exo-330c), 3.93–3.76 (1H, m, OCHH’ endo-330c; 2H, m, OCH2 exo-330c), 3.67 (1H, dd,
J = 7.6, 5.1, OCHCHCH endo-330c), 3.62–3.54 (1H, m, OCHH’ endo-330c), 3.24–3.20
(1H, d, J = 7.6, OCHCHCH endo-330c; 1H, m, CHC(O) exo-330c), 3.00 (1H, d, J = 6.4,
CHC(O) exo-330c), 2.92 (3H, s, NCH3 exo-330c), 2.81 (3H, s, NCH3 endo-330c), 1.57–
1.47 (1H, m, CH(CH2)2 endo-330c), 1.44–1.38 (1H, m, CH(CH2)2 exo-330c), 1.34 (3H,
t, J = 7.0, CH2CH3 exo-330c), 1.26 (3H, t, J = 7.1, CH2CH3 endo-330c), 0.79–0.49 (4H,
m, CH(CH2)2 endo-330c, 3H, m, CH(CH2)(CHH’) exo-330c), 0.34–0.30 (1H, m,
CH(CH2)(CHH’) exo-330c); 13C NMR (100 MHz; MeOH-d4) 177.2 (C(O)), 176.2
(C(O)), 175.6 (C(O)), 174.9 (C(O)), 167.5 (COEt), 164.7 (COEt), 98.6 (C=CH exo-330c),
95.9 (C=CH endo-330c), 89.1 (cPrC), 88.4 (cPrC), 79.1 (COCH exo-330c), 77.3 (COCH
endo-330c), 66.4 (OCH2), 66.4 (OCH2), 54.6 (CHC(O) exo-330c), 51.2 (OCHCHCH
endo-330c), 49.5 (CHC(O) exo-330c), 48.8 (OCHCHCH endo-330c), 23.4 (NCH3), 23.3
(NCH3), 13.2 (CH2CH3), 13.1 (CH2CH3), 9.5 (CH(CH2)2), 7.9 (CH(CH2)2), 0.9
(CH(CH2)2), 0.5 (CH(CH2)2), 0.3 (CH(CH2)2); HRMS (CI+) found [M+H]+ 264.1239;
C14H18NO4 requires 264.1236.
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tert-Butyl 4-(((3aS,4R,7R,7aR)-5-ethoxy-2-methyl-1,3-dioxo-2,3,3a,4,7,7a-
hexahydro-1H-4,7-epoxyisoindol-4-yl)methyl)piperidine-1-carboxylate (endo-330d)
and tert-Butyl 4-(((3aR,4R,7R,7aS)-5-ethoxy-2-methyl-1,3-dioxo-2,3,3a,4,7,7a-
hexahydro-1H-4,7-epoxyisoindol-4-yl)methyl)piperidine-1-carboxylate (exo-330d)
Prepared from furan 325d (44 mg, 0.14 mmol) and N-methylmaleimide according to the
General Cycloaddition Procedure over 4 h to give a mixture of the cantharimides 330d
as a colorless oil (51 mg, 0.12 mmol, 85%, endo:exo = 75:25); Rf = 0.50 (1:1
cyclohexane:EtOAc); νmax (film/cm–1) 2929s (C-H), 1701s (C=O), 1428m; 1H NMR
(600 MHz; CDCl3) 5.19–5.16 (1H, m, COCH endo-330d; 1H, m, COCH exo-330d), 5.05
(1H, s, C=CH exo-330d), 4.94 (1H, s, C=CH endo-330d), 4.04 (2H, br. s, NCHH’ endo-
330d; 2H, br. s, NCHH’ exo-330d), 3.89–3.75 (1H, m, OCHH’ endo-330d; 2H, m, OCH2
exo-330d), 3.64 (1H, dd, J = 7.7, J = 5.0, OCHCHCH endo-330d), 3.58–3.52 (1H, m,
OCHH’ endo-330d), 3.17 (1H, d, J = 7.7, OCHCHCH endo-330d), 3.08 (1H, d, J = 6.2,
CHC(O) exo-330d), 2.98 (3H, s, NCH3, exo-330d), 2.84 (3H, s, NCH3 endo-330d), 2.83
(1H, d, J = 6.2, CHC(O) exo-330d), 2.76–2.63 (2H, m, NCHH’ endo-330d; 2H, br. s,
NCHH’ exo-330d), 2.30 (1H, dd, J = 15.0, 5.5, COCCHH’ endo-330d), 2.09 (1H, dd,
J = 15.4, 5.5, CHOCCHH’ exo-330d), 1.91–1.65 (1H, m, COCCHH’ endo-330d; 2H, m,
N(CH2CHH’)2 endo-330d; 1H, m, N(CH2CH2)2CH endo-330d; 2H, m, COCCHH’ exo-
330d; 2H, m, N(CH2CHH’)2 exo-330d; 1H, m, N(CH2CH2)2CH exo-330d), 1.59 (9H, s,
C(CH3)3 exo-330d), 1.46 (9H, s, C(CH3)3 endo-330d), 1.35 (3H, t, J = 7.0, CH2CH3 exo-
330d), 1.28 (3H, t, J = 7.0, CH2CH3 endo-330d), 1.25–1.11 (1H, m, N(CH2CHH’)2 endo-
330d; 2H, m, N(CH2CHH’)2 exo-330d); 13C NMR (150 MHz; CDCl3) 176.4 (C(O)N),
175.5 (C(O)N), 175.0 (C(O)N), 174.1 (C(O)N), 166.9 (EtOC), 164.1 (EtOC), 154.9
(COtBu), 98.8 (C=CH exo-330d), 96.1 (C=CH endo-330d), 89.6 (COCH), 89.2 (COCH),
79.9 (COCH), 79.2 (CMe3), 79.1 (CMe3), 78.1 (COCH), 66.8 (OCH2), 66.6 (OCH2), 54.2
(CH), 51.0 (CH), 50.8 (CH), 49.8 (CH), 43.9 (br. NCH2 endo-330d; NCH2 exo-330d),
36.1 (CH2), 33.1 (br. NCH2CH2), 32.9 (N(CH2CH2)2CH), 32.6 (N(CH2CH2)2CH), 32.5
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(br. NCH2CH2), 28.5 (C(CH3)3 endo-330d; C(CH3)3 exo-330d) 24.8 (NCH3), 24.4
(NCH3), 14.2 (CH2CH3), 14.1 (CH2CH3); HRMS (CI+) found [M+H]+ 421.2333;
C22H33N2O6 requires 421.2339; Strong ROE between OCHCHCH endo-330d and COCH
endo-330d; Weak ROE between OCHCHCH exo-330d and COCH exo-330d.
(3aS,4S,7R,7aR)-5-Ethoxy-2-methyl-4-phenyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-330e) and (3aR,4S,7R,7aS)-5-Ethoxy-2-methyl-
4-phenyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (exo-330e)
Experiment A (0.428 mmol scale): Prepared from furan 325e (94 mg, 0.50 mmol) and
N-methylmaleimide according to the General Cycloaddition Procedure over 6 h to give a
mixture of the cantharimides 330e as a white crystalline solid (128 mg, 0.428 mmol, 86%,
endo:exo = 80:20).
Experiment B (5.32 mmol scale): Prepared from furan 325e (1.00 g, 5.32 mmol) and N-
methylmaleimide according to the General Cycloaddition Procedure over 24 h to give the
crude product, which was purified by flash column chromatography (0 to 70%
TBME:cyclohexane) to give cantharimide endo-330e as a white crystalline solid (1.04 g,
3.47 mmol, 65%). Further elution of the column gave the cantharimide exo-330e as a
white crystalline solid (334 mg, 1.12 mmol, 21%).
Cantharimide endo-330e: m.p. 96–98 °C; Rf = 0.45 (3:1 petrol 40–60 °C:EtOAc); νmax
(film/cm–1) 2982 (C-H), 1774s, 1700s (C=O), 1623s, 1500s, 1432s; 1H NMR (600 MHz;
CDCl3) 7.89–7.79 (2H, m, ArH), 7.47–7.38 (3H, m, ArH), 5.32 (1H, dd, J = 5.2, 2.1,
COCH), 5.02 (1H, d, J = 2.1, C=CH), 3.84–3.78 (2H, m, OCHH’; OCHCHCH), 3.58–
3.52 (2H, m, OCHH’; PhCCH), 2.91 (3H, s, NCH3), 1.18 (3H, t, J = 7.1, CH2CH3);
13C NMR (150 MHz; CDCl3) 175.4 (C(O)), 174.3 (C(O)), 164.9 (COEt), 134.7 (Ar),
128.7 (Ar), 128.4 (Ar), 127.2 (Ar), 95.5 (C=CH), 90.3 (CPh), 77.9 (COCH), 67.1 (OCH2),
51.8 (OCHCHCH), 51.0 (PhCCH), 24.6 (NCH3), 13.9 (CH2CH3); HRMS (CI+) found
[M+H]+ 300.1239; C17H18NO4 requires 300.1230.
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Cantharimide exo-330e: m.p. 119–121 °C; Rf = 0.38 (3:1 petrol 40–60 °C:EtOAc);
1H NMR (400 MHz; MeOH-d4) 7.51–7.45 (2H, m, ArH), 7.39–7.29 (3H, m, ArH), 5.28
(1H, d, J = 2.2, C=CH), 5.22 (1H, d, J = 2.2, COCH), 3.83 (2H, q, J = 7.1, OCH2), 3.46
(1H, d, J = 6.4, CHC(O)), 3.38–3.34 (1H, m, CHC(O)), 2.80 (3H, s, NCH3), 1.28 (3H, t,
J = 7.1, CH2CH3); 13C NMR (400 MHz; MeOH-d4) 177.0 (C(O)), 174.5 (C(O)), 167.1
(COEt), 132.6 (Ar), 127.5 (Ar), 127.1 (Ar), 126.4 (Ar), 98.1 (C=CH), 90.2 (CPh), 79.8
(COCH), 66.6 (OCH2), 54.6 (CHC(O)), 49.9 (CHC(O)), 23.3 (NCH3), 13.0 (CH2CH3).
(3aS,4S,7R,7aR)-5-Ethoxy-2-methyl-4-(4-(trifluoromethyl)phenyl)-3a,4,7,7a-
tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (endo-330f) and (3aR,4S,7R,7aS)-
5-Ethoxy-2-methyl-4-(4-(trifluoromethyl)phenyl)-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (exo-330f)
Prepared from furan 325f (64 mg, 0.25 mmol) and N-methylmaleimide according to the
General Cycloaddition Procedure over 24 h to give a mixture of the cantharimides 330f
as a white crystalline solid (69 mg, 0.18 mmol, 75%, endo:exo = 80:20); m.p. = 243–
245 °C; Rf = 0.55 and 0.75 (1:1 cyclohexane:EtOAc); νmax (film/cm–1) 2986m (C-H),
1776m, 1702s (C=O), 1625s; 1H NMR (400 MHz; MeOH-d4) 7.98 (2H, d, J = 7.7, ArH
endo-330f), 7.71 (2H, d, J = 7.7, ArH endo-330f), 7.66–7.65 (4H, m, ArH exo-330f),
5.31–5.30 (1H, dd, J = 5.1, 2.2, COCH endo-330f; 1H, m, COCH exo-330f), 5.24 (1H, d,
J = 2.2, C=CH exo-330f), 5.14 (1H, d, J = 2.2, C=CH endo-330f), 3.87 (1H, dd, J = 5.1,
7.6, OCHCHCH endo-330f), 3.86–3.77 (1H, m, OCHH’ endo-330f; 2H, m, OCH2 exo-
330f), 3.60 (1H, d, J = 7.6, OCHCHCH endo-330f), 3.60–3.55 (1H, m, OCHH’ endo-
330f), 3.51 (1H, d, J = 6.4, CHC(O) exo-330f), 3.36 (1H, d, J = 6.4, CHC(O) exo-330f),
2.87 (3H, s, NCH3 endo-330f), 2.78 (3H, s, NCH3 exo-330f), 1.26 (3H, t, J = 7.1, CH2CH3
exo-330f), 1.15 (3H, t, J = 7.1, CH2CH3 endo-330f); 13C NMR (150 MHz; MeOH-d4)
176.7 (C(O)), 175.6 (C(O)), 174.5 (C(O)), 174.3 (C(O)), 166.4 (COEt), 164.3 (COEt),
139.6 (Ar), 137.1 (Ar), 130.1 (q, JC-F = 33.2, Ar), 129.9 (q, JC-F = 32.4, Ar), 127.7 (Ar),
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127.2 (Ar), 124.4 (q, JC-F = 4.4, Ar), 124.0 (q, JC-F = 4.4, Ar), 124.4 (q, JC-F = 270.9, CF3),
124.3 (q, JC-F = 270.9, CF3), 98.4 (C=CH exo-330f), 95.6 (C=CH endo-330f), 89.6
(COCH), 89.3 (COCH), 80.1 (COCH exo-330f), 77.9 (COCH endo-330f), 66.9 (OCH2),
66.9 (OCH2), 54.4 (CHC(O) exo-330f), 51.5 (OCHCHCH endo-330f), 50.8 (OCHCHCH
endo-330f), 49.9 (CHC(O) exo-330f), 23.4 (NCH3), 23.3 (NCH3), 13.0 (CH2CH3), 12.9
(CH2CH3); HRMS (CI+) found [M+H]+ 368.1111; C18H17F3NO4 requires 368.1110.
(3aS,4S,7R,7aR)-5-Ethoxy-4-(4-methoxyphenyl)-2-methyl-3a,4,7,7a-tetrahydro-1H-
4,7-epoxyisoindole-1,3(2H)-dione (endo-330g) and (3aR,4S,7R,7aS)-5-Ethoxy-4-(4-
methoxyphenyl)-2-Methyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-
dione (exo-330g)
Prepared from furan 325g (55 mg, 0.25 mmol) and N-methylmaleimide according to the
General Cycloaddition Procedure over 4 h to give a mixture of the cantharimides 330g
as a colorless oil (74 mg, 0.23 mmol, 90%, endo:exo = 80:20); Rf = 0.15 and 0.08 (3:1
cyclohexane:EtOAc); νmax (film/cm–1) 2981s (C-H), 1773m, 1702s (C=O), 1622s, 1519s;
1H NMR (400 MHz; CDCl3) 7.76–7.71 (2H, m, ArH endo-330g), 7.46–7.43 (2H, m, ArH
exo-330g), 7.01–6.94 (2H, m, ArH endo-330g; 2H, m, ArH exo-330g), 5.33–5.30 (1H,
dd, J = 2.0, 5.1, COCH endo-330g; 1H, m, COCH exo-330g), 5.15 (1H, d, J = 2.2, C=CH
exo-330g), 5.04 (1H, d, J = 2.0, C=CH endo-330g), 3.87–3.76 (3H, m, OCH3 endo-330g,
1H, m, OCHCHCH endo-330g; 1H, m, OCHH’ endo-330g; 3H, m, OCH3 exo-330g; 1H,
m, OCH2 exo-330g), 3.60–3.52 (1H, m, OCHCHCH endo-330g; OCHH’ endo-330g),
3.30 (1H, d, J = 6.3, C(O)CH exo-330g), 2.26 (1H, d, J = 6.3, C(O)CH exo-330g), 2.92
(3H, m, NCH3 endo-330g), 2.88 (3H, m, NCH3 exo-330g), 1.30 (3H, t, J = 7.1, CH2CH3
exo-330g), 1.20 (3H, t, J = 7.1, CH2CH3 endo-330g); 13C NMR (100 MHz; CDCl3) 176.2
(C(O)), 175.3 (C(O)), 174.2 (C(O)), 173.9 (C(O)), 167.5 (EtOC), 164.9 (EtOC), 159.8
(Ar), 159.3 (Ar), 128.5 (Ar), 127.7 (Ar), 126.8 (Ar), 124.1 (Ar), 113.7 (Ar), 113.2 (Ar),
97.9 (C=CH exo-330g), 95.4 (C=CH endo-330g), 90.2 (COCH), 90.1 (COCH), 79.8
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(COCH exo-330g), 77.7 (COCH endo-330g), 66.9 (OCH2 endo-330g; OCH2 exo-330g),
55.3 (OCH3), 55.1 (OCH3), 54.7 (CH), 51.8 (CH), 50.9 (CH), 50.0 (CH), 24.8 (NCH3),
24.6 (NCH3), 14.8 (CH2CH3), 13.8 (CH2CH3); HRMS (CI+) found [M+H]+ 330.1347;
C18H20NO5 requires 330.1342.
(3aS,4S,7R,7aR)-4-(4-Bromophenyl)-5-ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-
4,7-epoxyisoindole-1,3(2H)-dione (endo-330h) and (3aR,4S,7R,7aS)-4-(4-
Bromophenyl)-5-ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-
1,3(2H)-dione (exo-330h)
Prepared from furan 325h (134 mg, 0.500 mmol) and N-methylmaleimide according to
the General Cycloaddition Procedure over 24 to give the crude product (endo:exo =
80:20), which was purified by flash column chromatography (0 to 100%
TBME:cyclohexane) to give a mixture of the cantharimides 330h as a colorless oil
(149 mg, 0.392 mmol, 78%, endo:exo = 20:1); Rf = 0.28 and 0.49 (1:1
cyclohexane:EtOAc); νmax (film/cm–1) 2981s (C-H), 1775w, 1702s (C=O), 1624s, 1491s;
1H NMR (400 MHz; MeOH-d4, endo-330h) 7.75–7.61 (2H, m, ArH), 7.61–7.55 (2H, m,
ArH), 5.29 (1H, dd, J = 5.1, 2.1, COCH), 5.13 (1H, d, J = 2.1, C=CH), 3.87 (1H, dd,
J = 5.1, 7.8, OCHCHCH), 3.84–3.77 (1H, m, OCHH’), 3.60 (1H, d, J = 7.8, OCHCHCH),
3.60–3.53 (1H, m, OCHH’), 2.88 (3H, s, NCH3), 1.17 (3H, t, J = 7.1, CH2CH3); 13C NMR
(100 MHz; MeOH-d4, endo-330h), 175.7 (C(O)), 174.6 (C(O)), 164.4 (COEt), 134.5 (Ar),
130.7 (Ar), 129.0 (Ar), 122.1 (Ar), 95.5 (C=CH), 89.4 (COCH), 77.7 (COCH), 66.8
(OCH2), 51.5 (CHC(O)), 50.7 (CHC(O)), 23.4 (NCH3), 12.9 (CH2CH3); HRMS (CI+)
found [M+H]+ 378.0340; C17H1779BrNO4 requires 378.0341.
Chapter IV 215
(3aS,4S,7R,7aR)-4-(o-Tolyl)-5-ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-330i) and (3aR,4S,7R,7aS)-4-(o-Tolyl)-5-
ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (exo-
330i)
Prepared from furan 325i (101 mg, 0.500 mmol) and N-methylmaleimide according to
the General Cycloaddition Procedure over 24 h to give a mixture of the cantharimides
330i as a colorless oil (135 mg, 0.431 mmol, 86%, endo:exo = 80:20); Rf = 0.63 and 0.59
(1:1 cyclohexane:EtOAc); νmax (film/cm–1) 2981s (C-H), 1773m, 1700s (C=O), 1625s,
1433s; 1H NMR (400 MHz; DMSO-d6) 8.01–7.97 (1H, m, ArH endo-330i), 7.36–7.28
(2H, m, ArH endo-330i; 1H, m, ArH exo-330i), 7.23–7.17 (1H, m, ArH endo-330i; 2H,
m, ArH exo-330i), 7.13–7.08 (1H, m, ArH exo-330i), 5.36 (1H, d, J = 2.2, C=CH exo-
330i), 5.31 (1H, dd, J = 5.1, 2.0, COCH endo-330i), 5.19–5.16 (1H, m, C=CH endo-330i;
1H, m, COCH exo-330i). 4.07 (1H, d, J = 7.8, OCHCHCH endo-330i), 3.83–3.73 (1H,
m, OCHH’ endo-330i; 1H, m, OCHCHCH endo-330i; 1H, m, OCH2 exo-330i; 1H, m,
CHC(O) exo-330i), 3.60–3.52 (1H, m, OCHH’ endo-330i), 3.34–3.31 (1H, m, CHC(O)
exo-330i; HOD), 2.76 (3H, s, NCH3 endo-330i), 2.69 (3H, s, NCH3 exo-330i), 2.59 (3H,
s, ArCH3 exo-330i), 2.31 (3H, s, ArCH3 endo-330i), 1.16 (3H, t, J = 7.0, CH2CH3 exo-
330i), 1.02 (3H, t, J = 7.0, CH2CH3 endo-330i); 13C NMR (100 MHz; CDCl3) 176.7
(C(O)), 175.5 (C(O)), 174.5 (C(O)), 174.3 (C(O)), 166.9 (COEt), 164.3 (COEt), 139.3
(Ar), 137.3 (Ar), 132.4 (Ar), 132.4 (Ar), 131.4 (Ar), 131.2 (Ar), 130.4 (Ar), 129.4 (Ar),
128.2 (Ar), 125.9 (Ar), 125.5 (Ar), 100.0 (C=CH exo-330i), 96.0 (C=CH endo-330i), 91.3
(COCH), 90.8 (COCH), 78.8 (COCH exo-330i), 77.9 (COCH endo-330i), 67.0 (OCH2),
66.8 (OCH2), 53.7 (CHC(O) exo-330i), 51.0 (OCHCHCH endo-330i), 49.3 (CHC(O)
exo-330i), 49.0 (OCHCHCH endo-330i), 24.7 (NCH3), 24.7 (NCH3), 22.3 (ArCH3), 20.8
(ArCH3), 14.4 (CH2CH3), 14.2 (CH2CH3); HRMS (CI+) found [M+H]+ 314.1399;
C18H20NO4 requires 314.1392.
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Methyl 3-((3aS,4S,7R,7aR)-5-ethoxy-2-methyl-1,3-dioxo-2,3,3a,4,7,7a-hexahydro-
1H-4,7-epoxyisoindol-4-yl)benzoate (endo-330j) and Methyl 3-((3aR,4S,7R,7aS)-5-
ethoxy-2-methyl-1,3-dioxo-2,3,3a,4,7,7a-hexahydro-1H-4,7-epoxyisoindol-4-
yl)benzoate (exo-330j)
Prepared from furan 325j (123 mg, 0.500 mmol) and N-methylmaleimide according to
the General Cycloaddition Procedure over 24 h to give the crude product (endo:exo =
75:25). This was purified by flash column chromatography (0 to 100%
TBME:cyclohexane) to give the cantharimide endo-330j (107 mg, 0.300 mmol, 60%).
Further elution of the column gave the cantharimide exo-330j (41 mg, 0.12 mmol, 23%).
Cantharimide endo-330j: Isolated as a white crystalline solid; m.p. = 126–128 °C;
Rf = 0.44 (1:1 cyclohexane:EtOAc); νmax (film/cm–1) 2980s (C-H), 1775m, 1720s (C=O
ester and imide), 1624s, 1433s; 1H NMR (400 MHz; DMSO-d6) 8.30 (1H, t, J = 1.6, ArH),
8.06–7.96 (2H, m, ArH), 7.63 (1H, t, J = 7.7, ArH), 5.36 (1H, dd, J = 5.1, 2.0, COCH),
5.22 (1H, d, J = 2.0, C=CH), 3.92–3.85 (4H, m, CO2CH3; OCHCHCH), 3.83–3.74 (1H,
m, OCHH’), 3.68 (1H, d, J = 7.6, OCHCHCH), 3.59–3.50 (1H, m, OCHH’), 2.78 (3H, s,
NCH3), 1.05 (3H, t, J = 7.0, CH2CH3); 13C NMR (100 MHz; DMSO-d6) 175.3 (C(O)N),
174.5 (C(O)N), 166.5 (C(O)OMe or COEt), 164.0 (C(O)OMe or COEt), 136.4 (Ar), 132.5
(Ar), 130.0 (Ar), 129.6 (Ar), 129.2 (Ar), 128.2 (Ar), 97.0 (C=CH), 89.3 (COCH), 77.7
(COCH), 67.1 (OCH2), 52.7 (OCH3 or OCHCHCH), 51.7 (OCH3 or OCHCHCH), 50.9
(OCHCHCH), 24.8 (NCH3), 14.1 (CH2CH3); HRMS (CI+) found [M+H]+ 358.1294;
C19H20NO6 requires 358.1291.
Cantharimide exo-330j: Isolated as a white crystalline solid; m.p. = 118–120 °C;
Rf = 0.27 (1:1 cyclohexane:EtOAc); 1H NMR (400 MHz; DMSO-d6) 7.99 (1H, t, J = 1.4,
ArH), 7.93 (1H, dd, J = 7.7, 1.4, ArH), 7.75–7.69 (1H, m, ArH), 7.58–7.52 (1H, m, ArH),
5.37 (1H, d, J = 2.2, C=CH), 5.24 (1H, d, J = 2.2, COCH), 3.87 (3H, s, OCH3), 3.80 (2H,
q, J = 7.0, OCH2), 3.56 (1H, d, J = 6.4, CHC(O)), 3.37 (1H, d, J = 6.4, CHC(O)), 2.69
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(3H, s, NCH3), 1.18 (3H, t, J = 7.0, CH2CH3); 13C NMR (100 MHz; DMSO-d6) 176.4
(C(O)N), 174.2 (C(O)N), 166.6 (C(O)OMe or COEt), 165.9 (C(O)OMe or COEt), 133.9
(Ar), 132.2 (Ar), 129.5 (Ar), 129.1 (Ar), 128.5 (Ar), 127.4 (Ar), 99.7 (C=CH), 89.7
(COCH), 80.0 (COCH), 67.1 (OCH2), 54.5 (CHC(O)), 52.7 (OCH3), 50.0 (CHC(O)), 24.7
(NCH3), 14.3 (CH2CH3).
(3aS,4S,7R,7aR)-4-(Furan-2-yl)-5-ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-330k) and (3aR,4S,7R,7aS)-4-(Furan-2-yl)-5-
ethoxy-2-methyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (exo-
330k)
Prepared from furan 325k (104 mg, 0.584 mmol) and N-methylmaleimide according to
the General Cycloaddition Procedure over 24 h to give the crude product (endo:exo =
90:10). This was purified by flash column chromatography (0 to 100%
EtOAc:cyclohexane) to give the a mixture of the cantharimides 330k as a white
crystalline solid (143 mg, 0.494 mmol, 85%, endo:exo = 95:5); m.p. = 122–124 °C;
Rf = 0.16 (2:1 cyclohexane:EtOAc); νmax (film/cm–1) 2982s (C-H), 1775m, 1701s (C=O),
1631s 1434s; 1H NMR (400 MHz; DMSO-d6, endo-330k) 7.83–7.73 (1H, m, ArH), 6.84
(1H, d, J = 3.4, ArH), 6.57 (1H, dd, J = 3.4, 2.0, ArH), 5.31–5.21 (2H, m, C=CH; COCH),
3.92 (1H, d, J = 7.6, OCHCHCH), 3.88–3.81 (2H, m, OCHH’; OCHCHCH), 3.59–3.51
(1H, m, OCHH’), 2.72 (3H, s, NCH3), 1.10 (3H, t, J = 7.1, CH2CH3); 1H NMR (400 MHz;
DMSO-d6, exo-330k) 7.72–7.71 (1H, m, ArH), 6.70 (1H, d, J = 3.2, ArH), 6.46 (1H, dd,
J = 2.0, 3.4, ArH), 5.36 (1H, d, J = 2.0, C=CH or COCH), 5.16 (1H, d, J = 2.0, C=CH or
COCH), 2.78 (3H, s, NCH3), 1.21 (3H, t, J = 6.9, CH2CH3), remaining resonances
obscured by the major diastereoisomer; 13C NMR (100 MHz; DMSO-d6, endo-330k),
175.4 (C(O)), 173.6 (C(O)), 162.5 (COEt), 147.6 (Ar), 144.9 (Ar), 112.8 (Ar), 111.2 (Ar),
97.9 (C=CH), 84.4 (COCH), 76.0 (COCH), 67.2 (OCH2), 51.0 (CHC(O)), 48.9
(CHC(O)), 24.6 (NCH3)), 14.3 (CH2CH3); HRMS (CI+) found [M+H]+ 290.1028;
C15H16NO5 requires 290.1029.
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(3aS,4R,7R,7aR)-5-Ethoxy-2-methyl-4-(thiophen-2-yl)-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-330l) and (3aR,4R,7R,7aS)-5-Ethoxy-2-methyl-
4-(thiophen-2-yl)-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (exo-
330l)
Prepared from furan 325l (97 mg, 0.50 mmol) and N-methylmaleimide according to the
General Cycloaddition Procedure over 24 h to give a mixture of the cantharimides 330l
as a colorless oil (147 mg, 0.481 mmol, 96%, endo: exo = 70:30); Rf = 0.42 and 0.63 (1:1
cyclohexane:EtOAc); νmax (film/cm–1) 2982s (C-H), 1774m, 1700s (C=O), 1626s, 1433s;
1H NMR (400 MHz; DMSO-d6) 7.63 (1H, dd, J = 5.0, 1.1, ArH endo-330l), 7.57–7.48
(1H, m, ArH endo-330l; 1H, m, ArH exo-330l), 7.25 (1H, dd, J = 3.5, 1.1, ArH exo-330l),
7.14 (1H, dd, J = 5.0, 3.7, ArH endo-330l), 7.07 (1H, dd, J = 5.1, 3.5, ArH exo-330l),
5.34 (1H, d, J = 2.0, C=CH exo-330l), 5.27 (2H, dd, J = 5.1, 2.2, COCH endo-330l), 5.21
(1H, d, J = 2.2, C=CH endo-330l), 5.18 (1H, d, J = 2.0, COCH exo-330l), 3.90–3.77 (1H,
m, OCHCHCH endo-330l; 1H, m, OCHH’ endo-330l; 1H, m, OCH2 exo-330l), 3.74 (1H,
d, J = 7.8, OCHCHCH endo-330l), 3.59–3.51 (1H, m, OCHH’ endo-330l), 3.37 (1H, d,
J = 6.6, CHC(O) exo-330l), 3.33–3.32 (1H, m, CHC(O) exo-330l; HOD), 2.75 (3H, s,
NCH3 endo-330l; 3H, s, NCH3 exo-330l), 1.22 (3H, t, J = 7.1, CH2CH3 exo-330l), 1.09
(3H, t, J = 7.0, CH2CH3 endo-330l); 13C NMR (100 MHz; DMSO-d6) 176.3 (C(O)), 175.4
(C(O)), 173.9 (C(O)), 173.7 (C(O)), 165.7 (EtOC), 163.4 (EtOC), 137.2 (Ar), 134.5 (Ar),
128.4 (Ar), 127.7 (Ar), 127.4 (Ar), 127.2 (Ar), 127.0 (Ar), 126.4 (Ar), 99.4 (C=CH exo-
330l), 97.2 (C=CH endo-330l), 88.2 (COCH), 87.2 (COCH), 80.2 (COCH exo-330l), 77.9
(COCH endo-330l), 67.2 (OCH2), 67.2 (OCH2), 55.0 (CH), 51.7 (CH), 51.6 (CH), 51.0
(CH), 24.8 (NCH3), 24.7 (NCH3), 14.4 (CH2CH3), 14.2 (CH2CH3); HRMS (CI+) found
[M+H]+ 306.0795; C15H16NO4S requires 306.0800.
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(3aS,4S,7R,7aR)-5-Ethoxy-2-methyl-4-(pyridin-3-yl)-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-330m) and (3aR,4S,7R,7aS)-5-Ethoxy-2-
methyl-4-(pyridin-3-yl)-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione
(exo-330m)
Prepared from furan 325m (25 mg, 0.015 mmol) and N-methylmaleimide according to
the General Cycloaddition Procedure over 24 h to give a mixture of the cantharimides
330m as a colorless oil (37 mg, 0.12 mmol, 92%, endo: exo = 70:30); Rf = 0.28 and 0.16
(1:1 cyclohexane:EtOAc); νmax (film/cm–1) 2980s (C-H), 1774s, 1695s (C=O), 1623s,
1480s; 1H NMR (400 MHz; DMSO-d6) 8.93 (1H, m, ArH endo-330m), 8.66 (1H, m, ArH
exo-330m), 8.58 (1H, d, J = 5.0, ArH endo-330m), 8.52 (1H, d, J = 5.0, ArH exo-330m),
8.26 (1H, d, J = 8.2, ArH endo-330m), 7.95 (1H, d, J = 8.3, ArH exo-330m), 7.52 (1H,
dd, J = 8.2, 5.0, ArH endo-330m), 7.47 (1H, dd, J = 8.3, 5.0, ArH exo-330m), 5.36–5.35
(1H, m, COCH endo-330m; 1H, m, C=CH exo-330m), 5.29 (1H, d, J = 2.0, COCH exo-
330m), 5.19 (1H, d, J = 2.2, C=CH endo-330m), 3.92–3.79 (1H, m, OCHCHCH endo-
330m; 1H, m, OCHH’ endo-330m; 2H, m, OCH2 exo-330m), 3.67 (1H, d, J = 7.6,
OCHCHCH endo-330m), 3.64–3.56 (1H, m, OCHH’ endo-330m; 1H, m, CHC(O) exo-
330m), 3.39 (1H, d, J = 6.4, CHC(O) exo-330m), 2.89 (3H, s, NCH3 endo-330m), 2.81
(3H, s, NCH3 endo-330m), 1.28 (3H, t, J = 7.1, CH2CH3 exo-330m), 1.18 (3H, t, J = 7.1,
CH2CH3 endo-330m); 13C NMR (100 MHz; MeOH-d4) 176.6 (C(O)), 175.5 (C(O)),
174.4 (C(O)), 174.3 (C(O)), 166.2 (COEt), 163.9 (COEt), 148.6 (Ar), 148.0 (Ar), 147.5
(Ar), 147.0 (Ar), 135.8 (Ar), 135.3 (Ar), 132.0 (Ar), 129.7 (Ar), 123.3 (Ar), 123.0 (Ar),
98.5 (C=CH exo-330m), 95.8 (C=CH endo-330m), 88.3 (COCH), 87.9 (COCH), 80.4
(COCH exo-330m), 78.2 (COCH endo-330m), 67.0 (OCH2), 67.0 (OCH2), 54.3 (CHC(O)
exo-330m), 51.3 (OCHCHCH endo-330m), 50.8 (OCHCHCH endo-330m), 49.7 (COCH
exo-330m), 23.4 (NCH3), 23.4 (NCH3), 13.0 (CH2CH3), 12.9 (CH2CH3); HRMS (CI+)
found [M+H]+ 301.1189; C16H17N2O4 requires 301.1188.
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1-(4-Ethoxy-5-phenethylfuran-2-yl)-N,N-dimethylmethanamine (332)
Prepared according to the modified procedure of Sheppard et al.190: A stirring solution of
furan 325a (50 mg, 0.23 mmol) in MeCN (2.3 mL) was treated with
dimethylmethylideneammonium iodide (85 mg, 0.46 mmol) and the resulting mixture
was stirred at RT for 16 h before it was concentrated in vacuo to give the crude product.
This was purified by flash column chromatography (1:1 petrol 40–60 °C: Et2O with 1%
NEt3) to give the furan 332 as a colorless oil (49 mg, 0.18 mmol, 78%); Rf = 0.30 (1:1
petrol 40–60 °C: EtOAc); νmax (film/cm–1) 2927s (C-H), 1635s, 1495s, 1453s, 1420s;
1H NMR (600 MHz; MeOH-d4) 7.22–7.18 (2H, m, ArH), 7.14–7.10 (3H, m, ArH), 6.19
(1H, s, ArH), 3.71 (2H, q, J = 7.1, OCH2), 3.39 (2H, s, CH2N), 2.90–2.82 (4H, m,
CH2CH2Ph), 2.22 (6H, s, N(CH3)2), 1.17 (3H, t, J = 7.1, CH2CH3); 13C NMR (150 MHz;
MeOH-d4) 148.6 (Ar), 144.1 (Ar), 142.7 (Ar), 140.6 (Ar), 129.5 (Ar), 129.2 (Ar), 126.9
(Ar), 104.8 (Ar), 68.7 (OCH2), 56.6 (NCH2), 44.7 (N(CH3)2), 35.3 (CH2), 28.0 (CH2),
15.4 (CH3);. HRMS (ESI+) found [M+H]+ 274.1818; C17H24NO2 requires 274.1807.
(3aS,4R,7R,7aR)-5-Ethoxy-2-methyl-4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-333) and (3aR,4R,7R,7aS)-5-Ethoxy-2-methyl-
4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (exo-333)
Prepared from furan 332 (88 mg, 0.32 mmol) and N-methylmaleimide according to the
General Cycloaddition Procedure over 24 to give a mixture of the cantharimides 333 as
a colorless oil (116 mg, 0.302 mmol, 94%; endo:exo = 20:80); Rf = 0.35 (Et2O); νmax
(film/cm–1) 2938s (C-H), 1772m, 1698s (C=O), 1626s, 1454s; 1H NMR (600 MHz;
MeOH-d4) 7.29–7.12 (5H, m, ArH endo-333; 5H, m, ArH exo-333), 5.28 (1H, s, C=CH
exo-333), 5.01 (1H, s, C=CH endo-333), 3.97–3.91 (1H, m, OCHH’ exo-333), 3.88–3.82
(1H, m, OCHH’ endo-333; 1H, m, OCHH’ exo-333), 3.59–3.51 (1H, m, OCHH’ endo-
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333), 3.47 (1H, d, J = 7.5, Me2NCH2CCHC(O) endo-333), 3.37 (1H, d, J = 14.7,
Me2NCHH’ exo-333), 3.33 (1H, d, J = 7.5, EtOCCCHC(O) endo-333), 3.22 (1H, d,
J = 14.3, Me2NCHH’ endo-333), 3.15 (1H, d, J = 6.4, Me2NCH2CCHC(O) exo-333), 3.02
(1H, d, J = 6.4, EtOCCCHC(O) exo-333), 2.89 (3H, s, C(O)NCH3 exo-333), 2.82–2.68
(3H, m, C(O)NCH3 endo-333; 2H, m, CH2CH2 endo-333; 3H, m, C(O)NCH3 endo-333;
2H, m, CH2CH2 exo-333), 2.74 (1H, d, J = 14.3, Me2NCHH’ endo-333), 2.55 (1H, d,
J = 14.7, Me2NCHH’ exo-333), 2.48–2.43 (1H, m, CH2CHH’ endo-333), 2.34 (6H, s,
N(CH3)2 endo-333; 6H, s, N(CH3)2 exo-333), 2.33–2.06 (1H, m, CH2CHH’ endo-333; 1H,
m, CH2CH2 exo-333), 1.37 (3H, t, J = 7.1, CH2CH3 exo-333), 1.25 (3H, t, J = 7.1, CH2CH3
endo-333); 13C NMR (150 MHz; MeOH-d4) 177.4 (C(O)), 176.6 (C(O)), 176.5 (C(O)),
176.3 (C(O)), 167.3 (COEt), 165.0 (COEt), 143.4 (Ar), 143.1 (Ar), 129.5 (Ar), 129.4 (Ar),
129.3 (Ar), 127.0 (Ar), 127.0 (Ar), 102.6 (C=CH exo-333), 99.1 (C=CH endo-333), 91.2
(COC), 90.9 (COC), 90.8 (COC), 90.2 (COC), 68.0 (OCH2 endo-333), 67.9 (OCH2 exo-
333), 61.7 (NCH2 endo-333), 60.3 (NCH2 exo-333), 57.7 (Me2NCH2CCHC(O) exo-333),
54.6 (Me2NCH2CCHC(O) endo-333), 52.7 (EtOCCCHC(O) endo-333), 52.6
(EtOCCCHC(O) exo-333), 47.3 (N(CH3)2 endo-333), 47.2 (N(CH3)2 exo-333), 33.2
(CH2CH2 endo-333), 32.1 (CH2CH2 exo-333), 31.6 (CH2CH2 endo-333), 31.1 (CH2CH2
exo-333), 24.9 (NCH3 imide exo-333), 24.7 (NCH3 imide endo-333), 14.7 (CH2CH3 exo-
333), 14.6 (CH2CH3 endo-333); Significant NOE between Me2NCH2CCHC(O) and
Me2NCH2 for endo-333; No Significant NOE between Me2NCH2CCHC(O) and
Me2NCH2 for exo-333; HRMS (CI+) found [M+H]+ 385.2127; C22H29N2O4 requires
385.2127.
(3aS,4R,7R,7aR)-5-Ethoxy-2-phenyl-4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-334a) and (3aR,4R,7R,7aS)-5-Ethoxy-2-phenyl-
4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (exo-334a)
Prepared from furan 325a (108 mg, 0.500 mmmol) and 1-phenyl-1H-pyrrole-2,5-dione
according to the General Cycloaddition Procedure over 4 h to give a mixture of the
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cantharimides 334a as a pale wax (183 mg, 0.470 mmol, 94%, endo:exo = 65:35);
Rf = 0.64 (1:1 cyclohexane:EtOAc); νmax (film/cm–1) 2977s (C-H), 1713s (C=O), 1624s,
1498s; 1H NMR (400 MHz; CDCl3) 7.51–7.17 (10H, m, ArH, endo-334a; 10H, m, ArH,
exo-334a), 5.32 (1H, t, J = 2.0, COCH endo-334a), 5.31 (1H, d, J = 2.0, COCH exo-
334a), 5.19 (1H, d, J = 2.0, C=CH exo-334a), 5.15 (1H, d, J = 2.0, C=CH endo-334a),
3.96–3.80 (1H, m, OCHCHCH endo-334a; 1H, m, OCHH’ endo-334a; 2H, m, OCH2
exo-334a), 3.76–3.68 (1H, m, OCHH’ endo-334a), 3.38 (1H, d, J = 7.8, OCHCHCH
endo-334a), 3.32 (1H, d, J = 6.6, C(O)CH exo-334a), 3.10 (1H, d, J = 6.6, C(O)CH exo-
334a), 2.95–2.82 (2H, m, PhCH2 endo-334a; 2H, m, PhCH2 exo-334a), 2.73–2.63 (1H,
m, PhCH2CHH’ endo-334a), 2.50–2.42 (1H, m, PhCH2CHH’ exo-334a), 2.41–2.28 (1H,
m, PhCH2CHH’ endo-334a; 1H, m, PhCH2CHH’ exo-334a), 1.40 (3H, t, J = 7.1, CH2CH3
exo-334a), 1.33 (3H, t, J = 7.1, CH2CH3 endo-334a); 13C NMR (100 MHz; CDCl3) 175.3
(C(O)), 174.3 (C(O)), 173.8 (C(O)), 172.8 (C(O)), 167.2 (COEt), 164.4 (COEt), 142.0
(Ar), 141.6 (Ar), 131.8 (Ar), 131.7 (Ar), 129.1 (Ar), 129.1 (Ar), 128.7 (Ar), 128.4 (Ar),
128.4 (Ar), 128.3 (Ar), 126.6 (Ar), 126.0 (Ar), 125.9 (Ar), 125.8 (Ar), 99.6 (C=CH exo-
334a), 97.0 (C=CH endo-334a), 90.0 (COCH), 89.7 (COCH), 80.5 (COCH), 78.5
(COCH), 66.9 (OCH2), 66.8 (OCH2), 54.3 (CHC(O) exo-334a), 51.2 (OCHCHCH endo-
334a), 49.5 (OCHCHCH endo-334a), 49.2 (CHC(O) exo-334a), 31.9 (CH2), 30.7 (CH2),
30.4 (CH2), 29.5 (CH2), 14.3 (CH2CH3), 14.3 (CH2CH3); HRMS (CI+) found [M+H]+
390.1708; C24H24NO4 requires 390.1705.
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(3aS,4R,7R,7aR)-5-Ethoxy-2-(4-methylbenzyl)-4-phenethyl-3a,4,7,7a-tetrahydro-
1H-4,7-epoxyisoindole-1,3(2H)-dione (endo-334b) and (3aR,4R,7R,7aS)-5-Ethoxy-
2-(4-methylbenzyl)-4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-
1,3(2H)-dione (exo-334b)
Prepared from furan 325a (108 mg, 0.500 mmol) and imide 329a according to the General
Cycloaddition Procedure over 4 h to give a mixture of the cantharimides 334b as a pale
wax (173 mg, 0.414 mmol, 83%, endo:exo = 55:45); Rf = 0.51 (1:1 cyclohexane:EtOAc);
νmax (film/cm–1) 2977s (C-H), 1771m, 1701s (C=O), 1623m, 1513m, 1430m; 1H NMR
(600 MHz; CDCl3) 7.32–7.11 (9H, m, ArH endo-334b; 9H, m, ArH exo-334b), 5.22 (1H,
d, J = 1.8, COCH exo-334b), 5.18 (1H, dd, J = 5.1, 1.5, COCH endo-334b), 5.12 (1H, d,
J = 1.8, C=CH exo-334b), 4.75 (1H, d, J = 1.5, C=CH endo-334b), 4.62 (2H, AB system,
J = 14.7, NCH2 exo-334b), 4.53 (1H, d, J = 14.0, NCHH’ endo-334b), 4.39 (1H, d,
J = 14.0, NCHH’ endo-334b), 3.91–3.89 (1H, m, OCHH’ exo-334b), 3.83–3.78 (1H, m,
OCHH’ exo-334b), 3.69 (1H, dd, J = 7.7, 5.1, OCHCHCH endo-334b), 3.33–3.28 (1H,
m, OCHH’ endo-334b), 3.21 (1H, d, J = 7.7, OCHCHCH endo-334b), 3.14 (1H, d,
J = 6.4, C(O)CH exo-334b), 2.92 (1H, d, J = 6.4, C(O)CH exo-334b), 2.86–2.75 (2H, m,
CH2Ph endo-334b; 2H, m, CH2Ph exo-334b), 2.58–2.51 (1H, m, CHH’CH2Ph endo-
334b), 2.51–2.46 (1H, m, OCHH’ endo-334b), 2.40–2.32 (1H, m, CHH’CH2Ph exo-
334b; 3H, m, ArCH3 endo-334b; 3H, m, ArCH3 endo-334b), 2.17–2.09 (1H, m,
CHH’CH2Ph endo-334b; 1H, m, CHH’CH2Ph exo-334b), 1.38 (3H, t, J = 7.0, exo-334b
CH2CH3), 1.06 (3H, t, J = 7.0, CH2CH3 endo-334b); 13C NMR (150 MHz; CDCl3) 175.8
(C(O)), 175.0 (C(O)), 174.5 (C(O)), 173.6 (C(O)), 167.1 (COEt), 164.2 (COEt), 142.0
(Ar), 141.6 (Ar), 137.7 (Ar), 137.4 (Ar), 133.1 (Ar), 132.7 (Ar), 129.6 (Ar), 129.2 (Ar),
129.2 (Ar), 128.4 (Ar), 128.4 (Ar), 128.3 (Ar), 128.2 (Ar), 125.9 (Ar), 125.8 (Ar), 99.3
(C=CH exo-334b), 95.9 (C=CH endo-334b), 89.3 (COCH), 89.3 (COCH), 79.9 (COCH
exo-334b), 78.2 (COCH endo-334b), 66.7 (OCH2 exo-334b), 65.8 (OCH2 endo-334b),
54.3 (CHC(O) exo-334b), 51.0 (OCHCHCH endo-334b), 49.5 (OCHCHCH endo-334b),
224 Experimental Details
49.1 (CHC(O) exo-334b), 42.1 (NCH2), 41.9 (NCH2), 31.9 (CH2), 30.6 (CH2), 30.3
(CH2), 29.3 (CH2), 21.1 (ArCH3), 21.1 (ArCH3), 14.3 (CH2CH3), 14.2 (CH2CH3); HRMS
(CI+) found [M+H]+ 418.2020; C26H28NO4 requires 418.2018.
(3aS,4R,7R,7aR)-2-Cyclopropyl-5-ethoxy-4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-334c) and (3aR,4R,7R,7aS)-2-Cyclopropyl-5-
ethoxy –4-phenethyl-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione
(exo-334c)
Prepared from furan 325a (108 mg, 0.500 mmol) and imide 329b according to the General
Cycloaddition Procedure over 4 h to give a mixture of the cantharimides 334c as a pale
wax (153 mg, 0.433 mmol, 87%, endo:exo = 60:40); Rf = 0.69 (1:1 cyclohexane:EtOAc);
νmax (film/cm–1) 2977s (C-H), 1775m, 1707s (C=O), 1401s; 1H NMR (600 MHz; CDCl3)
7.34–7.18 (5H, m, ArH, endo-334c; 5H, m, ArH, exo-334c), 5.19 (1H, dd, J = 5.4, 2.0,
COCH endo-334c), 5.17 (1H, d, J = 2.0, COCH exo-334c), 5.11 (1H, d, J = 2.0, C=CH
exo-334c), 5.00 (1H, d, J = 2.0, C=CH endo-334c), 3.92–3.75 (1H, m, OCHH’ endo-
334c; 1H, m, OCH2 exo-334c), 3.65–3.58 (1H, m, OCHH’ endo-334c; 1H, m,
OCHCHCH endo-334c), 3.15 (1H, d, J = 7.8, OCHCHCH endo-334c), 3.07 (1H, d,
J = 7.8, CHC(O) exo-334c), 2.89–2.74 (2H, m, CH2Ph endo-334c; 1H, m, OCHH’ endo-
334c; 2H, m, CH2Ph exo-334c; 1H, m, CHC(O) exo-334c), 2.63–2.55 (1H, m, NCH exo-
334c; 1H, m, CHH’CH2Ph endo-334c), 2.50–2.46 (1H, m, NCH endo-334c), 2.42–2.34
(1H, m, CHH’CH2Ph exo-334c), 2.31–2.17 (1H, m, CHH’CH2Ph endo-334c; 1H, m,
CHH’CH2Ph exo-334c), 1.37 (3H, t, J = 7.1, CH2CH3 exo-334c), 1.34 (3H, t, J = 7.1,
CH2CH3 endo-334c), 0.98–0.85 (2H, m, CH(CH2)2 endo-334c; 4H, m, CH(CHH’)2 exo-
334c), 0.82–0.78 (2H, m, CH(CHH’)2 exo-334c); 13C NMR (150 MHz; CDCl3) 176.7
(C(O)), 175.9 (C(O)), 175.4 (C(O)), 174.4 (C(O)), 167.0 (COEt), 164.1 (COEt), 142.0
(Ar), 141.6 (Ar), 128.4 (Ar), 128.4 (Ar), 128.4 (Ar), 128.3 (Ar), 126.0 (Ar), 125.8 (Ar),
99.4 (C=CH exo-334c), 96.5 (C=CH endo-334c), 89.6 (COCH), 89.3 (COCH), 80.1
(COCH), 78.2 (COCH), 66.7 (OCH2), 66.6 (OCH2), 53.8 (CHC(O) exo-334c), 50.6
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(OCHCHCH endo-334c), 49.0 (OCHCHCH endo-334c), 48.5 (CHC(O) exo-334c), 31.8
(CH2), 30.7 (CH2), 30.3 (CH2), 29.3 (CH2), 22.2 (NCH), 21.9 (NCH), 14.3 (CH2CH3),
14.3 (CH2CH3), 5.0 (NCHCH2), 5.0 (NCHCH2), 4.9 (NCHCH2), 4.6 (NCHCH2); HRMS
(CI+) found [M+H]+ 354.1708; C21H24NO4 requires 354.1705.
(3aS,4R,7R,7aR)-5,5-Diethoxy-2-methyl-4-phenethylhexahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (endo-335) and (3aR,4R,7R,7aS)-5,5-Diethoxy-2-
methyl-4-phenethylhexahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (exo-335)
A solution of [PPh3AuNTf2]2PhMe (60 mg, 1.0 mol%, 2.0 mol% [Au]) in EtOH (1.9 mL)
was added dropwise to a stirring solution of propargylic alcohol 316a (1.00 g, 3.81 mmol)
and N-methylmaleimide (0.508 g, 4.57 mmol) in EtOH (5.7 mL) at RT. The resulting
solution was stirred for 16 h before being filtered through an aminopropyl cartridge,
eluting with EtOAc. The filtrate was concentrated in vacuo to give the crude product
(endo:exo = 70:30), which was purified by flash column chromatography (0 to 100%
TBME:cyclohexane) to give the cantharimide endo-335 (276 mg, 0.740 mmol, 19%).
Further elution of the column gave a mixture of the cantharimides endo-335 and exo-335
(528mg, 1.41 mmol, 37%). Further elution of the column gave the cantharimide exo-335
(228 mg 0.605 mmol, 16%).
Cantharimide endo-335: Isolated as a white crystalline solid. m.p. = 123–125 °C;
Rf = 0.61 (1:1 cyclohexane:EtOAc); νmax (film/cm–1) 2973s (C-H), 1772w, 1697s (C=O),
1431s; 1H NMR (400 MHz; CDCl3) 7.34–7.28 (2H, m, ArH), 7.26–7.18 (3H, m, ArH),
4.75 (1H, t, J = 6.3, COCH), 3.67–3.62 (1H, m, OCHCHCH), 3.50–3.42 (2H, m,
OCHCHCH; OCHH’), 3.27–3.21 (3H, m, OCHH’; OCH2), 2.87–2.79 (4H, m, NCH3;
PhCHH’), 2.75–2.66 (1H, m, PhCHH’), 2.48–2.40 (1H, m, PhCH2CHH’), 2.37–2.31 (1H,
m, CHH’C(OEt)2), 2.08–1.99 (1H, m, PhCH2CHH’), 1.41 (1H, d, J = 13.7, CHH’(OEt)2),
1.12 (3H, t, J = 7.1, CH2CH3), 0.95 (3H, t, J = 7.1, CH2CH3); 13C NMR (100 MHz; CDCl3)
175.8 (C(O)), 174.8 (C(O)), 142.4 (Ar), 128.9 (Ar), 128.6 (Ar), 126.3 (Ar), 107.6
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(C(OEt)2), 92.9 (COCH), 75.4 (COCH), 58.3 (OCH2), 55.9 (OCH2), 52.4 (OCHCHCH),
49.8 (OCHCHCH), 38.9 (CH2C(OEt)2), 31.9 (CH2), 30.1 (CH2), 24.8 (NCH3), 15.3
(CH2CH3), 15.2 (CH2CH3); HRMS (CI+) found [M+H]+ 374.1971; C21H28NO5 requires
374.1968.
Cantharimide exo-335: Isolated as a colorless oil. Rf = 0.48 (1:1 cyclohexane:EtOAc);
1H NMR (400 MHz; CDCl3); 7.38–7.16 (5H, m, ArH), 4.82 (1H, d, J = 5.9, COCH), 3.29
(1H, d, J = 7.1, CHC(O)), 3.10 (1H, d, J = 7.1, CHC(O)), 3.03 (3H, s, NCH3), 2.89–2.76
(1H, m, CHH’CH2Ph), 2.63–2.44 (2H, m, CHH’CHH’Ph), 2.44–2.31 (1H, m, CHH’Ph;
1H, m, CHH’(OEt)2), 1.71 (1H, d, J = 13.0, CHH’(OEt)2), 1.27 (3H, t, J = 7.0, CH2CH3),
1.18 (3H, t, J = 7.1, CH2CH3); 13C NMR (100 MHz; CDCl3) 177.1 (C(O)), 177.0 (C(O)),
142.7 (Ar), 128.5 (Ar), 128.3 (Ar), 125.8 (Ar), 108.0 (C(OEt)2), 91.4 (COCH), 77.2
(COCH), 58.5 (OCH2), 57.5 (OCH2), 51.2 (CHC(O)), 46.8 (CHC(O)), 41.4
(CH2C(OEt)2), 30.6 (CH2), 29.4 (CH2), 25.1 (NCH3), 15.3 (CH2CH3), 15.1 (CH2CH3).
(3aS,4S,7R,7aR)-2-Methyl-4-phenyltetrahydro-1H-4,7-epoxyisoindole-
1,3,5(2H,6H)-trione (336)
A solution of cantharimide endo-330e (290 mg, 0.970 mmol) in EtOAc (5.0 mL) was
loaded onto silica plug (SCX-2, 20 g), which was then washed with EtOAc after
10 minutes. The filtrate was concentrated in vacuo to give the crude product, which was
treated with cyclohexane (5.0 mL), sonicated and filtered to give the cantharimide 336 as
a white crystalline solid (210 mg, 0.775 mmol, 80%); m.p. 171–173 °C; Rf = 0.45 (2:1
petrol 40–60 °C:EtOAc); νmax (film/cm-1) 2988s (C-H), 1765s (C=O), 1694s (C=O),
1500s;. 1H NMR (400 MHz; CDCl3) 7.76–7.72 (2H, m, ArH), 7.47–7.38 (3H, m, ArH),
5.31 (1H, t, J = 6.0, OCH), 3.95 (1H, dd, J = 9.1, 6.0, OCHCHCH), 3.66 (1H, d, J = 9.1,
PhCCH), 3.00 (3H, s, NCH3), 2.85 (1H, dd, J = 18.3, 6.0, Ha), 4.32 (1H, d, J = 18.3, Hb);
13C NMR (100 MHz; CDCl3) 204.7 (C(O) ketone), 173.8 (C(O) imide), 172.3 (C(O)
imide), 132.3 (Ar), 128.9 (Ar), 128.5 (Ar), 126.5 (Ar), 90.6 (PhCO), 74.7 (COCH), 53.2
(PhCCH), 51.5 (OCHCH), 41.7 (CHa), 25.2 (NCH3); HRMS (CI+) found [M+H]+
272.0920; C15H14NO4 requires 272.0923.
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(3aS,4S,5R,7R,7aR)-5-Hydroxy-2-methyl-4-phenylhexahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (337)
NaBH4 (35 mg, 0.92 mmol) was added portionwise to a stirring solution of cantharimide
336 (50 mg, 0.18 mmol) in MeOH (1.8 mL) at 0 °C. The resulting solution was stirred at
0 °C for 1 h, before being filtered through a silica plug, eluting with EtOAc. The solvent
was removed in vacuo to give the crude product, which was purified by flash column
chromatography (0 to 100% TBME:cyclohexane) to give the cantharimide 337 as a white
crystalline solid (35 mg, 0.13 mmol, 70%); m.p. = 185–187 °C; Rf = 0.43 (1:1
cyclohexane:EtOAc); νmax (film/cm-1) 3388s br. (O-H), 2943w (C-H), 1763m, 1685s
(C=O); 1492s; 1H NMR (400 MHz; CDCl3) 7.88–7.80 (2H, m, ArH), 7.51–7.42 (2H, m,
ArH), 7.42–7.35 (1H, m, ArH), 4.98 (1H, t, J = 6.1, COCH), 4.28 (1H, dd, J = 9.7, 3.0,
CHOH), 3.77 (1H, dd, J = 10.0, 6.1, 1.8, COCHCH), 3.50 (1H, d, J = 10.0, PhCCHC(O)),
3.06 (3H, s, NCH3), 2.57 (1H, dddd, J = 13.8, 9.7, 6.1, 1.8, Ha), 1.96 (1H, br. s, OH), 1.63
(1H, dd, J = 13.8, 3.0 Hb); 13C NMR (100 MHz; CDCl3) 175.4 (C(O)), 175.1 (C(O)),
138.3 (Ar), 128.8 (Ar), 128.4 (Ar), 125.7 (Ar), 91.8 (PhC), 79.5 (COH), 77.7 (COCH),
53.0 (COCHCH), 52.5 (PhCCHC(O)), 36.1 (CHa), 25.0 (NCH3); HRMS (CI+) found
[M+H]+ 274.1075; C15H16NO4 requires 274.1079.
(3aS,4S,5R,7R,7aR)-5-Ethoxy-2-methyl-4-phenylhexahydro-1H-4,7-epoxyisoindole-
1,3(2H)-dione (338)
A solution of cantharimide endo-325e (52 mg, 0.17 mmol) in EtOH (3.5 mL) was added
to a flask primed with 10% Pd/C (30 mg, 0.28 mmol) at RT. The flask was placed under
an atmosphere of hydrogen gas (1 atm.) and stirred at RT for 16 h, before the reaction
mixture was filtered through Celite and the filtrate concentrated in vacuo to give the
cantharimide 338 as a white crystalline solid (39 mg, 0.13 mmol, 76%); m.p. = 152–
154 °C; Rf = 0.65 (1:1 cyclohexane:EtOAc); νmax (film/cm-1) 2977s (C-H), 1775m, 1699s
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(C=O), 1433s; 1H NMR (400 MHz; CDCl3) 7.83 (2H, d, J = 7.3, ArH), 7.47–7.40 (2H,
m, ArH), 7.40–7.34 (1H, m, ArH), 4.96 (1H, t, J = 6.1, COCH), 3.95 (1H, dd, J = 9.8,
3.2, CHOEt), 3.80–3.72 (1H, m, COCHCHCH), 3.52 (1H, d, J = 9.8, PhCCHC(O)), 3.38–
3.29 (1H, m, OCHH’), 3.21–3.11 (1H, m, OCHH’), 3.04 (3H, s, NCH3), 2.55–2.46 (1H,
m, Ha), 1.66 (1H, dd, J = 13.7, 3.2, Hb), 1.04 (3H, t, J = 7.0, CH2CH3); 13C NMR
(100 MHz; CDCl3) 175.3 (C(O)), 174.5 (C(O)), 139.3 (Ar), 128.5 (Ar), 128.1 (Ar), 126.0
(Ar), 91.4 (PhC), 85.9 (CHOEt), 77.4 (COCH), 66.8 (OCH2), 53.0 (CHC(O)), 52.9
(CHC(O)), 35.6 (CHa), 24.9 (NCH3), 15.1 (CH2CH3); HRMS (CI+) found [M+H]+
302.1399; C17H20NO4 requires 302.1392.
(3aS,4S,5R,6S,7S,7aR)-5-Ethoxy-6-hydroxy-2-methyl-4-phenylhexahydro-1H-4,7-
epoxyisoindole-1,3(2H)-dione (339)
A solution of 9-BBN (0.50 M in THF, 1.7 mL, 0.85 mmol) was added dropwise to a
stirring solution of cantharimide endo-330e (50 mg, 0.17 mmol) in anhydrous THF
(0.85 mL) at 0 °C. The resulting reaction mixture was stirred at 0 °C for 5 h before the
reaction was treated with 2.0 M aq. NaOH (2.0 mL) and hydrogen peroxide (30% in
water, 1.0 mL) at 0 °C. The resulting mixture was stirred at RT for 16 h before the reaction
was quenched with 10% aq. Na2S2O3 (10 mL) and extracted with EtOAc (3 × 20mL). The
combined organic fractions were dried (phase separator) and concentrated in vacuo to
give the crude product, which was purified by flash column chromatography (0 to 100%
TBME:cyclohexane) to give the cantharimide 339 as a white crystalline solid (28 mg
0.088 mmol, 52%); m.p. = 216–218 °C; Rf = 0.65 (1:1 petrol 40–60 °C:EtOAc); νmax
(film/cm-1) 3447m br. (O-H), 2973w (C-H), 1774w, 1695s (C=O), 1434; 1H NMR
(400 MHz; DMSO-d6) 7.77–7.70 (2H, m, ArH), 7.47–7.41 (2H, m, ArH), 7.40–7.34 (1H,
m, ArH), 5.65 (1H, d, J = 4.6, COH), 4.61 (1H, dd, J = 7.0, 1.5, COCH), 3.78 (1H, dd,
J = 9.7, 7.0, OCHCHC(O)), 3.67 (1H, dd, J = 4.6, 1.5, CHOH), 3.59–3.56 (1H, m,
CHOEt), 3.39 (1H, d, J = 9.7, PhCCHC(O)), 3.27–3.19 (2H, m, OCH2), 2.84 (3H, s,
NCH3), 0.95 (3H, t, J = 7.0, CH2CH3); 13C NMR (100 MHz DMSO-d6) 175.2 (C(O)),
174.3 (C(O)), 139.6 (Ar), 128.7 (Ar), 128.5 (Ar), 126.4 (Ar), 95.8 (COEt), 90.3 (PhC),
83.4 (PhCOCH), 76.1 (CHOH), 66.4 (OCH2), 52.1 (PhCCHC(O)), 50.1 (OCHCHC(O)),
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24.9 (NCH3), 15.3 (CH2CH3); HRMS (CI+) found [M+H]+ 318.1342; C17H20NO5 requires
318.1342; Weak (but real) ROE between CHOH and NCH3; No significant ROE between
CHOEt and NCH3.
(1R,2S,3R,4R)-Dimethyl 6-ethoxy-1-phenethyl-7-oxabicyclo[2.2.1]hept-5-ene-2,3-
dicarboxylate (endo-343a) and Dimethyl (1R,2R,3S,4R)-6-ethoxy-1-phenethyl-7-
oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate (exo-343)
2
2
a
b
2
2
endo exo
Prepared from furan 325a (108 mg, 0.500 mmol) and dimethyl maleate according to the
General Cycloaddition Procedure over 3 days to give the crude product (endo:exo = 12:1),
which was purified by flash column chromatography (0 to 100% TBME:cyclohexane) to
give a mixture of the enol ethers 343 as a colorless oil (125 mg, 0.347 mmol, 69%,
endo:exo = 12:1); Rf = 0.32 (3:1 cyclohexane:EtOAc); νmax (film/cm–1) 2951s (C-H),
1739s (C=O), 1630s, 1435s; 1H NMR (400 MHz; CDCl3, endo-343) 7.35–7.19 (5H, m,
ArH), 5.34 (1H, d, J = 2.0, C=CH), 5.03 (1H, dd, J = 2.0, 3.9, COCH), 3.91–3.84 (1H,
m, OCHH’), 3.78–3.72 (1H, m, OCHH’), 3.65 (3H, s, OCH3), 3.64 (3H, s, OCH3), 3.49
(1H, dd, J = 9.8, 3.9, CHa), 3.31 (1H, dd, J = 9.8, CHb), 2.88–2.74 (2H, m, CH2Ph), 2.46–
2.38 (1H, m, CHH’CH2Ph), 2.20–2.12 (1H, m, CHH’CH2Ph), 1.30 (3H, t, J = 7.1,
CH2CH3); 1H NMR (400 MHz; CDCl3, exo-343) the following peaks in the 1H NMR
spectra indicate the presence of exo-343; 5.19 (1H, d, J = 2.0, COCH), 5.11 (1H, d, J = 2.0,
C=CH). The remaining resonances were obscured by the major diastereoisomers and
could not be full assigned; 13C NMR (100 MHz; CDCl3, endo-343) 171.2 (C(O)), 170.1
(C(O), 163.0 (COEt), 142.1 (Ar), 128.4 (Ar), 125.9 (Ar), 99.2 (C=CH), 90.4 (COCH),
78.3 (COCH), 66.0 (OCH2), 51.8 (CH or CH3), 51.6 (CH or CH3), 51.5 (CH or CH3),
50.9 (CH or CH3), 31.4 (CH2), 30.6 (CH2), 14.4 (CH2CH3); HRMS (CI+) found [M+H]+
361.1654; C20H25O6 requires 361.1651.
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(1R,2R,3R,4R)-Dimethyl 6-oxo-1-phenethyl-7-oxabicyclo[2.2.1]heptane-2,3-
dicarboxylate (3-endo-344a) and (1R,2S,3S,4R)-Dimethyl 6-oxo-1-phenethyl-7-
oxabicyclo[2.2.1]heptane-2,3-dicarboxylate (3-exo-344a)
Prepared from furan 325a (108 mg, 0.500 mmol) and dimethyl fumarate according to the
General Cycloaddition Procedure over 4 h to give the crude product (3-endo-344a: 3-exo-
344a = 20:80), which was purified by flash column chromatography (0 to 100%
TBME:cyclohexane) to give a mixture of the enol ethers 344a as a colorless oil (139 mg,
0.386 mmol, 77%; 3-endo-344a: 3-exo-344a = 20:80); Rf = 0.39 (2:1
cyclohexane:EtOAc); νmax (film/cm–1) 2952s (C-H), 1736s (C=O), 1630s, 1436s; 1H
NMR (400 MHz; DMSO-d6) 7.35–7.18 (5H, m, ArH 3-endo-344a; 5H, m, ArH 3-exo-
344a), 5.20 (1H, dd, J = 4.5, 2.0, COCH 3-endo-344a), 5.18 (1H, d, J = 2.0, COCH 3-
exo-344a), 5.11 (1H, d, J = 2.0, C=CH 3-endo-344a), 5.01 (1H, br. s, C=CH 3-exo-344a),
3.94–3.55 (6H, m, 2 × CO2CH3 3-endo-344a; 6H, m, 2 × CO2CH3 3-exo-344a; 2H, m,
OCHCHCH 3-endo-344a; 2H, m, OCH2 3-endo-344a; 2H, m, OCH2 3-exo-344a), 3.20
(1H, d, J = 3.9, CHCO2Me 3-exo-344a), 3.06 (1H, d, J = 3.9, CHCO2Me 3-exo-344a),
2.78–2.69 (1H, m, PhCHH’ 3-exo-344a), 2.66–2.54 (2H, m, PhCH2 3-endo-344a; 1H, m,
PhCHH’ 3-exo-344a), 2.35–2.26 (1H, m, CHH’CH2Ph 3-exo-344a), 2.20–2.08 (1H, m,
CHH’CH2Ph 3-endo-344a; 1H, m, CHH’CH2Ph 3-exo-344a), 1.78–1.69 (1H, m,
CHH’CH2Ph 3-endo-344a), 1.25 (3H, t, J = 7.0, CH2CH3 3-endo-344a), 1.19 (3H, t,
J = 7.1, CH2CH3 3-exo-344a);13C NMR (100 MHz; DMSO-d6) 172.7 (C(O)), 172.1
(C(O)), 171.3 (C(O)), 170.8 (C(O)), 165.6 (COEt), 163.4 (COEt), 142.1 (Ar), 142.0 (Ar),
128.9 (Ar), 128.8 (Ar), 128.6 (Ar), 128.5 (Ar), 126.4 (Ar), 126.3 (Ar), 100.3 (C=CH), 99.3
(C=CH), 90.7 (COCH), 89.4 (COCH), 80.6 (COCH), 78.4 (COCH), 66.9 (OCH2), 66.4
(OCH2), 54.2 (CH or CH3), 52.6 (CH or CH3), 52.5 (CH or CH3), 52.4 (CH or CH3), 50.6
(CH), 50.4 (CH), 31.2 (CH2), 31.0 (CH2), 30.6 (CH2), 30.0 (CH2), 14.6 (CH2CH3), 14.3
(CH2CH3); HRMS (CI+) found [M+H]+ 361.1658; C20H25O6 requires 361.1651.
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(1R,2R,3R,4R)-Diethyl 6-oxo-1-phenethyl-7-oxabicyclo[2.2.1]heptane-2,3-
dicarboxylate (3-endo-344b) and (1R,2S,3S,4R)-Diethyl 6-oxo-1-phenethyl-7-
oxabicyclo[2.2.1]heptane-2,3-dicarboxylate (3-exo-344b )
2
2
2
2
endo exo
3 3
Prepared from furan 325a (108 mg, 0.500 mmol) and diethyl fumarate according to the
General Cycloaddition Procedure over 4 h to give the crude product (3-endo-344b: 3-exo-
344b = 15:85), which was purified by flash column chromatography (0 to 100%
TBME:cyclohexane) to give a mixture of the enol ethers 344b as a colorless oil (172 mg,
0.443 mmol, 89%, 3-endo-344b: 3-exo-344b = 15:85); Rf = 0.83 (1:1
cyclohexane:EtOAc); νmax (film/cm–1) 2981s (C-H), 1731s (C=O), 1629s; 1H NMR
(400 MHz; MeOH-d4) 7.31–7.14 (5H, m, ArH 3-endo-344b; 5H, m, ArH 3-exo-344b),
5.18 (1H, d, J = 2.0, C=CH 3-exo-344b), 5.14 (1H, dd, J = 4.4, 2.0, COCH 3-endo-344b),
5.11–5.08 (1H, m, C=CH 3-endo-344b; 1H, m, COCH 3-exo-344b), 4.25–4.03 (4H, m,
CO2CH2 3-endo-344b; 4H, m, CO2CH2 3-exo-344b), 3.87–3.76 (1H, m, OCHCHCH 3-
endo-344b; 2H, m, C=COCH2 3-endo-344b; 2H, m, C=COCH2 3-exo-344b), 3.29 (1H,
d, J = 3.7, CHC(O) 3-exo-344b), 3.14 (1H, d, J = 3.7, CHC(O) 3-exo-344b), 2.92 (1H, d,
J = 4.4, OCHCHCH 3-endo-344b), 2.86–2.65 (2H, m, CH2Ph 3-endo-344b; 2H, m,
CH2Ph 3-exo-344b), 2.46–2.39 (1H, m, CHH’CH2Ph 3-exo-344b), 2.29–2.17 (1H, m,
CHH’CH2Ph 3-endo-344b; CHH’CH2Ph 3-exo-344b), 1.86–1.78 (1H, m, CHH’CH2Ph
3-endo-344b), 1.38–1.20 (9H, m, CH2CH3 3-endo-344b; 9H, m, CH2CH3 3-exo-344b);
13C NMR (100 MHz; CDCl3) 172.6 (C(O)), 172.2 (C(O)), 171.0 (C(O)), 170.5 (C(O)),
165.9 (COEt), 162.8 (COEt), 142.0 (Ar), 141.9 (Ar), 128.1 (Ar), 128.0 (Ar), 127.9 (Ar),
127.8 (Ar), 125.6 (Ar), 125.5 (Ar), 99.2 (C=CH), 98.2 (C=CH), 90.9 (COCH), 89.4
(COCH), 80.9 (COCH), 78.5 (COCH), 66.4 (OCH2), 65.9 (OCH2), 60.8 (OCH2), 60.8
(OCH2), 60.7 (OCH2), 60.6 (OCH2), 54.3 (CHC(O)), 52.6 (CHC(O)), 50.2 (CHC(O)),
50.1 (CHC(O)), 31.2 (CH2), 30.6 (CH2), 30.2 (CH2), 30.0 (CH2), 13.3 (CH2CH3), 13.2
(CH2CH3), 13.2 (CH2CH3), 13.2 (CH2CH3); HRMS (CI+) found [M+H]+ 389.1967;
C22H29O6 requires 389.1964.
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(1R,4R,5R)-1-Phenethyl-5-propionyl-7-oxabicyclo[2.2.1]heptan-2-one (endo-345),
(1R,4R,5S)-1-Phenethyl-5-propionyl-7-oxabicyclo[2.2.1]heptan-2-one (exo-345) and
(1R,4S)-1-Phenethyl-6-propionyl-7-oxabicyclo[2.2.1]heptan-2-one (345’)
Pent-1-en-3-one (49 μl, 0.50 mmol) was added to a stirring solution of furan 325a (54 mg,
0.25 mmol) in DMC (0.25 mL) in a sealed tube at RT. The resulting reaction mixture was
stirred at 80 °C for 16 h before the reaction was allowed to cool to RT. The reaction
mixture was filtered through a silica plug (SCX-2, 10 g) with EtOAc and the filtrate
concentrated in vacuo to give the crude product (endo-345: exo-345: 345’ = 60:40:5),
which was purified by flash column chromatography (0 to 100% TBME:cyclohexane) to
give a mixture of the ketones 13 as a colorless oil (22 mg, 0.081 mmol, 32%, endo-345:
exo-345: 345’ = 10:3:1, fraction A). Further elution of the column gave a second fraction
of the ketones 13 as a colorless oil (19 mg, 0.070 mmol, 28%, endo-345: exo-345:
345’ = 1:12:1, fraction B); Rf = 0.47 (4:1 hexane:EtOAc); νmax (film/cm–1) 2939s (C-H),
1756s (C=O), 1715s (C=O), 1456s; HRMS (CI+) found [M+H]+ 273.1493; C17H21O3
requires 273.1491.
The three title compounds were not fully separated from each other. The following NMR
assignments are based upon analysis of fractions A and B.
Ketone endo-345:
1H NMR (600 MHz; DMSO-d6) 7.30–7.26 (2H, m, ArH), 7.22–7.16 (3H, m, ArH), 5.13
(1H, t, J = 5.1, COCH), 3.60–3.57 (1H, m, CHC(O)), 2.76–2.70 (1H, m, PhCHH’), 2.60–
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2.45 (3H, m, CH2CH3; PhCHH’), 2.48 (1H, dd, J = 17.7, 5.1, Ha), 2.09–1.96 (2H, m,
PhCH2CH2), 1.96 (1H, d, J = 17.7, Hb), 1.93 (1H, dd, J = 13.2, 4.9, Hd), 1.86 (1H, dd,
J = 13.2, 10.5, Hc), 0.93 (3H, t, J = 7.2, CH2CH3); 13C NMR (150 MHz; DMSO-d6) 211.0
(C(O)), 208.7 (C(O)), 141.6 (Ar), 128.4 (Ar), 128.1 (Ar), 125.9 (Ar), 88.5 (COCH), 74.9
(COCH), 53.9 (CHC(O)Et), 40.9 (CHa), 35.5 (CH2CH3), 30.8 (CHc), 30.5 (PhCH2CH2),
29.8 (PhCH2), 7.4 (CH2CH3).
Ketone exo-345:
1H NMR (400 MHz; MeOH-d4) 7.34–7.11 (5H, m, ArH), 5.02 (1H, d, J = 6.1, COCH),
3.15 (1H, dd, J = 9.0, 4.9, CHC(O)), 2.81 (1H, ddd, J = 13.6, 11.7, 5.5, PhCHH’), 2.74–
2.49 (4H, m, CH2CH3; PhCHH’; Ha), 2.30 (1H, d, J = 17.6, Hb), 2.20–2.02 (3H, m,
PhCH2CH2; Hc), 1.80 (1H, dd, J = 13.2, 9.0, Hd), 1.08 (3H, t, J = 7.2, CH2CH3); 13C NMR
(150 MHz; MeOH-d4) 212.0 (C(O)), 209.6 (C(O)), 141.8 (Ar), 128.0 (Ar), 127.9 (Ar),
125.6 (Ar), 87.7 (COCH), 76.3 (COCH), 54.2 (CHC(O)), 43.7 (CHa), 33.5 (CH2CH3),
30.8 (CHc), 30.5 (PhCH2CH2), 30.0 (PhCH2), 6.7 (CH2CH3).
Ketone exo-345’:
1H NMR (600 MHz; DMSO-d6) 4.94 (1H, t, J = 5.7, COCH), 2.90 (1H, dd, J = 8.7, 5.3,
CHC(O)), 2.50 (1H, dd, J = 17.7, 5.7, Ha), 2.29 (1H, d, J = 17.7, Hb), 2.21–2.17 (1H, m,
Hc), 1.96 (1H, dd, J = 12.4, 8.7, Hd), 0.87 (3H, t, J = 7.2, CH2CH3); remaining peaks
obscured by the major products.
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Ethyl (1R,2R,4R)-5-oxo-4-phenethyl-7-oxabicyclo[2.2.1]heptane-2-carboxylate
(endo-352) and Ethyl (1R,2S,4R)-5-oxo-4-phenethyl-7-oxabicyclo[2.2.1]heptane-2-
carboxylate (exo-352)
A solution of HfCl4 (1.6 mg, 2.0 mol%) in DMC (0.06 mL) was added dropwise to a
stirring solution of ethyl acrylate (41 µL, 38 mg, 0.38 mmol) and furan 325a (54 mg,
0.25 mmol) in DMC (0.18 mL). The resulting solution was stirred at RT for 6 h before it
was filtered through a silica plug (SCX-2, 10 g) with EtOAc and the filtrate concentrated
in vacuo to give a mixture of the enol ethers 352 as a colorless oil (64 mg, 0.22 mmol,
89%, endo:exo = 70:30; no evidence for a minor regioisomer); Rf = 0.73 (1:1
cyclohexane:EtOAc); νmax (film/cm–1) 2938s (C-H), 1762s (C=O), 1730s (C=O), 1604m,
1493m, 1454s; HRMS (ESI+) found [M+H]+ 289.1437; C17H21O4 requires 289.1434. In
order to aid characterisation a sample of the mixed product was separated by Mass
Directed Automated Purification to give the two diastereoisomers.
Ketone endo-352: 1H NMR (600 MHz; CDCl3) 7.35–7.21 (2H, m, ArH), 7.26 (2H, d,
J = 7.0, ArH), 7.25–7.22 (1H, m, ArH), 5.01 (1H, t, J = 5.4, COCH), 4.22 (2H, q, J = 7.2,
OCH2), 3.40 (1H, dt, J = 11.2, 5.4, CHCO2Et), 2.85 (1H, td, J = 12.9, 5.0, PhCHH’), 2.71
(1H, td, J = 12.9, 5.0, PhCHH’), 2.57 (1H, dd, J = 17.8, 5.4, Ha), 2.38 (1H, d, J = 17.8,
Hb), 2.29 (1H, ddd, J = 14.4, 12.9, 5.0, PhCH2CHH’), 2.18–2.12 (2H, m, PhCH2CHH’,
CHH’CHCO2Et), 2.08–2.02 (1H, m, CHH’CHCO2Et), 1.32 (3H, t, J = 7.2, CH2CH3);
13C NMR (150 MHz; CDCl3) 210.2 (CO2Et), 171.3 (C(O)), 141.6 (Ar), 128.4 (Ar), 128.3
(Ar), 126.0 (Ar), 88.9 (COCH), 75.6 (COCH), 61.2 (OCH2), 47.3 (CHCO2Et), 41.4
(C(O)CH2), 32.8 (CH2CHCO2Et), 30.9 (CH2CH2Ph), 30.2 (CH2Ph), 14.2 (CH2CH3); No
ROE between Hb and CHCO2Et.
Ketone exo-352: 1H NMR (600 MHz; CDCl3) 7.31–7.27 (2H, m, ArH), 7.24–7.21 (2H,
m, ArH), 7.21–7.17 (1H, m, ArH), 5.10 (1H, d, J = 6.1, COCH), 4.23 (2H, q, J = 7.2,
OCH2), 2.88 (1H, dd, J = 9.2, 4.8, CHCO2Et), 2.83 (1H, td, J = 12.9, 5.0, PhCHH’), 2.67
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(1H, td, J = 12.9, 5.0, PhCHH’), 2.59 (1H, dd, J = 17.2, 6.1, Ha), 2.28–2.14 (4H, m,
PhCH2CH2’, Hb, CHH’CHCO2Et), 1.90 (1H, dd, J = 13.6, 9.2, CHH’CHCO2Et), 1.31
(3H, t, J = 7.2, CH2CH3); (150 MHz; CDCl3) 211.2 (C(O)), 172.3 (C(O)), 141.6 (Ar),
128.4 (Ar), 128.4 (Ar), 126.0 (Ar), 88.0 (COCH), 77.3 (COCH), 61.4 (OCH2), 47.9
(CHCO2Et), 44.2 (C(O)CH2), 32.4 (CH2CHCO2Et), 30.6 (PhCH2CH2), 30.3 (PhCH2),
14.2 (CH2CH3); ROE between Hb and CHCO2Et.
2-Methyl-4,5-dihydro-1H-naphtho[2,1-e]isoindole-1,3(2H)-dione (364)
A solution of Tf2O (43 µL, 73 mg, 0.43 mmol) in CH2Cl2 (0.25 mL) was added to a
stirring solution of cantharimide endo-330a (28 mg, 0.086 mmol) in CH2Cl2 (0.25 mL).
The reaction was stirred for 16 h before the reaction was cooled to 0 °C and quenched
with aq. sat. NaHCO3 (10 mL) and diluted with CH2Cl2 (10 mL). The aq. extract was
washed with CH2Cl2 (3 × 10 mL) and the combined organic extracts washed with brine
(20 mL), dried (MgSO4) and concentrated in vacuo to give the crude product. This was
purified by flash column chromatography (2:1 petrol 40–60 °C:EtOAc) to give
phthalimide 364 as a white crystalline solid (7 mg, 0.027 mmol, 31%); m.p. 160–162 °C;
Rf = 0.40 (8:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2942s (C-H), 1765s, 1705s
(C=O), 1479s; 1H NMR (600 MHz; CDCl3) 8.02 (1H, d, J = 7.9, ArH), 7.78–7.75 (2H,
m, ArH), 7.37–7.32 (2H, m, ArH), 7.31–7.29 (1H, m, ArH), 3.44 (2H, t, J = 7.2, CH2),
3.18 (3H, s, CH3), 2.91 (2H, t, J = 7.2, CH2); 13C NMR (150 MHz; CDCl3) 169.5 (C(O)),
168.4 (C(O)), 141.3 (Ar), 138.0 (Ar), 137.3 (Ar), 132.8 (Ar), 131.1 (Ar), 129.3 (Ar), 128.6
(Ar), 128.5 (Ar), 127.5 (Ar), 124.7 (Ar), 121.8 (Ar), 27.9 (CH2), 24.0 (CH3), 23.1 (CH2);
HRMS (CI+) found [M]+ 263.0949; C17H13NO2 requires 263.0946.
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(3aS,3bR,9bS,11R,11aR)-9b-Methoxy-2-methyl-4,5,9b,10,11,11a-hexahydro-3b,11-
epoxynaphtho[2,1-e]isoindole-1,3(2H,3aH)-dione (369) and (3aS,4R,5R,7R,7aR)-5-
Hydroxy-2-methyl-4-phenethylhexahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione
(371)
TFA (0.50 mL) was added to a stirring solution of cantharimide endo-320 (46 mg,
0.15 mmol) in CH2Cl2 (1.0 mL) at –78°C. The reaction was allowed to reach RT and
stirred for 16 h before the reaction was quenched with aq. sat. NaHCO3 (10 mL) and
diluted with CH2Cl2 (10 mL). The aq. extract was washed with CH2Cl2 (3 × 10 mL) and
the combined organic extracts washed with brine (20 mL), dried (MgSO4) and
concentrated in vacuo to give the crude product (369:370 = 3:1). This was partially
purified by flash column chromatography (2:1 petrol 40–60 °C:EtOAc) to give a mixture
of 369 and 370 (3:1). The mixture of products was then dissolved in hot MeOH (2.0 mL),
cooled to 0 °C and treated with NaBH4 (10 mg, 0.31 mmol). The resulting suspension
was stirred at 0 °C for 4 h before the reaction was diluted with CH2Cl2 (10 mL) and treated
with Amberlyst IRA743 boron scavenger (ca. 100 mg). The mixture was filtered and the
solution concentrated in vacuo to give the crude product, which was purified by flash
column chromatography (2:1 petrol 40–60 °C:EtOAc) to give the cantharimide 369 as a
white crystalline solid (32 mg, 0.10 mmol, 69%); m.p. 174–176 °C; Rf = 0.55 (1:1 petrol
40–60 °C:EtOAc); νmax (film/cm–1) 2934s (C-H), 1771s, 1693s (C=O), 1434s; 1H NMR
(600 MHz; CDCl3) 7.27–7.22 (2H, m, ArH), 7.19 (1H, t, J = 7.1, ArH), 7.10 (1H, d,
J = 7.7, ArH), 4.77 (1H, t, J = 6.2, OCH), 3.71 (1H, dd, J = 9.8, 6.2, OCHCH), 3.16 (1H,
d, J = 9.8, OCHCHCH), 3.02–2.96 (4H, m, NCH3; ArCHH’), 2.85 (1H, dd, J = 16.6, 5.7,
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ArCHH’), 2.76 (3H, s, OCH3), 2.53 (1H, dd, J = 13.8, 6.2, Ha), 2.43 (1H, td, J = 14.2,
6.0, ArCH2CHH’), 2.34 (1H, dd, J = 14.2, 6.0, ArCH2CHH’), 2.25 (1H, d, J = 13.8, Hb);
13C NMR (150 MHz; CDCl3) 175.5 (C(O)), 174.7 (C(O)), 138.3 (C1), 135.8 (Ar), 128.5
(Ar), 128.5 (Ar), 127.6 (Ar), 127.5 (Ar), 91.2 (COCH), 82.7 (MeOC), 76.9 (COCH), 54.6
(OCHCH), 54.3 (OCHCHCH), 53.1 (OCH3), 46.7 (CHa), 28.4 (ArCH2), 26.0
(ArCH2CH2), 25.0 (NCH3); HRMS (CI+) found [M+H]+ 314.1382; C18H20NO4 requires
314.1387. A HMBC experiment measured 3JCH (C1, Ha) = 5.0 Hz (torsion angle ca. 0°);
3JCH (C1, Hb) = 1.0 Hz (torsion angle ca. 120°).
Further elution of the column gave the cantharimide 371 as a colorless oil (8 mg,
0.027 mmol, 18%); Rf = 0.23 (1:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 3445s (O-
H), 2927s (C-H), 1771s, 1691s (C=O), 1434s; 1H NMR (600 MHz; CDCl3) 7.31 (2H, t,
J = 7.4, ArH), 7.27 (2H, d, J = 7.4, ArH), 7.22 (1H, t, J = 7.2, ArH), 4.77 (1H, t, J = 6.1,
OCH), 4.23 (1H, m, CHOH), 3.64 (1H, dd, J = 9.7, 6.1, OCHCH), 3.20 (1H, d, J = 9.7,
OCHCHCH), 3.00–2.88 (4H, m, NCH3; PhCHH’), 2.42–2.27 (3H, m, BnCH2; Ha), 1.98–
1.95 (1H, m, OH), 1.49 (1H, dd, J = 13.8, 3.0, Hb), 1.25 (1H, m, PhCHH’); 13C NMR
(150 MHz; CDCl3) 175.8 (C(O)), 175.7 (C(O)), 141.2 (Ar), 128.8 (Ar), 128.4 (Ar), 126.4
(Ar), 90.8 (BnCH2C), 77.7 (OCHCH), 75.5 (COH), 52.8 (OCHCH), 51.9 (OCHCHCH),
36.8 (HOCHCH2), 35.0 (BnCH2), 30.0 (PhCH2), 24.9 (NCH3); HRMS (CI+) found
[M+H]+ 302.1385; C17H20NO4 requires 302.1387.
5-Ethoxy-2-methyl-4-phenylisoindoline-1,3-dione (368)
A solution of propargylic alcohol 316e (100 mg, 0.427 mmol) in EtOH (1.0 mL) was
treated with N-methylmaleimide (57 mg, 0.51 mmol) and [PPh3AuNTf2]2PhMe (7 mg,
0.043 mmol, 2.0 mol% [Au]) at RT. The resulting solution was stirred at RT for 9 h before
it was filtered through a silica plug, eluting with EtOAc, and the filtrate concentrated in
vacuo to give the crude intermediate. This was then treated with EtOH (0.20 mL) and
MsOH (2.0 mL) at RT and stirred for 16 h. The reaction was then diluted with water
(30 mL) and EtOAc (30 mL) and the aq. extract washed EtOAc (3 × 20 mL). The
combined organic extracts were then washed with 10% aq. K2CO3 (50 mL) and brine
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(50 mL), dried (MgSO4) and concentrated. The concentrated material was then treated
with EtOH (0.20 mL) and MsOH (2.0 mL) at RT and stirred for 16 h. The reaction was
then diluted with water (30 mL) and EtOAc (30 mL) and the a. extract washed EtOAc (3
× 20 mL). The combined organic extracts were then washed with 10% aq. K2CO3 (50 mL)
and brine (50 mL), dried (MgSO4) and concentrated in vacuo to give the crude product.
This was purified by flash column chromatography (7:1 petrol 40–60 °C: EtOAc) to give
the phthalimide 368 as a white crystalline solid (55 mg, 0.20 mmol, 47%); m.p. 93–95 °C;
Rf = 0.31 (7:1 petrol 40–60 °C:EtOAc); νmax (film/cm–1) 2922s (C-H), 1764m (C=O),
1709s (C=O), 1466s; 1H NMR (600 MHz; CDCl3) 7.80 (1H, d, J = 8.2, ArH), 7.46–7.40
(3H, m, ArH), 7.38–7.36 (2H, m, ArH), 7.15 (1H, d, J = 8.2, ArH), 4.09 (2H, q, J = 6.8,
OCH2), 3.07 (3H, s, NCH3), 1.32 (2H, t, J = 6.8, CH2CH3); 13C NMR (150 MHz; CDCl3)
168.2 (C(O)), 167.8 (C(O)), 161.2 (Ar), 132.0 (Ar), 130.5 (Ar), 130.3 (Ar), 130.2 (Ar),
128.3 (Ar), 127.7 (Ar), 124.3 (Ar), 124.0 (Ar), 115.5 (Ar), 65.1 (OCH2), 23.9 (NCH3),
14.5 (CH2CH3); HRMS (CI+) found [M]+ 281.1047; C17H15NO3 requires 281.1052.
(2S,3R,4S,E)-5-(2,2-Dimethylhydrazono)pentane-1,2,3,4-tetraol (441a)247
Prepared from L-arabinose (13.5 g, 90.0 mmol) according to the General Hydrazone
Synthesis Procedure to give the hydrazone 441a as a white crystalline solid (17.1 g,
89.5 mmol, 99%); m.p. = 93–95 °C (lit. m.p. = 88–90 °C)247; Rf = 0.24 (acetone); νmax
(film/cm–1) 3420s (O-H), 3264s (O-H), 2938s (C-H), 1470s; 1H NMR (600 MHz; DMSO-
d6) 6.61 (1H, d, J = 6.2, HC=N), 4.61 (1H, d, J = 5.8, CHOH), 4.53 (1H, d, J = 5.7,
CHOH), 4.42 (1H, d, J = 7.2, CHOH), 4.33 (1H, t, J = 5.6, CH2OH), 4.23–4.19 (1H, m,
N=CHCH), 3.66–3.55 (1H, m, CHH’OH), 3.51–3.46 (1H, m, CHCH2OH), 3.41–3.33
(1H, m, CHH’OH; HOD), 3.31–3.27 (1H, m, N=CHCHCH), 2.67 (6H, s, N(CH3)2); 13C
NMR (150 MHz; DMSO-d6) 138.5 (C=N), 73.8 (CHCH2OH), 71.2 (N=CHCHCH), 70.5
(N=CHCH), 63.5 (CH2OH), 42.6 (N(CH3)2); [α]D (20 °C) = –44.0 (MeOH, C = 1.0); data
in accordance with the literature.247
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(2R,3S,4S,E)-5-(2,2-Dimethylhydrazono)pentane-1,2,3,4-tetraol (441b)
Prepared from D-ribose (1.00 g, 6.67 mmol) according to the General Hydrazone
Synthesis Procedure to give the hydrazone 441b as a white crystalline solid (1.26 g,
6.56 mmol, 98%); m.p. = 70–72 °C; Rf = 0.24 (acetone); νmax (film/cm–1) 3335s br. (O-
H), 2992s (C-H), 1597s, 1469s, 1444s; 1H NMR (600 MHz; DMSO-d6) 6.56 (1H, d,
J = 6.4, N=CH), 4.85 (1H, d, J = 5.1, CHOH), 4.63 (1H, d, J = 5.3, CHOH), 4.48 (1H, d,
J = 4.9, CHOH), 4.31 (1H, t, J = 5.7, CH2OH), 4.12–4.09 (1H, m, N=CHCH), 3.57–3.54
(1H, m, CHH’), 3.46–3.35 (3H, m, CHH’CHCH), 2.67 (6H, s, N(CH3)2); 13C NMR
(150 MHz; DMSO-d6) 137.4 (N=C), 74.4 (CH), 72.3 (CH), 72.2 (CH), 63.2 (CH2), 42.6
(N(CH3)2); HRMS (ESI+) found [M+H]+ 193.1180; C7H17N2O4 requires 193.1188; [α]D
(20 °C) = –22.6 (MeOH, C = 1.0).
(2R,3R,4R,E)-5-(2,2-Dimethylhydrazono)pentane-1,2,3,4-tetraol (441c)
Prepared from D-lyxose (1.00 g, 6.67 mmol) according to the General Hydrazone
Synthesis Procedure to give the hydrazone 441c as a white crystalline solid (1.26 g,
6.56 mmol, 98%); m.p. = 73–75 °C; Rf = 0.14 (acetone); νmax (film/cm–1) 3336s br. (O-
H), 2865s (C-H), 1599s, 1468s, 1443s; 1H NMR (600 MHz; DMSO-d6) 6.56 (1H, d,
J = 6.2, N=CH), 4.84 (1H, d, J = 5.3, CHOH), 4.45 (1H, t, J = 5.6, CH2OH), 4.22 (1H, d,
J = 6.6, CHOH)), 4.19 (1H, d, J = 7.2, CHOH), 4.01–3.96 (1H, m, N=CHCH), 3.66–3.62
(1H, m, CHCH2), 3.43–3.38 (2H, m, N=CHCHCH, CHH’OH), 3.37–3.33 (1H, m,
CHH’OH; HOD), 2.68 (6H, s, N(CH3)2); 13C NMR (150 MHz; DMSO-d6) 138.5 (N=C),
72.8 (N=CHCHCH), 71.0 (N=CHCH), 70.3 (CHCH2OH), 62.8 (CH2OH), 42.6
(N(CH3)2); HRMS (ESI+) found [M+H]+ 193.1196; C7H17N2O4 requires 193.1188; [α]D
(20 °C) = +16.4 (MeOH, C = 0.58).
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(2S,3S,4S,5S,E)-1-(2,2-Dimethylhydrazono)hexane-2,3,4,5-tetraol (441e)
Prepared from L-rhamnose monohydrate (2.58 g, 14.2 mmol) according to the General
Hydrazone Synthesis Procedure to give the hydrazone 441e as a white crystalline solid
(2.90 g, 14.1 mmol, 99%); m.p. = 101–103 °C; Rf = 0.30 (acetone); νmax (film/cm–1) 3347s
br. (O-H), 2920w (C-H), 1611m, 1444s; 1H NMR (600 MHz; DMSO-d6) 6.57 (1H, d,
J = 6.0, N=CH), 4.82 (1H, d, J = 5.3, CHOH), 4.41 (1H, d, J = 5.6, CHOH), 4.12 (1H, d,
J = 7.7, CHOH), 4.08 (1H, d, J = 7.2, CHOH), 3.98–3.93 (1H, m, N=CHCH), 3.64–3.60
(1H, m, N=CHCHCH), 3.59–3.53 (1H, m, CHCH3), 3.32–3.29 (1H, m, CHCHCH3), 2.66
(6H, s, N(CH3)2), 1.10 (3H, d, J = 6.2, CHCH3); 13C NMR (150 MHz; DMSO-d6) 138.8
(N=C), 73.5 (CH), 71.1 (CH), 71.0 (CH), 66.3 (CH), 42.6 (N(CH3)2), 20.8 (CH3); HRMS
(ESI+) found [M+H]+ 207.1347; C8H19N2O4 requires 207.1345; [α]D (20 °C) = +4.1
(MeOH, C = 1.3).
(2R,3S,4R,5S,E)-6-(2,2-Dimethylhydrazono)hexane-1,2,3,4,5-pentaol (441f)247
A stirring solution of D-galactose (1.80 g, 10.0 mmol) in MeOH (20 mL, 0.50 M) was
treated with NH2NMe2 (1.5 mL, 1.2 g, 20 mmol) and Amberlyst 15 (2.00 g) at RT and
the reaction stirred at RT for 3 days. The reaction was then filtered and the filtrate
concentrated in vacuo to give the crude product, which was purified by flash column
chromatography (acetone) to give the hydrazone 441f as a yellow crystalline solid
(680 mg, 3.06 mmol, 31%); m.p. = 106–108 °C (lit. m.p. = 96–100 °C) 247; Rf = 0.20 (1:5
MeOH:acetone); νmax (film/cm–1) 3362s br. (O-H), 2931s (C-H), 1593s, 1469s, 1412s; 1H
NMR (600 MHz; DMSO-d6) 6.65 (1H, d, J = 6.0, N=CH), 4.53 (1H, d, J = 6.4, CHOH),
4.43 (1H, t, J = 5.6, CH2OH), 4.33 (1H, d, J = 7.5, CHOH), 4.27–4.24 (1H, m, N=CHCH),
4.14–4.10 (2H, m, 2 × CHOH), 3.70 (1H, dd, J = 6.5, 1.4, CHOH), 3.51–3.47 (1H, m,
CHOH), 3.44–3.36 (3H, m, CHOH, CH2OH), 2.67 (6H, s, N(CH3)2); 13C NMR
(150 MHz; DMSO-d6) 139.0 (N=C), 72.5 (CH), 70.4 (CH), 69.9 (CH), 69.1 (CH), 63.1
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(CH2), 42.7 (N(CH3)2); [α]D (20 °C) = –30.0 (MeOH, C = 1.0); Data in accordance with
the literature. 247
(2R,3S,4S)-2-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuran-3,4-diol (anti-
443a) and (2S,3S,4S)-2-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuran-3,4-
diol (syn-443a)
Experiment A (6.60 mmol scale): Prepared from hydrazone 441a (1.26 g, 6.60 mmol)
according to the General Acid-Catalyzed Cyclization Procedure, to give the crude product
(anti:syn = 75:25). This was purified by flash column chromatography (80:100
hexane:acetone) to give the tetrahydrofuran 443a (772 mg, 4.44 mmol, 67%,
anti:syn = 75:25).
Experiment B (104 mmol scale): Prepared from hydrazone 441a (20.0 g, 104 mmol)
according to the General Acid-Catalyzed Cyclization Procedure, to give the crude product
(anti:syn = 75:25). This was purified by flash column chromatography (80:100
hexane:acetone) to give a mixture of the tetrahydrofuran anti-443a and the
tetrahydrofuran syn-443a (11.9 g, 68.3 mmol, 66%, anti:syn = 75:25).
Tetrahydrofuran anti-443a: Isolated as a single stereoisomer following recrystallization
from boiling CPME. Isolated as a white crystalline solid; m.p. = 65–67 °C; Rf = 0.33 (1:1
acetone:hexane); νmax (film/cm–1) 3415s br. (O-H), 2875s (C-H), 1586s, 1467s, 1445s; 1H
NMR (600 MHz; MeOH-d4) 6.51 (1H, d, J = 6.6, N=CH), 4.23–4.18 (2H, m, N=CHCH,
CH2CH), 4.08 (1H, dd, J = 9.6, 4.9, OCHH’), 4.02 (1H, dd, J = 7.3, 5.1, N=CHCHCH),
3.76–3.72 (1H, m, OCHH’), 2.79 (6H, s, N(CH3)2); 13C NMR (150 MHz; MeOH-d4)
135.6 (C=N), 82.5 (CHCH2), 76.5 (N=CHCHCH), 73.9 (OCH2), 72.4 (CH2CHCH), 42.8
(N(CH3)2); HRMS (EI+) found [M]+ 174.0979; C7H14N2O3 requires 174.0999; [α]D
(20 °C) = +85.8 (anti-443a, MeOH, C = 1.4).
Tetrahydrofuran syn-433a: 1H NMR (600 MHz; MeOH-d4) 6.71 (1H, d, J = 7.2, N=CH),
4.36–4.31 (2H, m, N=CHCH; CH2CH), 4.15 (1H, t, J = 4.8, CHCHCH2), 3.91 (1H, dd,
J = 8.7, 6.2, OCHH’), 3.76–3.72 (1H, m, OCHH’), 2.79 (6H, s, N(CH3)2); 13C NMR
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(150 MHz; MeOH-d4) 135.6 (C=N), 83.1 (CHCH2), 74.3 (N=CHCHCH), 73.2
(N=CHCH), 72.5 (OCH2), 42.8 (N(CH3)2).
(2S,3R,4R)-2-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuran-3,4-diol (ent-
syn-443a) and (2R,3R,4R)-2-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuran-
3,4-diol (ent-syn-443a)
Prepared from hydrazone 441b (1.16 g, 6.03 mmol) according to General Acid-Catalyzed
Cyclization Procedure to give the crude product (anti:syn = 75:25). This was purified by
flash column chromatography (80:100 hexane:acetone) the tetrahydrofuran 433a as a
yellow oil (620 mg, 3.56 mmol, 59%, anti:syn = 75:25); 1H NMR consistent with 433a;
[α]D (20 °C) = –24.2 (ent-433a, MeOH, C = 1.1).
(2R,3R,4S)-2-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuran-3,4-diol (anti-
433b) and ((2S,3R,4S)-2-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuran-3,4-
diol (syn-433b)
Method A: Prepared from hydrazone 441c (1.22 g, 6.35 mmol) according to the General
Acid-Catalyzed Cyclization Procedure to give the crude product (d.r. = 55:45). This was
purified by flash column chromatography (80:100 hexane:acetone) to give the
tetrahydrofuran 433b (731 mg, 4.20 mmol, 66%, d.r. = 55:45).
Method B: Prepared according to the General Hydrazone Synthesis Procedure from D-
xylose (1.00 g, 6.67 mmol) to give a crude hydrazone, which was subjected to the General
Acid-Catalyzed Cyclization Procedure to give the crude product (d.r. = 55:45). This was
purified by flash column chromatography (80:100 hexane:acetone) to give a mixture of
the tetrahydrofurans 433b as a yellow oil (711 mg, 4.09 mmol, 61% over 2 steps from D-
xylose, d.r. = 55:45).
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Isolated as a yellow oil; Rf = 0.20 (1:1 acetone:hexane); νmax (film/cm–1) 3360s br. (O-H),
2875s (C-H), 1595s, 1470s, 1445s; 1H NMR (600 MHz; D2O) 6.92 (1H, d, J = 6.6, N=CH
major), 6.88 (1H, d, J = 6.4, N=CH minor), 4.60 (1H, dd, J = 6.4, 3.6, N=CHCH minor),
4.40–4.38 (1H, m, CHCH2 minor), 4.35–4.33 (2H, m, CHCH2, N=CHCH major), 4.26–
4.23 (2H, m, CHCHCHH’ minor), 4.20–4.19 (1H, m, CHCHCH2 major), 4.10 (1H, dd,
J = 10.0, 4.1, CHH’ major), 3.98 (1H, dd, J = 10.0, 2.0, CHH’ major), 3.83 (1H, dd,
J = 10.0, 1.1, CHH’ minor), 2.80 (6H, s, N(CH3)2 minor), 2.78 (6H, s, N(CH3)2 major);
13C NMR (150 MHz; D2O, with a MeOH standard) 140.6 (C=N), 138.1 (C=N), 85.3
(CH), 81.0 (CH), 80.9 (CH), 78.1 (CH), 77.2 (CH), 77.1 (CH), 73.8 (CH2), 73.7 (CH2),
43.0 (N(CH3)2); HRMS (EI+) found [M]+ 174.0969; C7H14N2O3 requires 174.0999; [α]D
(20 °C) = +45.6 (MeOH, C = 1.1).
(2R,3S,4R)-2-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuran-3,4-diol (ent-
anti-433b) and ((2S,3S,4R)-2-((E)-(2,2-
Dimethylhydrazono)methyl)tetrahydrofuran-3,4-diol (ent-syn-433b)
Prepared according to the General Hydrazone Synthesis Procedure from L-xylose (1.00 g,
6.67 mmol) to give a crude hydrazone, which was subjected to the General Acid-
Catalyzed Cyclization Procedure to give the crude product (d.r. = 55:45). This was
purified by flash column chromatography (90:100 petroleum ether 40–60 °C:acetone) to
give the tetrahydrofuran ent-433b as a yellow oil (656 mg, 3.77 mmol, 57% over 2 steps
from L-xylose, d.r. = 55:45); 1H NMR consistent with 443b; [α]D (20 °C) = –45.3 (MeOH
C = 1.2).
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(2S,3R,4R,5S)-2-((E)-(2,2-Dimethylhydrazono)methyl)-5-methyltetrahydrofuran-
3,4-diol (anti-433c) and (2R,3R,4R,5S)-2-((E)-(2,2-Dimethylhydrazono)methyl)-5-
methyltetrahydrofuran-3,4-diol (syn-433c)
Prepared from hydrazone 431e (1.37 g, 6.65 mmol) according General Acid-Catalyzed
Cyclization Procedure to give the crude product (d.r. = 60:40). This was purified by flash
column chromatography (80:100 hexane:acetone) to give the tetrahydrofuran 433c as a
yellow oil (866 mg, 4.61 mmol, 69%, d.r. = 60:40); Rf = 0.38 (1:1 acetone:hexane); νmax
(film/cm–1) 3377s br. (O-H), 2921s (C-H), 1642s, 1445s; 1H NMR (600 MHz; MeOH-d4)
6.64 (1H, d, J = 7.0, N=CH minor), 6.61 (1H, d, J = 6.4, N=CH major), 4.41 (1H, dd,
J = 7.0, 4.6, N=CHCH minor), 4.25 (1H, t, J = 6.4, N=CHCH major), 4.03 (1H, t, J = 6.4,
N=CHCHCH major), 4.01–3.98 (1H, m, N=CHCHCH minor), 3.88 (1H, quintet, J = 6.4,
CHCH3 major), 3.79–3.74 (2H, m, CHCHCH3 minor), 3.69 (1H, t, J = 6.4, CHCHCH3
major), 2.81 (6H, s, N(CH3)2 minor), 2.79 (6H, s, N(CH3)2 major), 1.34 (3H, d, J = 6.0,
CHCH3 minor), 1.28 (3H, d, J = 6.4, CHCH3 major); 13C NMR (150 MHz; MeOH-d4)
136.1 (C=N major), 134.3 (C=N minor), 84.8 (CH minor), 84.1 (CH major), 83.7 (CH
major), 82.7 (CH minor), 82.5 (CH minor), 81.8 (CH major), 80.9 (CH minor), 80.2 (CH
major), 42.9 (N(CH3)2 major), 42.8 (N(CH3)2 minor), 19.6 (CHCH3 minor), 19.3 (CHCH3
major); HRMS (ESI+) found [M+H]+ 189.1235; C8H17N2O3 requires 189.1239; [α]D
(20 °C) = –33.2 (MeOH, C = 3.3).
(2R,3S,4R,5R)-2-((E)-(2,2-Dimethylhydrazono)methyl)-5-
(hydroxymethyl)tetrahydrofuran-3,4-diol (443d) and (2S,3S,4S,5R)-2-((E)-(2,2-
Dimethylhydrazono)methyl)tetrahydro-2H-pyran-3,4,5-triol (448)
Prepared from hydrazone 441f (222 mg, 1.00 mmol) according to the General Acid-
Catalyzed Cyclization Procedure to give the crude product (443d:448 = 60:40). This was
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purified by flash column chromatography (30:70 hexane:acetone) to give the
tetrahydrofuran 443d as a colorless oil (59 mg, 0.29 mmol, 29%). Further elution of the
column gave the tetrahydropyran 436 as a colorless oil (49 mg, 0.24 mmol, 24%, 20%
impurity of 433d).
Tetrahydrofuran 443d: Rf = 0.43 (70:30 acetone:hexane); νmax (film/cm–1) 3372s br. (O-
H), 2898s (C-H), 1599w, 1444m, 1406m; 1H NMR (600 MHz; D2O) 6.93 (1H, d, J = 6.0,
N=CH), 4.22 (1H, dd, J = 9.4, 6.0, N=CHCH), 4.15–4.12 (1H, m, CHCHCH2), 4.04 (1H,
dd, J = 9.4, 3.2, N=CHCHCH), 4.01–3.98 (2H, m, CHCHH’), 3.85–3.82 (1H, m, CHH’),
2.89 (6H, s, N(CH3)2); 13C NMR (150 MHz; D2O with MeOH standard) 139.0 (C=N),
75.8 (CH), 70.0 (CH), 69.8 (CH), 67.6 (CH), 66.7 (CH2), 43.0 (N(CH3)2); HRMS (ES+)
found [M+H]+ 205.1181; C8H17N2O4 requires 205.1188; [α]D (20 °C) = +1.2 (MeOH,
C = 0.5).
Tetrahydropyran 448: Isolated with a 20% impurity of 443d; Rf = 0.28 (1:1
acetone:hexane); 1H NMR (600 MHz; D2O) 6.97 (1H, d, J = 5.1, N=CH), 4.24 (1H, d,
J = 5.1, N=CHCH), 4.16–4.11 (2H, m, CHH’, N=CHCHCH), 3.98–3.94 (1H, m,
CHCH2), 3.74 (1H, dd, J = 9.6, 3.4, CHCHCH2), 3.37 (1H, t, J = 10.9, CHH’), 2.86 (6H,
s, N(CH3)2); 13C NMR (150 MHz; D2O with MeOH standard) 139.1 (C=N), 79.1 (CH),
74.4 (CH), 71.4 (CH), 69.6 (CH2), 66.9 (CH), 43.1 (N(CH3)2).
(2S,3S,4S)-2-(Dihydroxymethyl)tetrahydrofuran-3,4-diol (anti-449a) and
(2R,3S,4S)-2-(Dihydroxymethyl)tetrahydrofuran-3,4-diol (syn-449a)
Amberlyst 15 (6.90 g) was added to as stirring solution of hydrazone 443a (1.20 g,
6.90 mmol) in water (34 mL) at RT. After 5 minutes the reaction was filtered and
concentrated in vacuo and lyophilized to give the hydrolyzed product as a white gum
(894 mg); Rf = 0.42 (acetone); νmax (film/cm–1) 3345s br. (O-H), 2945s (C-H), 1720w,
1441m; [α]D (20 °C) = +36.9 (MeOH, C = 1.0).
Analysis of the 1H NMR in H2O, D2O, DMSO-d6 and MeOH-d4 suggested that the
structure of the hydrolyzed product 449 was dependent on the solvent. In H2O and D2O
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(accounting for deuterium exchange) the NMR data was consistent with a mixture of
(2S,3S,4S)-2-(dihydroxymethyl)tetrahydrofuran-3,4-diol anti-449a and (2R,3S,4S)-2-
(dihydroxymethyl)tetrahydrofuran-3,4-diol syn-449a (anti:syn = 85:15). In DMSO-d6
and MeOH-d4 the NMR data was consistent with a more complex composition [see
Section 4.2.5. for further discussion].
(2S,3S,4S)-2-(Dihydroxymethyl)tetrahydrofuran-3,4-diol anti-449a and (2R,3S,4S)-
2-(Dihydroxymethyl)tetrahydrofuran-3,4-diol syn-449a: 1H NMR (600 MHz; D2O)
5.16 (1H, d, J = 7.2, CH(OD)2 syn-449a), 5.04 (1H, d, J = 5.1, CH(OD)2 anti-449a), 4.49
(1H, td, J = 7.2, 4.0, CHCH2 syn-449a), 4.31–4.27 (1H, m, CHCH2 anti-449a; 1H, m,
CHCHCH2 syn-449a), 4.24 (1H, t, J = 5.1, CHCHCH2 anti-449a), 4.06–4.02 (1H, dd,
J = 10.0, 4.1, CHH’ anti-449a; 1H, m, CHH’ syn-449a), 3.82 (1H, dd, J = 10.0, 3.0, CHH’
anti-449a), 3.79 (1H, dd, J = 7.2, 4.0, CHCH(OD)2 syn-449a), 3.75 (1H, t, J = 5.1,
CHCH(OD)2 anti-449a), 3.71 (1H, t, J = 7.2, CHH’ syn-449a); 13C NMR (150 MHz; D2O
with MeOH standard) 90.4 (CH(OD)2 anti-449a), 89.2 (CH(OD)2 syn-449a), 84.2
(CHCH(OD)2 anti-449a), 83.3 (CHCH(OD)2 syn-449a), 73.0 (CHCH2 anti-449a), 72.7
(OCH2 anti-449a), 71.9 (CHCHCH2 anti-449a), 71.8 (CHCH2CH2 syn-449a), 71.5
(CHCH2 syn-449a), 70.8 (OCH2 syn-449a).
(2S,3R,4S)-2-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuran-3,4-diol (anti-
450)251 and (2R,3R,4S)-2-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuran-
3,4-diol (syn-450)
A stirring solution of hydrolyzed product 449 (103 mg, 0.780 mmol, anti:syn = 85:15) in
MeOH (3.9 mL) was treated with NaBH4 (43 mg, 1.2 mmol) portionwise at 0 °C. The
reaction was stirred at 0 °C for 1 h before the reaction was quenched with AcOH (1 drop)
and treated with Amberlyst 15 (1.60 g) and Amberlyst A26 (1.60 g). The mixture was
then stirred at RT for 30 minutes before it was filtered the filtrate concentrated in vacuo
to give the triol 450 as a white crystalline solid (104 mg, 0.776 mmol, 100%,
anti:syn = 85:15); m.p. = 83–85 °C; Rf = 0.57 (acetone); νmax (film/cm–1) 3342s br. (O-
H), 2930s (C-H), 1683w, 1411m; 1H NMR (600 MHz; D2O) 4.44 (1H, q, J = 5.8, CHCH2
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syn-450), 4.33 (1H, t, J = 4.8, CHCHCH2 syn-450), 4.31–4.29 (1H, m, CHCH2 anti-450),
4.13 (1H, dd, J = 7.3, 4.9, CHCHCH2 anti-450), 4.09 (1H, dd, J = 10.2, 4.3, CHH’ anti-
450), 4.08–4.06 (1H, m, CHCH2 syn-450), 3.99 (1H, dd, 9.2, 6.4, CHH’ syn-450), 3.90–
3.86 (1H, m, CHCH2 anti-450), 3.85–3.81 (2H, m, CHH’, CHH’ anti-450; 1H, m, CHH’
syn-450), 3.77–3.73 (2H, m, CHH’, CHH’ syn-450), 3.67 (1H, dd, J = 12.5, 5.1 CHH’
anti-450); 13C NMR (150 MHz; D2O with MeOH reference) 82.1 (CH anti-450), 81.4
(CH syn-450), 72.8 (CH2 anti-450), 72.2 (CH anti-450), 71.8 (CH syn-450), 71.7 (CH
syn-450), 71.7 (CH anti-450), 71.0 (CH2 syn-450), 61.9 (CH2 anti-450), 61.0 (CH2 syn-
450); HRMS (CI+) found [M+H]+ 135.0652; C5H11O4 requires 135.0652; [α]D
(20 °C) = +50.9 (MeOH, C = 2.0); data in accordance with the literature.251
tert-Butyl butyl(((2R,3S,4S)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)carbamate
(anti-453) and tert-Butyl butyl(((2S,3S,4S)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl)carbamate (syn-453)
A stirring solution of hydrolyzed product 449 (124 mg, 0.939 mmol, anti:syn = 85:15) in
MeOH (4.7 mL) was treated with AcOH (27 µL, 28 mg, 0.47 mmol), nBuNH2 (0.47 mL,
640 mg, 8.7 mmol) and 10% Pd/C (124 mg) at RT before the reaction was placed under
an atmosphere of hydrogen gas. The reaction was stirred at RT for 4 h before it was
filtered through Celite and the filtrate concentrated in vacuo. The crude product was then
dissolved in CPME (2.0 mL) and stirred at RT. The reaction was treated with a solution
of Boc2O (308 mg, 1.41 mmol) in CPME (3.0 mL) and resulting mixture stirred at RT for
16 h. The reaction was then concentrated in vacuo to give the crude product, which was
purified by flash column chromatography (70:30 hexane:acetone) to give the carbamate
453 as a white gum (179 mg, 0.619 mmol, 66%, anti:syn = 80:20); Rf = 0.38 (30:70
acetone:hexane); νmax (film/cm–1) 3406s br. (O-H), 2931s (C-H), 1690s, 1665s, 1479s,
1468s, 1416s; 1H NMR (400 MHz; DMSO-d6, 80 °C) 4.90–4.06 (2H, br. m, 2 × OH anti-
453; 3H, br. m, 2 × OH syn-453, CH syn-453), 4.05–4.00 (1H, m, CH anti-453), 3.94–
3.88 (1H, m, H syn-453), 3.91 (1H, dd, J = 9.3, 5.3, CHH’ anti-453), 3.88–3.83 (1H, m,
CH syn-453), 3.76–3.70 (1H, m, CH anti-453, 1H, m, H syn-453), 3.66 (1H, dd, J = 6.0,
5.3, CH anti-453), 3.54–3.47 (2H, m, H syn-453), 3.51 (1H, dd, J = 9.3, 4.0, CHH’ anti-
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453), 3.44 (1H, dd, J = 14.3, 4.0, CHH’ anti-453), 3.27–3.15 (2H, m, CH2nPr anti-453;
3H, m, CH2nPr syn-453, H syn-453), 3.11 (1H, dd, J = 14.3, 7.3, CHH’ anti-453), 1.52–
1.44 (2H, m, CH2CH2CH3 anti-453; 2H, m, CH2CH2CH3 syn-453), 1.42 (9H, s, C(CH3)3
anti-453), 1.41 (9H, s, C(CH3)3 syn-453), 1.31–1.21 (2H, m, CH2CH3 anti-453; 2H, m,
CH2CH3 syn-453), 0.90 (3H, t, J = 7.3, CH2CH3 anti-453; 3H, t, J = 7.3, CH2CH3 syn-
453); 13C NMR (150 MHz; DMSO-d6) 154.9 (C(O)), 154.6 (C(O)), 81.2 (CH), 80.8 (CH),
78.3 (COtBu), 73.5 (CH), 72.2 (CH2), 71.3 (CH), 70.9 (CH), 70.5 (CH2), 70.1 (CH), 49.1
(CH2), 48.8 (CH2), 47.0 (CH2), 46.5 (CH2), 30.0 (CH2), 29.5 (CH2), 28.1 (C(CH3)3), 19.5
(CH2), 13.8 (CH2CH3)); HRMS (ESI+) found [M+H]+ 290.1979; C14H28NO5 requires
290.1967; [α]D (20 °C) = +25.0 (MeOH, C = 1.0).
(2S,3S,4S)-2-(Dimethoxymethyl)tetrahydrofuran-3,4-diol (anti-454) and
(2R,3S,4S)-2-(Dimethoxymethyl)tetrahydrofuran-3,4-diol (syn-454)
Amberlyst 15 (83 mg) was added to a stirring solution of hydrolyzed product 449
(109 mg, 0.820 mmol, anti:syn = 85:15) in MeOH (4.1 mL) RT. The reaction was stirred
at RT for 48 h before the reaction mixture was filtered and the filtrate concentrated in
vacuo to give the crude product (anti:syn = 65:35). This was purified by flash column
chromatography (80:100 hexane:acetone) to give the acetal-454 as a colorless oil
(111 mg, 0.624 mmol, 76%, anti:syn = 75:25); Rf = 0.34 (1:1 hexane:acetone); νmax
(film/cm–1) 3443s br. (O-H), 2947s (C-H); 1H NMR (600 MHz; MeOH-d4) 4.59 (1H, d,
J = 7.5, CH(OMe)2 syn-454), 4.33–4.29 (1H, m, CHCH2 syn-454), 4.31 (1H, d, J = 4.7,
CH(OMe)2 anti-454), 4.13 (1H, q, J = 4.7, CHCH2 anti-454), 4.10–4.06 (1H, m,
CHCHCH(OMe)2 syn-454), 4.09 (1H, t, J = 4.7, CHCHCH(OMe)2 anti-454), 3.93 (1H,
dd, J = 9.2, 4.7, CHH’ anti-454), 3.89 (1H, t, J = 7.9, CHH’ syn-454), 3.83 (1H, t, J = 4.7,
CHCH(OMe)2 anti-454), 3.79 (1H, dd, J = 7.5, 3.4, CHCH(OMe)2 syn-454), 3.68 (1H,
dd, J = 9.2, 4.7, CHH’ anti-454), 3.65 (1H, t, J = 7.9, CHH’ syn-454), 3.44 (3H, s, OCH3
syn-454), 3.43 (3H, s, OCH3 anti-454), 3.42 (3H, s, OCH3 anti-454), 3.39 (3H, s, OCH3
syn-454); 13C NMR (150 MHz; MeOH-d4) 106.3 (C(OMe)2 anti-454), 104.2 (C(OMe)2
syn-454), 84.1 (CHCH(OMe)2 anti-454), 81.5 (CHCH(OMe)2 syn-454), 73.6 (CHCHCH2
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anti-454), 73.3 (CH2O anti-454), 73.0 (CHO syn-454), 72.6 (CHCH2 anti-454), 72.5
(CHO syn-454), 72.1 (CH2O syn-454), 56.1 (O(CH3)2 anti-454), 55.2 (O(CH3)2 syn-454);
HRMS (ESI+) found [M+Na]+ 201.0741; C7H14NaO5 requires 201.0739; [α]D (20 °C) =
+30.1 (MeOH, C = 0.38).
(3aS,4S,6aS)-4-(Dimethoxymethyl)tetrahydrofuro[3,4-d][1,3]dioxol-2-one (455)
K2CO3 (7 mg, 10 mol%) was added to a stirring solution of acetal 454 (90 mg, 0.51 mmol,
anti:syn = 75:25) in DMC (2.5 mL) at RT. The reaction was heated at reflux for 16 h
before the reaction was allowed to cool to RT, filtered through a silica plug (eluting with
Et2O) and the filtrate concentrated in vacuo to give the carbonate 455 as a colorless oil
(90 mg, 0.44 mmol, 87%, single diastereoisomer); Rf = 0.35 (80:20 hexane:acetone); νmax
(film/cm–1); 2942s (C-H), 1797s (C=O), 1459s; 1H NMR (600 MHz; CDCl3) 5.26 (1H, d,
J = 7.0, CHCHCH2), 5.18–5.16 (1H, m, CHCH2), 4.33 (1H, d, J = 2.7, CH(OMe)2), 4.25
(1H, d, J = 2.7, CHCH(OMe)2), 4.14–4.12 (2H, m, OCH2), 3.46 (3H, s, OCH3), 2.43 (3H,
s, OCH3); 13C NMR (150 MHz; CDCl3) 154.5 (C(O)), 105.6 (C(OMe)2), 84.0
(CHCH(OMe)2), 81.3 (CHCHCH2), 80.9 (CHCH2), 73.9 (OCH2), 56.9 (OCH3), 56.5
(OCH3); HRMS (CI+) found [M+H]+ 205.0708; C8H13O6 requires 205.0707; [α]D
(20 °C) = +25.0 (MeOH, C = 0.45).
Methyl (E)-3-((2R,3S,4S)-3,4-dihydroxytetrahydrofuran-2-yl)acrylate (anti-456)
and Methyl (E)-3-((2S,3S,4S)-3,4-dihydroxytetrahydrofuran-2-yl)acrylate (syn-
456)
K2CO3 (78 mg, 0.57 mmol) and trimethyl phosphonoacetate (74 µL, 82 mg, 0.43 mmol)
were added to a stirring solution of hydrolyzed product 449 (50 mg, 0.38 mmol, anti:syn
= 85:15) in MeOH (1.9 mL) at 0 °C. The reaction was stirred at 0 °C for 4 h before the
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reaction mixture was filtered through a silica plug (eluting with EtOAc) and the filtrate
concentrated in vacuo to give the crude product (anti:syn = 85:15). This was purified by
flash column chromatography (CH2Cl2) to give the alkene 456 as a colorless oil (53 mg,
0.28 mmol, 74%, anti:syn = 85:15); Rf = 0.58 (1:1 acetone:hexane); νmax (film/cm–1)
3400s br. (O-H), 2944s (C-H), 1715s (C=O), 1649s, 1319s; 1H NMR (600 MHz; MeOH-
d4) 7.02 (1H, dd, J = 15.6, 4.7, MeO2CCH=CH syn-456), 6.98 (1H, dd, J = 15.8, 6.3,
MeO2CCH=CH anti-456), 6.08 (1H, dd, J = 15.8, 1.7, MeO2CCH anti-456), 6.07–6.04
(1H, m, MeO2CCH syn-456), 4.50 (1H, td, J = 4.7, 1.7, CH=CHCH syn-456), 4.34–4.31
(1H, m, CHCH2 syn-456), 4.30–4.27 (1H, m, CH=CHCH anti-456), 4.19 (1H, t, J = 4.7,
CHCHCH2 syn-456), 4.18–4.15 (1H, m, CH2CH anti-456), 4.12 (1H, dd, J = 9.8, 4.5,
CHH’ anti-456), 3.96–3.93 (1H, m, CHH’ syn-456), 3.88–3.78 (2H, m, CHH’CHCH
anti-456), 3.76–3.74 (1H, m, CHH’ syn-456), 3.73 (3H, s, OCH3 anti-456), 3.72 (3H, s,
OCH3 syn-456); 13C NMR (150 MHz; MeOH-d4) 168.3 (C(O), anti-456; C(O), syn-456),
148.1 (MeO2CCH=CH anti-456), 146.7 (MeO2CCH=CH syn-456), 122.5
(MeO2CCH=CH syn-456), 121.5 (MeO2CCH=CH anti-456), 81.6 (CH=CHCH syn-456),
81.5 (CH=CHCH anti-456), 77.7 (CH2CHCH anti-456), 74.3 (CH2 anti-456), 74.2
(CHOD syn-456), 73.1 (CHOD syn-456), 72.6 (CH2 syn-456), 72.4 (CH2CH anti-456),
52.1 (OCH3 anti-456), 52.1 (OCH3 syn-456); HRMS (EI+) found [M]+ 188.0680; C8H12O5
requires 188.0679; [α]D (20 °C) = +40.5 (MeOH, C = 0.45).
(2R,3S,4R)-2-(Hydroxymethyl)tetrahydrofuran-3,4-diol (anti-458)252 and
(2S,3S,4R)-2-(Hydroxymethyl)tetrahydrofuran-3,4-diol (syn-458)
Amberlyst 15 (701 mg) was added to a stirring solution of hydrazone 443b (122 mg,
0.701 mmol, 55:45 d.r.) in water (3.5 mL) at RT. After 5 minutes the reaction mixture
was filtered and the filtrate concentrated in vacuo and lyophilized to give a white gum.
The intermediate was then dissolved in MeOH (3.5 mL) and treated with NaBH4 (40 mg,
1.1 mmol) portionwise at 0 °C and the reaction stirred at 0 °C for 1 h. The reaction was
then quenched with AcOH (1 drop) and treated with Amberlyst 15 (1.4 0g) and Amberlyst
A26 (1.40 g). The mixture was then stirred at RT for 30 minutes before it was filtered the
filtrate concentrated in vacuo to give triol 458 as a colorless oil (85 mg, 0.63 mmol, 90%,
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anti:syn = 65:35); Rf = 0.57 (acetone); νmax (film/cm–1) 3330s br. (O-H), 2939s (C-H),
1655m, 1414s; 1H NMR (600 MHz; D2O) 4.33–4.29 (1H, m, CH syn-458), 4.27–4.25
(1H, m, CH anti-458), 4.23 (1H, dd, J = 3.6, 1.3, CH syn-458), 4.18 (1H, dd, J = 10.3,
4.2, CHH’ syn-458), 4.16–4.12 (1H, m, CH syn-458), 4.05–4.02 (2H, m, CH, CHH’ anti-
458), 3.89–3.84 (2H, m, CH, CHH’ anti-458; 1H, m, CHH’ syn-458), 3.80–3.71 (2H, m,
CH2 anti-458; 2H, m, CHH’, CHH’ syn-458); 13C NMR (150 MHz; D2O with MeOH
standard) 86.1 (CH anti-458), 81.4 (CH syn-458), 78.5 (CH anti-458), 77.5 (CH anti-
458), 77.2 (CH syn-458), 76.7 (CH syn-458), 73.4 (CH2 anti-458), 73.3 (CH2 syn-458),
62.2 (CH2 anti-458), 60.5 (CH2 syn-458); HRMS (ESI+) found [M+H]+ 135.0658;
C5H11O4 requires 135.0652; [α]D (20 °C) = +69.6 (MeOH, C = 0.17); Data for anti-458
in accordance with the literature.252
(2R,3R,4R,5S)-2-(Hydroxymethyl)-5-methyltetrahydrofuran-3,4-diol (syn-459)253
and (2S,3R,4R,5S)-2-(Hydroxymethyl)-5-methyltetrahydrofuran-3,4-diol (anti-459)
Amberlyst 15 (888 mg) was added to a stirring solution of hydrazone 433c (167 mg,
0.888 mmol, 60:40 d.r.) in water (4.4 mL) at RT. After 5 minutes the reaction mixture
was filtered and the filtrate concentrated in vacuo and lyophilized to give a white gum.
The intermediate was then dissolved in MeOH (4.4 mL) and treated with NaBH4 (49 mg,
1.3 mmol) portionwise at 0 °C and the reaction stirred at 0 °C for 1 h. The reaction was
then quenched with AcOH (1 drop) and treated with Amberlyst 15 (1.80 g) and Amberlyst
A26 (1.80 g). The mixture was then stirred at RT for 30 minutes before it was filtered and
the filtrate concentrated in vacuo to give the triol 459 as a colorless oil (122 mg,
0.824 mmol, 93%, syn:anti = 70:30); Rf = 0.26 (1:1 acetone:hexane); νmax (film/cm–1)
3317s (O-H), 2930s (C-H), 1450s; 1H NMR (600 MHz; D2O) 4.21–4.19 (1H, m, CH anti-
459), 4.09–4.06 (1H, m, CH anti-459), 4.04 (1H, t, J = 6.4, CHOD syn-459), 3.96–3.91
(2H, m, CHCH2, CHCH3 syn-459), 3.86–3.80 (1H, m, CHOD syn-459; 3H, m, CHCH3,
CHH’, CH anti-459), 3.78–3.73 (1H, m, CHH’ syn-459; 1H, m, CHH’ anti-459), 3.72–
3.69 (1H, dd, J = 12.4, 5.8, CHH syn-459), 1.37–1.35 (3H, m, CHCH3 anti-459), 1.32
(3H, d, J = 6.4, CHCH3 syn-459); 13C NMR (150 MHz; D2O with MeOH standard) 83.4
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(CH anti-459), 82.5 (CH syn-459), 82.3 (CH syn-459), 81.3 (CH anti-459), 80.9 (CH
anti-459), 78.6 (CH syn-459), 78.2 (CH anti-459), 77.2 (CH syn-459), 61.9 (CH2 syn-
459), 60.7 (CH2 anti-459), 18.7 (CH3 anti-459), 18.3 (CH3 syn-459); HRMS (CI+) found
[M+H]+ 149.0821; C6H13O4 requires 149.0808; [α]D (20 °C) = –28.7 (MeOH, C = 3.3);
Data for syn-459 accordance with the literature.253
(3aR,4R,6aS)-4-((E)-(2,2-Dimethylhydrazono)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-2-one (467)
A solution of tetrahydrofuran anti-433a (316 mg, 1.82 mmol) in DMC (9.1 mL) was
treated with K2CO3 (25 mg, 10 mol%) and the reaction mixture heated at reflux for 16 h.
The reaction mixture was then allowed to cool to RT before it was filtered through a silica
plug (elution with Et2O) and the filtrate concentrated in vacuo to give the carbonate 467
as a colorless oil (364 mg, 1.82 mmol, 100%); Rf = 0.71 (1:1 acetone:hexane); νmax
(film/cm–1) 2863m (C-H), 1798s (C=O), 1587s, 1468s, 1444s; 1H NMR (600 MHz;
CDCl3) 6.35 (1H, d, J = 2.6, N=CH), 5.63 (1H, d, J = 6.8, CHCHCH2), 5.18 (1H, d,
J = 6.8, 3.8, CHCH2), 4.90 (1H, d, J = 2.6, N=CHCH), 4.12 (1H, d, J = 11.5, CHH’), 3.76
(1H, dd, J = 11.5, 3.8, CHH’), 2.82 (6H, s, N(CH3)2); 13C NMR (150 MHz; CDCl3) 154.8
(C(O)), 127.0 (N=CH), 82.2 (N=CHCH), 81.4 (CHCHCH2), 80.9 (CHCH2), 70.5
(CH2O), 42.5 (N(CH3)2); HRMS (EI+) found [M]+ 200.0796; C8H12N2O4 requires
200.0792; [α]D (20 °C) = +122.2 (MeOH, C = 1.0).
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(E)-2-(((3aR,4S,6aS)-2,2-Dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)methylene)-1,1-dimethylhydrazine (syn-442) and (E)-2-(((3aR,4R,6aS)-2,2-
Dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylene)-1,1-dimethylhydrazine
(anti-442)245
A stirring solution of tetrahydrofuran anti-443a (154 mg, 0.885 mmol) in acetone
(4.4 mL) was treated with (MeO)2CMe2 (0.89 mL) and PTSA.H2O (34 mg, 0.18 mmol,
20 mol%) at RT and the reaction stirred at RT for 24 h. The reaction was then quenched
with aq. sat. NaHCO3 and filtered through a silica plug, eluting with acetone. The filtrate
was concentrated in vacuo to give acetonide 442 as a colorless oil (182 mg, 0.850 mmol,
96%, syn:anti = 60:40); Rf = 0.45 and 0.35 (1:4 acetone:hexane); νmax (film/cm–1) 2934s
(C-H), 1689s, 1597s, 1470s; HRMS (ESI+) found [M+H]+ 215.1398; C10H19N2O3 requires
215.1396; [α]D (20 °C) = +103.0 (MeOH, C = 1.0); data in accordance with the
literature.245
Acetonide syn-442: 1H NMR (600 MHz; MeOH-d4) 6.57 (1H, d, J = 6.8, N=CH), 4.86–
4.82 (1H, m, CHCH2), 4.71–4.66 (1H, m, CHCHCH2), 4.00 (1H, dd, J = 6.8, 3.9,
N=CHCH), 3.94 (1H, d, J = 10.5, OCHH’), 3.53 (dd, J = 10.5, 3.7, OCHH’), 2.81 (6H,
s, N(CH3)2), 1.46 (3H, s, C(CH3)), 1.31 (3H, s, C(CH3)); 13C NMR (150 MHz; MeOH-
d4) 132.1 (C=N), 113.2 (C(CH3)2), 83.7 (N=CHCH), 83.3 (CHCHCH2), 82.7 (CHCH2),
73.6 (OCH2), 42.8 (N(CH3)2), 26.3 (CCH3), 24.7 (CCH3); data in accordance with the
literature.245
Acetonide anti-442: 1H NMR (600 MHz; MeOH-d4) 6.50 (1H, d, J = 4.3, N=CH), 4.97
(1H, d, J = 6.0, CHCHCH2), 4.81 (1H, dd, J = 6.0, 4.3, CHCH2), 4.54 (1H, d, J = 4.3,
N=CHCH), 3.86 (1H, d, J = 10.5, CHH’), 3.75 (1H, d, J = 10.5, 4.3, CHH’), 2.77 (6H, s,
N(CH3)2), 1.46 (3H, s, C(CH3)), 1.32 (3H, s, C(CH3)); 13C NMR (150 MHz; MeOH-d4)
132.5 (C=N), 113.4 (C(CH3)2), 85.1 (CH), 84.4 (CH), 82.4 (CH), 73.0 (OCH2), 42.8
(N(CH3)2), 26.7 (CCH3), 25.0 (CCH3); data in accordance with the literature.245
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tert-Butyl (((2R,3S,4S)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)carbamate (469)
A stirring solution of tetrahydrofuran anti-443a (100 mg, 0.57 mmol) in CPME (2.9 mL)
was treated with a solution of Boc2O (313 mg, 1.44 mmol) in CPME (2.9 mL) at RT. The
resulting solution was then treated with Pd(OH)2 (20% on carbon, 163 mg) and the
reaction was placed under an atmosphere of hydrogen gas (1 atm). The reaction was
stirred at RT for 24 h before it was filtered through Celite and the filtrate concentrated in
vacuo to give the crude product, which was purified by flash column chromatography
(100:90 hexane:acetone) to give carbamate 469 as a colorless oil (80 mg, 0.34 mmol,
60%); Rf = 0.40 (100:90 hexane:acetone); νmax (film/cm–1) 3362s br. (O-H, N-H), 2977s
(C-H), 1688s (C=O), 1523s, 1367s, 1251s; 1H NMR (600 MHz; CDCl3) 5.21–5.17 (1H,
m, NH), 4.22–4.19 (1H, m, OCH2CH), 4.05 (1H, dd, J = 10.2, 4.9, OCHH’), 3.84–3.80
(1H, m, NCH2CHCH), 3.78–3.75 (2H, m, OCHH’, NCH2CH), 3.42–3.36 (1H, m,
NCHH’), 3.31–3.26 (1H, m, NCHH’), 1.41 (9H, s, C(CH3)3); 13C NMR (150 MHz;
CDCl3) 157.0 (C(O)), 80.6 (NCH2CH), 80.2 (CMe3), 73.2 (OCH2), 73.1 (NCH2CHCH),
71.2 (OCH2CH), 42.0 (NCH2), 28.5 (C(CH3)3); HRMS (ES+) found [M+H]+ 234.1339;
C10H20NO5 requires 234.1341; [α]D (20 °C) = +32.9 (MeOH, C = 1.0).
(E)-2-(((3aR,4R,6aS)-2,2-Di-tert-butyltetrahydrofuro[3,4-d][1,3,2]dioxasilol-4-
yl)methylene)-1,1-dimethylhydrazine (474)
A solution of tetrahydrofuran anti-443a (312 mg, 1.79 mmol) in DMC (18 mL) at 0 °C
was treated with 2,6-lutidine (0.63 mL, 580 mg, 5.4 mmol) and di-tert-butylsilyl
bis(trifluoromethanesulfonate) (0.64 mL, 870 mg, 2.0 mmol). The resulting mixture was
stirred at 0 °C for 1 h before the reaction was quenched with water (1 drop) and filtered
through a silica plug, eluting with Et2O. The filtrate was concentrated in vacuo to give
the crude product, which was purified by flash column chromatography (10:90
EtOAc:hexane) to give silyl ether 474 as a colorless oil (269 mg, 0.857 mmol, 48%);
Rf = 0.44 (20:80 EtOAc:hexane); νmax (film/cm–1) 2930s (C-H), 2856s (C-H), 1594w,
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1472s; 1H NMR (600 MHz; CDCl3) 6.44 (1H, d, J = 4.0, N=CH), 4.87 (1H, dd, J = 6.6,
2.6, CHCHCH2), 4.75–4.70 (1H, m, CHCH2), 4.51–5.49 (1H, m, N=CHCH), 3.94 (1H,
dd, J = 10.4, 5.3, CHH’), 3.84 (1H, dd, J = 10.4, 3.0, CHH’), 2.80 (6H, s, N(CH3)2), 1.09
(9H, s, C(CH3)3), 1.04 (9H, s, C(CH3)3); 13C NMR (150 MHz; CDCl3) 131.3 (C=N), 85.2
(CH), 81.4 (CH), 79.3 (CH), 73.9 (CH2), 42.7 (N(CH3)2), 27.4 (C(CH3)3), 26.9 (C(CH3)3),
21.9 (C(CH3)3), 20.1 (C(CH3)3); HRMS (EI+) found [M]+ 314.2022; C15H30N2O3Si
requires 314.2020; [α]D (20 °C) = +78.0 (MeOH, C = 1.0).
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6.4. Crystallography Data
All the information in the section was provided by Dr Dejan-Krešimir Bučar and Dr Laure 
Benhamou.
General Experimental Procedure: Single X-ray diffraction data were collected using an
Agilent SuperNova (Dual Source) single crystal X-ray diffractometer equipped with an
Atlas CCD Detector. The diffraction experiment was conducted at 150 K using CuKα
radiation (λ = 1.54184 Å). Data collection and processing was accomplished using the
CrysAlisPro program.285 Empirical absorption correction was performed using spherical
harmonics implemented in the SCALE3 ABSPACK scaling algorithm.285 Structure
solution and refinement were accomplished using SHELXS-97 and SHELXL-97,
respectively.286 The structure was solved using direct methods. All non-hydrogen atoms
were refined anisotropically, while hydrogen atoms associated with carbon and oxygen
atoms were refined isotropically in geometrically constrained positions.
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Table A. General and crystallographic data for endo-330e.
Empirical formula C17H17NO4
Formula weight / g mol-1 299.32
Temperature / K 150.00(10)
Crystal system triclinic
Space group Pī 
a / Å 7.2630(2)
b / Å 10.8264(3)
c / Å 19.9792(4)
α / ° 78.833(2)
β / ° 89.832(2)
γ / ° 71.899(2)
Volume / Å3 1462.22(6)
Z 4
ρcalc/ g cm-3 1.36
μ / mm-1 0.801
F(000) 632.0
Crystal size / mm3 0.41 × 0.17 × 0.07
Radiation CuKα (λ = 1.5418 Å)
2θ range for data collection / ° 8.78 to 133.2
Index ranges -8 ≤ h ≤ 8, –12 ≤ k ≤ 12, –23 ≤ l ≤ 23 
Reflections collected 22496
Independent reflections 5146 [Rint = 0.0363, Rsigma = 0.0235]
Data / restraints / parameters 5146 / 0 / 400
Goodness-of-fit on F2 0.998
Final R indexes [I ≥ 2σ(I)] R1 = 0.0393, wR2 = 0.0975
Final R indexes [all data] R1 = 0.0453, wR2 = 0.1016
Largest diff. peak/hole / e Å-3 0.23 / –0.20
CCDC deposition number 1035038
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Table B. General and crystallographic data for exo-330e.
Empirical formula C17H17NO4
Formula weight / g mol-1 299.32
Temperature / K 150.00(10)
Crystal system monoclinic
Space group P21/c
a / Å 6.64710(10)
b /Å 14.1775(2)
c /Å 15.4276(2)
α /° 90
β /° 97.1400(10)
γ /° 90
Volume / Å3 1442.61(4)
Z 4
ρcalc / g cm-3 1.378
μ / mm-1 0.812
F(000) 632.0
Crystal size / mm3 0.26 × 0.15 × 0.09
Radiation CuKα (λ = 1.5418 Å)
2θ range for data collection / ° 8.5 to 133.18
Index ranges -7 ≤ h ≤ 7, –16 ≤ k ≤ 16, –18 ≤ l ≤ 18 
Reflections collected 20945
Independent reflections 2532 [Rint = 0.0455, Rsigma = 0.0194]
Data / restraints / parameters 2532 / 0 / 201
Goodness-of-fit on F2 1.063
Final R indexes [I ≥ 2σ(I)] R1 = 0.0372, wR2 = 0.0976
Final R indexes [all data] R1 = 0.0402, wR2 = 0.1007
Largest diff. peak/hole / e Å-3 0.24 / –0.19
CCDC deposition number 1035039
Chapter IV 259
Table C. General and crystallographic data for anti-443a.
Empirical formula C7H14N2O3
Formula weight / g mol-1 174.2
Temperature / K 150.00(10)
Crystal system orthorhombic
Space group P212121
a / Å 5.08850(10)
b / Å 17.8742(3)
c / Å 19.7947(3)
α / ° 90
β / ° 90
γ / ° 90
Volume / Å3 1800.38(5)
Z 8
ρcalc/ g cm-3 1.285
μ / mm-1 0.843
F(000) 752
Crystal size / mm3 0.31 × 0.04 × 0.03
Radiation CuKα (λ = 1.5418 Å)
Index ranges -3 ≤ h ≤ 6, -21≤ k ≤ 16, -23 ≤ l ≤ 17
Reflections collected 4258
Unique reflections 2812
Rint 0.0197
Reflections with I ≥ 2σ(I) 2639
Number of parameters 233
Final R indexes [I ≥ 2σ(I)] R1 = 0.0281, wR2 = 0.0659
Final R indexes [all data] R1 = 0.0309, wR2 = 0.0677
Largest diff. peak/hole /
e Å-3 0.160 / -0.138
CCDC deposition number 1411520
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Abstract: (Cyclooctadiene)(pentamethylcyclopenta-
diene)ruthenium chloride [Cp*RuCl ACHTUNGTRENNUNG(cod)] has been
used to catalyze the regioselective cyclization of
amide-tethered diynes with monosubstituted alkynes
to give polysubstituted isoindolinones. Notably, the
presence of a trimethylsilyl group on the diyne gen-
erally led to complete control over the regioselectivi-
ty of the alkyne cyclotrimerization. The cyclization
reaction worked well in a sustainable non-chlorinat-
ed solvent and was tolerant of moisture. The opti-
mized conditions were effective with a diverse range
of alkynes and diynes. The 7-silylisoindolinone prod-
ucts could be halogenated, protodesilylated or ring
opened to access a range of usefully functionalized
products.
Keywords: alkynes; amide tether; cyclotrimerization;
isoindolinones; ruthenium; trimethylsilyl group
Introduction
Substituted isoindolinones have recently generated
considerable interest because of their diverse biologi-
cal activities, including the inhibition of angiogene-
sis,[1] tumour necrosis factor production,[2] MDM2-p53
protein-protein interactions,[3] hypoxia-inducible
factor-1a[4] and histone deacetylase.[5] The majority of
existing protocols for isoindolinone synthesis require
the construction of a g-lactam adjacent to a pre-
formed aromatic core.[6] Recent examples include the
one-pot transformation of 2-halobenzaldimines into
chiral 3-substituted isoindolinones and the Ni-mediat-
ed cyclization of N-benzoyl aminals in the presence of
a stoichiometric Lewis acid.[7,8] However, the inevita-
ble limitation of these approaches is the accessibility
of the arene starting material itself. The synthesis of
polysubstituted arenes is often non-trivial, frequently
requiring numerous steps, the use of protecting group
strategies and/or functional group interconversions.
The transition metal-catalyzed [2+2+2] cyclotrime-
rization of alkynes is emerging as an elegant, atom ef-
ficient and convergent approach to the synthesis of
highly substituted arenes.[9] The strategy allows for
the regioselective synthesis of compounds that would
be extremely difficult to make via traditional aromatic
chemistry. The regioselectivity of a cyclotrimerization
is normally controlled by tethering two or three of
the alkyne components together, so this strategy is
best suited to the synthesis of bicyclic and tricyclic
ring systems. This allows for the assembly of substitut-
ed multiple-ring aromatic compounds from alkyne
precursors in a single step.
Yamamoto and co-workers have previously recog-
nized the potential of alkyne cyclotrimerizations for
the synthesis of isoindolinones bearing substituents on
the aromatic ring.[10] They reported the cyclization of
amide-tethered diynes 1 with monoynes 2 using
Cp*RuCl ACHTUNGTRENNUNG(cod) 3 as the catalyst to give regioisomeric
isoindolinones 4 and 5 (Scheme 1). In general the re-
gioselectivity of the cyclotrimerization was poor to
moderate, with the exception of a single example
bearing a methyl group at R1. In addition, a significant
limitation of this method is the use of 1,2-dichloro-
ethane (DCE) as solvent, a substance which is poten-
tially detrimental to human health and is generally
avoided within industry.[11]
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The aim of this study was to explore the regioselec-
tive synthesis of polysubstituted isoindolinones using
more industrially viable reaction conditions, to estab-
lish the general applicability of the reaction, and to
develop the synthetic potential of the cyclized prod-
ucts. On the basis of previously reported cyclizations
we envisaged that the introduction of a trimethylsilyl
group at R1 in diyne 1 would direct the regioselectivi-
ty of the cyclisation reaction effectively with a broad
range of monoynes.[10,12] The arylsilane unit present in
the isoindolinone product could then be transformed
using standard chemical techniques to access a variety
of 7-substituted derivatives.
Results and Discussion
Diyne Synthesis
Initially several amide-tethered diynes 6 were pre-
pared by the coupling of propargylic amines 7 with 3-
(trimethylsilyl)propiolic acid 8, via the corresponding
acid chloride (Scheme 2).[13] Where necessary the cor-
responding amines were prepared using literature
procedures.[14–15]
Optimization
Various conditions were screened for the cyclotrimeri-
zation of diyne 6a with 1-hexyne 9a to form isoindoli-
none 10a, and the results are summarized in Table 1.
All reactions were conducted for 16 h at which point
Scheme 2. Synthesis of diynes 6a–e.
Scheme 1. Isoindolinone synthesis as reported by Yamamoto
and co-workers.[10]
Table 1. Optimization of the cyclotrimerization of 6a and 9a.
Entry Solvent Equivalents of 9a Catalyst Catalyst loading [mol%] Conversion[a,b] [%] Ratio 10a :11[a]
1 PhMe[c] 4 RhCl ACHTUNGTRENNUNG(PPh3)3 5 <5 –
2 PhMe[c] 4 Co2(CO)8 10 <5 –
3 CH2Cl2
[c] 4 Grubbs I 5 5 n.d.
4 DCE[c] 4 Cp*RuCl ACHTUNGTRENNUNG(cod) 1 5 n.d.
5 neat[d] 4 Cp*RuCl ACHTUNGTRENNUNG(cod) 1 50 3:2
6 neat[d] 4 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 100 3:1
7 CPME 4 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 100 5:1
8 CPME 4 Cp*RuCl ACHTUNGTRENNUNG(cod) 1 60 4:1
9 CPME 2 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 100 2:1
10[e] CPME 4 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 100 8:1
11[e] CPME 2 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 100 9:1
12[e] CPME 1.1 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 100 5:2
13[e] MTBE 2 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 100 5:1
14[e] 2-MeTHF 2 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 90 5:1
15[e] CPME/10% water 2 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 70 3:1
16 water 4 Cp*RuCl ACHTUNGTRENNUNG(cod) 3 30 3:1
[a] Determined by analysis of the crude 1H NMR spectrum.
[b] Conversion of 6a into 10a and 11 (determined by crude 1H NMR without the use of an internal standard).
[c] Solvent dried over activated 4  molecular sieves and degassed.
[d] Cp*RuCl ACHTUNGTRENNUNG(cod) 3 was added to the reaction mixture at 0 8C, which was then allowed to reach room temperature.
[e] Diyne 6a in CPME was added dropwise over 3 h to a stirring solution of 9a and 3 in CPME.
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conversion and selectivity were determined by analy-
sis of the crude 1H NMR spectrum.
The cyclotrimerization of diyne 6a and alkyne 9a
was examined using four different literature proce-
dures. Neither RhCl ACHTUNGTRENNUNG(PPh3)3 nor Co2(CO)8 were effec-
tive in catalyzing the alkyne cyclotrimerization, with
no measurable conversion of diyne 6a (entries 1 and
2).[16] Treating diyne 6a with 5 mol% Grubbs first
generation catalyst and 4 equivalents of 1-hexyne 9a
in dried, degassed CH2Cl2 resulted in formation of the
target isoindolinone 10a with only 5% conversion
(entry 3).[17] Treating diyne 6a with 1-hexyne 9a and
1 mol% Cp*RuCl ACHTUNGTRENNUNG(cod) in dried, degassed DCE also
gave isoindolinone 10a, again with 5% conversion of
6a (entry 4).[10] Given that the latter procedure gave
a similar conversion with a lower catalyst loading,
Cp*RuCl ACHTUNGTRENNUNG(cod) was selected for subsequent optimiza-
tion.
Interestingly, treating diyne 6a with 1-hexyne 9a
and 1 mol% Cp*RuCl ACHTUNGTRENNUNG(cod) with no solvent (neat) at
0 8C gave isoindolinone 10a with a 50% conversion
(entry 5). This suggests that using DCE as a solvent
for this reaction is actually detrimental. In addition to
the desired isoindolinone 10a, dimer 11 was also
formed as a significant by-product.[12]
Crucially, regioisomeric cyclotrimerization product
12 was not observed at all in the crude 1H NMR spec-
trum. The reaction under neat conditions reached
completion within 16 h when 3 mol% of catalyst 3
was used, and with a significant reduction in the pro-
portion of homo-coupled product 11 produced
(entry 6).
We were interested in using cyclopentyl methyl
ether (CPME) as a solvent for this cyclization as it
has been recently established as a safer and more en-
vironmentally benign alternative to many traditional
organic solvents.[18] As shown in entry 7, when the re-
action was conducted in CPME with 3 mol% of cata-
lyst 3, diyne 6a was completely consumed within 16 h
and an improved selectivity for the cross-coupled
product 10a was observed. By comparison, the same
reaction using only 1 mol% catalyst resulted in a com-
parable level of selectivity, but a lower conversion
(entry 8). Reducing the number of equivalents of 1-
hexyne 9a to two resulted in the complete consump-
tion of diyne 6a but also a significantly increased level
of homo-coupling.
In an attempt to minimise the formation of dimer
11, diyne 6a was added dropwise over 3 h to a stirring
solution of monoyne 9a and catalyst 3,[19] and this
proved to be highly effective (entry 10). When using
the 3-hour dropwise addition it was possible to reduce
the number of equivalents of 1-hexyne 9a from four
to two with no increase in homo-coupling (entry 11).
A further reduction to 1.1 equivalents of 1-hexyne 9a
did result in increased homo-coupling, but target iso-
indolinone 10a was still the major product (entry 12).
The cyclization of 6a and 9a was also effective when
2-MeTHF or MTBE were used as solvents, but in
both cases a greater degree of homo-coupling of 6a
was observed than with CPME (entries 13 and 14).
The reaction proved to be relatively water tolerant,
with a significant conversion and a reasonable selec-
tivity observed when the reaction was conducted in
the presence of 10% water (entry 15). Cyclization was
even observed when the reaction was conducted in
water as solvent (entry 16). This is important as it
could enable the extension of the reaction to aqueous
conditions for reactions of water-soluble substrates.
Following the optimization study the conditions de-
scribed in entry 11 were taken as the “optimized” cy-
ACHTUNGTRENNUNGclization conditions as they required a reduced excess
of monoyne and minimized the formation of dimer
11. Crucially this protocol did not require the CPME
solvent to be either degassed or dried. This, together
with the environmental benefits of CPME, makes this
reaction a very practical method for the synthesis of
isoindolinones. Dimer 11 could be readily separated
from the desired product by flash column chromatog-
raphy, and the optimized conditions described in
entry 11 gave the target isoindolinone 10a in 81% iso-
lated yield (Table 2, entry 1). This reaction was also
scaled up to a 500-mg scale and isoindolinone 10a was
isolated in 66% yield (428 mg product).
Monoyne Scope
The cyclization of 6a was then examined with a variety
of monoynes using the optimized conditions described
above to determine how robust the reaction was for
a range of different substrates. Diyne 6a cyclized with
a wide range of monynes 9 as detailed in Table 2.
Crucially, no evidence for the formation of regioiso-
meric isoindolinones was observed in any of the cycli-
zation reactions. Alkyl monoynes 9a–e cyclized effi-
ciently with 6a to give the corresponding isoindoli-
nones 10a–e in good isolated yield (entries 1–5, 66–
83%). Little formation of the undesired dimer 11 was
observed, except in the reaction of tert-butylacetylene
9b, presumably due to high steric crowding about the
monoalkyne. Carbamate 9f cyclized with 6a to give
10f in reasonable yield and with modest levels of
homo-coupling (entry 6).
Ether 9g and acetal 9h both underwent cyclotrime-
rization with 6a, but with the formation of significant
quantities of dimer 11. Propargylic alcohol 9i and me-
thoxyacetylene 9j both failed to cyclize with diyne 6a,
with only starting material being recovered in both
cases. In addition to aliphatic monoynes, diyne 6a cy-
clized effectively with a broad range of aromatic mon-
oynes. Electron-rich (entries 12, 13, 17 and 18), elec-
tron-poor (entry 16) and sterically hindered substrates
(entries 12 and 14) could all be tolerated and products
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were isolated in good yields (79–93%) with low levels
of diyne homo-coupling. For most of these examples
longer reaction times (up to 24 h), and in some cases
higher catalyst loadings, were required to drive the re-
action to completion. However the reactions with
ortho-substituted arylacetylenes 9l and 9n reached
Table 2. Reaction of diyne 6a with a selection of monoynes 9.[a]
Entry Alkyne 9 3 [mol%] Time [h] Product 10 Yield of 10 [%][b] Ratio 10 :11[c]
1 3 16 10a 81 9:1
2 3 16 10b 66 2:1
3 3 16 10c 81 9:1
4 3 16 10d 81 6:1
5 3 16 10e 83 8:1
6 5 24 10f 63 2:1
7 3 16 10g 56 3:2
8 3 24 10h 43 4:5
9 3 16 – 0 –
10 3 16 – 0 –
11 4 24 10k 83 6:1
12 3 16 10l 93 >10:1
13 4 24 10m 83 6:1
14 3 16 10n 80 8:1
15 3 24 10o 83 5:1
16 3 24 10p 79 5:1
17 5 24 10q 79 6:1
18 10 24 10r 79 7:1
19 3 16 – 0 -
20 20 24 10t 50 2:1
21 3 16 10u 0 -
22 5 24 10v 55 3:1
[a] Reaction conditions: A solution of 6a in CPME was added dropwise to a stirring solution of 9 and 3 in CPME over 3 h at
room temperature.
[b] Isolated yield.
[c] Determined by the analysis of crude 1H NMR spectra.
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completion within 16 h with only 3 mol% of catalyst 3
(entries 12 and 14). Monoyne 9l also cyclized with ex-
ceptionally high selectivity for the cross-coupled prod-
uct 10l over dimer 11, whereas ortho-bromo alkyne
9n gave a slightly lower selectivity. Although Yama-
moto et al. have reported the [2+2+2] cycloaddition
of an electron-deficient nitrile and an amide-tethered
diyne to give a pyridine,[20] in our reaction nitrile 9s
failed to cyclize with 6a to form any product via reac-
tion of either the alkyne or the nitrile (entry 19).
Only a limited quantity of 11 (~10%) was formed in
this reaction suggesting that 9s may inhibit the cata-
lyst. Heterocycle-containing alkyne 9t cyclized effec-
tively with 6a to give the corresponding 2-pyridyl de-
rivative 10t in a moderate 50% yield (entry 20). In
contrast N-methylimidazole 9u failed to cyclize with
6a, with unreacted starting material being recovered
(entry 21). Alkyne 9v cyclized with 6a to give bora-
mide 10v in reasonable yield (entry 22).[21]
Diyne Scope
The cyclization of amide-tethered diynes bearing dif-
ferent N-substituents was examined and the results
are summarized in Table 3. N-t-Bu diyne 6b proved to
be an excellent substrate for the synthesis of 5,7-sub-
stituted isoindolinones. Treatment of 6b with 1-
hexyne 9a under the optimized reaction conditions
gave isoindolinone 13a in 84% yield with little forma-
tion of the dimer 14a (entry 1). The cyclization of 6b
with 9k required 4 mol% 3 and 24 h to reach comple-
tion, giving isoindolinone 13b in 89% yield (entry 2).
The reaction of 6b with 2-ethynyltoluene 9l proceeded
in 94% yield without an elevated reaction time or an
increased loading of catalyst 3, and also occurred with
very little formation of dimer 14a (entry 3).
The N-H diyne 6c proved less effective for the syn-
thesis of isoindolinones, with the cyclization of 6c and
1-hexyne 9a requiring 10 mol% Cp*RuCl ACHTUNGTRENNUNG(cod) 3 and
24 h to achieve a 90% conversion of diyne 6c
(entry 4). Isoindolinone 13d was only formed in
modest yield (51%) and significant formation of
dimer 14b was observed. Under the same conditions
the cyclization of 2-tolylacetylene 9l and N-H diyne
6c gave the desired isoindolinone 13e in a slightly
higher yield with 90% conversion. Again, the reaction
with 2-ethynyltoluene 9l proved to be unusually selec-
tive, with 13e and 14b formed in the ratio 7:1
(entry 5). The lack of a sterically bulky N-substituent
is presumably responsible for both the reduced reac-
tivity of N-H diyne 6c with monoynes and the high
level of diyne homo-coupling observed in these reac-
tions.
The cyclization of amide-tethered diynes bearing
different alkyne substituents was also explored
(Table 4). With doubly substituted diynes 6d and 6e,
no homo-coupling of the diyne was observed and
dropwise addition of the diyne to the reaction
was unnecessary (entries 1–3). With 10 mol% of
Cp*RuCl ACHTUNGTRENNUNG(cod), methyl-substituted diyne 6d cyclized
with 1-hexyne 9a to form a 9:1 mixture of regioiso-
meric isoindolinones 15a and 16a (entry 1).
Ethyl-substituted diyne 6e reacted with 1-hexyne
11a with lower regioselectivity, giving a 2:1 mixture of
isoindolinones 15b and 16b (entry 2). However, diyne
6e cyclized with 2-ethynyltoluene 9l, to give a 5:1 mix-
ture of isoindolinones 15c and 16c (entry 3). Interest-
ingly, the presence of diastereotopic benzylic protons
in the 1H NMR spectrum suggests that isoindolinone
Table 3. Cyclizations involving diynes with different N-substituents.[a]
Entry R1 R2 3 [mol%] Time [h] Product 13 Yield of 13 [%][b] Ratio of 13 :14[c]
1 t-Bu 6b n-Bu 9a 3 16 13a 84 10:1
2 t-Bu 6b Ph 9k 4 24 13b 89 >10:1
3 t-Bu 6b o-tolyl 9l 3 16 13c 94 >10:1
4 H 6c n-Bu 9a 10 24 13d 51 (90%[d]) 2:1
5 H 6c o-tolyl 9l 10 24 13e 62 (90%[d]) 7:1
[a] Reaction conditions: a solution of 6 in CPME was added dropwise to a stirring solution of 9 and 3 in CPME over 3 h at
room temperature.
[b] Isolated yield.
[c] Determined by the analysis of crude 1H NMR spectra.
[d] Conversion of diyne 6 to 13/14 (determined by crude 1H NMR without the use of an internal standard).
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15c is a chiral molecule, presumably due to restricted
rotation about the hindered biaryl unit.
The dependence of the cyclotrimerization on an
SiMe3 regiodirecting group was also investigated.
Diyne 6f with a terminal methyl substituent reacted
with 1-hexyne 9a under the optimized cyclization con-
ditions to give isoindolinone 15d in 85% yield
(entry 4). Crucially, there was no trace of the regioiso-
meric isoindolinone 16d by crude 1H NMR. Similarly,
diyne 6f cyclized with 2-ethynyl toluene 9l to give iso-
indolinone 15e in 94% yield, with no evidence for the
formation of regioisomer 16e (entry 5).
Functional Group Manipulation of Cyclized Products
Conversion of the cyclized isoindolinone products
into a number of synthetically interesting motifs was
examined. Isoindolinone 10a was converted to aryl
halides 17 and 18, in 79% and 90% yields, respective-
ly, via an ipso substitution of the silyl group
(Scheme 3).[22] Treatment of N-t-butylisoindolinone
13a with triflic acid resulted in a simultaneous depro-
tection of the lactam and protodesilylation within
30 min to give N-H isoindolinone 20 in good yield.[23]
Alternatively, treatment of 13a with iodine mono-
chloride followed by deprotection with triflic acid
gave 7-iodoisoindolinone 19 in 83% yield. Thus, an N-
t-Bu diyne can be used as an indirect method for the
synthesis of N-H isoindolinones via this acid-mediated
deprotection.
It was also possible to access a tetrasubstituted
monocyclic benzene. Treatment of N-H isoindolinone
19 with di-tert-butyl dicarbonate gave N-Boc isoindo-
linone 21, which could be reduced with lithium boro-
hydride to form N-Boc protected amino alcohol 22,
Table 4. Cyclizations involving diynes with different alkyne substitutents.[a]
Entry Diyne 6 R1 R2 R3 3 [mol%] Time [h] Isolated products Yield of (15+16) [%][b] Ratio of 15 :16[c]
1 6d SiMe3 Me n-Bu 9a 10 24 15a/16a 69 9:1
2 6e SiMe3 Et n-Bu 9a 10 24 15b/16b 57 2:1
3 6e SiMe3 Et o-tolyl 9l 10 24 15c/16c 73 5:1
4[d] 6f Me H n-Bu 9a 3 16 15d[e] 85 >20:1
5[d] 6f Me H o-tolyl 9l 3 16 15e 94 >20:1
[a] Reaction conditions: A solution of 6 in CPME was added to a stirring solution of 9 and 3 in CPME over 1 min at room
temperature.
[b] Isolated yield.
[c] Determined by the analysis of crude 1H NMR spectra.
[d] Diyne 6f in CPME was added dropwise over 3 h to a solution of 9 and 3 in CPME.
[e] Evidence of limited homo-coupling of 6f was observed in the crude 1H NMR spectrum.
Scheme 3. Synthesis of usefully functionalized isoindoli-
nones.
Scheme 4. Synthesis of a tetrasubstituted benzene ring.
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together with cyclic aminol 23, in a combined yield of
78% (Scheme 4). The preparation of mono-cyclic sub-
stituted arenes via tethered alkyne cyclotrimerizations
has little precedent and such systems are somewhat
difficult to access via traditional aromatic substitution
reactions, highlighting the value of this strategy.[24]
Conclusions
In summary, we have demonstrated the regioselective
synthesis of polysubstituted isoindolinones via the
Cp*RuCl ACHTUNGTRENNUNG(cod)-catalyzed cyclotrimerization of amide-
tethered diynes and monoynes. This cyclization is ef-
fective with a wide range of structurally diverse mon-
oynes and was demonstrated to work with a variety of
different diynes. We have also demonstrated that the
cyclization products could be converted into a range
of functionalized isoindolinones and a tetrasubstituted
benzene derivative.
Experimental Section
Full experimental details are provided in the Supporting In-
formation.
Cp*RuCl ACHTUNGTRENNUNG(cod)-Catalyzed Cyclization of a Diyne and
a Monoyne
A solution of 6a (500 mg, 1.86 mmol) in CPME (11 mL) was
added dropwise over 3 h to a stirring solution of 1-hexyne
9a (0.43 mL, 300 mg, 3.7 mmol) and Cp*RuCl ACHTUNGTRENNUNG(cod) (21 mg,
3 mol%) in CPME (7.7 mL) at room temperature. The reac-
tion mixture was stirred for a further 13 h before being fil-
tered through a silica pad, eluting with ethyl acetate. The
solvent was removed under vacuum to give the crude prod-
uct, which was purified by flash column chromatography
(13:1 petrol:ethyl acetate) to give 2-benzyl-5-butyl-7-(trime-
thylsilyl)isoindolin-1-one 10a ; yield: 428 mg (1.22 mmol,
66%); Rf=0.36 (6:1 petrol:ethyl acetate); IR (film): nmax=
2955 (m, CH), 2930 (m, CH), 1688 (s, C=O), 1454 (m),
1409 cm1 (m); 1H NMR (600 MHz, DMSO-d6): d=7.34–
7.21 (7H, m, ArH), 4.68 (2H, s, CH2N), 4.24 (2H, s, CH2N),
2.60 (2H, t, J=7.7, ArCH2CH2), 1.51, (2H, m, ArCH2CH2),
1.26 (2H, m, CH2CH3), 0.83 (3H, t, J=7.4, CH2CH3), 0.34
[9H, s, SiACHTUNGTRENNUNG(CH3)3];
13C NMR (125 MHz, DMSO-d6): d=
168.5, 144.8, 142.1, 137.7, 136.9, 134.3, 134.0, 128.6, 127.6,
127.2, 123.7, 48.9, 45.4, 35.1, 33.2, 21.8, 13.7, 0.4; HR-MS
(EI+): m/z=351.2011 [M]+, C22H29ONSi requires 351.2013.
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Gold catalysed synthesis of 3-alkoxyfurans at
room temperature†
Matthew N. Pennell,a Robert W. Foster,a Peter G. Turner,b Helen C. Hailes,a
Christopher J. Tameb and Tom D. Sheppard*a
Synthetically important 3-alkoxyfurans can be prepared eﬃciently
via treatment of acetal-containing propargylic alcohols (obtained
from the addition of 3,3-diethoxypropyne to aldehydes) with 2 mol%
gold catalyst in an alcohol solvent at room temperature. The resulting
furans show useful reactivity in a variety of subsequent transformations.
Furans are important structural motifs which appear in a wide
array of natural products, biologically active compounds and
pharmaceuticals.1 They also have potential uses in the construction
of conjugated polymers for applications such as organic electronics.2
As a consequence, the synthesis of polysubstituted furans has
attracted considerable interest. Recent synthetic approaches
have included a number of transition-metal catalysed cyclisation
reactions3 mediated by a variety of catalysts4–8 including systems
based on palladium,4 rhodium,5 ruthenium6 and silver.7 Over
the past few years, the use of homogeneous gold catalysts for
facilitating the addition of nucleophiles to carbon–carbonmultiple
bonds has emerged as a very powerful synthetic method9 and a
number of gold-catalysed approaches to the synthesis of hetero-
cyclic aromatic rings,10 including simple furans,11 have been
reported. Simple 3-alkoxyfurans such as 3-methoxyfuran are
highly electron rich systems which show useful reactivity,12
and have found application in natural product synthesis13 as
well as in the construction of polysubstituted tetrahydrofurans.14
However, the chemistry of more complex 3-alkoxyfurans has not
been widely explored, largely as a consequence of their synthetic
inaccessibility.15 Herein, we describe a gold-catalysedmethod for the
synthesis of a wide variety of 3-alkoxyfurans from readily available
propargylic alcohols, via a process that allows straightforward varia-
tion of substituents both on the furan ring and the alkoxy group.
We have recently reported that the gold-catalysed rearrange-
ment of propargylic alcohols to enones (the Meyer–Schuster
rearrangement) proceeds at room temperature in toluene, in
the presence of a small amount of alcohol additive (MeOH or
EtOH).16 During the course of our study into the scope of this
reaction, we observed that attempted rearrangement of acetal-
containing propargylic alcohol 1a (Scheme 1, R1 = 4-CF3C6H4)
Scheme 1 Gold-catalysed synthesis of 3-ethoxyfurans and 3-methoxyfurans.
a 600 mg scale reaction. b Clean conversion of the aldehyde in propargylic
alcohol 1o into the dimethylacetal occurred under the reaction conditions.
a Department of Chemistry, University College London, 20 Gordon St, London,
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b GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage,
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† Electronic supplementary information (ESI) available: Experimental proce-
dures, spectroscopic data for all compounds and 1H and 13C NMR spectra for
novel compounds. See DOI: 10.1039/c3cc48290a
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gave a mixture of the expected enone 2a and 3-ethoxyfuran 3a,
where the alcohol additive had become incorporated.17 Given
the importance of polysubstituted furans in a wide variety of
applications, we sought to optimise this transformation.18
Pleasingly in ethanol furan 3a was formed in 89% yield with
complete selectivity. With these optimised conditions in hand, the
synthesis of a wide range of 3-ethoxyfurans and 3-methoxyfurans
was then explored. High yields (68–98%) of the corresponding
furans 3 and 4were obtainedwith a selection of propargylic alcohols
1a–1o. A wide range of aromatic groups can be incorporated at the
2-position of the furan ring, including electron deficient (1a, 1h,
1m), electron rich (1c, 1n) and sterically encumbered (1f ) benzene
rings, as well as thiophene (1i) and furan (1j) rings. Propargylic
alcohols containing aliphatic groups were also smoothly converted
into the corresponding 2-alkyl furans (1b, 1d, 1g, 1k). When
methanol was used as the reaction solvent, direct solvolysis to
generate the 3-methoxyfurans 4 occurred selectively over formation
of 3-ethoxyfurans 3, which could potentially occur via incorporation
of an ethoxy group derived from the acetal group. Many functional
groups including an alkene (1g), a nitrile (1h), a halide (1l), an ester
(1m), and even a free phenol (1n) were compatible with the reaction.
In the case of the aldehyde containing substrate 1o, concomitant
formation of the corresponding dimethylacetal 4o was observed.
The synthesis of furan 3b was performed on a 600 mg scale without
difficulty to give the alkyl furan in 85% yield.
The synthesis of more complex 3-alkoxyfurans was then
explored, by incorporation of other alcohols in the furan
formation reaction (Scheme 2). Primary (5b, 6b, 7b), secondary
(8b) and tertiary (9b) alcohols were incorporated eﬃciently,
including functionalised examples such as allyl alcohol (6b)
and ethylene glycol (7b).
It was also possible to construct a conjugated bis-(3-alkoxy-2-
furyl)benzene 4p in excellent yield by gold-catalysed reaction of
bis-propargylic alcohol 1p with MeOH (Scheme 3). The conjugated
triaryl unit in 4p is reminiscent of the oligofuran systems currently
being investigated for a variety of applications in organic electronics.2
Interestingly, propargylic alcohol 1q containing a nearby alkene unit
underwent tandem alcohol addition/ene-yne cyclisation to give fused
cyclohexylfurans 10 in excellent yield, with incorporation of the
alcohol on the cyclohexane ring. This provides a rapid assembly of
the fused furan–cyclohexane motif present in the terpene natural
product furadysin.19
Appropriate control experiments18 were performed to
demonstrate that the gold catalyst was required for the furan
formation, and that the reaction was unlikely to be catalysed by
Brønsted acid (Tf2NH)
20 or silver salts (AgNTf2).
16b,21 The furan
formation reaction potentially proceeds via regioselective gold-
catalysed addition of the alcohol to the alkyne to generate vinyl
gold intermediate 11 (Scheme 4). Loss of ethanol can then lead
to allenyl ether 12 which can undergo further activation by gold
to give oxonium ion 13. Oxonium ion 13 can then be attacked
by the nearby alcohol to generate dihydrofuran intermediate 14
which will evolve to the furan 3 after protodeauration and loss of
ethanol. An alternative pathway which proceeds via Lewis-acid
activation of the acetal to generate oxonium ion 15, followed by
conjugate addition of the alcohol to give 12, can also be
envisaged. However, this seems less likely given the fact that
the furan formation does not readily occur in the presence of a
simple Brønsted acid catalyst.18
The electron-rich 3-alkoxyfurans are highly reactive, and
care should be taken during the isolation of these compounds
in order to prevent decomposition of the products via atmo-
spheric oxidation.18 The reactivity of these furan systems can
nevertheless be readily harnessed in a variety of other useful
transformations (Scheme 5). Furan 4b readily underwent a
Diels–Alder reaction with N-methylmaleimide at room temperature
to generate the cycloadduct 16 as a 2 : 1 mixture of separable
stereoisomers in excellent overall yield (94%). Treatment of the
major diastereoisomer with TFA led to stereoselective cyclisation
to give the polycyclic ether 17 in 69% yield. Cyclohexyl fused
furan 10b gave tertiary amine 18 in 92% yield upon reaction with
Eschenmoser’s salt.12a We were also able to promote Claisen
rearrangement22 of the allyloxyfuran 6b by heating at reflux in
toluene to generate 2,2-disubstituted 3-furanone 19 in 80% yield.
Electrophilic bromination23 of furan 3e proceeded in 75% yield
Scheme 2 Incorporation of diﬀerent alcohols in the 3-alkoxyfuran for-
mation reaction with 1b.
Scheme 3 Synthesis of polycyclic furans.
Scheme 4 Possible mechanism for the gold-catalysed conversion of
propargylic alcohols 1 to furans 3.
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to give bromide 20, providing a useful building block for cross-
coupling reactions.
In summary, we have developed a mild gold-catalysed
method for the formation of synthetically useful 3-alkoxyfurans
which enables these versatile molecules to be prepared in two steps
from readily available aldehydes, alcohols and 3,3-diethoxypropyne.
The reaction gives access to a wide range of 3-alkoxyfurans in good
to excellent yield, and the products can be used in subsequent
transformations to access more complex structures.
We would like to acknowledge the Engineering and Physical
Sciences Research Council (EP/E052789/1 and EP/G040680/1)
and GlaxoSmithKline (CASE award, PhD studentship support
and supply of selected aldehydes) for supporting this work.
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Scheme 5 Selected reactions of the furan products.
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Irreversible endo-Selective Diels–Alder Reactions of Substituted
Alkoxyfurans: A General Synthesis of endo-Cantharimides
Robert W. Foster,[a] Laure Benhamou,[a] Michael J. Porter,[a] Dejan-Kresˇimir Bucˇar,[a]
Helen C. Hailes,[a] Christopher J. Tame,*[b] and Tom D. Sheppard*[a]
Abstract: The [4+2] cycloaddition of 3-alkoxyfurans with N-
substituted maleimides provides the first general route for
preparing endo-cantharimides. Unlike the corresponding re-
action with 3H furans, the reaction can tolerate a broad
range of 2-substitued furans including alkyl, aromatic, and
heteroaromatic groups. The cycloaddition products were
converted into a range of cantharimide products with prom-
ising lead-like properties for medicinal chemistry programs.
Furthermore, the electron-rich furans are shown to react
with a variety of alternative dienophiles to generate 7-oxabi-
cyclo[2.2.1]heptane derivatives under mild conditions. DFT
calculations have been performed to rationalize the activa-
tion effect of the 3-alkoxy group on a furan Diels–Alder reac-
tion.
Introduction
To access new areas of chemical space, medicinal chemistry
programs are increasingly focusing on fragments and scaffolds
with rigid 3D structures that contain a significant proportion of
sp3 carbon atoms.[1] This in turn presents a considerable syn-
thetic challenge as these molecules are generally not straight-
forward to synthesize, and late-stage derivatization is often far
from trivial. Further challenges reside in the control of relative
and absolute stereochemistry due to the presence of numer-
ous chiral centres. Current structural scaffolds of interest in-
clude strained small-ring molecules (cyclopropanes, oxetanes,
azetidines),[2] as well as fused (dihydrobenzofurans, indolines,
tetrahydroquinolines)[3] and bridged bicylic and polycyclic com-
pounds (bicyclopentanes, cubanes, etc).[4] Natural products
have also traditionally provided chemists with inspiration, as
they include bioactive molecules with complex 3D architec-
tures.[5] Many of these compounds, however, have high molec-
ular weights or are too structurally complex to be suitable for
use as scaffolds for medicinal chemistry applications. Neverthe-
less, smaller natural products contain ring systems that are po-
tentially ideal scaffolds for use in medicinal chemistry, provided
that efficient synthetic routes can be developed with appropri-
ate functional groups at positions on the central core.
The exo-cantharimide skeleton (Figure 1, derived from can-
tharidin, a natural product secreted by many species of blister
beetle with well-established cytotoxic activity)[6] has been ex-
ploited in a wide range of molecules with useful biological
properties. The motif is present in several cytotoxic com-
pounds,[7] antiplasmodial agents,[8] androgen receptor antago-
nists[9] and in a positive allosteric modulator of the metabo-
tropic glutamate receptor 4 (mGlu4).[10] More generally, the 7-
oxabicyclo[2.2.1]heptyl skeleton is found in a number of other
important natural products[11–13] and it has proved to be a val-
uable intermediate for synthetic chemists.[14–17] The properties
of the exo-cantharimide skeleton have been extensively ex-
plored with a range of N-substituted derivatives showing
useful biological properties. However, there are few methods
for the introduction of substituents around the 7-oxabicy-
clo[2.2.1]heptyl ring system.[18] Furthermore, the corresponding
endo-cantharimide scaffold has rarely been reported at all.[19]
The exo-cantharimide skeleton is typically prepared by the
[4+2] cycloaddition of furans and maleic anhydride, followed
by alkene reduction and condensation with an amine
(Scheme 1).[20] A curious feature of the cycloaddition reaction is
Figure 1. Natural product cantharidin and cantharimide.
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the high stereoselectivity for the exo diastereomer ob-
served, believed to be the result of a highly reversible cy-
cloaddition process which is operating under thermody-
namic control.[21,22] It is possible to access the corre-
sponding endo-cantharimide by a Diels–Alder reaction of
furan with maleimide;[23] however, experimental and com-
putational studies have shown that this reaction is under
thermodynamic control with the exo-cantharimide being
the thermodynamic product.[24] As a consequence, the
endo-adduct of maleimide and furan is known to rapidly
isomerize either in hot solvent or when exposed to visi-
ble light, which impedes both the isolation and applica-
tion of these compounds.[25] Another serious limitation of
furan Diels–Alder reactions is that any deactivating sub-
stituents on the furan have a profound effect on the
equilibrium position of the cyclization. For example, there
are no reported examples of the [4+2] cycloaddition of
2-aryl or 2-heteroaryl furans with dienophiles of any type.
There is a long tradition of activating dienes for Diels–
Alder reactions through the use of electron-donating
substituents, which are known to reduce the activation
energy for the cycloaddition reaction.[26] However, this is gener-
ally a kinetic effect and reducing the kinetic barriers to a ther-
modynamically controlled reaction would only increase the
rate at which isomerization occurs. To access stable endo-can-
tharimides it is therefore necessary to develop reactions with
a significantly improved thermodynamic driving force.[24]
We have recently developed a straightforward approach to
2-substituted-3-alkoxyfurans by gold-catalysed solvolytic cycli-
sation of suitably functionalised propargylic alcohols
(Scheme 2).[27] Preliminary studies indicated that 3-alkoxyfurans
underwent rapid and endo-selective reactions with N-methyl-
maleimide to generate kinetically stable cantharimide prod-
ucts. The distinct 3D structure of the endo-cantharimide motif,
coupled with its physical properties, should make it a valuable
new scaffold for medicinal chemistry applications. Such an ap-
proach should enable control of substituents at a variety of po-
sitions on the tricyclic ring system.
Results and Discussion
The reaction of 3-ethoxyfuran 2a with 1.2 equivalents of N-
methylmaleimide proceed in a variety of solvents at room tem-
perature to give cantharimide 3a in near quantitative yield
(Table 1, entries 1 to 4). Crucially the cantharimide was formed
with a clear preference for the endo diastereomer and the two
isomers could be readily separated by flash column chroma-
tography. The identity of the solvent had little impact on yield
or diastereoselectivity, so dimethyl carbonate (DMC) was se-
lected on the grounds of its excellent environmental profile.[28]
The reaction could also be scaled up to use 1 g of furan 2a,
giving cantharimide 3a in 95% yield (entry 5, endo/exo ratio of
75:25). A purified sample of endo-3a was treated under the
same reaction conditions and no isomerization was observed,
suggesting the reaction proceeds under kinetic control. How-
ever, it was possible to increase the proportion of exo-3a by
heating the reaction at 80 8C for 16 h (entry 6). The cyclization
was equally effective when 3-methoxyfuran 2b was used as
a diene, giving the corresponding adduct in excellent yield as
an 80:20 mixture of endo and exo diastereomers (entry 7).
These reaction conditions were applied to a wide range of
3-ethoxyfurans with different substituents at the 2-position,
Scheme 1. Synthetic approaches to cantharimides.
Scheme 2. Gold-catalysed synthesis of 3-alkoxyfurans 2 from propargylic al-
cohols 1.[27]
Table 1. [4+2] cycloaddition of 3-alkoxyfurans 2 with N-methylmaleimide.
Entry R Solvent[a] T [8C] Reaction t [h] Product Yield [%] endo/exo[b]
1 Et Et2O 25 4 3a 98
[c] 65:35
2 Et PhMe 25 4 3a 100[c] 65:35
3 Et EtOH 25 4 3a 100[c] 70:30
4 Et DMC 25 4 3a 93[d] 70:30
5[e] Et DMC 25 4 3a 95[d] 75:25
6 Et DMC 80 16 3a 93[d] 55:45
7 Me DMC 25 4 3b 89[d] 80:20
[a] DMC refers to dimethyl carbonate. [b] Determined by analysis of the crude
1H NMR spectrum. [c] Yield determined by 1H NMR spectroscopy using penta-
chlorobenzene as an internal standard. [d] Isolated yield. [e] Reaction conducted
with 1.0 g of furan 2a.
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with the results summarized in Table 2. The reaction
tolerated furans with primary and secondary aliphat-
ic substituents (Table 2, entries 2 and 3). It was also
possible to incorporate a tert-butoxycarbonyl (N-Boc)
piperidine, as shown in entry 4. The reaction was
very effective with an aromatic group at the 2-posi-
tion, giving the first reported examples of 4-arylcan-
tharimides (entries 5 to 10). The reaction of 2-phenyl-
furan 2 f gave an 80:20 mixture of endo and exo dia-
stereomers in good yield. This reaction could also be
conducted on a 1.0 g scale, giving the two diastereo-
mers 3 f in a combined yield of 86%, and with com-
plete isomeric separation following chromatography
on silica gel. The relative stereochemistry of the
two diastereomers was confirmed by X-ray crystallography
(Figure 2).
The reaction was tolerant of electron-poor aromatic substitu-
ents (Table 2, entries 6 and 9), an electron-rich aromatic sub-
stituent (entry 8) and an aryl bromide substituent (entry 7). It
was also possible to use a sterically encumbered 2-tolyl sub-
stituent to give cantharimide 3k in 86% yield. Furthermore,
the reaction was effective when the 3-alkoxyfuran possessed
a heteroaromatic substituent, as can be seen in entries 11 to
13 (85–96% yields). The chemoselective reaction of bis-furan
2 l with N-methylmaleimide to give exclusively the enol ether
adduct is an interesting demonstration of the high reactivity of
the 3-alkoxyfuran unit in a [4+2] cycloaddition reaction. It was
also possible to functionalize a 3-alkoxyfuran at the 5-position
prior to the cycloaddition reaction, in order to introduce a sub-
stituent at the 7-position of the endo-cantharimide scaffold
(Scheme 3).
The cycloaddition of 3-alkoxyfuran 2a was effective with
a number of alternative N-substituted maleimides, as illustrat-
ed in Table 3.[30] Sterically more challenging N-substituents
could be incorporated in high yield and without an extended
reaction time.
Additionally, it was possible to combine the gold-mediated
furan synthesis with the cycloaddition reaction in a single step
(Scheme 4, conditions i). Treating propargylic alcohol 1a with
gold catalyst and N-methylmaleimide gave diethyl acetal 6 in
good yield. It appeared that the gold catalyst was responsible
for the in situ conversion of enol ether 3a into the correspond-
ing diethyl acetal, as the interconversion can be avoided by
poisoning the catalyst with 2.5 mol% PPh3 prior to addition of
Table 2. [4+2] cycloaddition of 3-alkoxyfurans 2 with N-methylmalei-
mide.
Entry R Isolated yield [%][a] endo/exo[b]
1 93 70:30
2 95 85:15
3 90 80:20
4 85 75:25
5 86 (86)[c] 80:20
6 75 80:20
7 78 80:20
8 95 80:20
9 84 75:25
10 86 80:20
11 85 90:10
12 96 70:30
13 92 70:30
[a] Combined isolated yield of endo-3 and exo-3. [b] Determined by analy-
sis of the 1H NMR spectrum of the crude product. [c] Reaction conducted
with 1.0 g of furan 2 f.
Figure 2. Crystal structures of cantharimides 3 f. Ellipsoids are shown at the 50% proba-
bility level. Only hydrogen atoms belonging to the cyclic core are shown for clarity.[29]
Scheme 3. Synthesis of a 7-substituted endo-cantharimide: i) (H2C=NMe2)I
(2 equiv), MeCN, 16 h, RT; ii) N-methylmaleimide (1.2 equiv), DMC, 24 h, RT.
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the N-methylmaleimide, to give enol ether 3a (endo/exo ratio
of 70:30). Treatment of a sample of enol ether 3a with catalyt-
ic PPh3AuNTf2 in ethanol was also observed to result in forma-
tion of acetal 6.
Transformation of cycloaddition products
The endo-cantharimides contain an enol ether moiety, which
can be readily transformed into a variety of functional groups
(Scheme 5). For example, enol ether endo-3 f can by hydrogen-
ated to generate ether 7 with complete diastereocontrol.[31]
The enol ether also underwent hydroboration and oxidation to
give alcohol 8, with complete regio- and stereocontrol. Enol
ether endo-3 f could be hydrolysed to give ketone 9 in good
yield by passing it through a strong cation exchange (SCX-2)
cartridge.[32] Treating ketone 9 with NaBH4 afforded alcohol 10,
again with high stereocontrol.
The acid-mediated aromatization of 7-oxabicyclo[2.2.1]hep-
tane derivatives has been previously applied to the synthesis
of aromatic rings, and this approach could be used to prepare
substituted phthalimide 11.[33] The one-pot cantharimide syn-
thesis described in Scheme 4 was used to convert alcohol 1 f
into the crude cantharimide, which could be converted into
phthalimide 11 by acid-mediated ring-opening and aromatiza-
tion (Scheme 6).
Physicochemical properties
An important challenge for drug development is the genera-
tion of novel heterocyclic building blocks with suitable proper-
ties for use in screening and medicinal chemistry programs.[34]
The cantharimides accessed using this methodology have ap-
propriate physicochemical properties for lead-like compounds,
including lipophilicity,[35] molecular weight and polar surface
area[36] (Figure 3). Another attractive feature of these scaffolds
is the high proportion of sp3-hybridized carbon atoms, which
is typically associated with improved protein binding selectivity
and frequency, better solubility and a reduced chance of off-
target effects.[37] Indeed, cantharimides 7, 10, endo-3 f and exo-
3 f were screened against the hERG receptor (IC50>50 mm) and
the aryl hydrocarbon receptor (EC50>100 mm), which are re-
sponsible for common off target effects, and no affinity was
observed. In addition the in vitro clearance of alcohol 10 in the
presence of human microsomes was determined and only
a low level of turnover was observed (<0.53 mLmin¢1g¢1).[38]
Table 3. [4+2] cycloaddition of 3-alkoxyfuran 2a with maleimides 4.
Entry R Yield 5 [%] endo/exo[a]
1 Ph 4a 94 65:35
2 4-MeC6H4 4b 83 55:35
3 c-Pr 4c 87 60:40
[a] Determined by analysis of the 1H NMR spectrum of the crude product.
Scheme 4. One-pot cantharimide synthesis from propargylic alcohol 1a. i) N-
methylmaleimide, 2 mol% PPh3AuNTf2, EtOH; ii) 2 mol% PPh3AuNTf2, EtOH
then 2.5 mol% PPh3 then N-methylmaleimide.
Scheme 5. Functional-group interconversion of enol ether endo-3 f : i) H2,
10% Pd/C; ii) 9-BBN then H2O2/NaOH; iii) SCX-2 cartridge; iv) NaBH4, MeOH.
9-BBN=9-borabicyclo[3.3.1]nonane.
Scheme 6. Synthesis of substituted phthalimide 11 by acid-catalysed aroma-
tisation of cantharimide intermediates.
Figure 3. Physicochemical properties of endo-cantharimides.[39]
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[4+2] cycloadditions with other dienophiles
The [4+2] cycloaddition of furans with maleate esters is known
but was reported to require either forcing pressure[40] or high
catalyst loadings of a Lewis acid.[41] In contrast, the catalyst-
free reaction of dimethyl maleate 12a and furan 2a proceeded
at room temperature to give adduct 13a in a good yield and
with excellent endo selectivity (Table 4, entry 1). The reactions
of dimethyl and diethyl fumarate (12b and 12c) with furan 2a
proceeded more rapidly, giving the corresponding adducts in
77–89% yield after 4 h (entries 2 and 3). There is a clear selec-
tivity in both examples for the product which possessed exo
stereochemistry with respect to the 3-position (3-exo-13).[42]
Heating furan 2a with ethyl vinyl ketone at 80 8C for 16 h, fol-
lowed by hydrolysis of the enol ether on an SCX-2 cartridge,
gave diketone 13d with high regiocontrol (95:5), although as
a 60:40 mixture of endo/exo isomers.
The catalyst-free reaction of furan 2a with ethyl acrylate
12e was relatively slow at room temperature, with <100%
conversion after 24 h. However, it was possible to accelerate
the reaction through the use of 2 mol% HfCl4, giving the
ketone 13e in 89% yield and with good regiocontrol (95:5)
after 6 h at room temperature (Table 4, entry 5). The catalyst
loading for this reaction is much lower than the high (some-
times stoichiometric) loading re-
ported for the Lewis acid-cata-
lyzed reactions of 3H furans and
acrylates.[41,43]
Computational study
The reactions of five 3-alkoxy-
furans and N-methylmaleimide
were explored with the M06-2X
exchange–correlation function
of Truhlar et al. ,[44] a density
functional that has been suc-
cessfully used to model the re-
action and activation energies
of different cycloaddition pro-
cesses.[45] 2-Substituted-3-me-
thoxyfurans were chosen as
suitable models for our 3-al-
koxyfurans and these were
compared to the corresponding
3H furans.
The 3-alkoxy group has a dra-
matic effect on the thermody-
namics of the cycloaddition re-
action, as is evident in Table 5.
All five reactions of 3-alkoxyfur-
ans have a clear thermodynamic
driving force for the formation
of both endo- and exo-addition
products (Figure 5) and the
data is consistent with a reaction
that is likely to be kinetically
controlled. In contrast, the values of DG for the corresponding
reactions of 3H furans are all greater by 24–34 kJmol¢1
Table 4. [4+2] cycloaddition of 3-alkoxyfuran 2a with different dienophiles.
Entry Dienophile 12 Reaction
t [h]
Product 13 Isolated yield
[%]
Product
ratio[a]
1 72 70 12:1
2 4 77 15:85
3 4 89 15:85
4[b,c] 16 60 95:5
5[c,d] 6 89 95: 5
[a] Determined by analysis of the 1H NMR spectrum of the crude product. [b] Reaction conducted at 80 8C.
[c] Crude product flushed through a SCX-2 cartridge. [d] Reaction conducted with 2 mol% HfCl4.
[41]
Table 5. Calculated DG and DG for the reactions of furans 14 and N-
methylmaleimide 15.[a]
14 R X endo exo
DG DG DG DG
14a Me OMe ¢41.5 81.1 ¢47.7 82.1
14b cPr OMe ¢44.1 75.0 ¢53.2 78.6
14c 4-MeOC6H4 OMe ¢32.5 76.8 ¢30.1 85.3
14d Ph OMe ¢34.0 83.6 ¢28.2 91.4
14e 4-F3CC6H4 OMe ¢25.3 85.9 ¢23.8 96.8
14 f Me H ¢11.8 97.9 ¢16.8 96.2
14g cPr H ¢12.5 92.2 ¢10.3 92.8
14h 4-MeOC6H4 H ¢6.1 95.4 ¢3.6 98.8
14 i Ph H ¢1.7 101.1 0.7 105.5
14 j 4-F3CC6H4 H ¢0.9 101.6 0.9 108.3
[a] All values in kJmol¢1. All data is calculated for species in the gas
phase.
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(Figure 4). This effect is most significant when the 2-substitu-
ent is aromatic, as this results in a value of DG close to zero
for the furans 14h–j. As expected, the 3-alkoxy group also has
a significant effect on the free energy of activation for the cy-
cloaddition reaction, with the kinetic barrier reduced by 11–
23 kJmol¢1. The effect of solvation on these reactions was also
considered but was found to have little effect (see Supporting
Information).
The reversibility of most furan Diels–Alder reactions has
been attributed to the loss of aromatic stabilization upon for-
mation of an adduct, which results in a facile retro-cycloaddi-
tion.[22] In order to examine the effect of a 3-methoxy group
on this phenomenon, thermodynamic cycles involving the par-
tial hydrogenation of 3-methoxyfuran 17a and furan 20a to
the corresponding 2,5-dihydrofurans 18a and 21a were con-
sidered (Scheme 7). It is notable that the free energy of hydro-
genation for furan 20a was 25.9 kJmol¢1 greater than for 3-
methoxyfuran 17a. The corresponding reaction free energies
for cyclopentadienes 17b and 20b were also calculated but
no significant difference was observed. The implications of
these calculations are that 1) the difference in behaviour be-
tween 3H and 3-methoxy furans in cycloaddition reactions can
be attributed to differences associated with loss of aromaticity
rather than with C¢C bond formation and 2) a 3-methoxy
group can reduce the energetic penalty associated with the
loss of aromaticity upon the Diels–Alder reaction of a furan, in-
creasing the thermodynamic stability of the cycloaddition
product.
Conclusions
We have demonstrated that 3-alkoxyfurans are excellent
dienes for [4+2] cycloadditions with a wide variety of male-
imides and other dienophiles. This methodology significantly
expands the nature of cantharimides that can be readily pre-
pared with high endo selectivity. The reaction tolerates alkyl,
aryl and heteroaryl substituents and the enol ether cycloaddi-
tion product can be transformed into a diverse collection of
drug-like compounds. Finally, DFT calculations have confirmed
that a 3-alkoxy group has a significant effect on both the ther-
modynamic driving-force and the activation energy of the
Diels–Alder reaction of 2-substituted furans with N-methylma-
leimides. The former effect can potentially be attributed to the
3-alkoxygroup leading to a reduced energetic penalty associat-
ed with the loss of furan aromaticity that occurs during the cy-
cloaddition reaction.
Experimental Section
General cycloaddition procedure
A solution of the maleimide (1.2 equiv) in dimethyl carbonate
(3.6m) was added to a stirring solution of 3-alkoxyfuran (1.0 equiv)
in dimethyl carbonate (1.5m) at room temperature and the reac-
tion stirred at room temperature for 4–24 h. The reaction was then
diluted with ethyl acetate and loaded onto an aminopropyl car-
tridge. After 5 min the cartridge was then flushed with ethyl ace-
tate and the solvent removed in vacuo to give the crude cycload-
dition product.
Experimental procedures, 1H and 13C NMR spectra, characterization
data of all compounds, compound screening data, details of com-
putational studies including energy minimized geometries and
XRD crystallography files are available in the Supporting Informa-
tion.
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Figure 4. Calculated DG and DG values for the reactions of 2-phenylfurans
14d and 14 i and N-methylmaleimide 15 in kJmol¢1.
Figure 5. M06-2X/6-31G(d)-optimized endo and exo transition states for the
reaction of furan 14d and N-methylmaleimide 15.[46] Distances in æ.
Scheme 7. Thermodynamic cycle involving the hydrogenation of dienes 17
and 20.
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Sustainable Synthesis of Chiral Tetrahydrofurans via the 
Selective Dehydration of Pentoses 
Robert W. Foster,[a] Christopher J. Tame,[b] Dejan-Krešimir Bučar,[a] Helen C. Hailes,[a] and Tom D. 
Sheppard[a] 
 
Abstract: L-Arabinose is an abundant resource available as a waste 
product of the sugar beet industry. Through use of a hydrazone-based 
umpolung strategy, L-arabinose was selectively dehydrated to form a 
chiral tetrahydrofuran on a multi-gram scale without the need for 
protecting groups. This approach was extended to other biomass-
derived reducing sugars and the mechanism of the key cyclization 
investigated. This methodology was applied to the synthesis of chiral 
tetrahydrofurans, including a formal synthesis of 3R-3-
hydroxymuscarine. 
The more effective use of biomass, and in particular that 
generated as waste,[1] is essential to reduce the global 
dependence on petrochemical resources for the manufacture of 
valuable compounds, fuels and materials.[2] The majority of 
biomass is made up of carbohydrates, which are an abundant 
source of pentoses and hexoses.[3] For example, the refinement 
of sugar beet generates beet pulp as a major waste product, and 
this is a rich source of L-arabinose.[4] A variety of techniques have 
been developed to convert these biomass resources into valuable 
small molecules, such as the dehydration of pentoses under 
forcing acidic conditions to give furfural (Scheme 1), which can 
then be converted into various alcohols, alkenes and 
heterocycles.[5] However, the majority of compounds prepared 
from pentoses and hexoses in this fashion are either achiral[6] or 
racemic mixtures where the stereochemistry of the chiral 
precursors is lost.[7] Therefore using these products as 
intermediates in the synthesis of more complex targets may 
require the reintroduction or single-isomeric stereocentres using 
asymmetric catalysis[8] or resolutions.[9] 
The tetrahydrofuran (THF) is a privileged scaffold within medicinal 
chemistry[10] and the stereoselective synthesis of chiral THFs has 
been an major area of recent research.[11] An attractive approach 
is to utilize the inherent chirality present in single isomer biomass-
derived carbohydrates.[12] However, existing methods often 
require the selective conversion of a primary alcohol into an alkyl 
sulfonate or halide [13] and/or the use of protecting groups,[14] both 
of which are detrimental to the economy of a synthetic route.[15] 
Herein we describe the application of N,N-dimethylhydrazine[16] 
for the selective dehydration of biomass-derived reducing sugars 
to prepare chiral THFs under mildly acidic conditions (Scheme 
1).[17] 
Scheme 1. The preparation of furfural and THFs from biomass feedstock. 
Treating L-arabinose 1a with N,N-dimethylhydrazine and 
Amberlyst® 15 acidic resin in methanol at room temperature gave 
hydrazone 2a in 99% yield (Table 1). Stirring hydrazone 2a in 
methanol at 40 °C for 16 h with 20 mol% TFA resulted in 100% 
conversion of 2a. Analysis of the crude 1H NMR indicated the 
formation of THF 3a as a 75:25 mixture of diastereoisomers and 
purification by flash column chromatography gave a mixture of the 
two stereoisomers in 67% yield. The reaction was scaled up from 
a 6.7 mmol scale to a 104 mmol scale without any significant drop 
in yield, giving 11.9 g of THF 3a. The major diastereoisomer was 
isolated by recrystallization and the stereochemistry was 
confirmed by single crystal X-ray diffraction (Figure 1). Both steps 
were conducted in a sustainable solvent[18] (methanol) without the 
need for either pre-drying or for a drying agent to be present.  
The same reaction conditions were used to prepare the 
enantiomeric THF ent-3a from D-ribose (Table 1, entry 2) in a 
59% yield over two steps. It is notable that the diastereoselectivity 
of this reaction was comparable with that observed for the 
cyclization of arabinose-derived hydrazone 2a. 
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Table 1. Two-step synthesis of THFs 3 from sugars 1. 
 
Entry Sugar 1 Step 1 
yield/%  
THF 3[b] Step 2 
yield% 
d.r.[c] 
1 
 
99 
 
67 
(66)[d] 
75:25 
 
2 
 
98 
 
59 75:25 
3 
 
98 
 
66 55:45 
4 
 
not 
isolated 
 
61[e] 55:45 
5 
 
not 
isolated 
 
57[e] 55:45 
6 
 
99 
 
69 60:40 
[a] Reagents and Conditions: NH2NMe2 (2 equiv.), Amberlyst® 15, MeOH, 24 h, RT. [b] Reaction 
conducted on a 6.00–6.70 mmol scale unless otherwise stated. [c] Determined by analysis of the 
crude 1H NMR spectra. [d] Reaction conducted using 20.0 g (104 mmol) of hydrazone 2a. [e] Yield 
over two steps from xylose. 
Rhamnose, another constituent of sugar beet 
pulp, to give THF 3c in 69% yield as a 60:40 
mixture of diastereoisomers (entry 6). 
Figure 1. ORTEP of the asymmetric unit in the crystal 
structure of hydrazone anti-3a. The thermal ellipsoids 
are shown at a 50% probability level. Only hydrogen 
atoms belonging to the cyclic core are shown for 
clarity.[19] 
Recrystallization of hydrazone 3a yielded the 
major anti-diastereoisomer in high purity. 
Reducing hydrazone anti-3a using hydrogen, 
a palladium catalyst and Boc2O gave 
carbamate 4 in 60% yield as a single 
stereoisomer (Scheme 2). 
Treatment of THF 3a (d.r. = 75:25) with 
Amberlyst® 15 acidic resin in water at room 
temperature resulted in rapid hydrolysis of the 
hydrazone to give hydrolyzed product 5 
(Scheme 3).[20] Reduction of compound 5 with 
NaBH4 in methanol gave triol 6 as an 85:15 
mixture of diastereoisomers in 98% yield over 
two steps from hydrazone 3a. Reductive 
amination of intermediate 5 using n-
butylamine, acetic acid and 
hydrogen/palladium, followed by trapping of 
the intermediate amine with Boc2O, gave 
carbamate 7 in 65% yield from hydrazone 3a 
as an 80:20 mixture of diastereoisomers. 
Compound 5 was also converted to alkene 8 
using trimethyl phosphonoacetate in 73% 
yield over two steps with excellent E-
selectivity. Finally, treating compound 6 with 
Amberlyst® 15 in methanol resulted in the 
formation of dimethyl acetal 9 in 74% yield 
over two steps from 3a as a 65:35
The methodology was also extended to D-lyxose (Table 1, entry 
3), with the corresponding hydrazone prepared in good yield. The 
TFA-mediated cyclization step gave THF 3b in 66% yield as a 
55:45 mixture of diastereoisomers. THF 3b could also be 
prepared from D-xylose in 61% yield over two steps, again as a 
55:45 mixture of diastereoisomers (entry 4). This is a particularly 
important result as D-xylose is one of the major components of 
biomass.[3] Xylose is naturally available in both enantiomers and 
using L-xylose it was possible to access ent-3b in a comparable 
yield (entry 5). The methodology was extended to deoxy sugar L- 
 
 
 
mixture of stereoisomers. The hydrolysis/reduction sequence was 
also applied to the hydrazones 3b and 3c, gave the corresponding 
triols 10 and 11 in 90% and 93% yield respectively. L-Rhamnose-
derived triol 11 is a late-stage intermediate in Fleet’s synthesis of  
 
Scheme 2. Reduction of hydrazone anti-3a. Reagents and conditions; H2 
(1 atm.), Pd(OH)2/C, Boc2O, CPME, 24 h, RT. 
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3R-3-hydroxymuscarine 12.[21] Triol 11 was previously prepared 
from L-rhamnose using stoichiometric bromine, 
trifluoromethanesulfonic anhydride and lithium aluminium hydride, 
so our route represents a less hazardous and more sustainable 
alternative. 
Scheme 4. Hydrolysis of hydrazones 3 and transformation into a range of 
tetrahydrofuran products. Reagents and conditions; (i) Amberlyst® 15, H2O, 
5 minutes, RT; (ii) NaBH4, MeOH, 1 h, 0 °C; (iii) n-BuNH2, AcOH, H2 
(1 atmosphere), 10% Pd/C, MeOH, 4 h, r.t. then Boc2O, CPME, 16 h, RT; (iv) 
trimethyl phosphonoacetate, K2CO3, MeOH, 4 h 0 °C; (v) Amberlyst® 15, MeOH, 
48 h, RT. 
A plausible reaction mechanism for the cyclization of hydrazone 
2a is proposed in Scheme 4. The N,N-dialkylhydrazone group of 
2a could promote the acid-mediated elimination of the adjacent 
hydroxyl to give vinyldiazenium intermediate 13.[22] Cyclization of 
this intermediate would give THF 3a as either an anti- or syn-
diastereoisomer. Resubmission of an isomerically pure sample of 
anti-3a to the reaction conditions resulted in the same 75:25 
mixture of anti- and syn-diastereoisomers that is observed in the 
original reaction, which suggests that the diastereoselectivity is 
under thermodynamic control. Conducting the reaction in MeOH-
d4 did not result in the measurable incorporation of deuterium 
adjacent to the hydrazone, indicating that epimerization occurs 
through a reversible ring closure rather than via a vinylhydrazine 
intermediate. The proposed mechanism is also consistent with 
the observation that hydrazones 2a and 2b converge to THF 3a 
and ent-3a with the same diastereoselectivity (Table 1, entries 1 
and 2), as the two reactions would proceed through enantiomeric 
vinyldiazenium intermediates. Without TFA present no reaction 
was observed. 
  
Scheme 5. Postulated mechanism and mechanistic studies. 
In a preliminary study, the extension of this approach to hexoses 
was explored. Hydrazone 14, formed from D-galactose, was 
treated was subjected to the TFA-mediated cyclization conditions. 
This gave a 60:40 mixture of THF 15 and tetrahydropyran 16 in 
53% isolated yield, with both heterocycles formed as single 
stereoisomers. 
Scheme 2. Extending the methodology to D-galactose. Reagents and 
conditions; 20 mol% TFA. 
In summary, we have developed an efficient multi-gram approach 
to low-molecular weight chiral molecules from biomass feedstock. 
This route allows access to a range of THF products without the 
need for protecting groups, including a formal synthesis of 3R-3-
hydroxymuscarine. On the basis of experimental evidence, we 
have also proposed a reaction mechanism for the key cyclization 
which is based on an unusual vinylhydrazine intermediate. 
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Experimental Section 
Experimental procedures, 1H and 13C NMR spectra, 
characterization data of all compounds and XRD crystallography 
files are available in the supporting information. 
 
A stirring mixture of hydrazone 2a (20.0 g, 104 mmol) in methanol 
(210 mL, 0.5 M) was treated with TFA (1.5 mL, 2.4 g, 20 mol%) at 
room temperature and the reaction stirred at 40 °C for 16 h. The 
reaction was then quenched with aq. sat. NaHCO3 and 
concentrated in vaccuo to give the crude hydrazone (anti:syn = 
75:25). This was purified by flash column chromatography 
(80:100 hexane:acetone) to give THF 3a (11.9 g, 68.3 mmol, 
66%).  
THF anti-3a: Isolated as a single stereoisomer following 
recrystallization from boiling CPME. Isolated as a white crystalline 
solid; m.p. = 65–67 °C; Rf = 0.33 (1:1 acetone:hexane); νmax 
(film/cm–1) 3415s br. 2875s, 1586s, 1467s, 1445s; 1H NMR 
(600 MHz; MeOH-d4) 6.51 (1H, d, J = 6.6, N=CH), 4.23–4.18 (2H, 
m, N=CHCH, CH2CH), 4.08 (1H, dd, J = 9.6, 4.9, OCHH’), 4.02 
(1H, dd, J = 7.3, 5.1, N=CHCHCH), 3.76–3.72 (1H, m, OCHH’), 
2.79 (6H, s, N(CH3)2); 
13C NMR (150 MHz; MeOH-d4) 135.6 (C=N), 
82.5 (CHCH2), 76.5 (N=CHCHCH), 73.9 (OCH2), 72.4 
(CH2CHCH), 42.8 (N(CH3)2); HRMS (EI
+) found [M+H]+ 174.0979; 
C7H14N2O3 requires 174.0999; [α]D (20 °C) = +85.8 (anti-3a, 
MeOH, C = 1.4). 
THF syn-3a: 1H NMR (600 MHz; MeOH-d4) 6.71 (1H, d, J = 7.2, 
N=CH), 4.36–4.31 (2H, m, N=CHCH; CH2CH), 4.15 (1H, t, J = 4.8, 
CHCHCH2), 3.91 (1H, dd, J = 8.7, 6.2, OCHH’), 3.76–3.72 (1H, m, 
OCHH’), 2.79 (6H, s, N(CH3)2); 13C NMR (150 MHz; MeOH-d4) 
135.6 (C=N), 83.1 (CHCH2), 74.3 (N=CHCHCH), 73.2 (N=CHCH), 
72.5 (OCH2), 42.8 (N(CH3)2). 
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